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Abstract 
 
Patient-level evidence obtained from clinical trials is essential in assessing the cost-
effectiveness of health care technologies. Given the increasing demand for primary evidence 
and limited public resources for health care research, research funding organisations are 
routinely called to make decisions on which clinical trials to fund. Such decisions need to be 
informed by evidence on the likely costs and benefits of competing research programmes. 
Two main analytic approaches have been proposed to provide such evidence, ‘payback of 
research’ and ‘value of information’. 
This work applied the ‘payback’ and ‘value of information’ methodologies to case studies 
representing proposals for clinical trials in cancer. This application gave estimates of the 
value of undertaking the trials and offered an insight into the strengths, limitations and 
usefulness of the methods.  
‘Payback of research’ and ‘value of information’ can help with different funding decisions in 
the context of different funding streams, they are practical to undertake and can be readily 
incorporated into the existing research funding processes. It is suggested that the methods 
should be introduced and used as part of existing deliberative processes, to provide 
additional assurance that limited public resources are allocated to clinical trials which are 
likely to result in benefits to the population.  
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1 
PART I. Background 
The first part of this thesis aims to provide the background to the topic. The part consists 
of Chapters 1 to 3. Chapter 1 discusses the role of primary evaluative research studies—
such as clinical trials—in producing evidence for health care treatment adoption 
decisions, summarises the main sources of funding for such research and looks into the 
need for priority-setting among competing research programmes.  
Chapter 2 discusses main aspects of priority-setting for evaluative research, distinguishes 
between deliberative and analytic approaches to priority-setting, describes analytic 
models put forward to assist with this task and categorises these models into two 
overarching frameworks: ‘payback of research’ and ‘value of information’.  
These frameworks are the focus of the last chapter of Part I, Chapter 3, which describes 
and discusses ‘payback of research’ and ‘value of information’ with regards to their aims, 
rationale, main components and methods by drawing on the relevant literature.  
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CHAPTER 1. Introduction and project aims 
This chapter seeks to introduce concepts relevant to the topic of interest, specify the 
research question and aims of the present work and outline the structure of this thesis. 
1.1. Health care service provision and applied clinical research 
The primary aim of health care systems around the world is to tackle disease and improve 
the health and wellbeing of the populations they serve1. Towards this aim, health care 
systems set up elaborate structures through which they make available a wide range of 
services, treatments and procedures—collectively known as health technologies—aiming 
to prevent, treat and rehabilitate2;3.  
Concerns over the fact that many commonly used technologies may be, in practice, 
ineffective or even harmful, have prompted the recognition that health care services 
provided to the population should be of proven effectiveness4;5. At the same time, efforts 
to contain rapidly growing health care expenditure6;7 and the acknowledgment that 
needs are infinite but resources to fulfil them are limited, have led to the introduction of 
a further criterion: provided technologies must also be ‘cost-effective’, that is, they must 
represent efficient use of limited resources8-10. 
Information on health technologies’ effectiveness and cost-effectiveness is nowadays 
used routinely to inform decisions on which treatments to adopt and provide to the 
population11-14. Such information, often called secondary evidence, is provided by health 
technology assessment studies, which evaluate the health and economic impact of 
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introducing and using a technology in clinical practice. Key input in such studies is 
primary, patient-level evidence generated through applied clinical research4;15;16. 
In contrast to basic research, which aims to generate general knowledge per se, applied 
clinical research is carried out to address specific questions. Such research encompasses a 
variety of activities, including studies on disease management, health care service 
delivery and evaluation of treatments and interventions17. Applied research that aims to 
generate primary, patient-level evidence on the effectiveness of health care technologies 
is often referred to as primary evaluative research15;17. With respect to their design, 
primary evaluative studies are either observational or experimental4;18. In observational 
studies, such as case-control and cohort studies, researchers aim to observe the course of 
a disease without intervening to alter its natural progression by providing a treatment, 
with a view to identifying possible associations between disease and exposure.  
On the other hand, experimental studiesare experiments where the investigators 
intervene to prevent or alter the natural progression of a disease by providing patients 
with a treatment and observing its impact. The most common form of experimental 
studies—and the most important type of primary evaluative research—are clinical 
trials19;20.  
1.2. Clinical trials  
The primary aim of clinical trials is to generate and provide evidence on treatments’ 
efficacy (i.e. whether the assessed treatment works under ideal conditions) and 
effectiveness (i.e. whether the treatment is expected to work in routine clinical 
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practice)21. In doing so, trials assume different forms and employ different design 
characteristics. Studies of a particular design—randomised controlled trials (RCTs)—have 
been described as “the crown jewel”22[p.673] and the “archetypal primary research 
methods”4[p.7] in clinical research, and they are considered as the best source of primary 
evidence for assessing and comparing health technologies19;23;24. The special status of 
RCTs in providing primary evidence on treatments’ effectiveness warrants looking into 
such studies in more detail, with respect to their design characteristics and phases.  
1.2.1. Design characteristics of randomised controlled trials 
RCTs present a number of distinctive design characteristics. First, such studies typically 
involve two or more ‘trial arms’, that is, distinct groups of participants who receive 
different treatments. Typically, one (or more) group(s) are given the treatment(s) of 
interest, with other groups receiving the best alternative treatment, placebo, or no 
treatment at all25. A second key characteristic relates to the way in which participants are 
allocated to trial arms. In RCTs, this is typically done by using random allocation 
methods26. Random allocation of participants ensures that trial arms are as similar as 
possible with respect to their participants’ characteristics, and reduces the chance of 
invalid comparisons due to dissimilar patient groups20;27. Last, RCTs differ in whether or 
not participants and investigators are aware of the trial arm they are assigned to, known 
as ‘blinding’26. ‘Blinding’ for both patients and investigators is expected to alleviate 
possible psychological factors that may affect patients’ compliance and response to 
treatment, and removes the possibility that patients whose trial arm is known to the 
investigators may be treated differently20;28.  
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1.2.2. Clinical trials according to phase of drug development 
A wide range of preventive and curative health care services and treatments can be 
investigated in clinical trials. Trials assessing pharmaceuticals are distinctive in that they 
typically involve phases representing specific stages in drug development. Four phases 
are commonly distinguished; these are summarised in Table 1.1. 
Table 1.1: Phases of experimentation in clinical trials of pharmaceuticals 
 
Trial phase Aim 
Phase I Investigation of clinical pharmacology and toxicity 
Phase II Initial investigation of treatment efficacy 
Phase III Full-scale evaluation of treatment effectiveness 
Phase IV Post treatment evaluation and marketing surveillance 
 
In phase I trials, the experimental drug is given to humans for the first time. The objective 
of such trials is to assess the drug’s safety, determine the maximum tolerated dose which 
can be given to patients without causing serious side effects and establish the optimal 
dose schedule, should the assessment continues into the next phase20;21;29. Phase I results 
are scrutinised to verify if the drug meets predetermined safety thresholds and can be 
further evaluated in a phase II trial.  
Phase II trials are aimed as the first investigation of a treatment’s efficacy. When more 
than one drug is assessed, phase II trials also serve as a screening process, to filter out 
drugs that are considered ineffective or potentially unsafe. Traditionally, such trials make 
use of conventional non-randomised designs; nonetheless, randomised phase II trials—
where participants are randomly assigned to different treatment arms—are becoming 
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increasingly common20;30. Data obtained from phase II trials inform decisions on whether 
the experimental drug appears effective enough to be taken forward into the next 
stage—a phase III trial. 
Phase III trials seek to carry out the first full-scale assessment of the investigated 
treatment(s). Such trials aim to provide definitive evidence on a drug’s effectiveness and, 
increasingly, they provide information on patients’ use of health care resources 
associated with the assessed treatment(s)31. Phase III trials usually involve hundreds, or 
even thousands, of patients which are often followed up for several years. Employing 
great numbers of patients helps to attain high levels of statistical power and increases the 
capacity to detect clinically relevant differences between treatments, but, on the other 
hand, it increases the study’s cost32. Given the above, RCTs are considered to be “the 
most rigorous and expensive type of clinical investigation”21[p.3]. 
Often, a further step in the drug assessment sequence involves conducting a phase IV 
trial. Such trials are carried out to monitor the long-term impact of treatments on 
morbidity and mortality, as well as to identify possible side effects. Typically phase IV 
trials take place after the treatment has been licensed and involve monitoring cohorts of 
patients which have been given the treatment over extensive periods of time20. 
1.2.3. Pragmatic clinical trials 
A distinction between phase III trials is often made with regards to the purpose of the 
trial and the type of evidence generated from it. In this respect, phase III trials have been 
classified as ‘explanatory’ or ‘pragmatic’33;34. As Schwartz and Lellouch33 explain, 
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explanatory phase III trials aim to advance scientific knowledge and explore whether a 
drug is efficacious under ideal conditions. On the other hand, pragmatic phase III trials 
aim to determine a treatment’s effectiveness by investigating whether the drug would 
work in routine clinical practice, and establishing the ‘real world’ benefits and resource 
use associated with it31;35;36. Although pragmatic trials are a preferable source of primary 
patient-level data on the effectiveness and use of resources associated with a treatment, 
evidence obtained from exploratory trials is also useful and it is often used as input in 
health technology assessment studies and economic evaluations37;38.  
1.3. Funding for clinical trials 
The importance of evaluative research in assisting the National Health Service (NHS) to 
achieve its objectives has been recently highlighted in a comprehensive review of the 
existing research funding structures in the UK17. Given this, it is not surprising that there 
exist a number of programmes to support and fund evaluative research. In the UK, 
funding for such research is made available from three main sources: the public sector, 
charitable institutions and the pharmaceutical industry. These are discussed briefly 
below. 
1.3.1. Public funders of evaluative research 
The two main pillars of governmental, publicly funded evaluative research are the NHS 
National Institute for Health Research (NHS NIHR) and the Medical Research Council 
(MRC). 
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The NHS NIHR co-ordinates and manages publicly funded research on behalf of the NHS. 
The organisation was established in 2006 with the primary aim to invigorate publicly 
funded research and produce evidence to support decision-making within the NHS39. The 
organisation provides funding for evaluative research mainly through the NIHR HTA 
programme, which is the largest of all the NIHR programmes with a budget of over £80 
million a year40. The NIHR HTA supports research with a view to producing evidence on 
the effectiveness and cost-effectiveness of technologies provided by the NHS. The 
programme funds primary research, mainly pragmatic clinical trials, but also evidence 
synthesis studies and economic evaluation studies40;41. Within the programme, funding is 
distributed through its ‘researcher-led’, ‘commissioned’ and ‘themed calls’ streams41-43.  
The other main pillar of publicly funded primary evaluative research in the UK is the MRC. 
The MRC supports research across a wide range of disease areas and various designs. 
Following suggestions on optimising research funding in the Cooksey report17, the MRC 
has turned its focus on basic and translational research; however, it also supports primary 
evaluative studies, such as RCTs, through the Efficacy and Mechanism Evaluation (EME) 
programme. Established by the National Institute for Health Research (NIHR) and the 
Medical Research Council (MRC) as a coordinated strategy for clinical trials, this 
programme supports clinical trials with the objective of advancing scientific knowledge in 
order to provide the best care to the population44. The programme provides funding for 
studies that seek to evaluate new diagnostic technologies, medical devices and public 
health interventions44. In 2009, the amount EME allocated to clinical trials reached £13 
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million. Similarly to NIHR HTA, EME funding is provided through ‘researcher-led’, 
‘commissioned’ and ‘themed calls’ work streams45;46.  
1.3.2. Charitable organisations 
Medical charities have traditionally been an important source of funding for medical 
research in the UK, providing financial support for both basic and applied evaluative 
research in a wide range of disease areas43. A prominent funder of evaluative research is 
Cancer Research UK (CRUK). The aim of the programme is to fund and support studies on 
diagnostic, curative or palliative treatments aimed to improve cancer patients’ survival 
and wellbeing47.  
CRUK funding for clinical trials is provided through a number of programmes (Feasibility 
Study Project Grants, New Agents Committee (NAC) trials, Phase III Clinical Trial Grants, 
Population Research Committee (PRC) Programme Grants and the Prospective Sample 
Collections Project Grants scheme), though the charity’s main programme for late phase 
clinical trials is the Phase III Clinical Trial Grants48. The programme makes available 
funding for phase III therapeutic trials and large scale phase II trials with expected follow-
up of more than two years. The programme is administered and run by the Clinical Trials 
Awards and Advisory Committee (CTAAC) which holds the responsibility of reviewing and 
prioritising research proposals49.  
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1.3.3. Pharmaceutical industry 
Pharmaceutical companies invest heavily on research, with a significant number of 
clinical trials carried out in the UK being fully or partially sponsored by the 
pharmaceutical industry50. Industry-funded clinical trials are primarily carried out for 
regulatory purposes, to ascertain the safety and efficacy of developed pharmaceutical 
compounds and support cases for reimbursement within the NHS. As the main objective 
of pharmaceutical companies in funding research is profit maximisation, commercially 
funded research falls outside the purposes of this study, although some of the methods 
discussed in this thesis may be, to some extent, applicable to commercial companies51;52. 
1.4. Priority-setting for evaluative research 
The increasing use of effectiveness and cost-effectiveness evidence for treatment 
adoption decisions has led to increased demand for primary evaluative studies. At the 
same time, public funds available for research are limited. 
Within the constraints of a finite budget for research, the decision to fund a particular 
research programme, such as a clinical trial, incurs an opportunity cost: the loss of 
benefits that would accrue from funding and conducting an alternative programme. 
Similarly to allocating resources between health care services, decisions are needed on 
how to allocate the available research budget to competing proposals for evaluative 
research.  
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Such decisions need to be made in a way that ensures that public resources—coming 
from the government’s pot or donations—are spent efficiently. This would require a 
systematic and explicit assessment of the costs and benefits expected to arise from 
allocating resources to alternative research programmes. A series of analytic methods 
aiming to provide such information with a view to assisting research funding decisions 
have been proposed in the literature since the early 1980s. Although these methods are 
well-defined, their value and role in informing research priority-setting remains 
ambiguous.  
1.5. Study aims and objectives 
With this in mind, this study sets out to assess the usefulness, potential role and value of 
prominent analytic frameworks for research priority-setting. Specific objectives are to 
identify methods proposed to assist with priority-setting for primary evaluative research, 
and, by applying these methods to case studies, assess their performance with relation to 
their practicality, theoretical and methodological soundness, ability to assist with relevant 
decisions, and potential to fit into existing research prioritisation processes. 
1.6. Thesis structure 
The thesis is structured as follows. The remainder of Part I sets out the background to the 
research questions. In particular, Chapter 2 reviews the literature to identify approaches 
put forward to assist and inform research priority-setting, and discusses currently used 
and alternative analytic approaches. Chapter 3 describes and discusses the most 
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prominent analytic approaches proposed for priority-setting—‘value of information’ (VoI) 
and ‘payback of research’—by drawing on relevant published literature. 
The next part, Part II, focuses on the practical application of the selected analytic 
approaches to two case studies, which represent proposals for clinical trials aimed to 
provide evidence on treatment adoption-related decisions in non-small cell lung cancer 
(NSCLC) and hormone-refractory prostate cancer (HRPC). This practical application was 
undertaken through a two-stage process: the first stage required identifying and 
summarising the available evidence around the relevant treatment adoption decisions 
before a decision on whether or not to fund the trials was made, and involved carrying 
out searches in the literature and constructing decision analytic models. Work 
undertaken at this stage is reported in Chapters 4 and 5 for the NSCLC and HRPC case 
studies, respectively. The second stage involved applying the ‘payback of research’ and 
‘value of information’ methods, to determine the expected benefits from, and the 
potential value of, undertaking the proposed trials. The methods involved in these 
analyses, as well as the obtained results, are reported in Chapters 6 and 7.  
The final part of the thesis, Part III, brings the study findings together and draws 
conclusions. Specifically, Chapter 8 interprets and discusses the results, and assesses the 
approaches with respect to their methodological and theoretical strengths and 
weaknesses, their sensitivity to different assumptions, their practicality, as well as their 
potential role in research priority-setting. The last chapter of this thesis, Chapter 9, 
discusses the findings, draws conclusions and formulates recommendations for further 
research.  
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CHAPTER 2. Review of proposed approaches to priority-
setting for research 
The aim of this chapter is to identify and discuss methods and approaches to priority-
setting for evaluative research. The first part of the chapter gives the methods used in 
conducting a literature review to identify relevant material on the topic. Information 
obtained from this review forms the basis for the second part of this chapter, where 
identified approaches are described and discussed. 
2.1. Literature review methods 
The focus of this literature review is on methodology work and, as such, it presents a 
number of distinctive characteristics in comparison to widely used Cochrane-type 
systematic reviews. While the latter aim to provide synthesised information about 
interventions’ effectiveness and cost-effectiveness, methodology reviews seek to identify 
and discuss methods, ‘schools of thought’ and arguments on a specific topic or idea. 
Although the methods and requirements for undertaking Cochrane-type systematic 
reviews of health care interventions are well documented53;54, guidelines for carrying out 
review of methodological literature are sparse55. Despite this, the present review aimed 
to be as systematic as possible, following, wherever applicable, methods set out in well-
established guidelines for undertaking literature reviews56. 
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2.1.1. Identification of relevant literature 
Different approaches to identifying relevant material were used in an attempt to 
maximise the yield of useful articles and limit the chance of potentially relevant articles 
being left out. Searches in electronic bibliographic databases—typically being the main 
focus of searches in systematic reviews—were complemented by additional techniques 
such as ‘citation searching’, related articles searches, ‘reference list scanning’ and general 
internet searches. 
Bibliographic databases are virtual, electronic libraries containing a large number of 
journal citations and abstracts, covering a wide range of fields. As such, they are usually 
the starting point for literature searches. Databases searched for the purposes of this 
review were MEDLINE, EMBASE, CINAHL, EconLit and the databases of the Centre for 
Reviews and Dissemination (DARE, NHS EED and HTA). Searches in these databases were 
conducted in a stepwise manner. First, pilot searches aiming to give an insight into the 
volume of the relevant literature were carried out using simple free-text terms. These 
were followed by a series of main searches using more elaborate search strategies. 
Strategies employed in main searches, listed in Appendix 1.A., consisted of combinations 
of key words, synonyms, term variants, expressions and indexing (MeSH) terms, and had 
a focus on sensitivity rather than specificity, in that they aimed to maximise the yield of 
relevant studies.  
In addition to searching electronic datasets using search strategies, ‘related article’ 
searches were carried out by using a built-in search feature available in MEDLINE 
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(PubMed portal). Such searches involved specifying key articles and retrieving 
publications related to these articles, identified through an algorithm that matches words 
in a key article with words in other articles’ titles and abstracts57. Further searches for 
relevant articles were carried out using citation searching techniques, where relevant 
references are sought by searching for articles that cite already identified key papers. 
Citation searching was carried out through the ISI Web of Knowledge platform and 
Google Scholar®. Searches were also carried out through scanning the reference lists of 
key articles as well as through general, free-text searches using the Google Scholar® 
engine. Further information was obtained through personal communication with 
employees in public and charitable research funding organisations (NIHR Health 
Technology Assessment, Efficacy and Mechanisms Evaluation, Cancer Research UK), 
official documentation, as well as from funding organisations’ websites.  
Searches were carried out in an iterative manner, in that, identifying an article and 
classifying it as a key source of evidence would trigger a new series of searches for 
articles cited by, and citing, this publication. Searches in databases using search strategies 
retrieved a total of 1285 unique articles (Appendix 1.A., Table 1.a) while additional 
searches (i.e. citation searching, related articles searches etc.) gave an additional 16 
references (Appendix 1.A, Table 1.b).  
2.1.2. Selection of studies 
Contrary to systematic reviews of effectiveness studies where inclusion is guided by 
specific requirements on the type of a study, in a methodology review there is a wealth of 
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different types of articles that may provide useful input, including letters, qualitative 
analyses and discussion papers53;58. In this review, all identified articles were considered 
against predetermined inclusion and exclusion criteria, irrespective of their type. Criteria 
were intentionally broad, to ensure that potentially useful material was not missed. 
Articles were included if:  
a. they described, discussed or proposed methods for identifying or setting 
priorities for evaluative research;  
and were excluded if: 
a. they were concerned with priority-setting in areas other than health care 
research, or 
b. they were concerned with priority-setting for basic or translational research. 
For pragmatic reasons, articles or textbooks published in languages other than English or 
Greek were not considered. The application of inclusion and exclusion criteria to the 
whole set of identified studies was conducted by one researcher (L. Andronis). In cases 
where inclusion or exclusion was unclear, a decision was made after discussion with the 
project supervisors Dr P. Barton and Professor L. Billingham.  
Selection of articles was carried out through a two-stage process. The first stage aimed to 
exclude clearly irrelevant papers and involved applying the inclusion criteria on the basis 
of each identified article’s title and abstract. Of the 1285 unique articles found, 1098 
clearly did not meet the inclusion criteria and were excluded. The remaining 187 were 
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articles that met the inclusion criteria, as well as papers for which an exclusion or 
inclusion decision could not be made on the basis of their abstract alone. These 187 
papers were deemed potentially relevant and were forwarded to the second stage. 
There, the full text of all of the 187 papers was obtained and assessed against the 
inclusion/exclusion criteria, resulting in 107 relevant papers being included in the review. 
Articles found through methods other than bibliographic database searches (i.e. ‘citation 
searching’, related articles searches, ‘reference list scanning’ and general internet 
searches) were considered for inclusion upon identification; such searches gave an 
additional 16 relevant publications. A flow chart showing the number of studies at 
different states of the identification and selection process is given in Appendix 1.A, Figure 
1.a.  
2.1.3. Quality assessment and data extraction 
In systematic reviews of effectiveness and cost-effectiveness studies, quality assessment 
aims to ensure that evidence from studies of poor quality is given a lower weight or it is 
filtered out53;59. In such reviews, good practice dictates assessing the quality of the 
considered studies by using published checklists60-63. In the present review, no articles 
were excluded on the basis of agreement with a quality checklist; nonetheless, in cases 
where methodological flaws were identified, these are explicitly highlighted and 
discussed. Useful information from included studies was extracted by one reviewer (LA).  
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2.2. Literature review results 
A total of 123 relevant articles were retrieved, the majority of which discuss the current 
‘state of play’ regarding research funding in different countries, comment on existing and 
proposed institutional arrangements, and examine mechanisms and criteria for setting 
priorities in research. Specific approaches to priority-setting are mentioned, reviewed, 
discussed or proposed in 29 of the identified articles. On the basis of this literature, the 
remainder of this chapter describes and discusses the main aspects of processes and 
approaches to priority-setting for research. The chapter closes with a description of 
specific priority-setting approaches identified in the literature. 
2.2.1. Need for priority-setting in evaluative research 
With regards to health care research, the term priority-setting is typically used to 
describe the outcome of an exercise aimed at prioritising and selecting research 
programmes for funding64-67. The necessity of identifying and setting priorities for 
evaluative research is evident and well documented in the literature65;68-71. Programmes 
such as the NIHR HTA Clinical Evaluation and Trials (HTA CET), the Efficacy and 
Mechanisms Evaluation (EME) and the CRUK Phase III Clinical Trial Grants receive a large 
number of proposals for research, of which only a small proportion can be funded. In 
2008, the NIHR Health Technology Assessment programme alone received 90 proposals 
for primary evaluative research, of which only about one-third28 studieswere 
supported40. Similarly, of the 75 outline proposals and 22 full proposals submitted to EME 
in 2009, only 12 received funding72.  
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Typically, priority-setting is required for specific research proposals; however, in some 
organisations, priorities also need to be set across research topics. Prioritising specific 
proposals is relevant to ‘researcher-led’ (reactive) programmes, where researchers are 
asked to submit proposals for applied research on topics of their choice42;46;48. On the 
other hand, priorities between topics are routinely set in ‘commissioned’ (proactive) 
programmes. In such programmes, decisions are needed about which of various topics to 
prioritise and commission research on40;45. Topics are typically identified through 
different ways, including consultations with institutes involved in making 
recommendations on the use of health technologies—such as the National Institute for 
Health and Clinical Excellence (NICE) in the UK—recommendations from organisations 
involved in the provision of health care services, direct consultation with patients and 
patient groups, as well as through ‘horizon scanning’ processes73-75.  
2.2.2. Approaches to priority-setting 
Once potential topics and proposals have been gathered, decisions need to be made on 
which of them should be funded. Such decisions require determining, explicitly or 
implicitly, the value of carrying out a proposed piece of evaluative research. Identifying 
the value of a research project is a necessary but complex task, which, in principle, 
requires a comparison between the benefits a research project is expected to bring about 
against its cost64;65.  
Within this context, prioritisation is typically ‘absolute’, in the sense that topics or 
proposals are judged on their own, rather than ‘relative’ where all considered proposals 
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or topics are compared against each other and ranked55;76-78[personal communication 
with Ms N. Reeve, research funding manager, Cancer Research UK, 31-03-2011]. Strictly, 
the distinction between absolute and relative prioritisation can be distorted by the fact 
that, when making absolute prioritisation decisions, it is possible that decision-makers 
may implicitly compare the proposal of interest against other proposals competing for 
funding.  
Two main approaches to determining the value of research in order to assist decisions 
around research funding allocation are discussed in the literature:  
a. ‘Deliberative’ approaches, which typically involve groups of experts and informed 
participants discussing and agreeing on the desirability of research in a 
deliberative and interpretive way64;66;71;79, and  
b. ‘Analytic’ approaches, which aim to calculate and provide numerical estimates of 
the expected benefits of research, typically by using statistical and mathematical 
techniques64;79.  
Deliberative and analytic approaches are discussed below, with regards to their main 
components and characteristics.  
2.2.3. Deliberative approaches 
Deliberative (or ‘subjective’80, ‘interpretive’79, ‘implicit’64) approaches are used 
extensively by public research funding organisations and medical research charities, 
including the NIHR HTA, MRC and CRUK40;44;49;81;82. Depending on the funding stream, 
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such approaches aim to assist in setting priorities between possible topics for research or 
specific research proposals. In such a process, experts seek to weigh the potential 
benefits of proposed research studies against their cost, with a view to agreeing on which 
of them should be funded [personal communication with Dr P. Davidson, Director of NIHR 
Evaluation Trials and Studies Coordinating Centre, 13-01-2012]. 
Although deliberative approaches are broadly similar, different arrangements have been 
proposed and are in place in different research funding organisations. Specific 
components depend on a number of factors, including the goals of the programme for 
which priorities need to be set, the type of research that the organisation focuses on and 
the allocation of responsibilities between this and other organisations which fund or 
undertake similar research65. The main characteristics of deliberative approaches are 
described below.  
2.2.3.A. Synthesis of decision-making panels and committees 
Panels deciding on research funding typically consist of representatives of groups that 
have an expertise in the topic, or a direct interest in the results of the funding process. 
Typically, these are decision-makers, researchers, health care professionals and 
representatives of research funding bodies40;64;68;82. There is an increasing argument for 
greater public involvement in the process as the public are potential recipients of the 
evaluated health care interventions. Indeed, research in Canada and the UK has 
highlighted that the public’s insights may assist in identifying important research 
questions83-85. The involvement of an interdisciplinary team including researchers, 
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decision-makers at local and central level, representatives of medical associations and 
patients has been also seen as a way to raise awareness of the value of the research 
programme and is expected increase the likelihood that research findings will be 
implemented65;79. 
2.2.3.B. Use of criteria 
More often than not, research proposals are discussed and assessed with reference to 
predetermined criteria41;76;78. Using criteria helps to ensure that research topics and 
proposals are judged against considerations which are relevant to the aims of funding 
organisations. Moreover, the use of criteria is seen as a means of ensuring that the 
priority-setting process is not reduced to a solely implicit judgement process and enables 
those tasked with making decisions to look at the proposals from a common 
viewpoint64;79.  
According to the identified literature, criteria should facilitate a comprehensive 
assessment of the proposal’s value, agree with the aims of the health care system and, at 
the same time, be relevant to the organisation which carries out the prioritisation 
exercise65;86-88. Criteria typically vary with respect to their intended use in the priority-
setting process. For decisions on prioritising topics for research, relevant criteria are 
focused on the importance of the topic and include considerations around:  
a. the burden of the disease or problem associated with the topic; 
b. the topic’s relevance to patients and the health care system, and  
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c. the extent of the existing uncertainty around the topic. 
On the other hand, at the stage where specific research proposals are assessed, criteria 
tend to concentrate on the proposals’ merits, by looking at:  
a. the scientific rigours of the proposal, including considerations about the 
robustness of the research plan and the feasibility of recruiting the necessary 
number of participants, and  
b. the ability of the team which submit the proposal to complete the proposed 
piece of research.  
Criteria used by main funding organisations with respect to relevant stages are given in 
Table 2.1. It is worth reiterating that these criteria are aimed at priority-setting for 
applied evaluative research, rather than for basic or translational research. Moreover, 
identifying the value of a research proposal requires judging the benefits expected from 
conducting research, rather than the benefits from the use of a technology under 
assessment. Although it is sensible to assume that a relationship exists between the 
benefits that may result from evaluative research on a technology and the benefits from 
the technology itself, this relationship is typically not straightforward65.  
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Table 2.1: Criteria for priority-setting used by selected research funding organisations 
 
Funding programme 
Criteria* 
Topic-related criteria Proposal-related criteria 
NIHR HTA
41;78
 Burden of the health problem 
 
Cost of the health problem 
 
Current uncertainty 
 
Urgency for assessment 
 
Cost of the treatment 
Scientific quality of the proposal 
 
Demonstration of the necessary skill mix, 
experience, project management and 
infrastructure for success 
 
Explanation and justification for 
estimated recruitment rates in primary 
research 
 
Ethical, legal and social implications of 
the research proposed have been 
considered 
 
Reasonable costs (value for money) 
EME
89
 Importance of the topic Scientific quality of the proposal 
 
Feasibility of the study 
 
Reasonable costs and value for money 
CRUK Phase III Clinical Trials 
Grant
48
 
Clinical importance of the 
research question 
 
Scientific importance of the 
research question 
 
Adequacy of background and 
preliminary data 
Strength of study design, including 
statistical design 
 
Expected interest/appeal to patients and 
likelihood of adequate accrual 
 
Anticipated opening for trial in portfolio 
* Reproduced from the NIHR HTA, EME and CRUK websites 
 
2.2.4. Analytic approaches 
The view that priority-setting for evaluative research would benefit from methods that 
generate explicit and quantifiable estimates of the potential value of research has driven 
the development of a number of analytic models64;90-92. Such models acknowledge that 
the primary objective of evaluative research is to inform treatment adoption decisions 
and, on this basis, they aim to identify the potential benefits of conducting such research. 
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The focus of these approaches is on evaluative research for existing treatments which 
have already been proven safe and potentially effective, rather than for trials carried out 
to assess treatments’ safety for regulatory purposes. 
Both prospective and retrospective analytic methods exist in the literature55;71. 
Retrospective methods estimate the benefits from research that has already been 
conducted and given results, and may be useful in assessing the impact of research 
funding93. On the other hand, prospective methods aim to infer the value of a research 
proposal by estimating the benefits that the proposal is likely to bring about before the 
study is considered for funding, with a view to guiding funding decisions. Given the 
above, the focus of this thesis is on prospective approaches.  
The literature search retrieved nine distinct prospective analytic models67;90-92;94-98. Three 
studies reporting literature searches for analytic approaches55;67;80 were also found. The 
available literature, including identified models and existing work on analytic approaches 
is described and discussed below.  
2.2.4.A. Weinstein’s model for priorities in cancer prevention  
In the early 1980s, Weinstein94 developed and published an analytic model aimed to 
guide priority-setting for research. The model’s specific objective was to determine which 
of two research programmes for identifying preventable causes of cancer should take 
priority: toxicological studies to identify possible carcinogenetics and limit human 
exposure to them, or epidemiological studies to improve the understanding of the impact 
of dietary agents on inhibiting cancer (a clinical trial on  -carotene). To answer this 
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question, the author94 set out to estimate ratios representing the total costs and the 
benefits associated with each of the proposed research programmes, and rank these 
ratios in order of magnitude. 
In this work, total cost was estimated as the sum of the costs of carrying out the study, 
although the cost of implementing the findings was not considered. As the aim of the 
studies in question was to prevent cancer mortality, benefits were measured in terms of 
avoided mortality under the assumptions that: a) carrying out each of the research 
programmes would establish the impact of carcinogenetics or dietary agents on cancer; 
b) research results would trigger changes in policy (e.g. industry regulations to reduce 
exposure to carcinogenetics, increased uptake of cancer-inhibiting dietary agents etc.) 
and c) changes in policy would have a beneficial impact on cancer prevention.  
In this model, Weinstein94 specified the magnitude of the possible effect that might be 
observed from each research programme, assumed a change in policy associated with 
observing those effect, and predicted the reduction in deaths due to the combination of 
observed effect and changes in policy. Separate analyses were carried out for each of the 
competing research programmes. The author concluded that conducting a trial to assess 
the benefits of  -carotene in preventing cancer is preferable to research on 
carconogenetics as it “offers a greater expected reduction in cancer mortality per research 
dollar”94[p.17]. 
Weinstein’s94 work is intuitive and follows a sequence of logical steps with regards to how 
research translates into benefits in the population. However, the model has limitations, 
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the most important of which relates to the fact that the occurrence of the events of 
interest, i.e. observation of study results, change in policy and health benefits accruing 
from this change, cannot be known in advance. Rather, these aspects must be treated as 
random variables, the occurrence of which depends on factors such as the prior 
probability of observing an effect (e.g. the probability that carcinogenetics trigger 
cancer), the ”sensitivity of the test system”94[p.18](i.e. the power of the research 
programme to detect a difference), the magnitude of change in policy in the light of 
research results, and the rate at which this change will translate into health benefits. As 
Weinstein94 admits, ambiguity around these aspects introduces uncertainty in the 
analysis and makes reliance to subjective guesses inevitable. 
Although relatively simplistic, this approach has been valuable in that it laid the 
foundations for a series of subsequent analytic models67. The influence of Weinstein’s 
early analytic model can been seen in other models, such as those by Eddy90, Detsky91;99, 
Drummond et al.100, Townsend and Buxton92, Davies et al.98 and Townsend and 
colleagues67. 
2.2.4.B. Eddy’s Technology Appraisal Priority-Setting System 
Six years after Weinstein’s work, Eddy90 introduced his Technology Appraisal Priority-
Setting System (TAPSS). This was developed in the context of work undertaken for the 
Institute of Medicine in the United States and its primary aim was to estimate the value 
of proposals for assessment in order to guide the Institute’s research funding agenda. 
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Similarly to Weinstein’s work94, the TAPSS model aims to predict the benefits which 
would accrue had a research project proposed to investigate specific technologies been 
carried out and provided information to guide the use of the technologies in clinical 
practice. Given this, if the research project is expected to lead to beneficial changes in 
clinical practice and additional benefits to the population, the study should be considered 
as a good candidate for funding. The model is partitioned into two main stages. The first 
stage predicts the possible effect of the research project on a single patient, while the 
second stage extrapolates this effect to the population. 
The starting point in Eddy’s90 work is the specification of results one would expect to see 
from research, which were termed ‘Delta results’. Delta results, according to Eddy90, must 
demonstrate some necessary features: they must a) be meaningful to practitioners, b) be 
mutually exclusive and collectively exhaustive, and c) must reflect the effect of the 
technology on relevant health outcomes. The approach makes the assumption that an 
assessment could result in one of two Delta results: a technology can be either effective 
or not effective. 
Following this, the model requires asking experts to predict the probability of observing 
each of the specified Delta results, as well as to forecast how clinical practice would 
change in the light of each result. The next step involves estimating the effect that each 
particular Delta result would be expected to have on an individual patient. For a typical 
individual and given a specific Delta result, this can be approximated by the difference 
between the benefits (e.g. survival improvement) expected to accrue to a patient who 
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receives an assessed technology and the benefits realised by a patient who does not 
receive this technology.  
Once the benefits of an assessment given a specific Delta result have been estimated, 
these can be used as a starting point for estimating the benefits likely to accrue to the 
whole population. This is found by multiplying the individual patient’s benefits by the 
number of people expected to be in need of the technology within a specified time 
period over which the results of the assessment are expected to be usable. Last, 
weighted, ‘expected’ benefits are estimated as the sum of the products of the benefit of 
the assessment given a specific Delta result, multiplied (weighted) by the probability that 
the assessment will show the specific result. On the basis of the calculated benefits, 
assessments can be ranked and prioritised in order of desirability90.  
To illustrate the principles of his work, Eddy90 used the TAPSS model to determine if an 
assessment of the cost-effectiveness of screening for maple syrup urine disease in 
newborn babies should take place. The study concluded that the predicted expected 
benefits from the study (0.17 severe retardations avoided per year) would justify 
devoting resources to it. 
2.2.4.C. Detsky’s model on the relationship between trial design, and costs and benefits of 
research 
A similar approach to TAPSS90 has been proposed by Detsky91;99, who developed a 
conceptual framework that relates the value of evaluative research to specific trial 
research design characteristics. The model makes a link between the cost of a study and 
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the possible benefits that might result from undertaking the study (in terms of health 
outcomes such as reduction in the risk of death), the latter expressed in the form of a 
frequency distribution. 
 In this model, the distribution of all possible health benefits is used in place of Eddy’s90 
‘Delta results’. In addition, Detsky91;99 goes a step further by accounting for the fact that 
the ability of an assessment to detect a real difference of a given size as significant (i.e. 
the power of a trial) is related to the number of patients taking part in the trial. On the 
one hand, larger sample sizes allow detecting a smaller minimum clinically important 
difference  , increase the chance of an effective intervention being detected as such, and 
are more likely to have an impact on clinical practice. On the other hand the larger the 
sample size, the greater the cost of the trial. On this basis, the model compares the cost 
required for obtaining more accurate information (i.e. the cost of increasing the trial’s 
sample size) against the potential benefits expected to arise from changing clinical 
practice according to the trial results. The comparison is expressed as a cost-effectiveness 
ratio.  
The application of the approach to seven randomised controlled trials showed that 
conducting each of these trials would be cost-effective, showing results which spanned 
from $2 to a maximum of $685 per life-year saved91. As expected, when the author 
changed the chosen minimum clinically important difference to a smaller value (i.e. when 
a larger trial was needed), the cost-effectiveness ratios increased substantially. 
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Detsky’s101 idea on the impact of trial design characteristics on the costs and benefits of 
research was subsequently taken forward by Coyle et al.102, who looked into the link 
between different values of the minimal clinically important difference   and ‘time-to-
payback’, representing the number of years until the benefits of a trial cover its cost. The 
work was based on a probabilistic model which aimed to predict the costs and survival of 
patients with colorectal cancer in two situations: with the trial being conducted and being 
followed by a change in clinical practice, as well as without the trial and no change in 
practice. The results confirmed that the ‘time-to-payback’ of an effectiveness trial varied 
with the selected level of statistical significance and the number of trial participants 
recruited. The authors found that, for a trial comparing minimal versus intensive follow 
up for patients with colorectal cancer involving 1000 participants, a change in the 
significance level from 5 percent to 1 percent led to a six-fold increase in the expected 
‘time-to-payback’ from 7 to 42 years.  
In summary, the proposed models91;99;102 expands on the methods found in previous 
work90;94. By considering how trial design characteristics impact on cost and benefits—the 
latter estimated as the benefits expected to arise from a beneficial change in clinical 
practice—this work is a useful addition to the existing literature, one that links the value 
of a trial with design choices.  
2.2.4.D. Retrospective analysis of the costs and benefits from a trial on diabetic 
retinopathy  
Drummond et al.100 set out to develop a methodology for assessing the societal costs and 
benefits resulting from medical research. The purpose of the model was to find out 
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whether the benefits arising from the Diabetic Retinopathy Study, a major and costly 
clinical trial supported by the National Eye Institute in the US, outweighs the cost of the 
trial. Although this model has been used after the trial was carried out, Drummond et 
al.100 point out that it can also be used prospectively to inform research funding 
decisions. 
The authors structured their model in line with decision analytic methods and followed 
the core steps outlined in Eddy’s TAPSS work90. In doing so, they specified two possible 
Delta results, ‘positive’ and ‘negative’, and structured their analysis in the form of a 
decision model (decision tree) assessing two states of the world: with the trial and 
without it. For each of these states, the decision tree showed the sequence of possible 
events, accumulated costs and benefits expected to accrue from a combination of a given 
result and its impact on clinical practice. Probabilities showing the likelihood of a patient 
following each of the different pathways were obtained from the actual trial. Using a 
societal perspective, the results of the study revealed that undertaking research would 
result in £27,800 per additional QALY at most.  
The authors100 recognised that predicting relevant parameters—such as the scale of 
change in clinical practice following the trial—is challenging. To address this, they used 
estimates from different sources including expert opinion, and tested different 
assumptions in the model in a series of sensitivity analyses. Drummond and colleagues’ 
model100 combines principles found in earlier models90;94 with methods commonly used 
in health economic evaluation. Although it does not avoid limitations seen in TAPSS-
based models, most notably the need to quantify the impact of trial results on clinical 
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practice, it improves on existing methods by introducing and employing commonly-used 
decision analytic structures.  
2.2.4.E. The welfare loss model 
An alternative model, based on different underlying principles, was proposed by Phelps 
and Parente95 and was subsequently updated by Phelps and Mooney103. The model is 
underpinned by the notion that variation in a health technology’s rate of use across 
different regions within the same country not explained by socioeconomic factors can be 
attributed to disagreement about the technology’s true efficacy. Owing to such 
disagreement, current use of a technology diverges from an optimal rate of use and this 
diversion results in a loss of welfare. Medical disagreement and welfare loss can be 
alleviated by evaluative research and technology assessment, as such studies can reveal a 
technology’s true efficacy. 
To illustrate their model, Phelps and colleagues95;103 estimated the welfare loss 
associated with the current use of a technology by using the following index: 
                 ∑   
   
      
       
Here,     represents the expenditure on technology   in region j,      is the coefficient of 
variations, in other words standard deviation of the current use of the technology divided 
by the average (assumed to be the optimal) use of the technology across regions, and    
is the change in the marginal welfare gain or loss as the use of the technology changes. 
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The index can be seen as a representation of the expected gain (expressed in monetary 
units) from carrying out research to alleviate welfare loss.  
The model was used to derive research priorities for research in the New York state95. 
The authors derived estimates of variations in the use of clinical interventions using 
Diagnostic Related Group in the state’s hospitals and found that priority should be given 
to evaluative research on health technologies tackling psychosis, chronic obstructory 
pulmonary disease and circulatory diseases, as these are areas of considerable variation 
in clinical practice and, consequently, large loss of benefits95;103. 
The proposed model provides an effective way of ranking candidates for assessments 
according to a measure of the ‘social need’ for research. Although the model can be 
easily operationalised by using information from hospital admissions across regions, 
there are limitations associated with it, most importantly the assumption that the 
appropriate level of a technology’s use can be approximated by the average rate across 
different regions55 and the fact that the study does not account for variations in use 
between hospitals within the same region. 
2.2.4.F. Townsend and Buxton’s prospective evaluation of a trial’s payback  
Townsend and Buxton92 developed a model for ex ante estimation of the potential 
returns of carrying out evaluative research and used it to estimate the possible 
implications of funding a large and costly clinical trial. Contrary to earlier retrospective 
work aimed to quantify the benefits from research and development spending104;105, 
Townsend and Buxton’s model was specifically tailored to assess the returns to research 
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prospectively, with a view to establishing whether a trial would be considered a good 
candidate for funding92.  
The model builds on ideas found in the work of Weinstein94;94 and Eddy90. In particular, it 
is based on the premise that carrying out research to assess the effectiveness and cost-
effectiveness of treatments is beneficial as it guides informed decisions about the use of 
technologies in clinical practice. Informed decisions bring about additional benefits to the 
population, in the form of health gains due to increased use of cost-effective treatments 
and reductions in the use of non-cost-effective treatments. These additional benefits are 
seen as a proxy for the value of conducting research, and can be measured as the 
difference between the benefits that would accrue if the proposed assessment took place 
and its results were used to inform clinical practice (‘factual state’), and the benefits that 
would be experienced in the absence of research (‘counterfactual state’). 
Carrying out a prospective assessment presents a main difficulty: the results of research 
and, consequently, the change in clinical practice following the results, cannot be known 
in advance. However, this is dealt with by specifying a number of possible research 
results, similar to Eddy’s Delta results90, termed “exemplar outcomes”92[p.184]. A wide 
variety of possible research results can be specified; however, for simplicity, Townsend 
and Buxton92 defined three broad outcomes: ‘positive’, ‘negative’ and ‘inconclusive’. On 
the premise that observing an exemplar outcome will trigger a change in policy, the 
authors92 specified a ‘positive’ outcome to lead to wider adoption and provision of the 
technology in clinical practice, while ‘inconclusive’ and ‘negative’ outcomes would result 
in no change and decrease in the use of the technology, respectively.  
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Carrying out research, observing an exemplar outcome and changing practice 
accordingly, the authors92 argue, brings about a stream of costs and benefits. For a given 
exemplar outcome, costs and benefits of the ‘factual’, (i.e. with research) state can be 
compared against the cost and benefits associated with the ‘counterfactual’ (i.e. without 
research) state. For each combination, the overall value of a study is given by the 
following formula:  
      
              
           
 
where     is the ‘cost-effectiveness’ of the proposal associated with exemplar outcome   
(i.e. ‘positive’, ‘negative’ or ‘inconclusive’),    is the discounted costs of the trial per se, 
      is the discounted costs associated with policy change in the light of outcome  ,        
is the discounted costs associated with no change in policy,       represents the 
discounted benefits associated with policy change in the light of outcome  , and        is 
the discounted benefits associated with no change in policy. 
To account for the fact that research results are not known in advance, each exemplar 
outcome was assigned a weight representing the likelihood of the particular outcome 
being observed. This allowed forming different combinations of outcomes, termed 
‘scenarios’. Values obtained for different scenarios gave a range within which the 
expected benefits of the study—expressed in terms of cost per unit of health benefit—is 
anticipated to fall. 
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Townsend and Buxton’s92 work was applied to a proposed trial of hormone replacement 
therapy (HRT), a promising treatment for alleviating menopausal symptoms in women 
which, as a downside, may be associated with greater risk of breast and endometrial 
cancer. A proposal for a trial was submitted for funding to the Medical Research Council 
(MRC). As the trial was expected to cost approximately £47 million, the MRC was 
interested in finding out whether this trial would be good use of the available resources.  
Following the sequence of steps described above, Townsend and Buxton92 estimated that 
conducting research and changing clinical practice according to its results would result in 
£240 (£1150 discounted) per additional QALY for an ‘optimistic’ scenario (i.e. greater 
weight given to ‘positive’ outcome), £160 (£770 discounted) per QALY for a ‘neutral’ 
scenario (i.e. equal weight to all scenarios) and £55 (£260 discounted) per QALY for a 
somewhat ‘pessimistic’ scenario (i.e. higher weight to ‘negative’ results).  
Townsend and Buxton’s model appears more comprehensive and refined than earlier 
models90;94. Nonetheless, similarly to previous work90, the model requires a large amount 
of empirical data in order to be operationalised. As the authors92 acknowledge, such data 
may not be readily available for many technologies, in which case empirical evidence will 
have to be substituted by expert opinion. Townsend and Buxton’s model represents a 
useful addition to the existing analytic approaches, one that appears to strike a balance 
between practicality and comprehensiveness.  
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2.2.4.G. ‘Value of information’ analysis to inform research funding decisions 
In the mid-1990s, Claxton and Posnett97 proposed ‘value of information’ (VoI) as an 
alternative tool for assessing the need for, and the value of, conducting research. The 
framework follows the principles of statistical decision theory106-108 and is applicable to 
situations where choices need to be made between alternative courses of action which 
are expected to result in uncertain payoffs.  
The approach is directly applicable to treatment coverage and research funding decisions 
in health care. As Claxton97 explains, decisions on treatment adoption are typically 
uncertain as the relevant payoff (here, health benefits accruing to the population) from 
adopting a treatment over another is not know with certainty. However, decisions are 
still needed and it has been argued that a treatment should be provided if, based on 
available evidence, it appears superior to its alternatives97;109. However, making decisions 
under uncertainty (or, put differently, under imperfect information) is expected to result 
in an opportunity loss: the loss of benefits due to adopting a decision which may turn out 
to be suboptimal and depriving the population of a more beneficial treatment. VoI 
analysis can be conducted to assess the expected loss of benefits due to making a 
decision under uncertainty and establish the expected value of acquiring better 
information through research, in order to minimise this loss97.  
Results of VoI analysis can be used as a criterion to establish whether conducting further 
research would be worthwhile110, thus the approach has become prominent as a means 
of assessing the need for further research111-114, with a number of economic evaluation 
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studies being complimented by VoI. The rationale, methods and concepts in VoI analysis 
are explained in more detail in Chapter 3.  
2.2.4.H. Davies and colleagues’ prioritisation model for the NHS HTA 
Davies and colleagues98 proposed their Economic Prioritisation Model to assist the NIHR 
Coordinating Centre for Health Technology Assessment (NCCHTA)(now NIHR HTA) select 
and prioritise health technology assessment studies. The model aimed to inform 
decisions at the stage of shortlisting candidates for assessment on the basis of evidence 
from ‘vignettes’, that is, summaries of available evidence on a specific topic. In addition 
to providing useful information to decision-makers, this work aimed to identify critical 
factors which determine the extent of the expected costs and benefits that might result 
from specific assessments.  
The model is based on the principles introduced by Eddy90 and builds upon earlier work 
by Drummond et al.100 on the retrospective quantification of the costs and benefits 
expected to result from an assessment. The analysis involves a series of steps, including 
specification of possible Delta results and probabilities of the assessment showing a 
specific result, specification of the likely change in clinical practice in terms of future 
utilisation of the technology under assessment, and estimation of the costs and benefits 
for each Delta result. The extent of future utilisation, Davies et al.98 point out, is affected 
by a number of factors, the most important of which are whether the assessment is 
exploratory (i.e. primary assessments aimed at answering questions not previously dealt 
with in rigorous studies) or confirmatory, (i.e. assessments for which a reasonably high 
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volume of evidence exists), the effectiveness of the result dissemination, the likelihood of 
new, competing technologies emerging, and the expected time horizon over which the 
technology under assessment is expected to be used.  
The model98 was used to estimate the expected costs and benefits of a series of 
assessments commissioned by the Pharmaceutical panel of the NCCHTA in 1997 and 
1998. Analysis could not be undertaken for 20 percent and 40 percent of the assessments 
considered in 1997 and 1998, respectively, due to lack of complete clarity on the topic, 
interventions or patient groups of interest. However, for topics for which analyses could 
be conducted the available data were sufficient to give base case estimates of expected 
costs and benefits.  
The analysis underlined the difficulty in making safe conclusions about the potential costs 
and benefits of an assessment; for approximately 58 percent of the assessments 
considered in 1997 and 73 percent of the assessments considered in 1998, the estimated 
results from the model were highly uncertain, spanning from net savings to net costs. 
This work98 also showed that key determinants of the results were the additional cost of 
the assessed technology as compared to usual care, the likely levels of utilisation and the 
probability of the assessment finding a technology to be effective. The authors’98 
conclusions follow from the result of the study: at the stage where topics are considered 
for prioritisation, predicting the absolute values of the costs and benefits associated with 
the assessment is challenging. However, obtaining an estimate of the potential costs and 
benefits by carrying out an ex ante assessments is still plausible and can be of value to 
decision-makers.  
41 
2.2.4.I. The Preliminary Assessment of Technology for Health Services model 
In an attempt to address limitations found in earlier models90;92;97;100;101, Townsend and 
colleagues67 developed and published their Preliminary Assessment of Technology for 
Health Services (PATHS) work. The PATHS model aimed to predict the additional benefits 
expected from conducting research on a specific topic, with a view to assisting research 
funding decisions. According to the authors67, the model can be used at two levels: at the 
‘topic’ level, to make recommendations on whether a specific technology or topic is 
worth evaluating, or at the ‘research proposal level’, to help with funding decisions 
around specific study proposals.  
The model appears to expand and refine Townsend and Buxton’s earlier work92. In brief, 
the model involves specifying alternative results that might be revealed in a clinical trial 
(‘favourable’, ‘unfavourable’ and ‘inconclusive’ for the treatments under assessment) 
and, for each of these results, it estimates the costs and benefits associated with two 
different states of the world—with and without evaluative research taking place. Possible 
research results are attached probabilities reflecting their likelihood of occurrence 
(weightings) and form a series of combinations.  
For each combination, a measure of the expected benefits of the trial is obtained, in the 
form of the Expected Incremental Cost-Effectiveness Ratio (EICER), which shows the cost 
for an additional unit of benefit. EICER values can be used to provide a plausible interval 
within which the expected benefits of the proposal is expected to fall and can be 
compared against decision-makers’ threshold values. According to the authors67, by 
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providing estimates of the possible returns from different research proposals, the model 
can help research funding organisation to allocate the available budget in a more 
transparent and efficient way. This model is looked at more closely in the next chapter.  
2.3. Main analytic frameworks 
Analytic models identified in this review followed three distinct methodologies and, on 
this basis, they were classified into different frameworks. Models following the rationale 
found in Weinstein94 and Eddy’s90 work have been collectively termed “direct 
assessments of the cost-benefit of research”55[p.37] or, more commonly, ‘payback of 
research’55;80;110. Seven models are classified under this framework67;90-92;94;98;100, all of 
which are underpinned by the notion that the value of evaluative research can be 
inferred by the benefits that this may bring about through changing clinical practice.  
The second framework is ‘value of information’ (VoI). This method, adapted to the 
specific context of health care decision-making in the mid-1990s97;115, is based on the 
notion that the value of research can be measured in term of reduction in uncertainty 
and improved decision-making. Last, the ‘welfare loss’ framework,laid out in Phelps and 
colleagues’ work95;103, aims to determine broad areas where research is needed. While 
this work can show which clinical areas would benefit from more research, its usefulness 
in identifying the benefits from conducting evaluative research in specific topics or 
proposals is deemed limited80;110.  
The interest in the present work is in the prospective ‘payback’ and ‘value of information’ 
(VoI) frameworks, which represent the two most prominent analytic frameworks 
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proposed to assist research priority-setting55;80;116. VoI and the latest ‘payback’ model, 
PATHS67, are described in more detail in the following chapter.  
2.4. Existing literature on ‘payback’ and ‘value of information’ 
Two publications looking at ‘payback’ and VoI with a view to contrasting and assessing 
the approaches were identified. Chilcott et al.55 published a review of the use of 
modelling in designing and prioritising clinical trials. As part of this review, the authors 
searched the literature for analytic approaches proposed to provide numerical estimates 
of the benefits of conducting clinical trials. Their work identified models published up to 
1999, which were grouped into two categories: those based on Eddy’s90 direct 
assessment of the cost-effectiveness of research (including the models by Eddy90, 
Detsky91, Drummond et al.117, Buxton et al.104, Townsend and Buxton92, and Davies et 
al.118), and those based on Bayesian expected value of information. At the time the 
review was published, the most recent model discussed118 was a precursor of the Davies 
et al.98 model, thus, for pragmatic reasons, the most comprehensive study following the 
‘payback’ methodology—the PATHS model67—was not discussed or assessed.  
As the purpose of Chilcott and colleagues55 was to review the literature and give 
indications of the methodologies available, no practical application of ‘value of 
information’ and ‘payback’ on case studies was conducted. However, some conclusions 
were drawn, on the basis of existing applications of ‘payback’ and VoI in the literature. 
The authors found the methodologies underlying ‘payback’ and VoI to be intuitive, logical 
and coherent, but they also highlighted potential limitations of the frameworks. With 
regards to ‘payback’ based methods, the authors55 stressed the subjectivity in the choice 
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of possible research outcomes and likelihoods for specified outcomes, and indicated that 
there is a need for the impact of such choices to be explored through sensitivity analysis. 
As far as VoI is concerned, the authors55 praised the framework’s potential to help with 
research design decisions, but also highlighted the fact that the framework appears to be 
more complex than ‘payback’. In addition, Chilcott et al.55 suggested more research to 
address the fact that, at the time the review was published, VoI results failed to account 
for the recognition that adoption decision are typically no implemented perfectly. 
Overall, the authors felt that analytic approaches have the potential to help in priority-
setting and predicted a growing interest in analytic approaches in the future. 
The second study119, authored by Fleurence and published in 2007, aimed to “provide a 
practical application between two different methods, ‘payback’ and EVI [value of 
information] that have been proposed to set priorities in research”119[p.1346]. To this end, 
the application made use of case studies in the form of three trials in the area of 
osteoporosis and one trial on pressure ulcers. Interventions considered in these trials 
were provision of hip protectors and prescription of vitamin D and calcium against 
osteoporosis and provision of alternating pressure mattresses in pressure ulcers. The 
application of the methods was facilitated by two decision analytic model, which were 
constructed for each of these disease areas.  
For the application of ‘payback’, Fleurence119 used the latest available model (PATHS67). 
In doing so, and in line with previous applications of PATHS67, the author specified three 
alternative scenarios: positive, inconclusive and negative. The clinical effectiveness of the 
interventions of interest (expressed as relative risk of experiencing an event (e.g. 
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fracture)), the change in clinical practice with and without the trial and the likelihood of 
observing the specified effectiveness in the trials were based on the author’s 
assumptions. Results, in terms of net monetary benefits, were first expressed in a non-
weighted form—effectively assuming that each outcome had the same probability of 
occurring—and they were subsequently weighted by different likelihood weights, forming 
an optimistic, neutral and pessimistic combination. Details on these practical 
applications, including a description of the specified possible results and hypothesised 
change in clinical practice are given in given in Appendix 2.B, Table 2.d.  
For the ‘value of information’ analysis, Fleurence80 used the simulated results of 
probabilistic sensitivity analyses undertaken as part of the osteoporosis and pressure 
ulcer models to look into the expected value of perfect information (EVPI) associated 
with further research in the investigated areas.  
The results of the ‘payback’ application suggested that the assessed trials in osteoporosis 
(RECORD, Vitamin D/Calcium trial and Hip Protector trials) were expected to be cost-
effective under the assumptions made about their possible outcomes, whereas the trial 
in pressure ulcers (Pressure trial) would be beneficial only if the assessed intervention 
(i.e. alternating pressure mattresses) was found to be effective (i.e. under a positive 
outcome). EVPI results suggested that all trials were associated with net monetary 
benefits in excess of the cost of the trial, making these trials potentially cost-effective 
investments. With regards to the methodologies per se, Fleurence119[p.1350] suggested that 
“‘Payback’ provides a method to assess the cost-effectiveness of specific research designs, 
while EVI [value of information] makes inferences concerning a wider range of potentially 
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relevant parameters, including interventions and study population that would be found in 
specific research designs, such as clinical trials”. According to Fleurence119, both ‘payback’ 
and VoI can be used by funding organisation to assist decisions on which proposed trials 
to fund while, in addition, VoI methods can help with research design and decisions about 
which interventions to research within a given disease area. The author highlighted 
potential problems around the feasibility of carrying out ‘payback’ and ‘value of 
information’, and drew attention to later method’s inability to account for imperfect 
implementation.  
2.5. Need for extension in existing evidence 
Fleurence’s study119 is novel in that it looks into ‘payback’ and VoI by applying the 
approaches to case studies of proposed trials. As such, it serves as a starting point for 
additional work to build on this study, with a view to providing a more comprehensive 
assessment of the frameworks.  
A shortcoming of Fleurence’s study119, and, at the same time, an opportunity for further 
work, is that ‘value of information’ analysis in the paper includes only an assessment of 
the expected value of perfect information (EVPI). While EVPI is an important concept, it is 
usually seen only as the starting point in VoI analysis, which is typically furthered to 
include expected value of perfect parameter information (EVPPI)120;121 and, if possible, 
expected value of sample information (EVSI) analyses115;122. In a recent publication, 
Eckermann et al.123 consider EVPI conducted on its own to provide only limited 
information, and stress that the full potentials of VoI can be only realised by conducting 
EVPPI and EVSI analysis. In addition, as Fleurence’s119 work was carried out and published 
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in 2007, it could not take into account recent advances related to the value of 
implementation. Recent work on value of implementation124 is, nonetheless, important, 
as it aims to address an issue often portrayed as a ‘soft spot’ of VoI, and aspires to 
strengthen the case for its use in decision making.  
With reference to the methodology for conducting ‘payback’ analysis, there also appears 
to be room for further work on aspects related to carrying out ‘payback’ analysis for trials 
assessing more than two treatments. In Fleurence’s study80, as explained in Chapter 6, 
the employed assumptions when comparing multiple treatments is that more than one 
treatment can be cost-effective at the same time. This assumption underpins the 
‘payback’ calculations for the RECORD case study which compares four treatments, but it 
is nevertheless weak, as, in a comparative analysis, only one of the assessed treatments 
may represent the most cost-effective option31;125. 
These limitations have important consequences. First, without an assessment of all the 
relevant VoI concepts (including EVPPI, EVSI and value of implementation) a discussion 
around the strengths, weaknesses and potential of the framework is bound to be 
incomplete. In addition, by not undertaking more complex and potentially time 
consuming analyses (EVPPI and EVSI) (see Ch.8, section 8.5 for a discussion of time and 
expertise required for undertaking these analyses), it is difficult to draw reliable 
conclusions about the feasibility of undertaking ‘payback’ and VoI analyses.  
Given the above, the present study seeks to extent the existing literature by undertaking 
a comprehensive analysis of ‘payback’ and VoI, one that a) accounts for recent advances 
in the methodologies, b) includes all the relevant concepts consisting the frameworks, 
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and c) looks into the value and potential role of the frameworks from different 
viewpoints that are considered relevant to research funding organisation. In this way, this 
work aims to provide a more spherical assessment of the frameworks and a more 
complete discussion of their potential role and value in research priority-setting. 
2.6. Discussion 
Two main approaches to priority-setting were identified and described in this chapter: 
deliberative and analytic. The main characteristics, similarities and differences of these 
approaches are summarised in Table 2.2.  
A key difference between ‘deliberative’ and ‘analytic’ approaches relates to the principles 
underpinning each of them. In ‘deliberative’ approaches, decisions on whether a 
proposed piece of research should be funded are made by appointed experts through a 
process involving deliberations about the need for research and the value of the 
proposed research programme. On the other hand, ‘analytic’ approaches aim to 
introduce an element of objectivity, by advocating a framework where research funding 
decisions would be made on the basis of explicit information on the value of research. 
Given this, in ‘deliberative’ approaches the value of a proposal is inferred through 
discussion with the help of pre-determined criteria, whereas, in analytic approaches, the 
value of research is inferred directly from the benefits that the programme is expected to 
produce, which are calculated by following specific methodologies.  
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Table 2.2: Summary of main characteristics of deliberative and analytic approaches 
 
 Deliberative approach 
Analytic approaches 
‘Payback of research’ ‘Value of information’ 
Underlying 
principle 
Judgements on the desirability of 
proposed research made by 
appointed experts on the basis of 
deliberations about the value of 
the proposed research programme. 
Judgements on the desirability of proposed 
research should be made on the basis of explicit 
numerical calculation of the benefits expected 
from conducting a proposed research study. 
Estimation of 
potential 
benefits of 
research 
Implicit, through discussion and 
deliberations. Discussion is typically 
guided by pre-determined criteria. 
Explicit quantification of 
potential benefits, 
through calculations that 
link possible results of 
research to change in 
clinical practice and 
subsequent benefits to 
the population. 
Explicit. Through the 
calculation of the 
expected gains from 
reduction in decision 
uncertainty. 
Decision rules Fund research which appears 
useful in light of expert opinion 
(panel and reviewers) with 
connection to specific criteria 
Estimate the cost and benefits of research. 
Recommend research which results in net benefits 
(benefits obtained for a value lower than a 
hypothetical willingness to pay for these benefits) 
Current use Widely used in decision making, by 
public research funding 
organisations and medical research 
charities. 
Not used at present 
Proposed use  Proposed as an 
additional consideration 
for research funding 
decisions, alongside 
other relevant criteria
67
. 
Proposed as a 
‘criterion’ for research 
funding decisions. 
Research proposals 
which do not meet the 
necessary conditions 
should be ruled out
120
 
 
In relation to decision rules, ‘deliberative’ approaches advocate prioritising proposals that 
appointed experts consider to perform well against predetermined criteria. Typically, 
such criteria relate to the need for research in the area, the scientific rigour of the study 
and the ability of the research team proposing the study to complete it successfully. On 
the other hand, analytic approaches advocate decision rules which are underpinned by 
economic principles, suggesting that an activity—here, a programme of evaluative 
research—should be undertaken if it is expected to result in net benefits. In this context, 
net benefits arise when the monetary value of a unit of health benefit (such as a quality-
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adjusted life year (QALY), exceeds the amount which society or decision-makers are 
willingness to pay for this benefit.  
While ‘deliberative’ approaches are commonplace, analytic approaches are not formally 
used by funding organisations. Suggestions on the use of the most prominent analytic 
frameworks, ‘payback’ and VoI, appear to converge towards use of ‘payback’ and VoI 
results alongside other criteria, which may be deemed relevant by the organisations 
tasked with making funding decisions67;120. 
Deliberative and analytic approaches present specific strengths and limitations. The 
former have been seen as fairly uncomplicated to undertake66 and appear to allow a 
quick turnover of results, which is an important strength when timely decisions on 
funding research are needed. In addition, deliberative approaches make use of informed 
views of panel members who typically have an expertise on the topic for which research 
is proposed as well as a thorough understanding of the research needs in this area. Last, 
decision-making based on criteria and deliberations gives funding bodies the flexibility to 
pursue objectives considered important to them. On the other hand, decisions reached 
using deliberative methods are, to a great extent, subjective as they depend largely on 
panel members’ judgements. Indeed, under such arrangements decision-making may be 
affected by the synthesis of the panel and committees, which increases the risk that 
decision may be based on the views of panel members who are more vocal during the 
discussion, and raises the possibility that the views of members absent from the 
discussion may be overlooked79.  
51 
These limitations, together with the acknowledgement that the allocation of research 
resources should be based on explicit evidence on research proposals’ costs and 
benefits90;100, have led researchers to develop analytic methods90;100. Such methods have 
been seen as a promising means of improving the transparency and explicitness in 
research priority-setting71. As Donaldson and Sox64[p.67] point out, analytic approaches are 
“open to review and accountability, and are amendable to examination and adjustment 
not only of the results but of the methodology itself”. Given this, analytic models appear 
to have the potential to offer greater reassurance as to whether research funding is 
allocated in an efficient way55;64;65.  
However, analytic approaches also have limitations. First, they are usually resource-
intensive, in the sense that they require more time and effort than deliberative 
approaches55;64. As a consequence, the additional time that analytic methods may require 
to give results may delay funding decisions and lead to delays in research. In addition, 
due to their nature, such approaches have been seen as ‘mechanistic' and, because of 
this, decision-makers might be reluctant to use results from such approaches as a basis 
for decisions64;110. The extent to which the benefits from the use of analytic approaches, 
in terms of improved transparency and efficient decision-making, compensate for these 
drawbacks is unclear. 
2.7. Chapter overview 
This chapter reports the results of a review carried out to identify approaches to priority-
setting for research. Two main approaches aimed at guiding research funding decisions 
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were distinguished: deliberative approaches, which involve discussing research topics and 
proposals on the basis of their merits according to predetermined criteria, and analytic 
approaches, which aim to infer the value of proposed research studies by quantifying the 
potential benefits that research may bring about. Strengths and limitation of each of the 
approaches were discussed drawing on published literature. 
Nine analytic models were identified. With the exception of Phelps and colleagues’ 
‘welfare loss’ work95;103, the models were classified in one of two overarching 
frameworks: ‘payback of research’ and ‘value of information’. The principles, methods 
and identified applications of these frameworks are the focus of the following chapter. 
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CHAPTER 3. ‘Payback of research’ and ‘value of 
information’ 
The previous chapter identified nine analytic models and classified them into two 
overarching frameworks: ‘payback of research’ and ‘value of information’ (VoI). Both 
‘payback’ and VoI make extensive use of methods used in economic evaluation of health 
care technologies, thus the first part of this chapter introduces and describes central 
concepts in economic evaluation. The second part of the chapter aims to provide an in-
depth description of ‘payback’ and VoI, by drawing on the existing literature.  
3.1. Economic evaluation of health care technologies 
In order to improve and maintain the health of the populations they serve, health care 
systems around the world provide a range of technologies and treatments. In publicly-
funded health care systems with constrained budgets, decisions are often needed about 
which treatments should be covered financially and provided to the population.  
Such decisions, it is acknowledged, need to be informed by evidence on treatments’ costs 
and health benefits8;31;126;127. Such evidence is routinely produced by economic 
evaluations, which are systematic comparisons of alternative technologies, interventions 
and treatments in terms of their cost and consequences31. Depending on the nature of 
the treatment, costs may include expenditure for obtaining or implementing the 
treatment itself, related use of hospital and community services, related personal 
expenditures and, in some cases, costs due to productivity loss31;128;129. Consequences are 
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typically health-related and can be expressed in monetary, natural or quality-adjusted 
units31;130. 
The rationale for the use of economic evaluation to inform resource allocation is based 
on two paradigms: the ‘welfarist’ approach, under which evaluations determine the 
relative desirability of different resource allocations on the basis of individuals’ 
utility128;131, and the ‘extra-welfarist’ or ‘social decision-maker’ approach where 
appointed decision-makers decide what actions should be pursued in order to maximise 
socially desirable attributes—most importantly health132;133. The nature of the question 
to be addressed and the way consequences are measured determine the choice between 
separate—but arguably similar—techniques of economic evaluation134;135. 
3.1.1. Cost-benefit analysis  
In line with principles of welfare economics, judgments on whether an activity (e.g. 
reimbursement and provision of a treatment) should be undertaken ought to be made 
with reference to whether its outcomes will contribute towards improving society’s 
welfare128. Such judgements target allocative efficiency questions and can be informed by 
cost-benefit analysis (CBA), a technique that expresses the costs and benefits associated 
with an activity in monetary terms132;136. 
Valuing both costs and benefits in monetary terms allows a comparison between an 
activity’s input (costs) and output (in the specific context, health benefits). If the health 
benefits expected to arise from the activity exceed its costs, the activity will result in ‘net 
social benefits’ and is worth undertaking. While costs can be easily measured in monetary 
55 
terms, obtaining a monetary valuation of health benefits is more complex and it requires 
translating health improvement into increased productivity according to wages (using the 
human capital approach)128, or by eliciting peoples’ willingness to pay for those benefits 
through observing their ‘stated’ and ‘revealed’ preferences130;137.  
Despite this technique’s firm foundations in welfare economics, its use in economic 
evaluation has been limited, to a great extent due to practical and ethical difficulties with 
valuing health and health benefits in monetary terms135;138. 
3.1.2. Cost-effectiveness and cost-utility analyses  
Whilst CBA can be used to answer questions on whether an activity is worth undertaking, 
cost-effectiveness analysis (CEA) can show which of competing activities should be 
undertaken if the aim is to achieve a given level of output (for example, health benefits) 
from the least input, or, equivalently, to achieve the greatest output out of a given level 
of input. In this respect, CEA is appropriate for addressing questions of technical 
efficiency135. Tackling such questions requires measuring each activity’s costs in terms of 
monetary units and benefits in terms of relevant natural units, which, for instance, may 
be years of life saved, cases detected or episodes avoided139. 
CEA involves pair wise comparisons between two or more treatments and its results are 
commonly expressed as an incremental cost-effectiveness ratio (ICER), a measure which 
represents the difference in costs between two compared treatments, over the 
difference in benefits between these treatments. As an example, if the comparison is 
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between a commonly used treatment A and an alternative, more costly and more 
effective treatment B, CEA results can be expressed in terms of the following ICER: 
        
             
                              
 
     
     
 
In this case, the ICER represents the additional cost of obtaining an additional unit of 
health benefit. A special form of CEA is cost-utility analysis (CUA)31;128;130. The defining 
difference between CEA and CUA is that the latter measures benefits in terms of units 
which combine length of life in a health state with people’s preference for this state. The 
most commonly used measure in CUA is the quality-adjusted life year (QALY). A QALY 
represents the equivalent of one year of life in full health and is calculated by weighting 
the period of time a person spends in a particular health state by the health-related 
quality of life (HRQoL) he or she experiences during this period. Typically an individual’s 
HRQoL is estimated by obtaining a description of his/her health state and valuing this 
state according to the individual’s140 or society’s141 preferences for it. Cost-effectiveness 
and cost-utility analyses are widely used to inform treatment coverage decisions in a 
number of countries14, including England and Wales114, Australia8 and Canada127. 
3.1.3. Cost-minimisation and cost-consequence analyses 
 A further form of economic evaluation is cost-minimisation analysis (CMA). The method 
is seen as a special case of CEA and has been considered appropriate in analyses where 
treatments are perceived to be of equal or equivalent effectiveness31;142. Given this, the 
comparison in CMA is in term of costs, with the less costly treatment being seen as 
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preferable. Although in theory CMA is a simpler version of CEA, in practice the situations 
where the use of CMA may be appropriate are rare. This is because, as Briggs and 
O’Brien143 explain, the uncertainty surrounding estimates from sample studies such as 
clinical trials means that failure to detect a difference between treatments’ effectiveness 
may be mistakenly perceived as a proof of equivalence, in which case CMA would lead to 
spurious conclusions143.  
Last, an economic evaluation can take the form of a cost-consequences analysis (CCA). 
This technique aims to address scepticism about combining results into a single number 
(e.g. cost per QALY) and its distinctive characteristic is that it presents results in a 
disaggregated way, typically in the form of a table documenting the costs and 
consequences associated with a treatment31;144. In CCA, no attempt is made to synthesise 
the available information into a unique number; instead decision-makers are left to 
interpret the information and assign their own values to the costs and consequences 
associated with the assessed treatment. This characteristic makes CCA an attractive 
approach as it is simple, consistent with the ‘welfarist’ roots of economic evaluation144 
and avoids assumption made in the process of constructing a single outcome130. 
However, the approach has been criticised on grounds that, by leaving interpretation and 
valuation of the results to decision-makers, it may allow room for unclear or arbitrary 
rules to enter the decision-making process125. 
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3.1.4. Decision rules in economic evaluation 
The primary aim of an economic evaluation is to inform resource allocation decisions. To 
this end, its results need to be interpreted clearly, using unambiguous decision rules. 
Decision rules for judging the results of economic evaluations differ across techniques. In 
CBA, the decision rule is relatively straightforward: if the benefits (valued in monetary 
terms) associated with a treatment exceed its cost, the treatment is expected to result in 
‘net benefits’ and should be provided128;135. 
On the other hand, CEA and CUA results can determine whether a specific treatment 
compares favourably to its best alternative, that is, whether it provides the same benefits 
for lower cost or more benefits for the same cost. However, CEA results cannot 
determine whether a treatment is worth undertaking, especially when there is a trade-off 
between increased costs and increased health benefits (and vice versa). This issue can be 
addressed by attaching a monetary value to a unit of health benefit. Such a value, often 
called the ‘cost-effectiveness threshold’ or ‘ceiling ratio’commonly denoted by   )has 
been seen as the decision-maker’s or society’s willingness to pay for an additional unit of 
benefit (or willingness to accept as compensation for a unit of benefit forgone)128;139. 
Both theoretical145 and empirical ways146 of establishing the value of   have been 
suggested but no consensus exists over how the ceiling ratio should be set147 and who 
should be responsible for setting such a value148. 
According to the decision rules used in CEA and CUA, if treatment B is more expensive 
and more effective than treatment A: 
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Equivalently, if treatment B is less expensive and less effective than its comparator, the 
decision rule would be reversed:  
                                                       
Here,       and       represent the difference in costs and effectiveness between 
treatments A and B, respectively. If treatment B is less effective and more costly, the 
treatment is deemed not to be cost-effective, while if treatment B is more effective and 
less costly that its comparator, treatment B is considered as cost-effective.  
Despite the usefulness of the ICER as a summary measure of cost-effectiveness, being a 
ratio means that it has some undesirable mathematical and statistical properties which 
hinder analysis and presentation of results115;149;150. As a response, researchers have 
suggested a simple re-arrangement which incorporates the ceiling ratio   and allows CEA 
and CUA results to be presented in a tractable, linear form115;151. In this, the standard 
measure of cost-effectiveness and the decision rule are combined to give the Incremental 
Net Monetary Benefit (INMB) formulation: 
                           
Here, positive INMBs indicate that treatment B is cost-effective. Decomposing the above 
formula to consider the average net benefits associated with specific treatments gives: 
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Here,    and    represent the effectiveness associated with treatments A and B, and    
and    are the costs of treatments A and B, respectively. Presenting the results of CEA 
and CUA analyses in this way offers significant advantages over ICERs: it provides an 
easier interpretation of the results of analyses where multiple treatments are 
compared152, offers a tractable estimate of the variability in the results150 and 
circumvents problems associated with the interpretation of ratios153. 
3.1.5. Decision analytic modelling for economic evaluation 
In relation to the analytic methods they employ, cost-effectiveness and cost-utility 
analyses are often distinguished between trial-based and modelling studies154;155. The 
former studies are carried out to analyse evidence obtained from a single clinical 
trial155;156, while the latter synthesise evidence from many sources by using analytic 
structures157. Limitations around evidence produced by a single study as well as the 
recognition that all available evidence needs to be taken into account have led health 
economists and decision-makers to regard modelling studies as the preferable framework 
for synthesising evidence and informing decision-making158-160.  
Decision modelling is an integral part of decision analysis107 and, apart from in health 
care, it has been successfully used in different disciplines including engineering, 
environmental risk analysis and operational research161-163. Brennan et al.164[p.1296] define 
a model-based analysis as “a formal comparison of health technologies, synthesising 
sources of evidence on costs and benefits, in order to identify the best option for decision-
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makers to adopt”. In the context of health care, results of models are routinely used in 
treatment coverage decisions by the National Institute for Health and Clinical 
Excellence160;165, which sees modelling as “an important framework for synthesising 
available evidence and generating relevant estimates of clinical and cost-
effectiveness”114[p.42]. 
Different types of decision analytic models exist, the most common of which are decision 
trees, Markov models and individual sampling models157;166;167. The main stages in 
modelling are depicted in Figure 3.1. 
 
Figure 3.1: Steps in decision analytic modelling 
 
The first step in modelling requires defining the question to be answered. This typically 
involves specifying the clinical area, the population of interest and the treatments to be 
Develop model structure 
Populate model with evidence and characterise uncertainty 
Specify decision problem and available actions 
Generate and present results 
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assessed. Once the decision problem and the comparators are specified, a choice is 
needed on the type and structure of the model. In choosing the appropriate type, 
pertinent considerations include, amongst other, the existence of interactions between 
affected individuals168, the importance of time164 and the availability of cohort 
information164;166. In addition, the model structure should allow a valid representation of 
the natural clinical progression of the disease in question, one that takes into account the 
particularities of the decision problem, that is whether the disease is acute or chronic, 
whether the options under comparison are diagnostic or therapeutic and whether the 
risk of experiencing an event changes over time51;157. 
The next step involves populating the model with available information. This process 
requires identifying and synthesising the available evidence, as well as converting this 
evidence into a form appropriate for use in the decision model. At this stage, uncertainty 
arising from the methods used in the model, from the model structure itself, as well as 
from the use of parameter values obtained from samples needs to be characterised and 
accounted for, preferably by using both probabilistic and deterministic sensitivity analysis 
techniques169;170. In deterministic sensitivity analysis, the impact of uncertainty is 
explored by recalculating the results for different plausible values of one or more 
uncertain parameters. On the other hand, in probabilistic sensitivity analysis, uncertain 
parameters are assigned probability distributions, rather than single values. Uncertainty 
in the results is then propagated by drawing a large number of values from each 
distribution in subsequent simulations—typically by using Monte Carlo methods171;172. 
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The process gives a large number of cost and effect pairs together with the uncertainty 
associated with them169. 
The final stage in modelling involves presenting results numerically, in terms of ICERs and 
NMBs, and graphically, typically by plotting the generated cost and effect pairs on cost-
effectiveness planes (CE planes)173, cost-effectiveness acceptability curves (CEACs)174 and, 
more recently, cost-effectiveness acceptability frontiers (CEAFs)175. In brief, a CE plane 
plots paired estimates of incremental costs and benefits obtained from Monte Carlo 
simulations on a four-quadrant plane. Depending on the quadrant on which cost-
effectiveness results are located, a treatment may be more effective and more costly 
(North East quadrant), more effective and less costly (South East quadrant), less effective 
and less costly (South West quadrant) or less effective and more costly (North West 
quadrant), as compared to an alternative treatment.  
In turn, CEACs can be used to represent the probability of a treatment being cost-
effective at different ceiling ratio values174;175. For different ceiling ratios, a CEAC is 
produced by counting the proportion of incremental cost and effect pairs with a value 
less than the ceiling ratio51. Last, as there is a possibility that the intervention with the 
highest probability of being cost-effective may not result in the highest NMBs due to non-
linearity in the model, results may also be presented as a CEAF. This is formed by a curve 
representing the interventions associated with the highest NMBs over a range of ceiling 
ratio values175;176. A description of the methods involved in structuring and analysing 
decision models for the case studies used in this project are given in Chapters 4 and 5. 
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3.2. The ‘payback of research’ framework 
This part aims to give a detailed description of the ‘payback’ framework, drawing on 
relevant publications in the literature.  
3.2.1. Rationale 
The ‘payback’ framework is based on the notion that research is valuable because it 
generates evidence about treatments’ effectiveness and cost-effectiveness, which can 
lead to beneficial changes in clinical practice. Change in clinical practice (i.e. adoption and 
provision of cost-effective treatments, and termination of non-cost-effective care) is 
expected to result in additional benefits to the population. On this basis, the desirability 
of a research programme proposed to produce evidence on a treatment of interest can 
be inferred from the benefits likely to arise from a change in clinical practice informed by 
the produced evidence.  
The framework’s rationale can be illustrated with an example. A hypothetical treatment A 
may be used by patients with a specific condition. A study (e.g. a clinical trial) is proposed 
to evaluate the effectiveness and cost-effectiveness of treatment A. If the study reveals 
the treatment to be beneficial, clinical practice would be expected to change towards 
greater use of treatment A. On the other hand, if treatment A is not cost-effective, its use 
will be limited. In either case, change in clinical practice is expected to result in additional 
benefits in the population, as more patients will be treated with a cost-effective 
treatment (or, in the case of ‘unfavourable’ results, less people will be using a non-cost-
effective treatment). According to the idea underlying ‘payback’, those additional 
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benefits can be attributed to research (as research generated the information that 
induced a change in clinical practice) and can be taken into account in judging whether 
funding and conducting a research programme would be beneficial. The core steps in 
‘payback’ analysis are given below: 
a. Specification of hypothetical research results. These represent assumptions 
about the possible results that a proposed study may reveal for the treatment of 
interest; 
b. Specification of possible change in clinical practice. Assuming that a particular 
result has been observed for a treatment of interest, this step specifies the 
change in the treatments’ use; 
c. Estimation of the stream of possible costs and benefits expected to arise under 
different research results and subsequent change in clinical practice, and 
d. Calculation of expected costs and benefits by accounting for different likelihood 
of possible research results being observed.  
Costs and benefits are usually calculated for two distinct ‘states of the world’, with 
research taking place and without research. The difference between them gives the 
additional benefits associated with funding and conducting the proposed study. 
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3.2.2. Main components of ‘payback’ models 
The main components and characteristics of the ‘payback’ framework are discussed 
below with reference to identified ‘payback’ models67;90-92;94;98;100. A brief summary of 
these characteristics is given in Table 3.1. 
3.2.2.A. Purpose 
With regards to their purpose, some ‘payback’-based models have an explicit focus on 
setting priorities for primary, evidence-generating research (typically clinical 
trials)91;92;97;100 while other67;90;94;95;98 can be potentially useful for funding decisions on 
both primary and secondary, evidence-synthesising research. Thus, depending on the 
variation used, the framework appears capable of informing funding decisions for either 
primary or secondary research. 
3.2.2.B. Specification of possible research outcomes 
The first important step in ‘payback’ models is the specification of possible research 
results. These represent hypothetical but plausible outcomes from research, typically 
expressed in terms of different measures of effectiveness. An important assumption is 
that a possible result represents the true effectiveness (or cost-effectiveness) of the 
treatments in question, which holds true irrespective of whether a study has been carried 
out and revealed it or not. Different terms are used for such results, including ‘Delta 
results’90 and ‘exemplar outcomes’92. In terms of considerations to be taken into account 
when specifying possible research results, most of the identified studies agree that these 
should cover a range of eventualities and be meaningful to decision-makers67;90;92;100. 
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Table 3.1: Characteristics of ‘payback’ models 
 
Study 
Aims Methods Results and conclusions 
Prioritisation of 
primary or 
secondary 
research 
Specification of possible 
outcomes 
Consideration of 
impact of 
outcomes on 
clinical practice 
Quantification 
of costs and 
benefits 
Measure of final results Decision criterion 
Weinstein(1983)
94
 
Primary research 
(clinical trials) 
Not explicitly. Potentially 
plausible to incorporate 
different exemplar 
outcomes  
Yes  Yes Cost per year of life saved Prioritise research 
programme with lowest cost 
per life-year saved 
Eddy (1989)
90
 Secondary 
research 
(technology 
assessments) 
Yes. Two possible 
exemplar outcomes 
(treatment cost- 
effective, treatment not 
cost-effective) 
Yes  Yes Number of severe 
retardations avoided per 
year 
Estimate cost per benefit 
ratio for each proposed 
research programme.  
Rank research programmes 
in increasing order of cost 
per number of deaths 
avoided ratio 
Prioritise research 
programme with most 
desirable ratio  
Detsky (1990)
91
 Primary research 
(clinical trials) 
 Yes. A number of 
possible results (risk 
reduction) were 
considered 
 Yes  Yes  Cost per year of life 
saved 
 Prioritise research 
programmes if they are 
considered cost-effective (in 
terms of cost of undertaking 
the assessment (sample size) 
per expected number of 
health benefits). 
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Study 
Aims Methods Results and conclusions 
Prioritisation of 
primary or 
secondary 
research 
Specification of possible 
outcomes 
Consideration of 
impact of 
outcomes on 
clinical practice 
Quantification 
of costs and 
benefits 
Measure of final results Decision criterion 
Drummond et al. 
(1992)
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Primary research 
(clinical trials) 
 Yes. Two possible 
exemplar outcomes: 
‘positive’ (patient 
identified with disease) 
and ‘negative’ (patient is 
missed) 
 Yes  Yes  Cost per years retaining 
vision 
Prioritise research 
programme if it results in 
acceptable cost per outcome 
ratio 
Townsend and 
Buxton (1997)
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Primary research 
(clinical trials) 
Yes. Three possible 
exemplar outcomes: 
‘positive’ (treatment 
effective), ‘negative’ 
(treatment not effective) 
and ‘inconclusive’  
 Yes  Yes Cost per QALY Prioritise research 
programme if it results in 
acceptable cost per outcome 
ratio 
Davies et al. 
(2000)
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Secondary 
research 
(technology 
assessments) 
Yes. Two possible 
exemplar outcomes: 
‘positive (treatment 
effective) and ‘negative’ 
(treatment not effective) 
 Yes  Yes   Cost per unit of outcome 
(various disease-specific 
measures for different 
case studies) 
 Prioritise research 
programme if it results in 
acceptable cost per outcome 
ratio 
Townsend et al. 
(2003)
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 Either primary 
or secondary 
research 
Yes. Three possible 
exemplar outcomes: 
‘positive’ (treatment 
effective), ‘negative’ 
(treatment not effective) 
and ‘inconclusive’  
 Yes  Yes  Cost per unit of outcome 
(various disease specific 
measures for different 
studies) 
 Prioritise research 
programme if it results in 
acceptable cost per outcome 
ratio 
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In three of the identified ‘payback’ models90;98;100, it is assumed that research will produce 
two kinds of results:  
a. ‘Positive’, where research reveals that the treatment of interest is effective and 
cost-effective, and 
b. ‘Negative’, where the treatment is shown to be inferior in terms of its effectiveness 
and cost-effectiveness. 
The studies by Townsend and Buxton92 and Townsend et al.67 allow for the additional 
possibility of ‘inconclusive’ outcomes67;92, while Detsky91 represents possible results in the 
form of a distribution. Arguably, the latter resembles more closely the type of results that 
are likely to be observed in a clinical study.  
3.2.2.C. Change in the use of the assessed treatment 
Another important point in the ‘payback’ methodology relates to the impact of the results 
on clinical practice. Here, it is assumed that observing a specific research outcome will 
trigger a change in clinical practice. Trial results showing the treatment not to be effective 
are expected to result in a gradual decline in its use, while ‘positive’ research results (i.e. 
treatment is effective or cost-effective) are anticipated to lead to greater use of the 
treatment in clinical practice. 
All the identified studies attempt to establish a link between the results and subsequent use 
of the treatment of interest. In general, clinical practice is assumed to change on the basis of 
a treatment’s hypothesised effectiveness. The contemporary view that cost-effectiveness is 
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a key consideration in policy change is explicitly accounted for in the PATHS model67. Eddy90 
stresses that change in policy will depend on a number of factors, including the results of 
other assessments, existing policies that might affect the uptake of the assessed 
technologies, geographic regions and time periods. In the absence of further research (i.e. if 
the proposed research study is not undertaken), it is typically assumed that clinical practice 
will not change90;92;100.  
The concept of change in use is particularly important in ‘payback’, because it allows 
translating possible research results into potential benefits experienced by the 
population67;91;98;100. As obtaining hard evidence on the possible change in clinical practice is 
problematic, estimates for this change usually comes in the form of expert opinion67. 
3.2.2.D. Estimation of costs and benefits 
All the ‘payback’ models attempted to quantify the costs and benefits following change in 
uptake of a treatment. Information for this is typically derived by combining existing 
evidence on costs of the treatment—typically obtained from the literature—with the 
hypothesised research results67;92;100.  
Costs and benefits are first estimated for an individual patient and they are subsequently 
extrapolated to the population that is expected to benefit from a decision informed by 
additional evidence over a number of years. Costs are typically measured from a provider’s 
perspective. An exception is the Diabetic Retinopathy Study, where Drummond et al.100 
explored a variety of alternative perspectives, including those of government, health care 
sector, patient and the community. Benefits are typically expressed as disease specific 
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measures67;90;98;100 and natural units such as premature death avoided91;94, while in one 
study benefits were expressed as QALYs92. 
3.2.2.E. Weighted results and decision rules 
Typically, the streams of costs and benefits associated with each possible research result are 
weighted by the likelihood of the result being observed. Such likelihoods weights were 
accounted for in all the identified models. Eddy90 determined the probability of observing a 
‘positive’ or ‘negative’ result to be 0.50; similarly, Davies et al.98 specified the probability of 
‘positive’ results at 0.67 on the premise that approximately two out of three treatments 
assessed in clinical trials show ‘positive’ findings. In two studies, the authors91;102 followed a 
more sophisticated approach, where a probability distribution was assigned to the possible 
difference in effectiveness between assessed treatments. Likelihood weights have a sizeable 
effect on final ‘payback’ results and thus, it is important that chosen values are plausible and 
justified.  
Different approaches have been followed in assigning likelihood weights to possible results. 
In early ‘payback’ models, each specified research result carries the same likelihood of 
occurrence90;94;98;100. A more sophisticated approach involving different combination of 
weights is employed by Townsend and colleagues67;92. In these studies, three possible 
research results (‘negative’, ‘positive’ and ‘inconclusive’) merge in ‘optimistic’, ‘neutral’ and 
‘pessimistic’ combinations.  
The area where ‘payback’ models present the greatest diversity is the interpretation of the 
generated results and the determination of rules for action. In general, models aim to be 
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consistent with decision rules used in economic evaluation and attempt, whenever possible, 
to calculate ratios of costs per expected benefits, with the difference that, in this context, 
the comparison is between a state with and without research67;92;98;100.  
It is often not clear how such ratios should be interpreted. In cases where ratios indicate that 
an assessment would result in cost savings and increased effectiveness, an obvious option 
would be to advocate carrying out research. Nonetheless, a clear rule is needed for the 
common situation where research is associated with additional benefits and higher costs. In 
such a case, Townsend and Buxton92 compared the estimated ICER of the Hormone 
Replacement Treatment (HRT) trial against cost per QALY values of commonly-used 
interventions such as renal transplant or breast cancer screening, and pointed out that the 
HRT trial appears to represent value for money. As Davies et al.98 point out, interpretation of 
results and decision rules are topics where further research would be particularly useful. 
3.2.3. The Preliminary Assessment of Technology for Health Services (PATHS) model 
As explained above, the ‘payback’ framework has been subject to constant development, 
with the methods introduced in early models90;94 being refined and updated in subsequent 
studies67;91;92;98;100. The latest identified ‘payback’ model is the Preliminary Assessment of 
Technology for Health Services (PATHS)67, published in 2003. This model combines the 
principles of early ‘payback’ work with methodological advances and current trends in health 
care decision-making (e.g. the introduction of economic consideration in treatment adoption 
decisions) and it is the focus of the present study. 
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Similarly to previous ‘payback’ models, PATHS aims to measure the additional benefits that 
would accrue from conducting research and changing clinical practice according to its 
results. As the results of research cannot be known in advance, this analysis is undertaken 
for a series of hypothetical, but possible, results. 
The model is operationalised through a series of core steps. The first step involves specifying 
the possible results that a trial on a specific treatment of interest may give. For practical 
reasons, these are usually narrowed down to a ‘favourable’ result, where the assessed 
technology is shown to be effective, an ‘inconclusive’ result, where it is not clear whether 
the technology is more effective than its comparators, and an ‘unfavourable’ result, where 
the assessed technology appears to be inferior to its comparators. 
Different research results are expected to have different impact on the prescription of the 
assessed treatments. For example, ‘favourable’ results might increase the use of the 
effective treatment in clinical practice; ‘unfavourable’ results would typically limit the use of 
the treatment, while ‘inconclusive’ results would typically not have an effect on current 
prescription patterns. On the other hand, if the trial is not conducted and no new evidence is 
generated, clinical practice is expected to remain largely unchanged.  
The next step involves estimating the stream of costs and benefits (or net monetary 
benefits) that would arise for each possible result under two situations: a) with the trial 
taking place and b) without the trial taking place. In the former case, that is, with research 
being conducted, costs and benefits are those expected to accrue given the specified 
research results and the hypothesised change in prescription patterns in the light of these 
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results. Costs will involve the expenditure for conducting the trial, as well as the cost 
associated with providing the treatment in question. In the latter case, where no trial is 
carried out and clinical practice is expected to remain as it was, costs and benefits are those 
associated with a specified research result, but in this case, as the results will not be 
observed, no change in practice is expected to take place and no additional benefits will 
accrue from increasing the use of a cost-effective treatment (or restricting the use of the 
non-cost-effective treatment).  
As some results are more likely than other, probabilities can be attached to them to 
represent the likelihood of each specific result occurring. Given this, different combinations 
can be formed, such as an ‘optimistic’ combination, where a ‘favourable’ result is more likely 
to be observed, a ‘pessimistic’ combination, where a greater likelihood is given to an 
‘unfavourable’ result and a ‘neutral’ combination, where each result is given equal likelihood 
of occurrence. 
For a given combination, the expected costs and benefits of the trial are expressed as an 
Expected Incremental Cost-Effectiveness Ratio (EICER), which is calculated as the difference 
in costs with and without the trial over the difference in effectiveness with and without the 
trial. EICERs can be subsequently compared to decision-makers’ willingness-to-pay value for 
a unit of benefit. As Townsend et al.67[p.17] suggest ”the results of the application of the 
model would be presented in a report to a research-funding organisation, in which this EICER 
would be weighted with other payback considerations in the final decision about whether the 
research project should be funded or not”. The authors also point out that the results 
obtained from the model do not aim to replace existing processes of research prioritisation, 
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but rather to complement them, as the currently used process of peer review and criteria-
based approaches are still needed to consider benefits that are not directly quantifiable and 
would not be reflected in the PATHS results67.  
3.2.4. Practical applications of the PATHS model  
Separate searches were carried out to identify studies reporting practical applications of the 
PATHS model. Details on search strategies and numbers of articles identified are given in 
Appendix 2.A. The majority of the identified studies related to retrospective ‘payback’, a 
stream of research undertaken at Brunel University and focusing on assessing the returns to 
health services research by evaluating the extent to which research enhances knowledge 
and brings about health sector and broader economic benefits93;177. As such work looks into 
the benefits from research which has already taken place and reported results, retrospective 
‘payback’ studies are not directly relevant to the aims of this thesis.  
Two studies reporting practical applications of PATHS were found in the literature. The first 
was the study where the PATHS model was first presented67. There, Townsend et al.67 
applied the developed model to three case studies representing proposals for randomised 
controlled trials. The application aimed to illustrate the PATHS methodology as well as to 
assess the validity of its results. For this, the predicted results from the ex ante application of 
PATHS were compared to ex post estimates of the costs and benefits expected to accrue 
from the trial, the latter being estimated on the basis of observed results derived from trials 
which were funded and completed. Comparisons were possible in two of the three case 
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studies, in which the ex ante and ex post estimates were found to be in broad agreement. 
This was seen as a positive indication of the model’s validity67. 
The second study was carried out by Fleurence116 in 2007. The author used the model to 
explore whether three clinical trials of preventive interventions against fractures and one 
trial against pressure ulcers should take priority for funding. In this study, Fleurence116 
presented results in the form of INMBs, rather than EICERs. The study findings indicated 
positive NMBs associated with three of the four trials, suggesting that funding these trials 
would be ‘cost-effective’. Details on the comparators, specified trial results and assumption 
on change in clinical practice following each possible result are given in Appendix 2.B, Table 
2.c and Table 2.d.  
3.2.5. Critique of ‘payback of research’ in the literature 
The potential of ‘payback’ models to assist with research funding decisions has been often 
highlighted in the literature55;65;98. Such models present strengths that make them attractive. 
First, the core ‘payback’ methodology appears to be consistent with well-established 
principles of economic evaluation, in that it seeks to determine the additional costs and 
benefits from an action (here, funding and conducting research) against another (not 
conducting research). Because of this, as Chilcott and colleagues55 explain, the framework 
can address the type of questions that decision-makers are ultimately interested in, that is, 
whether allocating resources to a specific research programme will be beneficial, given the 
costs and benefits associated with it. An additional strength of ‘payback’ is that it seeks to 
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identify ‘real benefits’ accruing to the population, by looking at how research results trigger 
changes in clinical practice67. 
Despite this, ‘payback’ models have been often criticised on the ground that, by judging the 
value of research according to its ability to trigger changes in clinical practice, the framework 
gives a greater weight to research on topics that have a potential to change clinical practice 
than other topics that should be researched because they are associated with significant 
uncertainty80;110. For instance, as Fleurence80 explains, there may exist a widely used 
treatment about which there is little uncertainty that it is not cost-effective, but a great 
potential for gains from switching clinical practice away from this technology, towards a 
more cost-effective option. Thus, although existing evidence on the technology not being 
cost-effective may already be robust, the fact that a switch in practice will result in benefits 
makes this assessment, according to ‘payback’, a good candidate for research80;110. This, it 
has been argued121, is in contrast with the primary aim of research, which should be to 
provide information which will reduce uncertainty.  
3.3. The ‘value of information’ framework 
The following section focuses on the second analytic framework of interest—’value of 
information’. The first part of the section gives an overview of the framework, by looking 
into its rationale and specific concepts. The section concludes with a discussion of prominent 
strengths and criticisms associated with the framework, as they appear in the literature. 
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3.3.1. Rationale 
‘Value of information’ analysis is part of statistical decision theory—a collection of analytic 
techniques aimed to assist decision-making under conditions of uncertainty108;163. The 
methodology asserts that, in cases where a choice of action needs to be made and the 
consequences of alternative actions are not known with certainty, statistical and 
mathematical tools can be used to assess what the optimal action appears to be on the basis 
of current information, and in what cases obtaining more evidence to substantiate or retract 
this choice would be beneficial106;107;178. Such decision theoretic techniques appear to be 
directly applicable to health care; in this field decisions need to be made as to which of 
alternative treatments should be covered and provided to the population, while, at the same 
time, the consequences of these decisions are typically uncertain179-181.  
Within this context, it has been argued that there are two separate but related tasks that 
health care systems are called to fulfil. First, a decision is needed on which of alternative 
technologies should be adopted, taking into account existing evidence on their cost-
effectiveness. Second, a separate decision is required on whether more information should 
be obtained through research to support the adoption-related decision115;179. 
The first task is accomplished with the help of economic evaluation studies, which indicate 
the optimal course of action (here, the optimal treatment adoption decision), given existing 
evidence181;182. If the objective of the decision-makers is to maximise health benefits out of 
the available resources, it has been argued, the choice to be made is the one with the 
greatest payoff given current information106;115. 
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The second task is equally important. Decisions are needed on whether and to what extent 
resources should be devoted to further research, given that research provides valuable 
evidence towards ensuring that optimal adoption decisions are made. VoI can assist with this 
task by quantifying the potential benefits from pursuing further information through 
research and, on this basis, the framework has been often advocated as a useful tool for 
informing research funding decisions80;109-112;179. A discussion of main concepts in VoI is given 
below.  
3.3.2. ‘Value of information’ concepts 
‘Value of information’ analysis consists of a set of distinct, although closely associated, 
techniques. The rationale and aims of each of these techniques are given in turn below. A 
description of the techniques with a specific focus on methods and formulae for calculations 
is given in Chapter 7. 
3.3.2.A. Expected value of perfect information 
Existence of uncertainty implies that decisions which appear optimal in the light of current 
information may turn out to be ‘wrong’ when uncertainties resolve. For example, a decision 
to reimburse and provide a hypothetical treatment A which appears cost-effective compared 
to an alternative treatment B on the basis of existing (imperfect) evidence may prove wrong 
if treatment A is, in fact, suboptimal. In such a case there will be a cost associated with 
making the wrong decision (i.e. adopting treatment A), which can be measured in terms of 
forgone benefits due to providing the patients with a suboptimal treatment. Forgone 
benefits represent a cost to society and are seen as an opportunity loss (or opportunity cost) 
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due to making decisions under uncertainty. The expected opportunity loss can be quantified 
by weighting the probability of making the wrong decision by the opportunity loss due to 
making such a decision97;115.  
This expected opportunity loss can be minimised by conducting research and acquiring 
information that reduces uncertainty. In this way, the value of conducting further research 
can be seen as the reduction in the expected opportunity loss due to uncertainty. At the 
extreme, perfect information—that is, no uncertainty and perfect knowledge of which of 
treatments A and B is optimal—would eliminate the opportunity loss associated with 
uncertainty and ensure that the best treatment is adopted97;115. Given this, the expected 
value of acquiring perfect information (EVPI) is equal to the expected opportunity loss due to 
uncertainty, as perfect information would eliminate the cost of uncertainty altogether. In 
simple terms, the benefits from a decision made with perfect information are equal to the 
benefits one would be bound to forgo when making a decision under uncertain, imperfect 
information97;107;108.  
Expressed as net monetary benefits (NMBs), EVPI is simply the difference between the 
expected net benefits that would accrue from a decision with no uncertainty (perfect 
information) and the expected net benefits from the same decision, this time made on the 
basis of imperfect information. In this sense, the EVPI associated with an adoption decision 
represents the maximum expected benefits that could be ever realised by conducting 
research and informing the adoption decision. At first, EVPI is calculated for a single decision 
(i.e. an individual patient) but, as information can be disseminated freely, EVPI can be 
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extrapolated to the population of existing and future patients who are anticipated to be 
affected by the treatment decision, to give the population EVPI51. 
Expressing EVPI in monetary terms (such as NMBs) allows comparisons between the 
expected maximum benefits from researchagainst the cost of research itself. If these gains 
exceed the expected costs of further research, conducting further research is potentially 
worthwhile. If, on the other hand, the gains are unlikely to exceed the cost of the research 
programme, conducting research would represent a waste of resources115. Given this, EVPI 
has been seen as the upper limit on the resources that a rational decision-maker should 
devote to acquiring further information through research and, in this sense, it consists the 
first criterion—or hurdle—for assessing whether carrying out evaluative research is 
justified175;179. 
3.3.2.B. Expected value of perfect information for parameters 
In many situations, uncertainty around a treatment adoption decision is due to imperfect 
information around specific parameters affecting this decision (e.g. uncertain effectiveness 
of a treatment). In such cases, the EVPI can be extended to provide an estimate of the ‘value 
of information’ associated with conducting research on a specific parameter or groups of 
parameters.  
The expected value of perfect information for specific uncertain parameters (i.e. the 
expected value of perfect parameter information (EVPPI)) is the difference between the 
expected benefits from a decision made with perfect information about specific uncertain 
parameter(s) and a decision made with current information about these parameters. The 
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obtained EVPPI is associated with an individual patient or decision and, as in the case of 
EVPI, it can be projected to the population affected by the decision to give the population 
EVPPI183. EVPPI can indicate parameters which contribute the most to decision uncertainty 
(e.g. quality of life) and, as a result, it can highlight the type of research that would be most 
beneficial (e.g. a non-experimental study to collect quality of life data)184;185. 
3.3.2.C. Value of information and implementation 
EVPI and EVPPI results show the maximum benefits of pursuing better information, on the 
premise that any adoption decision made in the light of this information will be fully 
implemented. However, the implementation of recommendations is often imperfect and, in 
practice, the benefits from adopting the optimal treatment and making it available are 
unlikely to be realised in full186. This acknowledgement has led to the development of a 
conceptual framework which aims to estimate the value of undertaking strategies to 
enhance implementation and identify the situations where such strategies may be more 
valuable than pursuing better information187;188.  
This methodology, laid out by Fenwick and colleagues187, evaluates the benefits expected to 
accrue from decisions made under different ‘states of the world’ regarding the availability of 
information about a treatment and the subsequent implementation, or uptake, of the 
treatment. Such states represent situations where decisions made under perfect information 
are followed by either perfect or ‘current’ (i.e. imperfect) implementation and states where 
decisions under current information are followed by perfect or current implementation. The 
framework aspires to address criticisms around the assumption typically used in VoI that is 
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that, once an adoption decision is made, this will be followed by perfect adherence80;189. 
Although the concept presents similarities with the ‘payback’ framework in that it aims to 
account for the impact of research in clinical practice, its developers have pointed out that 
they consider value of implementation as a distinct methodology187. 
3.3.2.D. Expected value of sample information 
As explained above, EVPI and EVPPI represent the maximum benefits that could be realised 
from further research and establish a necessary condition: for a further study to be 
potentially worth conducting, the maximum benefits from research, expressed as EVPI and 
EVPPI, must outweigh the costs of conducting further research97. 
However, obtaining perfect information would require ‘perfect’ research, of an infinitely 
great sample size. This is, in practice, out of reach as typically further evidence is obtained 
from studies of limited samples. To decide whether a piece of evaluative research involving a 
sample   will be indeed worthwhile, one needs to estimate the actual benefits expected to 
arise from this specific study. Such an estimate is given by the expected value of sample 
information of a study with sample size   (EVSIn)
115. 
By analogy to EVPI, EVSIn shows the difference between the expected value (measured in 
NMBs) of a decision made under information from a study with sample  , and the value of a 
decision made with current information190. Population EVSI can be compared against the 
cost of conducting a study of sample size  . The difference between EVSIn and the cost of a 
study involving   patients is the Expected Net Benefit of Sampling (ENBSn); a measure that 
represents the benefits expected to arise from a study of sample size  , net of the study’s 
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cost115;190. In this way, the ENBSn is seen as the net payoff to a proposed study and it 
represents the ‘sufficient’ condition for conducting this study: if ENBSn is positive (i.e. EVSI 
exceeds the cost of research), further experimental research will be ‘cost-effective’115. In 
addition, the ENBSn provides a condition for establishing a study’s desirable design 
characteristics: the employed sample size and the allocation of participants between 
treatment arms will be optimal when the difference between the cost of a trial and EVSI is 
the greatest possible (or, equivalently, when ENBSn is maximum)
51;97;175.  
3.3.3. Applications of ‘value of information’ in the literature 
A search in the literature was undertaken to identify studies documenting practical 
applications of VoI in the area of health care. The review involved searches in major 
electronic bibliographic databases, additional searches to identify studies citing and cited in 
key studies, ‘related articles’ searches, and general searches on the internet (Appendix 2.C.) 
Since the late 1990s VoI has been a well-researched topic, with a number of publications 
discussing the methods, proposing methodological advances or simply applying the method 
as an adjunct to economic evaluations existing in the literature. A review of the literature 
identified 128 VoI-related studies. The majority of these (77 studies) have a methodological 
focus, aiming to illustrate the method and describe methodological advances, while 
approximately one third of the identified studies (48) are applied economic evaluations 
incorporating EVPI and EVPPI calculations to underpin recommendations for future research. 
The majority of the identified literature is authored by researchers based in the UK, although 
a number of studies come from other countries, predominately the United States, the 
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Netherlands, Australia and Canada. A significant share of the papers is authored by a team at 
the University of York led by Professor K. Claxton, while other clusters of researchers 
publishing on VoI were identified at the Universities of Sheffield, Bristol, Oxford, Toronto and 
the Erasmus University in the Netherlands.  
Apart from published articles, VoI applicable to health care decision-making is described in 
prominent textbooks on economic evaluation31;51;139. The approach has been also 
recommended as a systematic way to establish the value of further research in the latest 
guide to methods for technology assessment issued by NICE114.  
3.3.4. Critique of ‘value of information’ in the literature 
The increasing attention given to ‘value of information’ has led researchers to highlight its 
strengths but also expose its limitations. A specific strength of the framework lies in its 
theoretical basis. VoI is part of statistical decision theory, a well-established methodology 
that makes use of Bayesian inference to determine the optimal course of action under 
uncertainty and the situations where further research is beneficial55;180;189;191. This is 
demonstrated in statements such as “To our knowledge, this is the only method with a 
theoretically sound basis; therefore we foresee an important role for value of information 
analysis in guiding future research.”192[p.424]. In addition, the framework is compatible with 
the methods of economic evaluation, to the extent that it has been seen as a natural 
extension of these methods. Combined with the results of decision modelling, the approach 
has been suggested as a comprehensive framework for addressing treatment adoption and 
research funding decisions110. 
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Moreover, the approach can be potentially useful in addressing both research funding and 
research design-related questions. As Briggs et al.51 argue, EVPI, EVPPI and EVSI analyses can 
establish which research programmes should take priority, identify comparators and 
endpoints to be included in further research and indicate subgroups of patients for which 
research would be valuable. The approach has also been proposed as an alternative to 
traditional approaches for trial research design, being able to determine the sample size and 
allocation of patients between treatments that would maximise the returns to its cost115;189.  
Despite this, VoI methods are also computationally demanding, especially when carrying out 
EVSI computations, where the value of sampling information needs to be evaluated for each 
possible trial result and different sample sizes and allocation of participants51. In addition, as 
VoI results quantify the uncertainty around an adoption decision, inappropriate 
representation of this uncertainty and flaws in an economic evaluation will inevitably lead to 
inaccurate—or potentially misleading—results about the value of further research.  
3.4. Main characteristics of ‘payback of research’ and ‘value of information’ 
Although they represent distinct frameworks, ‘payback’ and VoI share similarities. Main 
characteristics of the frameworks, in terms of the principles underpinning them, rationale 
and methods, are summarised in Table 3.2.  
The frameworks recognise that the aim of evaluative research is to provide evidence to 
inform decision making, and express the ‘value’ of a research programme in terms of the 
benefits expected to accrue to the population through improved decision making. For both 
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the frameworks, the ultimate aim is to obtain explicit numerical estimates of the expected 
benefits of research, which can be useful in informing research priority-setting.  
Table 3.2: Table summarising main characteristics of 'payback of research' and 'value of information' 
 
 Payback of research Value of information 
Rationale and aim  Calculation of the potential health 
benefits associated with proposed 
research as a means of assisting priority 
setting for research. 
Calculation of the potential health 
benefits associated with proposed 
research as a means of assisting priority 
setting for research. 
Underpinning 
methods 
Cost-effectiveness analysis. Comparison 
of costs and benefits associated with two 
distinct ‘states of the world’ (i.e. with 
research taking place and without 
research). 
Statistical decision theory. Comparison 
between the expected benefits of 
obtaining perfect or improved 
information and the maximum cost of 
acquiring perfect/improved information 
(i.e. cost of clinical trial). 
Specification of 
possible outcomes 
of research 
 
 
Explicitly specified (Delta results, 
exemplar outcomes). 
Not explicitly specified, but possible 
outcomes are expressed through a large 
number of possible realisations of results 
produced through probabilistic sensitivity 
analysis. 
Specification of 
change in clinical 
practice 
Direction and magnitude of change in 
clinical practice is accounted for explicitly 
for each possible outcome.  
Direction of expected change in clinical 
practice (i.e. adoption/rejection in light of 
different simulated results from 
probabilistic sensitivity analysis) 
accounted for implicitly.  
Perfect implementation of the most 
optimal strategy is assumed.  
Estimation of costs 
and benefits  
Estimation of cost and benefits associated 
with each possible outcome. 
Estimation of costs and benefits for 
different possible outcomes (i.e. different 
possible realisation of results in 
probabilistic sensitivity analysis). 
Calculation of 
results 
Results are calculated as the difference 
between the costs and benefits (i.e. net 
benefits) between a state with research 
and a state without research 
Results are calculated as the net 
monetary benefits expected to accrue due 
to reduction in, or elimination of, 
uncertainty  
Decision rules Value of a research proposal is inferred by 
the calculated ‘payback’ results. Positive 
net monetary benefits indicate that 
research is potentially beneficial.  
Value of a research proposal is inferred by 
the calculated VoI measures (e.g. EVPI, 
EVSI, EVPPI) net of the cost of research. 
Positive net monetary benefits indicate 
that research is potentially beneficial. 
 
Divergence in the approaches can be seen when looking at the methods used in predicting 
the expected benefits of research. In ‘payback’, possible research outcomes are specified 
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explicitly (i.e. Delta results90 or exemplar outcomes92) and are the starting point for the 
analysis. Under the assumption that research will provide valid and unbiased estimates of 
treatments’ effectiveness and cost-effectiveness, possible outcomes are used as a proxy for 
the true effectiveness and cost-effectiveness of the treatments of interest to the population. 
On the other hand, VoI methods do not explicitly specify possible research results, but, 
instead, express the possible effectiveness and cost-effectiveness of the compared 
treatments in the form of a large number of output results generated through probabilistic 
sensitivity analysis. Each of these results represents a possible realisation of treatments’ 
cost-effectiveness and is obtained externally, through decision modelling, rather than 
internally, through the VoI analysis itself. In general, though, the fact that both frameworks 
account for possible results implicitly or explicitly, can be seen as a noteworthy commonality 
between the approaches.  
A notable aspect in ‘payback’ is the specification of the direction and magnitude of change in 
clinical practice in light of each possible result. For example, the approach seeks to specify 
not only how the practice is expected to change (e.g. adoption of a treatment associated 
with ‘favourable’ outcomes) but it also requires determining explicitly the extent of change 
in the use of the treatment (i.e. treatment uptake). In VoI, direction of change in practice is 
implicitly specified by assuming that for a given realisation there will be a complete switch to 
the optimal treatment. Unlike ‘payback’, main VoI concepts assume that the chosen 
treatment will be implemented perfectly (i.e. all eligible patient will receive the treatment 
that appears optimal), although some allowance for this assumption is made in published 
work looking into the value of implementation124(see Chapter 7).  
89 
The aspect where the methods differ the most is the calculation of final results. To obtain an 
estimate of the value of a proposed research programme, ‘payback’ methods typically 
compare the benefits accruing from a ‘state of the world’ where research has taken place, 
and a state where research has not been conducted. This comparison gives the gain (or loss) 
associated with research and it is interpreted as the value of undertaking the proposed 
study. The interpretation of VoI results is less intuitive; results show the expected gains in 
benefits due to reduction or elimination of uncertainty. VoI is typically expressed in terms of 
NMBs and it is compared against the cost of research itself. Decision rules for ‘payback’ and 
VoI stipulate that the positive net benefits indicate that carrying out a proposed piece of 
research is anticipated to be beneficial. 
3.5. Chapter overview 
The chapter aimed to provide a detailed description of the most prominent analytic 
frameworks—‘value of information’ and ‘payback of research’. The frameworks have a 
common starting point: they are both underpinned by the notion that the aim of evaluative 
research, such as a clinical trial, is to provide evidence to inform better adoption decisions, 
and thus the desirability of conducting the trial can be inferred by the benefits expected 
from improved decision-making. Nonetheless, the frameworks present differences in the 
way they identify and measure those benefits. In ‘payback’ the value of the trial is inferred 
by the benefits expected to accrue from a change in practice induced by information 
generated from the study, while VoI values evaluative research according to the reduction in 
uncertainty—and, thus, the reduction in the expected loss of benefits—that the trial is 
expected to bring about. Despite these methodological differences, there exist conceptual 
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similarities in the approaches. Strengths and limitation of the frameworks, as seen in the 
literature, were also outlined.  
This and the previous chapter sought to introduce the aims of the project, describe the 
context of research priority-setting and look into proposed approaches, with a focus on 
analytic approaches. The next part of the study describes the application of ‘value of 
information’ and ‘payback of research’ analysis to case studies.  
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PART II. Practical application of ‘payback’ and 
‘value of information’ 
The first part (Chapters 1, 2 and 3) set the background and identified two main analytic 
frameworks proposed to assist with funding decisions in research—‘payback of research’ 
and ‘value of information’. This part, Part II, focuses on the practical application of these 
frameworks to case studies. The primary aim of this application is to provide an insight into 
the frameworks’ capabilities, strengths and limitations. Observations made in this part 
formed the basis for assessing the frameworks and drawing conclusions on their usefulness, 
practicality and potential value in the last part of the thesis (Part III). 
Case studies used in this application represent proposals for clinical trials (BTOG-2 and 
TRAPEZE phase III trials) aiming to give primary evidence for specific treatment adoption 
decisions in non-small cell lung cancer (NSCLC) and hormone-refractory prostate cancer 
(HRPC). The case studies gave access to the trials’ protocols and, in the case of HRPC, 
provided patient-level data from the early stage TRAPEZE phase II trial. 
The application of ‘payback’ and ‘value of information’ to the case studies was carried out 
iteratively, in a two-stage process. The first, preliminary stage required assessing the extent 
of the existing, pre-trial evidence around the treatment adoption decisions that each trial 
aimed to inform, while the second, main stage, involved using ‘payback’ (PATHS model) and 
‘value of information’ (VoI) to determine whether obtaining further evidence through 
conducting the proposed BTOG-2 and TRAPEZE phase III trials would be beneficial.  
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For each case study, the first task involved specifying the relevant adoption-related decision 
(i.e. which of specific treatments to adopt and provide to patients) and research-related 
decision (i.e. whether evaluative research should be carried out to generate more evidence 
to facilitate the adoption-related decision). As a next step, the existing evidence around the 
adoption-related decisions was identified and synthesised through decision analytic models. 
Work undertaken in this stage for the NSCLC and HRPC case studies is detailed in Chapters 4 
and 5, respectively. 
In the main stage of the study, the focus turns on the research-related decisions, that is, 
whether funding and carrying out additional research in the form of the proposed BTOG-2 
and TRAPEZE phase III trials would be worthwhile. For this, ‘payback of research’ and ‘value 
of information’ were applied to each case study with the help of the constructed models. 
The application of ‘payback’ to case studies involved specifying possible results that the 
proposed studies may show, translating these results into expected costs and health benefits 
through the decision models, evaluating the possible change in clinical practice in the light of 
these outcomes and estimating the additional benefits that would be expected to arise 
across the population. On the other hand, the application of VoI required translating the 
uncertainty around the adoption-related decisions into estimates of the expected benefits 
from conducting further research through different measures of perfect and sample 
information. ‘Payback’ and VoI analyses are reported in Chapters 6 and 7, respectively. 
At the time that this doctoral project started (September 2009), both the BTOG-2 and 
TRAPEZE trials were funded and on-going. To account for this fact, the analyses were 
undertaken in a retrospective manner, by making use of evidence that would have been 
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available at the time the funding decisions were considered (2004 and 2006 for NSCLC and 
HRPC, respectively).  
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CHAPTER 4. Adoption-related decision in non-small cell lung 
cancer 
This chapter describes the methods used in, and the results obtained from, a decision 
analytic modelling exercise aimed to summarise the current evidence around a treatment 
adoption-related decision in the area of non-small cell lung cancer (NSCLC). The developed 
model and the result of this work aimed to assist with the application of ‘payback of 
research’ and ‘value of information’ to the NSCLC case study. The first part of the chapter 
reports a review of the existing evidence on the effectiveness and cost-effectiveness of 
chemotherapy agents for NSCLC, while the second part focuses on the methods and the 
results of the model-based economic evaluation.  
4.1. Background  
Lung cancer is one of the most common types of cancer and the leading cause of cancer-
related deaths worldwide and in the UK193-196. According to the World Health 
Organization197, in 2004, lung cancer was responsible for the death of approximately 1.3 
million people around the world. In the UK, using 2008 data, Cancer Research UK estimated 
that lung cancer is responsible for approximately 35,300 deaths per year and accounts for 24 
percent and 21 percent of all male and female cancer deaths in the country, respectively194 
(Figure 4.1). 
A number of risk factors appear to contribute to lung cancer, most importantly tobacco 
smoking, exposure to carcinogens and air pollution198;199. Lung cancers are classified into two 
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types: non-small cell lung cancer (NSCLC), which includes squamous cell carcinoma, 
adenocarcinoma and large cell carcinoma, and small cell lung cancer198. Non-small cell lung 
cancer is the predominant type of lung cancer, accounting for approximately 80 percent of 
all lung cancer cases200;201. 
 
Figure 4.1: Number of lung-cancer-related and other cancer deaths in the UK 
 
Only a small proportion (about 20 percent) of NSCLC cases are potentially curable and these 
are usually patients with non-advanced disease eligible for curative surgery202. Thus, patients 
with advanced disease (i.e. NSCLC stage IIIB where cancer has spread to the mediastinum 
(i.e. heart, oesophagus and great vessels) and NSLCC stage IV where distant metastases are 
present203) are incurable at presentation and candidates for treatments that extend life or 
palliate symptoms. Common treatment options for this patient group include ‘best 
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supportive care’, which aims to control symptoms and usually comprises radiotherapy and 
non-cytotoxic drugs, or chemotherapy, which is usually given to extend survival204;205.  
A number of chemotherapy regimens are available, including paclitaxel, docetaxel and 
gemcitabine; the last is known to offer a valuable, though modest, increase in life 
expectancy and quality of life when compared to radiotherapy alone or best supportive 
care198;202;206. Gemcitabine (Gem) is considered the bedrock of chemotherapy and it is 
typically used in combination with platinum analogues which aim to trigger cell death. The 
combination of gemcitabine with a particular platinum analogue, cisplatin (Cisp) has been 
shown to prolong survival in advanced cancer patients and is recommended by the National 
Institute for Health and Clinical Excellence (NICE)198;207 as the standard first-line treatment 
for advanced NSCLC. 
Apart from cisplatin, gemcitabine is routinely given with carboplatin (Carb), another 
platinum analogue which acts similarly to cisplatin but it is considered to be less toxic and 
more convenient to administer208. As gemcitabine plus carboplatin (Gem+Carb) may also be 
beneficial, there is uncertainty around the optimal first-line treatment for the specific 
patient group208;209. 
4.2. Adoption-related and research-related decisions 
Given the above, the relevant adoption-related question relates to which of Gem+Carb or 
Gem+Cisp should be adopted and provided to patients with advanced NSCLC. In turn, 
stemming from this, the relevant research-related question is whether public funds should 
97 
be committed to a clinical trial aiming to provide additional evidence on the effectiveness 
and costs associated with Gem+Cisp and Gem+Carb. 
A phase III randomised controlled trial, the British Thoracic Oncology Group 2 (BTOG-2) trial, 
was proposed to provide primary evidence on the effectiveness and costs of chemotherapy 
treatments for NSCLC. The proposal was submitted for funding to the CRUK Phase III Clinical 
Trial Grants stream, secured funding in 2004 and started recruitment in 2005. Results of the 
trial were expected to become available in late 2011. The cost of the trial, as given in the 
research proposal, was £336,721 (in 2004 prices). This includes research-related costs (i.e. 
cost of researchers’ salaries, facilities and indirect costs) of £134,221 and service support 
costs (i.e. cost related to obtaining informed consent, additional clinic time and collection of 
quality of life questionnaires) of £202,500. Since the investigated treatments are routinely 
available in clinical practice, no funds for excess treatment costs were requested. 
4.3. Existing clinical and cost-effectiveness evidence 
A systematic review was undertaken to summarise the existing clinical and economic 
evidence, with the additional aim of retrieving information that could be used in the planned 
decision model. The review involved searches in bibliographic databases (MEDLINE, NHS 
CRD, ISI Web of Knowledge), searches in relevant portals (NICE Clinical Guidelines and 
Cochrane Collaboration Reviews), general searches on the internet through Google Scholar®, 
as well as searches in the reference lists of identified articles. Details on searches and 
retrieved articles are given in Appendix 3.A. Identified studies were included if they:  
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a. focused on patients with advanced NSCLC (stage IIIB or IV) eligible for 
chemotherapy; 
b. involved an assessment of gemcitabine, cisplatin or carboplatin alone or in 
combination with other chemotherapeutic agents as first-line treatment for 
advanced NSCLC; 
c. reported cost-effectiveness results, or clinical effectiveness results on at least one of 
the following outcomes: tumour response, survival, time-to-progressive disease, 
quality of life, toxicity, treatment discontinuation rates. 
In order to use only evidence existing up to the point when the research-related decision 
was considered, the review included studies available before July 2004. Twenty-one studies 
were included in this review. Of these, thirteen assessed treatments in terms of their clinical 
effectiveness, seven were economic analyses, while one study201 looked at both the clinical 
effectiveness and cost-effectiveness of first-line chemotherapy treatments for NSCLC. 
4.3.1. Clinical effectiveness evidence 
Fourteen publications assessing the clinical effectiveness of NSCLC treatments were found. 
Of these studies, thirteen reported the results of single trials, while the study by Clegg et 
al.201 summarised the results of multiple studies. Most of the identified clinical studies 
compared either gemcitabine plus cisplatin (Gem+Cisp) or gemcitabine plus carboplatin 
(Gem+Carb) against different combinations involving etoposide, mitomycin, vinblastine, 
vinorelbine, paclitaxel and ifosfamide, with or without cisplatin or carboplatin. A summary of 
the identified studies is given in Appendix 3.B, Table 3.b. In these studies, Gem+Cisp and 
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Gem+Carb appeared, in general, more effective than their comparators, resulting in small 
gains in survival and quality of life, but showing no marked difference in toxicity and rates of 
adverse events. 
A head-to-head comparisons of Gem+Cisp against Gem+Carb for NSCLC patients was 
reported in one study, by Zatloukal and colleagues208. This study208 gave the results of a 
phase III trial involving 89 and 87 patients in the Gem+Cisp and Gem+Carb arms. Findings 
showed the treatments to be of comparable effectiveness (in terms of response and overall 
survival) and toxicity; thus the authors concluded that Gem+Carb may be a sound alternative 
to Gem+Cisp, especially for patients unable to receive cisplatin. The main characteristics and 
conclusions of the Zatloukal et al.208 study are given in Table 4.1.  
Table 4.1: Summary of main effectiveness studies (NSCLC) 
 
Study Study 
type 
Intervention Comparator Outcome 
measures 
Authors’ conclusions 
Zatloukal et 
al. (2003)
208
 
Phase III 
RCT 
Gem+Cisp 
 
(89 patients in 
arm) 
Gem+Carb 
 
(87 patients 
in arm) 
Response 
 
Survival 
 
Toxicity 
 
Time-to-
progression 
Both Gem+Cisp and 
Gem+Carb are effective and 
comparable in efficacy and 
toxicity  
 
Gem+Carb may be acceptable 
for patients who cannot 
receive Gem+Cisp. 
 
4.3.2. Cost-effectiveness evidence 
Eight studies (including the study by Clegg et al.201) looking at the costs or cost-effectiveness 
of Gem+Cisp and/or Gem+Carb were identified. Of these, two were cost-minimisation 
analyses210;211, one was a cost analysis212, three cost-effectiveness analyses201;213;214 and two 
were reviews of existing economic studies215;216. The majority of these studies assessed 
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Gem+Cisp or Gem+Carb against other chemotherapeutic regimens. The main characteristics 
of the identified economic studies are given in Appendix 3.B, Table 3.c.  
Only one study reported a direct comparison of Gem+Cisp against Gem+Carb was found. 
This was a cost-minimisation analysis carried out in the United States by Khan and 
colleagues210. Assuming equivalent effectiveness across treatments, the authors investigated 
the costs per patient and cost per treatment course for cisplatin and carboplatin in 
combination with different agents, including gemcitabine, in the areas of non-small cell lung 
cancer, small cell lung cancer and ovarian cancer. The study results suggested that, in NSCLC, 
the use of carboplatin was associated with an extra US$9200 (£7180 in 2004 prices) and 
US$2100 (£1640 in 2004 prices) per patient and treatment course respectively210. A 
summary of the study by Khan et al.210 is given in Table 4.2.  
Table 4.2: Summary of main economic studies (NSCLC) 
 
Study Study type Compared treatments Authors’ conclusion 
Khan et al. 
(1999)
210
 
Cost-
minimisation 
analysis 
Cisplatin in combination with other 
agents (gemcitabine, paclitaxel, 
vinorelbine) 
Carboplatin in combination other 
agents (gemcitabine, paclitaxel, 
vinorelbine) 
In NSCLC, carboplatin-based regimens 
appear more costly than cisplatin-
based regimens 
 
4.4. Decision modelling for NSCLC 
A decision model was built with the aim to summarise the existing evidence and provide a 
comprehensive assessment of the effectiveness and cost-effectiveness of Gem+Cisp and 
Gem+Carb. The methods for constructing and populating the model are given below. 
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4.4.1. Model structure 
The model followed the progression of a cohort of 1000 NSCLC patients through three health 
states:  
a. ‘Progression-free’ (PGF), where patient remain on stable disease with no signs of 
disease progression; 
b. ‘Progression’ (PG), where disease has progressed, and  
c. ‘Death’ (D). 
The cohort enters the model at the ‘Progression-free’ state, where patients are scheduled to 
receive a four-cycle course of chemotherapy, with each cycle lasting 21 days. Patients stay in 
this state until they experience disease progression. Patients who experience disease 
progression, either during or after the four-cycle treatment period, move to ‘Progression’ 
and eventually to ‘Death’. Owing to the advanced stage of the disease and the short time 
period between the onset of advanced disease and death, the majority of the deaths are due 
to the disease208;217. Thus, moves from the ‘Progression-free’ state to ‘Death’ were not 
modelled. A graphical representation of the decision model can be seen in Figure 4.2.  
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Figure 4.2: Model structure for NSCLC 
 
The length of a model cycle was set to 21 days, equal to the treatment cycle. The cohort was 
followed for 3 years (53 cycles), by which time the vast majority of the patients are expected 
to have died. 
4.4.2. Model input 
Input parameters for the model were obtained from the published literature. When 
published evidence was not available, relevant information was obtained from expert 
opinion. Parameters and values used in the model, in terms of disease progression, costs and 
quality of life are described below.  
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4.4.2.A. Disease progression  
Information on disease progression, in the form of Kaplan-Meier survival and time-to-
progression curves for each treatment was obtained from the only study comparing 
Gem+Cisp against Gem+Carb208. These curves formed the basis for fitting Weibull models, 
which were used to derive estimates of the probability of a patient being at in any of the 
three model states at any given cycle. Weibull models are commonly used to describe the 
distribution of time-dependent events such as cancer survival and progression and are 
characterised by two parameters: the shape parameter alpha ( ) and the scale parameter 
beta ( )218;219.  
In fitting a Weibull model to existing survival curves, the task is to determine the values of 
the parameters   and  . This can be done by manipulating the survival function      of the 
Weibull distribution  
         [ (
 
 
)
 
] 
where   represents time (here, in discrete 21-day cycles) and  ,   represent the parameters 
of the Weibull model, to give 
  [       ]                   
This expression shows that the   [        ] is a linear function of      . Regressing 
  [        ] against       gives ordinary least square estimates of the model intercept and 
coefficients, which can be used to obtain the   and   parameters for the Weibull model, as 
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Once the parameters of the Weibull models for disease progression and death were 
estimated, the resulting progression-free survival and survival functions were used to 
calculate the probability of a patient staying at the ‘Progression-free’ state, being at the 
‘Progression’ state or being dead. This gave the number of patients in the ‘Progression-free’ 
and ‘Death’ states throughout the model. In turn, the number of patients in the ‘Progression’ 
state was calculated as the difference between the total number of patients in the cohort 
(i.e. 1000) and the sum of the patients in the remaining states (i.e. Patients in the 
‘Progression’ state = total number of patients in the cohort – (patients in ‘Progression-free’ 
state + patients in ‘Death’ state). For example, at cycle 10, 468 out of 1000 patients had not 
progressed and were in the ‘Progression-free’ state and 400 patients had died, leaving 132 
patients in the ‘Progression’ state.  
In the first two cycles for Gem+Cisp, the calculated sum of patients in the ‘Progression-free’ 
and ‘Death’ states exceeded the number of patients in the cohort (by ten patients in cycle 1 
and six patients in cycle 2). This resulted in observing negative numbers of patients in 
‘Progression’ state at cycles 1 and 2. In order to correct for this minor inconsistency, the 
number of patients in each of the states at cycles 1 and 2 were re-calculated by scaling the 
values down to 1000. Tables with the output of the regression model for disease progression 
and survival, the estimated   and   parameters as well as graphs of the fitted Weibull 
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models for each treatment are given in Appendix 3.C, Table 3.d to Table 3.k and Figure 3.b to 
Figure 3.e.  
4.4.2.B. Resource use and costs 
Costs associated with each treatment were estimated according to use of health care 
resource due to:  
a. drug acquisition and administration; 
b. adverse events; 
c. other medical resources, and  
d. terminal care. 
In estimating these costs, health care resource use derived from published studies was 
multiplied by unit cost estimates taken from national published sources220-222. Costs were 
converted to 2004 prices using the Hospital and Community Health Services pay and price 
inflation indices220, to reflect the relevant values in the year when the research funding 
decision was considered.  
Drug acquisition costs were calculated according to the standard treatment schedule of two 
administrations of gemcitabine on days 1 and 8 of a 21-day cycle, and one administration of 
platinum analogue (either cisplatin or carboplatin) on day 1 of the treatment cycle198. For 
these calculations, chemotherapy doses were multiplied by unit costs of drugs published in 
the British National Formulary222. The body surface area of an ‘average’ NSCLC patient (1.7 
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square metres) was taken from the literature201. Required doses, constituent parts and unit 
costs can be found in Table 4.3. 
Table 4.3: Unit costs of drug acquisition and administration (NSCLC) 
 
Resource Dose 
(assuming body surface area 
1.7 square metres) 
Cost 
(2004 prices) 
Source 
Gemcitabine (1250mg/m
2
) 2125mg £295 
British National 
Formulary
222
 
Cisplatin 80mg/m
2 
136mg £61 
Carboplatin AUC 6 680mg £252 
Dexomethasone 8mg £4 
Mannitol 200ml £2 
Chemotherapy 
administration (outpatient) 
£142 
NHS Reference Cost 
Schedules 2009-2010
221
 
 
According to the literature, chemotherapy administrations for NSCLC typically take place in 
an outpatient setting213;223;224. Outpatient chemotherapy administration cost was obtained 
from the NHS Reference Costs Schedules221. Different possibilities regarding the split 
between patients receiving chemotherapy in an inpatient and outpatient setting were 
explored in sensitivity analyses. The total cost of drug acquisition and administration per 
treatment cycle for Gem+Cisp and Gem+Carb are given in Table 4.4. 
Table 4.4: Cost of drug acquisition and administration for a treatment cycle (NSCLC) 
 
Treatment 
Day 1 of treatment cycle Day 8 of treatment cycle Total cost 
per 
treatment 
cycle 
Gem Platinum 
analogue 
Supple-
mentary 
agents 
Admini-
stration 
Gem Supple-
mentary 
agents 
Admini-
stration 
Gem+Cisp  £295 £61 £7 £142 £295 £4 £142 £946 
Gem+Carb £295 £252 £2 £142 £295 £4 £142 £1133 
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Separate calculations were carried out to obtain estimates of the expected cost of adverse 
events. In line with the literature, the focus was on significant toxicities which would 
typically lead to hospitalisation214;224. The probability of a patient in the cohort experiencing 
a serious adverse event was estimated from data on adverse event occurrence reported in 
the Zatloukal et al.208 study. This probability was combined with the unit cost of resolving 
each type of adverse event taken from the NHS Reference Costs Schedules221, using the 
formula: 
                                 ∑ (     )       
Here,  (     ) is the probability of a patient on treatment   experiencing adverse event   
and     is the unit cost for resolving the adverse event  . An alternative, fixed value for the 
cost of adverse events (£544 in 2004 prices) obtained from the literature201 was used in 
deterministic sensitivity analysis. The expected cost of experiencing an adverse event is 
given in Table 4.5. 
Table 4.5: Expected cost of adverse events (NSCLC) 
 
Adverse event 
Unit cost of 
resolving 
adverse 
event 
Gem+Cisp Gem + Carb 
Proportion of 
patients with 
adverse events* 
Expected 
cost 
 
Proportion of 
patients with 
adverse events* 
Expected 
cost 
 
Anaemia £465 0.126 £59 0.18 £84 
Thrombocytopenia £446 0.164 £73 0.326 £145 
Neutropenia £390 0.095 £37 0.146 £57 
Granulocytopenia £390 0.23 £90 0.303 £118 
Total expected cost - £258 £404 
* Data from Zatloukal et al.
208
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An estimate of the expected cost of other medical resources (additional outpatient visits and 
examinations) associated with Gem+Cisp was taken from Schiller and colleagues212 (£728 in 
2004 prices). In the absence of estimates of other medical cost specific to Gem+Carb, and in 
view of the fact that such costs are not expected to differ significantly between 
treatments225, the above value was used for both treatments. Last, an estimate of the costs 
associated with terminal care for cancer patients was obtained from Clegg et al.201 (£1460 in 
2004 prices). 
4.4.2.C. Health-related quality of life 
Although estimates of health-related quality of life (HRQoL) were reported in most of the 
trials identified in the search for effectiveness and cost-effectiveness evidence, these were 
non-preference-based measures, such as the EORTC-QLQ C30 and LC13206;226-231. In view of 
the fact that such instruments have limited applicability to economic evaluations130;232, a 
separate search for preference-based quality of life values was carried out. No preference-
based quality of life (utility) scores for advanced NSCLC were identified in the pre-2004 
literature. Therefore, utility scores were obtained from expert opinion (Professor L. 
Billingham, Professor of Biostatistics, University of Birmingham, 10-05-2011). The employed 
utility scores are given in Table 4.6.  
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Table 4.6: Preference-based health-related quality of life scores by health state (NSCLC) 
 
Health state Mean Standard error Source 
Progression-free 0.65 0.08 
Expert opinion 
(Professor L. Billingham, 
University of 
Birmingham) 
 
Progression 0.45 - 
Utility increment 
(i.e. Difference between ‘Progression-
free’ and ‘Progression’ scores) 
0.20 0.04 
 
4.4.3. Analysis of uncertainty 
Uncertainty in the model was propagated through probabilistic sensitivity analysis. Key 
parameters were represented by probability distributions, from which 5000 sets of values 
were drawn through Monte Carlo simulations169;171 to give 5000 estimates of the costs and 
effects associated with each treatment. 
As mentioned earlier, transition probabilities for the model were drawn from fitted Weibull 
time-to-progression and survival curves. Each curve is characterised by a shape parameter   
and a scale parameter  , which are derived from the intercepts and coefficients obtained 
from the fitted linear regression model. Thus varying the transition probabilities required 
varying   and  , through varying the coefficients of the linear regression model. The latter 
were given normal distributions with mean and standard errors taken directly from the 
linear model. Parameter values and assigned distributions are given in Appendix 3.D, Table 
3.l. 
Cost parameters were also varied in probabilistic sensitivity analysis. Drug acquisition and 
administration costs were assigned gamma distributions using the method of moments51. 
Owing to lack of information on the standard error of the cost of drug acquisition and 
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administration, and to avoid holding this cost fixed, the standard error was set at ten 
percent of the mean value. This value was chosen on the grounds that drug acquisition and 
administration costs are expected to be uniform across patients and are relatively well 
established in the British National Formulary222 and the NHS Reference Costs Schedules221. 
Making the cost of adverse events probabilistic involved varying the probability of a patient 
experiencing an adverse event, by fitting beta distributions to proportions of patients with 
different adverse events. Costs of other medical resources and terminal care were assigned 
gamma distributions. As no estimates of the variability around the latter values were 
available, a standard error of 25 percent of the mean value was used to reflect the greater 
variability in the use of other medical resources between patients. Details on assigned 
distributions and sources of employed values are given in Appendix 3.D, Table 3.m.  
Preference-based quality of life (utility) values were also subject to probabilistic sensitivity 
analysis, by varying the utility values for the ‘Progression-free’ and the difference in utility 
(i.e. utility increment) between the ‘Progression-free’ and ‘Progression’ states. The varied 
values (i.e. utility of ‘Progression-free’ state and utility increment) were assigned normal 
distributions, with estimates of means and standard errors obtained from expert opinion 
(Professor L. Billingham, Professor of Biostatistics, University of Birmingham, 10-05-2011). In 
this way, the utility score for the ‘Progression’ state was varied by varying the utility 
increment, which ensured that randomly drawn utility values for this state in probabilistic 
sensitivity analysis are not higher than those of the less severe ‘Progression-free’ state. A 
table with utility scores and assigned distributions is given in Appendix 3.D, Table 3.n.  
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In addition to probabilistic sensitivity analysis, a series of deterministic analyses were carried 
out, where input parameters were given different plausible values. Parameters targeted in 
deterministic sensitivity analysis were the discount rate, the average body surface area, the 
split between patients receiving chemotherapy in an outpatient and inpatient setting, and 
the expected cost of adverse events. 
4.4.4. Cost-effectiveness analysis 
The analysis adopted the perspective of the National Health Service (NHS). In agreement 
with existing recommendations114, both costs and health benefits (QALYs and life-years 
gained (LYG)) were discounted at an annual rate of 3.5 percent per year. The model was built 
and analysed in Microsoft Excel® (Microsoft Corporation, v.2007, Redmond, Washington, US) 
while STATA® (StataCorp, v. 11, College Station, Texas, US) and Parameter Solver (MD. 
Anderson Cancer Centre, University of Texas, Houston, Texas, US) were used for statistical 
analysis and distribution fitting tasks. 
4.5. Results 
Cost-effectiveness results, in terms of cost per QALY and cost per LYG, were obtained from 
5000 Monte Carlo simulations of the probabilistic model. These were expressed as point 
estimate ICERs and were presented graphically in cost-effectiveness planes (CE planes)173. 
Results were also plotted as cost-effectiveness acceptability curves (CEACs)174;175 and cost-
effectiveness acceptability frontiers (CEAFs)176. 
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4.5.1. Point estimate results  
Cost-effectiveness results of the model, expressed in terms of point estimate ICERs, are 
shown in Table 4.7. Gem+Cisp appeared less costly than Gem+Carb, resulting in cost savings 
of approximately £740. This difference is mainly due to higher Gem+Carb costs of drug 
acquisition and administration and higher expected costs of adverse events. In terms of 
QALYs, Gem+Cisp appeared to be slightly more effective than Gem+Carb, resulting in a gain 
of 0.015 QALYs. As Gem+Cisp is less costly and it is associated with additional QALYs, this 
treatment dominates Gem+Carb. In terms of cost per life-years gained, Gem+Carb appears 
to be marginally superior to Gem+Cisp, offering an additional 0.016 LYG (approximately 6 
days of additional survival). Given this, the cost per LYG of Gem+Carb compared to 
Gem+Cisp is approximately £45,000.  
Table 4.7: Point estimate cost-effectiveness results (NSCLC) 
 
Treatment Total cost Total QALYs Total LYG ICER 
(£ per QALY) 
ICER 
(£ per LYG) 
Gem+Cisp £5830 0.583 1.000 - - 
Gem+Carb £6568 0.568 1.016 Dominated £45,030 
 
4.5.2. Results of deterministic sensitivity analyses 
Deterministic sensitivity analyses were carried out to assess the impact of different 
assumptions on the cost-effectiveness results (Table 4.8). Alternative assumptions about a 
patients’ average body surface area and setting of chemotherapy administration had a 
minimal impact on the acquisition and administration costs of Gem+Cisp and Gem+Carb, and 
did not change the overall conclusion. Similarly, using alternative estimates of the cost 
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associated with adverse events inflated the total cost of both treatments by roughly the 
same amount, which had little impact on the difference in cost between Gem+Cisp and 
Gem+Carb. Last, different discount rates had a small impact on costs and benefits of 
Gem+Cisp or Gem+Carb, which did not affect the general conclusion of Gem+Carb being 
more costly and less effective than Gem+Cisp. 
Table 4.8: Results of deterministic sensitivity analysis (NSCLC) 
 
Parameter 
Gem+Cisp Gem+Carb 
ICER 
(£ per QALY) 
Total costs 
Total 
QALYs 
Total costs 
(£) 
Total 
QALYs 
Base case £5830 0.583 £6568 0.568 
Gem+Carb 
dominated 
Average body surface area 1.6m
2 
£5760 0.583 £6482 0.568 
Gem+Carb 
dominated 
Average body surface area 1.8m
2
 £5835 0.583 £6590 0.568 
Gem+Carb 
dominated 
Chemotherapy administration- 90% 
outpatient, 10% inpatient 
£5844 0.583 £6579 0.568 
Gem+Carb 
dominated 
Chemotherapy administration- 80% 
outpatient, 20% inpatient 
£5857 0.583 £6590 0.568 
Gem+Carb 
dominated 
Chemotherapy administration- 70% 
outpatient, 30% inpatient 
£5871 0.583 £6601 0.568 
Gem+Carb 
dominated 
Chemotherapy administration- 60% 
outpatient, 40% inpatient 
£5884 0.583 £6611 0.568 
Gem+Carb 
dominated 
Chemotherapy administration- 50% 
outpatient, 50% inpatient 
£5898 0.583 £6622 0.568 
Gem+Carb 
dominated 
Expected cost of adverse events at 
£544 as in Clegg et al. (2001)
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£6169 0.583 £6731 0.568 
Gem+Carb 
dominated 
No discounting £5877 0.598 £6618 0.582 
Gem+Carb 
dominated 
Discount rates- 6% p.a. for both costs 
and benefits 
£5799 0.573 £6534 0.559 
Gem+Carb 
dominated 
 
4.5.3. Results of the probabilistic sensitivity analysis  
Probabilistic sensitivity analysis results, in the form of estimated cost and QALY pairs 
generated through 5000 Monte Carlo simulations, are plotted in the CE plane shown in 
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Figure 4.3. In general, the generated estimates—appearing as points on the plane—are 
scattered across all four quadrants and appear clustered around the origin. 
 
Figure 4.3: Cost-effectiveness plane for comparison between Gem+Carb and Gem+Cisp (NSCLC) 
 
Proportions of the 5000 points on each of the quadrants in the plane are given in Table 4.9. 
Almost half of the points are located on the North West quadrant indicating that Gem+Carb 
is likely to be more costly and less effective than Gem+Cisp. Approximately one-third of the 
points are in the North East quadrant, suggesting that Gem+Carb may be more effective and 
more costly than Gem+Cisp. The remaining points are approximately split between the 
South East and South West quadrants.  
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Table 4.9: Proportion of incremental cost and QALY pairs on cost-effectiveness plane (NSCLC) 
 
Quadrant Proportion of points 
North East 0.35 
South East 0.08 
South West 0.09 
North West 0.48 
 
The CEACs for Gem+Cisp and Gem+Carb are given in Figure 4.4. In a situation where the 
decision-maker is not prepared to pay any amount for additional health benefits (i.e. the 
ceiling ratio is zero), the probabilities of Gem+Cisp and Gem+Carb being cost-effective are 
0.83 and 0.17, respectively.  
 
Figure 4.4: Cost-effectiveness acceptability curves (NSCLC) 
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Assuming a ceiling ratio of £30,000 per QALY gained, the probability that Gem+Cisp is more 
cost-effective than Gem+Carb is approximately 0.64. In other words, if society is willing to 
pay £30,000 for an additional QALY, there is a 64 percent chance that Gem+Cisp is the 
optimal treatment. At a high ceiling ratio of £80,000, the probability of Gem+Cisp being the 
most cost-effective option is approximately 0.60. As Gem+Carb does not result in the highest 
average net monetary benefits (NMBs) for values of the ceiling ratio at least as high as about 
£250,000 (not shown in this graph), the relevant CEAF corresponds to the CEAC for 
Gem+Cisp (Figure 4.5). 
 
Figure 4.5: Cost-effectiveness acceptability frontier (NSCLC) 
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effective than Gem+Carb; nonetheless, there is uncertainty surrounding the comparison, 
with the probability that Gem+Cisp is the preferred option at £30,000 per QALY being 
estimated at 0.64.  
As explained earlier, the purpose of this analysis is to assess the treatment adoption-related 
decision associated with this case study and to provide an analytic structure that can be used 
as a vehicle for the application of the analytic approaches to the NSCLC case study. Although 
this analysis was carried out for the purposes of the present doctoral project and does not 
aim to inform ‘real world’ treatment adoption decisions, care has been taken to ensure that 
the employed methods are appropriate and justifiable. 
Given this, the study presents certain strengths. In particular, the cost-effectiveness analysis 
makes use of a decision analytic model that traces the progression of NSCLC patients from a 
progression-free state to death. Key parameters used in the model, such as rates of disease 
progression, were identified through systematic searches in major bibliographic databases 
and were extrapolated using well-established methods232;233. In addition, the uncertainty 
around model parameters was accounted for by conducting probabilistic and deterministic 
sensitivity analyses. In particular, distributions representing the likelihood of each parameter 
to assume certain values were attached to all key parameters in the analysis and, when 
alternative values were found, these were also explored in deterministic sensitivity analyses. 
Last, results were presented as point-estimates and were plotted in CEACs and CEAFs, which 
show the probability of treatments being cost-effective and resulting in the highest net 
monetary benefits at different values of the ceiling ratio  .  
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Despite this, the analysis has a number of limitations. First, a more comprehensive model 
which would have taken into account treatment discontinuation might have offered better 
accuracy, nonetheless no evidence on the prognosis of people who discontinue treatment 
(i.e. transition probabilities from a discontinuation state to progression and death) was 
found, and using assumptions for such parameters would introduce considerable bias. 
Second, survival and progression data were taken from a relatively small study208. However, 
this was the only study reporting a head-to-head comparison between Gem+Cisp and 
Gem+Carb identified in the literature. In some cases, no estimates of the variance around 
specific parameters such as cost of drug acquisition and administration and cost of adverse 
events were available. In order to account for the uncertainty around such estimates, 
assumptions had to be made about their variance. This was deemed preferable to holding 
the parameters fixed at their mean values. Last, no estimates of utility scores for the specific 
patient group were found in the pre-2004 literature and thus values were obtained from 
expert opinion.  
4.7. Chapter overview 
The chapter reports a model-based analysis aimed to establish the effectiveness and cost-
effectiveness of Gem+Carb and Gem+Cisp for NSCLC given the information existing prior to a 
decision on funding a phase III trial on these treatments. In doing so, costs and QALYs 
associated with each treatment were estimated through a three-state decision analytic 
model. Overall, Gem+Cisp appeared superior to Gem+Carb, being less costly and resulting in 
additional QALYs. However, it must be noted that there is considerable uncertainty around 
the results, due to uncertainties around parameters such as transition probabilities, 
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probabilities of adverse events and preference-based quality of life scores. At a ceiling ratio 
of £30,000 per QALY there is a 0.36 probability that Gem+Cisp is not the optimal choice. The 
NSCLC model and the obtained results form the basis for addressing the research-related 
decision in subsequent chapters.  
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CHAPTER 5. Adoption-related decision in hormone-
refractory prostate cancer 
This chapter reports the methods employed in building a decision model to synthesise the 
available evidence on the treatment adoption decision for hormone-refractory prostate 
cancer (HRPC). As in the NSCLC case study, the decision model and its results aim to facilitate 
the application of the ‘payback’ and ‘value of information’ analyses to the relevant case 
study. The first part of the chapter gives the background to HRPC and specifies the pertinent 
adoption-related and research-related decisions. The chapter continues with the methods 
used in this model and the results of the cost-effectiveness analysis.  
5.1. Background  
Prostate cancer is the most common cancer in men and one of the most common causes of 
cancer-related deaths in the UK, second only to lung cancer. In 2009, there were about 
41,000 new cases of prostate cancer, approximately a quarter of which are anticipated to 
lead to death from the cancer234. 
In the early stages, prostate cancer is limited to the prostate gland and treatments for 
localised disease include early surgical resection, external beam radiotherapy or androgen 
suppression235. Although such treatments are initially beneficial, an estimated 10 to 50 
percent of patients eventually become metastatic, with cancer spreading to the pelvic lymph 
nodes and bone236;237. Metastatic disease is commonly treated with hormone ablation 
therapies, either by bilateral orchiectomy or medical castration. Hormone ablation is 
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associated with high initial response rates, but recurrence is almost unavoidable. Over time, 
the majority of patients stop responding and become refractory to hormone therapy238;239. 
Treatments for hormone-refractory prostate cancer (HRPC) are, in essence, palliative. 
Options typically include chemotherapy, further hormone manipulations as well as 
traditional palliative therapies such as radiotherapy and surgery for obstructive syndromes 
and bone problems240. 
Standard practice with reference to chemotherapy treatment has emerged to be docetaxel. 
This is routinely combined with prednisolone (or prednisone, which is metabolised to 
prednisolone by the patient’s organism), which has immunosuppressive and anti-
inflammatory properties. In England and Wales, docetaxel plus prednisone/prednisolone 
(DP) is recommended by NICE as the standard treatment for patients with hormone-
refractory prostate cancer241;242, largely on the basis of favourable survival and quality of life 
detected in the TAX327 randomised controlled trial243;244. 
Advanced HRPC typically spreads to bones, which in turn results in severe skeletal pain. Bone 
metastases are observed in about 80 percent of the HRPC patients245; therefore it is 
common for HRPC treatments to combine chemotherapy with agents capable of addressing 
bone-related problems. Two agents which have been proven beneficial in skeletal-related 
problems are zoledronic acid (ZA) and strontium-89 (Sr89)240;246;247. ZA is an intravenously 
administered bisphosphonate that aims to inhibit the loss of bone mass and has 
demonstrated anti-cancer activity248;249, while Sr89 is a bone-seeking radionuclide that acts 
by delivering therapeutic radiation to affected areas on bones. Both the treatments have 
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been proven effective in palliating bone metastases, and combining DP with ZA, Sr89 or both 
has been seen as potentially beneficial for patients suffering from advanced HPPC250;251. 
5.2. Adoption-related and research-related decisions 
In light of the above, a treatment adoption-related question arises as to which 
chemotherapy combination is the most beneficial and should be provided to HRPC patients 
with bone-related problems. Given this, the relevant research-related decision focuses on 
whether funding should be devoted to a clinical trial aiming to give further primary evidence 
on the effectiveness of the following combinations:  
a. docetaxel plus prednisolone (DP),  
b. DP plus zoledronic acid (DP+ZA), 
c. DP plus strontium-89 (DP+Sr89), and  
d. DP plus zoledronic acid plus strontium-89 (DP+ZA+Sr89).  
An early-stage trial, the Taxane Radioisotope Zoledronic Acid (TRAPEZE) phase II trial 
investigating these treatments had been already carried out. Continuation of this study to a 
phase III RCT was proposed to provide more robust evidence on the assessed treatments. 
The proposal was submitted for funding to the NIHR Health Technology Assessment 
programme through the programme’s ‘researcher-led’ stream and secured funds in 2006. 
The total cost of the trial was £2.54 million and involved research-related cost (i.e. 
researchers’ salaries, cost of facilities and trial organisation), excess treatment costs (i.e. cost 
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incurred due to participants in experimental arms receiving treatments other than standard 
care) and support costs (i.e. costs due to extra clinic time and patient recruitment).  
5.3. Existing clinical and economic evidence 
A literature review was carried out to retrieve existing evidence on the clinical effectiveness 
and cost-effectiveness of the chemotherapy combinations of interest. Searches for relevant 
literature were conducted in bibliographic databases (MEDLINE, NHS CRD, ISI Web of 
Knowledge), websites of institutions offering clinical guidance and systematic reviews (NICE 
Clinical Guidelines and Cochrane Collaboration Reviews), through Google Scholar®, as well as 
in the reference lists of relevant publications. Search term and methods used in this review 
are given in Appendix 4.A. 
Identified studies were selected and their full text was retrieved if they:  
a. had a focus on chemotherapy-eligible patients with advanced HRPC; 
b. investigated chemotherapy combinations including either of DP, DP+ZA, DP+Sr89 or 
DP+ZA+Sr89 aimed as first-line treatment for HRPC; 
c. reported cost-effectiveness results or clinical results on at least one of the following 
outcomes: tumour response, survival, time-to-progressive disease, quality of life, 
toxicity or treatment discontinuation rates. 
The review aimed to retrieve information available up to the point when the decision to 
fund the TRAPEZE phase III trial was considered, thus it included articles published before 
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the end of 2006. Only one study243 on clinical effectiveness and one economic study244 were 
identified; these studies are described below. 
5.3.1. Clinical effectiveness evidence 
Much of the existing evidence on the effectiveness of DP comes from a single study, the 
TAX327 phase III randomised controlled trial243. The trial involved 1006 patients, who were 
randomised to three chemotherapy arms: (a) docetaxel at 75mg/m2 plus 5mg prednisone or 
prednisolone administered every three weeks, (b) docetaxel at 30mg/m2 plus 5mg 
prednisone or prednisolone administered weekly, and (c) mitoxantrone 12mg/m2 plus 5mg 
prednisone or prednisolone every three weeks. The trial showed DP administered every 
three weeks to result in a statistically significant improvement in survival (HR: 0.76, CIs: 0.62 
to 0.94), pain and quality of life compared to mitoxantrone243. A summary of this study is 
given in Table 5.1.  
Table 5.1: Summary of main effectiveness studies (HRPC) 
 
Study Study 
type 
Intervention Comparator Outcome 
measures 
Authors’ conclusions 
Tannock et al. 
(2004)
243
 
Phase III 
RCT 
Mitoxantrone 
+ prednisone 
or 
prednisolone 
(Patients in 
arm=335) 
Docetaxel 75mg/m
2
 
every 3 weeks + 
prednisolone or 
prednisone 
(Patients in 
arm=332) 
Docetaxel 30mg/m
2
 
weekly + 
prednisolone or 
prednisone 
(Patients in 
arm=330) 
Survival 
Pain 
Prostate-specific 
antigen levels 
Adverse events 
Quality of life 
Docetaxel and 
prednisolone 
provided every three 
weeks is associated 
with superior 
survival and 
improved outcomes 
in terms of pain, 
prostate-specific 
antigen level, and 
quality of life, as 
compared with 
mitoxantrone plus 
prednisone. 
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Evidence from the TAX327 study was used in the NICE Technology Assessment Report 
commissioned to investigate the effectiveness and cost-effectiveness of DP244;252 and had a 
significant impact on the Institute’s decision to recommend DP as the preferable treatment 
for HRPC patients who are generally able to care for themselves242. No studies comparing DP 
and DP+ZA, DP+Sr89 and DP+ZA+Sr89 were identified in the literature.  
5.3.2. Cost-effectiveness evidence 
The only relevant cost-effectiveness study identified in the literature was the Technology 
Assessment Report mentioned above, by Collins and colleagues244. The study aimed to 
explore the effectiveness and cost-effectiveness of docetaxel in combination with 
prednisone or prednisolone compared to a series of alternative treatments including 
mitoxantrone and estramustine244. To investigate this, Collins et al.244 constructed a two-
state (alive and dead) Markov model and populated it with evidence from the case for 
adoption of Taxotere® (trade name of docetaxel) to NICE. The study found two treatments 
not to be dominated: DP given every three weeks, and mitoxantrone plus 
prednisone/prednisolone. In the comparison between them, DP resulted in an ICER of 
approximately £32,700 per additional QALY (£33,750 in 2006 prices). A summary of the 
study is given in Table 5.2 below.  
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Table 5.2: Summary of main economic studies (HRPC) 
 
Study Study type Compared treatments Authors’ conclusion 
Collins et al. 
(2005)
244
 
Systematic review, 
cost-effectiveness 
analysis and cost-
utility analysis 
Docetaxel + prednisone/prednisolone (3-
weekly) 
Mitoxantrone + prednisone/prednisolone 
Prednisolone/prednisone alone 
Docetaxel + prednisone/prednisolone 
(weekly) 
Docetaxel + estramustine 
Docetaxel + estramustine + 
prednisone/prednisolone (70mg/m
2
 every 
3 weeks) 
Docetaxel + estramustine + 
prednisone/prednisolone (35 mg/m
2 
twice 
every 3 weeks) 
Mitoxantrone + prednisone/prednisolone 
+ clodronate 
Docetaxel plus 
prednisone/prednisolone 
(3-weekly) appears cost-
effective in comparison to 
other chemotherapy and 
non-chemotherapy 
regimens, only if the NHS is 
willing to pay £32,706 per 
QALY. 
 
5.3.3. Evidence from the TRAPEZE phase II clinical trial 
As noted earlier, patient-level evidence on the specific treatments was available from the 
TRAPEZE phase II trial. This was a randomised controlled trial involving 200 HRPC 
participants allocated into four treatment arms: DP (50 participants), DP+ZA (49 
participants), DP+Sr89 (51 participants) and DP+ZA+Sr89 (50 participants). The study 
collected data on progression-free survival, adverse events, health care resource use and 
health-related quality of life.  
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5.4. Decision modelling for HRPC 
Decision analytic models are used widely to synthesise evidence and provide summary 
results on the cost and effectiveness of health technologies51;157. In the context of this study, 
a decision model was constructed to investigate the clinical and cost-effectiveness of DP, 
DP+ZA, DP+Sr89 and DP+ZA+Sr89 on the basis of available evidence. Methods involved in 
building, populating and analysing the model are given in the following section. 
5.4.1. Model structure 
A Markov model was developed to assess and compare the cost-effectiveness of the 
treatments of interest. Markov models are commonly used to represent disease pathways in 
areas where events occur at discrete time periods253;254. The model consists of four discrete 
health states:  
a. ‘Progression-free, on treatment’ (PGF-OT) where advanced HRPC patients with 
stable disease receive one of the compared chemotherapy treatments; 
b. ‘Progression-free, not on treatment’ (PGF), reflecting the state in which patients 
have not shown signs of progression, but they have stopped receiving treatment, 
either because they completed the course or because they discontinued before the 
end of the scheduled treatment period;  
c. ‘Progression’ (PG), where patients have developed progressive disease, and  
d. ‘Death’ (D). 
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A cohort of HRPC patients in stable disease enter the model in the PGF-OT state, where they 
are scheduled to receive six cycles of chemotherapy, with each cycle lasting three weeks. 
Patients stay in this state for six cycles, unless they discontinue treatment due to intolerable 
toxicity (in which case they move to the state PGF), discontinue due to disease progression 
(in which case they move to the state PG), or die.  
At the end of the treatment course, patients who have completed all six cycles move to the 
PGF state. Upon progression, patients move to the state PG and, eventually, to the 
absorbing state D. The structure of the decision model is given in Figure 5.1.  
 
Figure 5.1: Model structure for HRPC 
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The length of each discrete model cycle was set at three weeks to concur with a treatment 
cycle. Patients were followed for four and a half years (80 cycles), by which time nearly the 
entire cohort of patients had died. Evidence on patients’ transitions between model states 
was based on available patient-level data from the TRAPEZE phase II trial. When patient-
level data was not available, estimates were drawn from the published literature and expert 
opinion.  
5.4.1.A. Transition probabilities 
Probabilities of transitions between model states were sought for two main stages in the 
model: during the period of scheduled treatment (cycles 1 to 6), where transitions reflected 
treatment discontinuation, and thereafter (cycles 7 to 80), where transitions represented 
disease progression after a patient had gone past the treatment period. 
As mentioned earlier, the model was designed to take into account the fact that HRPC 
patients may discontinue treatment at any point before completion of the scheduled six 
cycles of chemotherapy. Reasons for discontinuations are toxicity, disease progression or 
death. In the case of discontinuation due to intolerable toxicity, a patient would move from 
PGF-OT to PGF; in case of discontinuation due to progression, a patient would move from 
PGF-OT to PG, while in the event of death, a patient would move from PGF-OT to D. 
Discontinuation rates were calculated using phase II trial data on numbers of patients who 
withdrew from treatment at different points during cycles 1 to 6. For example, the 
probability of a patient discontinuing DP due to progressive disease and thus moving from 
PGF-OT to PG was found by dividing the observed five transitions to PG by the total of 219 
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patient-cycles at risk of progression, to give a value of 0.023. For each treatment arm, 
numbers of patient-cycles spent at each of the four states during the first six cycles are given 
in Appendix 4.B, Table 4.b.  
Probabilities of transition taking place after the scheduled treatment period (i.e. after cycle 
6) were calculated in a similar way, by dividing the number of observed transitions by the 
total number of patient-cycles at risk. For example, the probability of a patient on DP 
treatment moving from PG to D was calculated from the observed number of 29 deaths, 
divided by the total of 596 patient-cycles at risk to give a probability of 0.049. Transition 
matrices showing counts of cycles spent at each health state in the period beyond cycle 6 
can be found in Appendix 4.B, Table 4.c. 
To test whether the use of non-time-dependent transition probabilities is appropriate for 
representing the available data, two Kaplan-Meier survival curves were generated for each 
treatment, the first depicting the raw patient-level survival data obtained from the TRAPEZE 
phase II trial and the second showing survival calculated from entering the estimated non-
time-dependent transition probabilities in the model. A close match between the curves was 
observed (see Appendix 4.C) suggesting that the calculated non-time dependent transition 
probabilities were a good representation of the empirical data and thus they were 
appropriate for use in the model.  
5.4.1.B. Resource use and costs 
Costs to the NHS were calculated by taking into account health care resource use accruing 
under four main categories:  
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a. cost of drug acquisition and administration, 
b. cost of serious adverse events, 
c. cost associated with second-line treatment, and  
d. cost of terminal care. 
The cost of drug acquisition was calculated according to dosages reported in the TRAPEZE 
trial protocol for a male patient of average body surface area of 1.9 square metres244. 
According to the study’s treatment schedule, both DP and ZA administrations—relevant to 
the DP, DP+ZA and DP+ZA+Sr89 arms—would take place on the first day of each 3-week 
cycle for a total of six chemotherapy cycles, while Sr89—relevant to DP+Sr89 and 
DP+ZA+Sr89 arms—would be administered once, at the end of the sixth cycle. Unit costs of 
drugs were taken from the British National Formulary222. As the unit cost of strontium-89 
was not available, an estimate was obtained from a NHS hospital [personal communication 
with Dr C. Boivin, Head of Nuclear Medicine, Queen Elizabeth Hospital Birmingham, 03-06-
2011]. Costs are reported in 2006 prices, in order to relate to the point in time when funding 
for the TRAPEZE phase III trial was considered. Information on doses, constituent parts and 
unit costs is given in Table 5.3.  
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Table 5.3: Unit costs of drug acquisition and administration (HRPC) 
 
Resource Dose 
(assuming body 
surface area 1.9 
square metres) 
Cost 
(2006 prices) 
Source 
Docetacel (75mg) 142.5mg £986 
British National Formulary
222
 
Prednisolone (10mg 
daily) 
10mg (daily, for 21 
days per cycle) 
£12 
Dexomethasone 
(antiemetics) 
8mg £5 
Zoledronic acid (4mg) 4mg £169 
Strontium-89  150MBq £1576 
Personal communication: Dr C. 
Boivin, Department of Nuclear 
Medicine, Queen Elizabeth 
Hospital Birmingham 
Chemotherapy 
administration 
(outpatient) 
£158 NHS Reference Cost Schedules
221
 
 
In accordance with the literature, chemotherapy was considered to be administered in an 
outpatient setting243;244. The cost of chemotherapy administration was taken from published 
NHS Reference Costs Schedules221 and represents the national average cost for an 
outpatient chemotherapy delivery. The total cost per treatment cycle for DP, DP+ZA, 
DP+Sr89 and DP+ZA+Sr89 is given in Table 5.4.  
Table 5.4: Total cost of drug acquisition and administration for a treatment cycle (HRPC) 
 
Treatment DP Zoledronic 
acid 
Strontium-
89 
Antiemetics Administra-
tion 
Total cost 
per 
treatment 
cycle 
DP £998 - - £5 £158 £1160 
DP+ZA £998 £169 - £5 £158 £1329 
DP+Sr89 £998 - £263* £5 £158 £1423 
DP+ZA+Sr89 £998 £169 £263* £5 £158 £1592 
*A single fraction of strontium-89 is given in a six-cycle course. For presentation purposes, the cost of strontium-89 
(£1576) has been amortised to one treatment cycle. 
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The cost of serious adverse events leading to hospitalisation was calculated by estimating 
the probability of a patient experiencing an adverse event on the basis of events observed in 
the phase II trial and multiplying this by the unit cost of resolving the adverse event, using 
the formula: 
                                  ∑ (     )      
Here,          is the probability of experiencing an adverse event   while on treatment   
and     is the unit cost of resolving the event  . Unit costs for resolving the most common 
adverse events (diarrhoea, febrile neutropenia, haemoglobin, infection, 
neutrophils/granulocytes, pain and urinary retention) were obtained from the NHS 
Reference Cost Schedules221. Other, less common adverse events were grouped together 
under ‘other adverse events’ and were assigned the national average cost of a non-elective 
inpatient hospital stay taken from the Unit Cost of Health and Social Care report220. The 
expected cost of adverse events is given in Table 5.5. Counts of patients experiencing 
different adverse events and the unit cost for treating these events are given in Appendix 
4.D, Table 4.d and Table 4.e, respectively. 
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Table 5.5: Expected cost of adverse events (HRPC) 
 
Adverse event 
Expected cost of adverse events 
DP DP+ZA DP+Sr89 DP+ZA+Sr89 
Diarrhoea £6 £6 £6 £12 
Febrile neutropenia  £26 £27 £51 £17 
Haemoglobin £10 £11 £0 £21 
Infection £37 £30 £14 £15 
Neutrophils/granulocytes £35 £0 £17 £0 
Pain £90 £55 £124 £54 
Urinary retention £0 £34 £0 £8 
Other £810 £537 £357 £972 
Total expected cost £1014 £699 £569 £1099 
 
Depending on their physical condition, patients who do not respond to chemotherapy may 
be eligible for second-line palliative care, typically in the form of radiotherapy, further 
chemotherapy or further treatment with radioisotopes. For each treatment, the expected 
cost of second-line care was calculated by weighting the probability of a patient receiving 
further chemotherapy, radiotherapy or radioisotopes treatment by the cost of these 
palliative options, according to the formula: 
                                          ∑             
Here,         is the probability of a patient on treatment   to receive second-line treatment 
 , obtained from phase II trial data and     is the unit cost of second-line treatment  . The 
total expected cost of second-line treatment is given in Table 5.6, while counts of patients 
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who received second-line treatment and unit costs of each of the provided treatments are 
given in Appendix 4.D, Table 4.f and Table 4.g, respectively. The expected cost was 
calculated on the basis of the fact that patients receiving further chemotherapy are typically 
given an average of four cycles of DP, while those who are treated with radiotherapy or 
further radioisotopes (strontium-89) typically receive a single fraction of radiation [personal 
communication with Professor N. James, Professor of Oncology, University of Birmingham, 
06-03-2011]. Last, the cost of terminal care was taken from the literature201 (£1532 in 2006 
prices). 
Table 5.6: Expected cost of second-line treatment (HRPC) 
 
 
DP DP+ZA DP+Sr89 DP+ZA+Sr89 
Expected cost of second-line 
treatment 
£606 £889 £743 £475 
 
5.4.1.C. Health-related quality of life 
Data on patients’ health-related quality of life were collected throughout the trial by using 
the EQ-5D health status classification instrument. Responses to EQ-5D were translated to 
preference-based (utility) scores by using a UK-specific tariff255;256. These data allowed 
estimating the mean utility scores by treatment and health state given in Table 5.7 below. 
The utility score for the state ‘Death’ is zero.  
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Table 5.7: Preference-based quality of life scores by health state and treatment (HRPC) 
 
Treatments 
‘Progression-free, on 
treatment’ state 
‘Progression-free, not on 
treatment’ state 
‘Progression’ state 
Mean Standard 
error 
Mean Standard 
error 
Mean Standard 
error 
DP 0.625 0.04 0.605 0.05 0.500 0.08 
DP+ZA 0.712 0.03 0.706 0.03 0.569 0.05 
DP+Sr89 0.714 0.04 0.693 0.04 0.503 0.09 
DP+ZA+Sr89 0.724 0.03 0.624 0.05 0.558 0.08 
 
5.4.2. Analysis of uncertainty 
Probabilistic sensitivity analysis was carried out to account for the uncertainty around key 
parameters in the model. Five thousand sets of values were drawn from distributions 
attached to parameters. For each set of values, results were recalculated to give 5000 
estimates of each treatment’s total costs and effects169;171. 
With reference to transitions probabilities, the move from state ‘Progression’ to ‘Death’ was 
informed by binomial data and was represented by a beta distribution. Beta distributions are 
characterised by parameters   and  , where 
                              
                                           
Following on from the earlier example, the probability of a patient in the DP arm moving 
from ‘Progression’ to ‘Death’ can be represented by a beta distribution with parameter   
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equal to the number of observed transitions (29) and parameter   equal to the number of 
patient-cycles at risk of transition (596) minus the observed transitions (beta(29,567)).  
Patients in states other than ‘Progression’ (i.e. PGF-OT and PGF) may move to more than one 
different states (e.g. from PGF-OT to PGF or PG or D), that is, the data informing these 
transitions are multinomial. Thus, uncertainty around the transition probabilities from 
‘Progression-free, on treatment’ and ‘Progression-free, not on treatment’ to other states can 
be represented by Dirichlet distributions. Dirichlet distributions are multivariate extensions 
of beta distributions, where the number of parameters is equal to the number of categories 
(here, transitions). For example, the uncertainty around the probability for a patient on DP 
moving from ‘Progression-free, on treatment’ to the rest of the states is represented by a 
Dirichlet(204,5,5,5). Details on parameters and their respective distributions are given in 
Appendix 4.E, Table 4.h. 
Similarly, estimated costs of drug acquisition and administration were assigned gamma 
distributions. No information on the variance of these estimates was available. Therefore, 
standard errors were hypothesised to be 10 percent of the mean values, on the premise that 
drug acquisition and administration costs are typically well specified in national 
formularies221;222 and they do not tend to vary greatly. 
The expected cost of adverse events was made probabilistic by varying the probability of 
patients on each treatment experiencing different serious adverse events. To do so, beta 
distributions were attached to counts of adverse events taken from the TRAPEZE phase II 
trial. Similarly, the cost of second-line treatment was varied through assigning beta 
138 
distributions to the probability of patients in each treatment receiving further 
chemotherapy, radiotherapy or radioisotopes as second-line care. The cost of terminal care 
was assigned a gamma distribution, with the standard error set at a value of 25 percent of 
the mean cost on the assumption that there is greater variability around such costs than for 
drug acquisition and administration costs. Details on distributions attached to cost-related 
parameters are given in Appendix 4.E, Table 4.i. 
Last, uncertainty around utility scores for each health state and treatment was propagated 
by calculating utility increments. Here, rather than varying utility scores of different health 
states, probability distributions were attached to differences in mean utility scores between 
states (PGF-OT and PGF; PGF-OT and PG), to ensure that utility scores for more severe health 
states do not assume values higher than those of ‘milder’ states. Utility increments were 
attached normal distributions with mean and standard errors estimated from the available 
data. These can be found in Appendix 4.E, Table 4.j. 
In addition to probabilistic analysis, deterministic sensitivity analyses were carried out to 
explore the impact of different assumptions around values of discount rates, patients’ mean 
body surface area and setting of chemotherapy administration on results.  
5.4.3. Cost-effectiveness analysis 
The perspective adopted in the analysis was that of the NHS. Costs and benefits(QALYs and 
life-years gained) were discounted at an annual rate of 3.5 percent, in line with current NICE 
recommendations114. The decision model was built and analysed in Microsoft Excel® 
(Microsoft Corporation, v.2007, Redmond, Washington, US), while statistical analysis tasks 
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were also carried out in STATA® (StataCorp, v. 11, College Station, Texas, US) and Parameter 
Solver (MD. Anderson Cancer Centre, University of Texas, Houston, Texas, US).  
5.5. Results 
Cost-effectiveness results obtained from the model are expressed as point estimate ICERs (in 
terms of cost per QALY and cost per LYG) and are plotted in cost-effectiveness planes (CE 
planes), cost-effectiveness acceptability curves (CEACs) and cost-effectiveness acceptability 
frontiers (CEAFs). 
5.5.1. Point-estimate results  
Mean total cost, QALYs and life-years gained for each treatment calculated through the 
model are given in Table 5.8. As the comparison involved more than two mutually exclusive 
treatments, ICERs were calculated by sorting the treatments in order of increasing cost, 
eliminating dominated treatments and comparing the remaining options139;257.  
Table 5.8: Point estimate cost-effectiveness results (HRPC) 
 
Treatment Total cost Total QALYs Total LYG ICER 
(£ per QALY) 
ICER 
(£ per LYG) 
DP £8,949 0.806 1.383 - - 
DP+ZA £9,855 0.829 1.251 
Weakly dominated 
(£39,726) 
Dominated 
DP+Sr89 £10,172 0.957 1.481 £8113(against DP) £12,491 
DP+ZA+Sr89 £11,436 0.874 1.341 Dominated Dominated 
 
The analysis showed DP to be the least costly treatment, followed by DP+ZA, DP+Sr89 and 
DP+ZA+Sr89. In terms of QALYs, DP was the least effective treatment. Although DP+ZA is 
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more effective than DP, this treatment is weakly dominated by a combination of DP and 
DP+Sr89. DP+ZA+Sr89 is more costly and less effective than DP+Sr89 and thus it is 
dominated by the latter. In the comparison between non-dominated treatments, DP+Sr89 is 
associated with a greater cost and additional QALYs and an ICER of about £8100 per 
additional QALY. In terms of cost per life-years gained, DP+ZA and DP+ZA+Sr89 are strongly 
dominated by DP and DP+Sr89, respectively. Here, too, the remaining comparison is 
between DP and DP+Sr89, with the latter being associated with an ICER of about £12,500 per 
life-year gained. 
5.5.2. Results of deterministic sensitivity analyses  
Deterministic sensitivity analyses were conducted to investigate the effect of various 
plausible assumptions on results. The results of these analyses are given in Table 5.9. 
Overall, the impact of different assumptions on the magnitude of the results was limited. 
Alternative dosages of chemotherapy treatments resulting from different assumptions about 
patients’ average body surface area did not result in additional or fewer drug vials used and 
thus these assumptions had no impact on total costs. The setting of chemotherapy 
administration had a minimal impact on costs; assuming that half of the patients received 
chemotherapy in an inpatient setting raised the total cost by approximately £18. A 
somewhat larger change in costs and benefits resulted by employing different discount 
rates—0 percent (i.e. no discounting) and 6 percent. 
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Table 5.9: Results of deterministic sensitivity analysis (HRPC) 
 
Parameter 
DP DP+ZA DP+Sr89 DP+ZA+Sr89 ICER 
(£ per QALY) (DP 
vs. DP+Sr89) 
Total cost Total 
QALYs 
Total cost Total 
QALYs 
Total costs Total 
QALYs 
Total 
costs 
Total 
QALYs 
Base case £8949 0.806 £9855 0.829 £10,172 0.957 £11,436 0.874 £8113 
Average body surface area 2m
2
 
(base case 1.9 m
2
) No changes in total costs due to greater/smaller average body surface area, as higher/lower active treatment dosage is 
covered by the same 8ml vial. Average body surface area 1.8 m
2
 
(base case 1.9 m
2
) 
Chemotherapy administration- 
90% outpatient, 10% inpatient 
£8966 0.806 £9872 0.829 £10,190 0.957 £11,454 0.874 £8105 
Chemotherapy administration- 
80% outpatient, 20% inpatient 
£8983 0.806 £9889 0.829 £10,207 0.957 £11,472 0.874 £8112 
Chemotherapy administration- 
70% outpatient, 30% inpatient 
£8999 0.806 £9906 0.829 £10,225 0.957 £11,490 0.874 £8118 
Chemotherapy administration- 
60% outpatient, 40% inpatient 
£9016 0.806 £9923 0.829 £10,243 0.957 £11,507 0.874 £8124 
Chemotherapy administration- 
50% outpatient, 50% inpatient 
£9033 0.806 £9940 0.829 £10,261 0.957 £11,525 0.874 £8130 
No discounting £9046 0.837 £9952 0.858 £10,290 0.992 £11,553 0.904 £8006 
Discount rates- 6% p.a. for both 
costs and benefits 
£8885 0.786 £9791 0.810 £10,094 0.934 £11,358 0.854 £8186 
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For different assumptions, incremental analysis of DP versus DP+Sr89 (i.e. the non-
dominated treatments) resulted in ICERs broadly similar to that in the base case. The 
additional cost arising from the hypothesis that up to half of the treatment administrations 
may take place at an inpatient setting had an approximately equal effect to all treatments 
and it was cancelled out in incremental analysis, resulting in ICER values similar to that of 
the base case analysis (range between £8105 and £8130). Compared to the base case value 
of £8113 per QALY, the ICER calculated from undiscounted costs and benefits was slightly 
more ‘favourable’ to DP+Sr89, while discounting at 6 percent per annum led to an increase 
in the ICER of DP+Sr89 of approximately £70. 
5.5.3. Results of the probabilistic sensitivity analysis  
Cost and QALY estimates obtained from the probabilistic sensitivity analysis were plotted in 
CE planes. These show the comparisons between DP and DP+ZA (Figure 5.2), DP+Sr89 
(Figure 5.3) and DP+ZA+Sr89 (Figure 5.4). Each point on the planes represents a simulated 
pair of incremental costs and effects (QALYs).  
The proportions of points in each quadrant of the CE planes are shown in Table 5.10. With 
respect to the comparison between DP and DP+ZA, approximately 79 percent of the 5000 
points appear in the north half of the plane, indicating that this treatment is likely to result 
in higher costs than DP. On the other hand, the points appear split evenly between the west 
and east halves of the plain (56 percent and 44 percent respectively), suggesting that there 
is considerable uncertainty on whether DP+ZA is more effective than DP. 
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Figure 5.2: Cost-effectiveness plane for comparison between DP+ZA and DP (HRPC) 
 
 
 
Figure 5.3: Cost-effectiveness plane for comparison between DP+Sr89 and DP (HRPC) 
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Figure 5.4: Cost-effectiveness plane for comparison between DP+ZA+Sr89 and DP (HRPC) 
 
 
Table 5.10: Proportion of cost and QALY pairs on cost-effectiveness planes (HRPC) 
 
Quadrant 
Proportion of points in each quadrant of the CE planes 
DP+ZA vs. DP 
(Figure 5.2) 
DP+Sr89 vs. DP 
(Figure 5.3) 
DP+ZA+Sr89 vs. DP 
(Figure 5.4) 
North East 0.45 0.70 0.66 
South East 0.11 0.10 0.01 
South West 0.10 0.03 0.01 
North West 0.34 0.17 0.32 
 
In the comparison between DP and DP+Sr89, the majority of the points (about 70 percent) 
appear in the north east quadrant, indicating that DP+Sr89 is more costly and more effective 
than DP. Last, with respect to the comparison between DP and DP+ZA+Sr89, the latter 
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treatment is highly likely to be more costly (98 percent of points in the north half), while 
there is a reasonably high likelihood that this treatment is also of superior effectiveness (66 
percent of points in the west half). 
CEACs representing the probability of each of the compared treatment being cost-effective 
for ceiling ratio values ranging from £0 to £80,000 are given in Figure 5.5. If a decision-
maker is not willing to pay any additional amount for extra health benefits (i.e. the ceiling 
ratio is zero), the most cost-effective option is DP, with a probability of 0.72. For a ceiling 
ratio of £30,000 per QALY, the treatment with the highest probability of being cost-effective 
switches to DP+Sr89 (probability of 0.53). At a high ceiling ratio value of £80,000 per QALY, 
the probability of DP+Sr89 being the optimal treatment is about 0.55 while DP+ZA+Sr89 has 
the second highest probability, of approximately 0.19.  
 
Figure 5.5: Cost-effectiveness acceptability curves (HRPC) 
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The results were also plotted as a cost-effectiveness acceptability frontier (CEAF), which 
plots the treatment resulting in the highest net monetary benefits (NMBs) at different 
values of the ceiling ratio. The frontier showed that DP is cost-effective at ceiling ratios up to 
£8100, with DP+Sr89 becoming cost-effective at ceiling ratios over this value (Figure 5.6). 
 
Figure 5.6: Cost-effectiveness acceptability frontier (HRPC) 
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This analysis sought to answer the adoption-related decision around HRPC given existing 
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resulting in a relatively low ICER of approximately £8100 per additional QALY. Nonetheless, 
the existence of uncertainty in the results suggests that, at a ceiling ratio of £30,000 per 
QALY, the probability that DP+Sr89 is the optimal choice is low, at 0.53. 
Although the generated results do not aim to inform ‘real world’ treatment adoption 
decisions, the work aimed to be as comprehensive as possible. Given this, the analysis 
presents certain strengths. A particular strength arises from the use of a Markov model. 
Such models trace patients from the point they receive treatment until death and measure 
the accumulated survival, costs and health outcomes at discrete points in time253;258. In 
addition, the model is structured in a way that takes into account treatment 
discontinuation, a factor which has a sizeable impact on treatments’ cost and effectiveness. 
Moreover, key parameters in the model, such as transition probabilities and probability of 
experiencing different adverse events were calculated on the basis of patient-level data 
obtained from a phase II study involving the very same population and very same treatment 
options that the analysis is concerned with. Last, uncertainty around model parameters was 
accounted for in deterministic as well as probabilistic sensitivity analyses.  
However, the analysis is not without limitations. First, the phase II trial from which 
estimates of treatment effect, adverse events and health-related quality of life are taken 
was relatively small, involving approximately 50 patients per treatment arm. However, the 
uncertainty around these was made explicit by assigning distributions to these parameters. 
An additional limitation is associated with the fact that entering the ‘Progression-free, not 
on treatment’ state are patients who either completed the treatment course, or 
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discontinued due to toxicity. These two subgroups may differ in the quality of life they 
experience, but this difference is expected to be small, given that toxicity events are 
typically resolved quickly and are not expected to result in prolonged hospitalization or 
chronic conditions which could have a notable impact on quality of life239. Last, to avoid 
ignoring uncertainty around parameters for which estimates of variance were not available 
(e.g. cost of a strontium-89 fraction, cost of terminal care), employed standard errors were 
based on assumptions.  
5.7. Chapter overview 
The chapter reports the methods and results obtained from a cost-effectiveness analysis 
aimed to address the adoption-related decision in the HRPC case study. Results showed that 
two of the assessed treatments (DP+ZA, DP+ZA+Sr89) were dominated. Of the remaining 
treatments, DP+Sr89 appeared cost-effective as compared to DP, resulting in a low ICER of 
approximately £8100 per QALY. This conclusion, however, should be viewed with caution, as 
the probability of DP+Sr89 being cost-effectiveness at a ceiling ratio of £30,000 is 
approximately 0.53, suggesting that there is considerable uncertainty around the results and 
a 0.47 probability that DP+Sr89 is not the optimal treatment. The constructed model and its 
results are key to the application of ‘payback’ and ‘value of information’ to the HRPC case 
study, which is reported in the following chapters. 
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CHAPTER 6. Practical application of ‘payback of research’ to 
case studies 
This chapter reports the practical application of the ‘payback of research’ framework to the 
NSCLC and HRPC case studies. The application was carried out by using the Preliminary 
Assessment of Technology for Health Services (PATHS)67, the most recent ‘payback’ model 
identified in the literature. Rather than to provide results for an actual decision on funding 
further research, the application aimed to identify strengths and limitations of this 
framework and suggest areas where improvements may be needed. Observations made 
throughout this analysis form the basis for assessing and discussing ‘payback’ in Chapters 8 
and 9. 
The chapter begins with a brief description of the rationale and methods underpinning the 
PATHS model and continues with the application of the model to each of the case studies. 
The final part of the chapter discusses points relevant to this application. 
6.1. Description of methods in PATHS 
As explained earlier in Chapter 3, ‘payback’ models are based on the notion that evidence 
generated through evaluative research is valuable because it enables informed choices 
about treatment provision, which, in turn, lead to additional benefits arising to the 
population. On this basis, the approach assumes that the value of conducting a piece of 
research—for example, a trial investigating two treatments—can be inferred by looking at 
the difference in costs and benefits (or, for simplicity, the difference in net monetary 
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benefits (NMBs)) expected to accrue to the population under two distinct situations: with 
and without the trial taking place. In the first situation, where a trial takes place, it is 
expected that it will generate evidence on the treatments’ effectiveness (for example, 
disease progression rates), this evidence will be used as input in an economic evaluation 
study to give estimates of the treatments’ per-patient cost and benefits, and, once these 
estimates become available, there will be a change in clinical practice. In the second 
situation, where research does not take place, clinical practice is expected to remain largely 
as it is. In each of these situations, the total sums of NMBs accruing to the population of 
patients eligible for the treatments in question depend on two factors: a) the costs and 
benefits associated with the treatments, and b) the use of these treatments in clinical 
practice, in terms of the proportion of patients receiving each of them. 
In a prospective situation, that is, before a trial has taken place, results cannot be known in 
advance and need to be hypothesised. Therefore, hypothetical outcomes need to be 
specified so that they cover different eventualities. In general, outcomes for an assessed 
treatment may be ‘favourable’ (i.e. the trial shows results according to which a treatment 
appears cost-effective), ‘inconclusive’ (i.e. trial results are such that the treatment appears 
of inconclusive cost-effectiveness) or ‘unfavourable’ (i.e. the trial reveals results such that 
the treatment does not appear cost-effective). 
An important assumption in the approach is that each specified possible outcome (i.e. 
‘favourable’, ‘inconclusive’ and ‘unfavourable’) taken one at a time represents the actual 
underlying cost and benefits of the treatment, which hold true no matter whether research 
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has been conducted and revealed them or not. This assumption underpins the calculation of 
benefits with and without research. In simple terms, if research takes place, the specified 
(considered ‘true’) effectiveness of a treatment will be revealed, its cost-effectiveness will 
be subsequently established and this will trigger a beneficial change in clinical practice. For 
example, if a trial assessing treatments A and B takes place and reveals A to be more cost-
effective than B, practice will change so that more patients will be given the cost-effective 
treatment A, while the use of the non-cost-effective treatment B will be limited. On the 
other hand, in the absence of research the specified (considered ‘true’) cost-effectiveness 
will still stand (in the example, A will still be the most cost-effective treatment), although 
this will not be revealed and will not induce a change in practice (i.e. the opportunity to 
increase the use of the cost-effective treatment A and restrict the use of the non-cost-
effective treatment B will be missed).  
In this way, an estimate of the ‘cost-effectiveness’ of a research study given each broad 
possible outcome and the change in clinical practice associated with it can be obtained by 
comparing costs and benefits under the ‘with research’ and ‘without research’ states using 
the formula: 
        
              
          
  
Here,   is an indicator for a possible outcome;   and    index the ‘with research’ and 
‘without research’ situations, respectively;     represents the cost of the proposed research 
study;      and       are the costs associated with outcome   in the ‘with research’ and 
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‘without research’ situations and, similarly,      and       are the benefits (e.g. QALYs) under 
outcome   , with and without research, respectively. These cost and benefits can be 
projected to the population of current and future patients by multiplying them by the 
number of eligible patients per year and the number of years the information produced by 
research is expected to be useful, that is, the ‘time horizon’ of the study. Expressed in terms 
of incremental net monetary benefits (INMBs), the formula can be written as:  
         (          )  (              )  
Here,   stands for the ceiling ratio, a hypothetical value of a decision-maker’s willingness to 
pay for an additional unit of benefit. The above formulae give the benefits accruing from 
each possible outcome  , but, in practice, only one of these outcomes may come true.  
Although it is not known in advance which of the possible outcomes represents the true 
cost-effectiveness of the treatments, it is possible to obtain a summary measure of the 
proposed study’s payoff by forming ‘combinations’. In doing so, specified possible outcomes 
are attached ‘likelihood weights’ representing the probability of a particular outcome to 
transpire67. For example, an ‘optimistic’ combination may assume that a ‘favourable’ result 
for a treatment is more likely to be observed, while a ‘pessimistic’ combination may attach 
greater likelihood to an ‘unfavourable’ outcome.  
Following the above notation, the weighted cost per QALY associated with a combination is 
given by: 
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∑                        
∑                    
  
or, equivalently, expressed in INMBs, by:  
         ∑   (          )  
 
∑   (              )
 
 
where   is an index for combinations and    is the probability of observing study outcome  . 
Costs and benefits expected to accrue over a specified time horizon after research results 
are disseminated need to be discounted in order to account for positive time preference.  
6.2. ‘Payback’ analysis for NSCLC 
The section reports the application of PATHS to the NSCLC case study, with a view to 
estimating the costs and benefits expected to arise from a trial comparing Gem+Cisp against 
Gem+Carb. In line with the core methodology of ‘payback’, the analysis involves: a) 
specifying possible research outcomes, b) determining the possible change in clinical 
practice in the light of each possible outcome, and c) estimating the stream of costs and 
benefits expected to arise under each possible outcome and the change in practice 
associated with it. The analysis assumes a ceiling ratio value of £30,000 per additional QALY. 
This is seen as the cost per QALY value above which NICE will need an increasingly stronger 
case in order to adopt a treatment114. Different ceiling ratios are equally applicable. A base 
case analysis is reported first, followed by additional analyses.  
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6.2.1. Base case analysis 
This section reports the results obtained from the base case analysis, which follows the core 
steps of the PATHS model67. 
6.2.1.A. Required information 
For this application, information was needed on the discounted number of patients eligible 
for the treatments of interest (gemcitabine plus cisplatin (Gem+Cisp) and gemcitabine plus 
carboplatin (Gem+Carb) as first-line treatments in NSCLC) for the period over which 
information produced from further research would be expected to be useful. The number of 
new cases of lung cancer per years has been estimated at approximately 41,500259. Of those 
cases, about 9 percent (about 3830 patients per year) are patients with advanced NSCLC 
eligible for first-line platinum-based chemotherapy260. The period over which information 
from the trial was assumed to be useful, that is, the relevant time horizon, was set at five 
years, starting from the time that results are expected to be disseminated. According to the 
BTOG-2 trial protocol, results were expected to become available in 2011. The number of 
eligible patients was discounted at an annual rate of 3.5 percent114 over five years to give a 
total number of approximately 13,800 eligible patients.  
In addition, information is needed on the proportion of patients treated with Gem+Cisp and 
Gem+Carb in the year when the trial results are expected to become available. No such 
estimates were identified in the literature, but expert opinion suggested that, in 2011, the 
treatments were used in equal proportions [personal communication with Mr Andrew 
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Stanley, pharmacist, NHS Pan Birmingham Cancer Network, 11-11-2011], with half of the 
eligible patients receiving Gem+Cisp and the rest receiving Gem+Carb. Last, the cost of the 
proposed trial itself was £336,721 and it was taken from the BTOG-2 trial proposal 
submitted for funding.  
6.2.1.B. Specification of possible outcomes 
In a ‘real world’ situation, a clinical trial would give clinical evidence on a treatment’s 
effectiveness (e.g. probability of cancer progression at one-year follow up). This evidence 
would be expected to be used as input in a cost-effectiveness analysis, which would 
establish the cost-effectiveness of the treatment in question. The outcome of the cost-
effectiveness analysis would be expected to have an impact on clinical practice. 
In a prospective assessment, different possible outcomes of the cost-effectiveness analysis 
need to be specified in advance. Thus, the first step in this analysis involved specifying such 
possible outcomes, which should be broad enough to cover different eventualities and 
should be associated with an impact on clinical practice90;98. To determine the link between 
possible outcomes and direction of change in clinical practice, the analysis adopted a stance 
similar to that of NICE, assuming that a treatment is likely to be recommended and used if it 
is associated with additional benefits at a cost lower than a presumed ‘threshold’ value—
here, £30,000 per QALY. With these considerations in mind, the specified outcomes were:  
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a. ‘Favourable’: The BTOG-2 trial shows results (disease progression rates) such that, 
when these results are entered in the NSCLC decision model, Gem+Carb is cost-
effective compared to Gem+Cisp (i.e. ICERGem+Carb well below £30,000 per additional 
QALY);  
b. ‘Inconclusive’: The BTOG-2 trial shows results (disease progression rates) such that, 
when these results are entered in the NSCLC decision model, Gem+Carb appears 
non-conclusively more (or less) cost-effective than Gem+Cisp (i.e. ICERGem+Carb near 
£30,000 per additional QALY), and 
c. ‘Unfavourable’: The BTOG-2 trial shows results (disease progression rates) such 
that, when these results are entered in the NSCLC decision model, Gem+Carb 
appears not cost-effective compared to Gem+Cisp (i.e. ICERGem+Carb well above 
£30,000 per additional QALY).  
The second step involved specifying the trial results, in terms of disease progression rates, 
that a trial would show if the specified possible outcomes were to transpire. Hypothetical 
trial results of the probability of progression at one-year follow up for Gem+Carb were 
specified in order to match the ‘favourable’, ‘inconclusive’ and ‘unfavourable’ possible 
outcomes. In the NSCLC model, the probability of Gem+Carb progression at each model 
cycle was drawn from a Weibull distributions with shape parameter   and scale parameter 
 . To adjust the progression probabilities so that they match the specified possible 
outcomes (i.e. ‘favourable’, ‘inconclusive’, ‘unfavourable’), the scale parameter of the 
Weibull time-to-progression model for Gem+Carb was modified accordingly. The scale and 
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shape parameters for the Weibull models for disease progression are given in Table 6.1, 
with the parameters changed to match each possible outcome appearing in bold. The new 
scale parameters of the Weibull model translate to Gem+Carb progression probability at 
one-year follow up of 0.64, 0.72 and 0.87 for the ‘favourable’, ‘inconclusive’ and 
‘unfavourable’ research outcome, respectively. 
Table 6.1: Parameters of Weibull distribution for disease progression for different possible outcomes (NSCLC) 
 
 
Favourable outcome Inconclusive outcome Unfavourable outcome 
Alpha Beta Alpha Beta Alpha Beta 
Progression (Gem+Cisp) 1.404 12.17 1.404 12.17 1.404 12.17 
Progression (Gem+Carb) 1.287 17.00 1.287 14.26 1.287 9.85 
 
The values of costs and QALYs for Gem+Carb resulting from the specified transition 
probabilities appear in Table 6.2 in bold. In must be noted that, for the ‘unfavourable’ 
scenario, transitions may be specified so that Gem+Carb could be either more effective than 
Gem+Cisp but not cost-effective (i.e. resulting in an ICER higher that the assumed value of 
the ceiling ratio) or less effective and not cost-effective (i.e. dominated by Gem+Cisp). For 
the base case analysis, a choice of transition probabilities that make Gem+Carb dominated 
was made, as this situation reflects more closely the existing evidence, that is, the fact that 
in the NSCLC model Gem+Carb was shown to be dominated.  
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Table 6.2: Cost-effectiveness results based on ‘favourable’, ‘inconclusive’ and ‘unfavourable’ outcomes (NSCLC) 
 
Outcome 
Gem+Cisp Gem+Carb ICER 
(Gem+Carb vs. 
Gem+Cisp) Total cost Total QALYs Total cost Total QALYs 
Favourable to 
Gem+Carb 
£5830 0.583 £6762 0.639 £16,700 
Inconclusive £5830 0.583 £6710 0.612 £30,280 
Unfavourable to 
Gem+Carb 
£5830 0.583 £6560 0.567 Dominated 
 
6.2.1.C. Change in clinical practice 
In a situation where research has been carried out and given evidence on a treatment’s 
effectiveness and cost-effectiveness, this evidence is expected to be disseminated and 
affect clinical practice. The exact magnitude of the change in clinical practice, in terms of 
changes in the prescription share (i.e. uptake) of the treatment of interest is difficult to 
predict. In this study, guesses on treatments’ future uptake in the light of different possible 
outcomes were formed through discussion with experts in cancer services commissioning 
based at the NHS Pan Birmingham Cancer Network. These were Mrs K. Metcalf (network 
director, responsible for the network’s overall commissioning strategy), Dr D. Ford (network 
clinical lead, oncologist) and Mr A. Stanley (network pharmacist, responsible for the 
network’s formulary and commissioning of chemotherapy treatments). 
As noted above, under current (2011) practice, Gem+Cisp and Gem+Carb are prescribed in 
equal proportions (50 percent each). In the absence of further evidence from a trial, the 
experts felt that prescription shares were unlikely to change in the future. In the event of an 
outcome ‘favourable’ to Gem+Carb and appropriate dissemination of results, it was agreed 
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that the treatment’s use would be likely to increase to a level of approximately 75 percent, 
with Gem+Cisp being prescribed to the rest 25 percent of the eligible population. Such a 
marked increase was thought to be possible given the fact that no significant barriers exist 
in switching between these two treatments. Following an ‘inconclusive’ outcome, the 
experts were in agreement that there would be no change in clinical practice and the 
current prescription patterns would continue to hold. Last, observing an ‘unfavourable’ 
outcome for Gem+Carb (that is, a ‘favourable’ outcome for Gem+Cisp) would be expected 
to lead to a decrease in the use of Gem+Carb to 25 percent of the eligible population. The 
hypothesised values of treatment uptake for the situations with and without research are 
summarised in Table 6.3. 
Table 6.3: Treatment uptake following the specified research outcomes (NSCLC) 
 
Possible outcome Prescription in ‘with research’ 
state 
Prescription in ‘without research’ 
state 
Favourable to Gem+Carb 
(i.e. Gem+Carb cost-effective) 
Gem+Cisp: 25% 
Gem+Carb: 75% 
Gem+Cisp: 50% 
Gem+Carb: 50% 
Inconclusive 
(i.e. Gem+Carb not clearly cost-
effective) 
Gem+Cisp: 50% 
Gem+Carb: 50% 
Unfavourable to Gem+Carb 
(i.e. Gem+Carb not cost-effective) 
Gem+Cisp: 75% 
Gem+Carb: 25% 
 
6.2.2. Results of the base case analysis 
Costs and benefits expected to arise to the population of eligible treatments under different 
possible outcomes in the ‘with research’ state can be calculated by multiplying the costs and 
QALYs under each outcome by each treatment’s hypothesised prescription share. Here, the 
likelihood of observing a possible outcome is the same across these outcomes; in other 
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words, no likelihood weights are attached to indicate that any of these outcomes is more 
likely to occur. Results of this non-weighted analysis are given in Table 6.4. 
Table 6.4: Non-weighted costs and benefits of research in base case analysis (NSCLC) 
 
 
Favourable outcome Inconclusive outcome Unfavourable outcome 
With research 
Cost £90,081,664 £86,511,060 £82,960,067 
Trial cost £336,721 £336,721 £336,721 
QALYs 8617 8241 7985 
Without research 
Cost £86,868,565 £86,511,060 £85,477,767 
QALYs 8425 8241 7931 
Net implications 
Net cost £3,549,820 £336,721 -£2,180,979 
Net QALYs 192 0 55 
Cost per QALY 
£18,450 per additional 
QALY 
Costs for no additional 
QALYs 
Cost savings for 
additional QALYs 
NMBwith research £168,103,680 £160,370,345 £156,267,944 
NMBwithout research £165,881,317 £160,707,066 £152,446,181 
INMBs (£30,000 per QALY) £2,222,363 -£336,721 £3,821,763 
 
With research and under a specific outcome, the cost (or QALYs) are found by multiplying 
the discounted eligible population by the sum resulting from the combination of costs (or 
QALYs) associated with the outcome and the hypothesised uptake in clinical practice. For 
example, under a ‘favourable’ outcome, the cost and QALYs ‘with research’ ( ) are found as:  
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Under the same outcome, in the absence of research (  ), clinical practice is assumed to 
remain as it is, with half of the patients taking Gem+Carb and the rest taking Gem+Cisp. In 
this situation, the costs and QALYs are estimated as follows: 
                 
                    
 (                                                                 
                                                                   )
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In this way, the costs and QALYs with and without further research (here, the proposed 
BTOG-2 trial) can be estimated for each of the three possible outcomes. On the basis of 
these costs and QALYs, the ICER and INMBs for the ‘favourable’ outcome are shown below: 
                
                                    
           
                 
and 
                                                       
The cost per QALY and the INMBs associated with each possible outcome have been 
calculated in the same way. 
Under the ‘favourable’ outcome for Gem+Carb, carrying out the BTOG-2 trial is estimated to 
result in greater costs and more QALYs than in a situation without the trial (Table 6.4). This 
is because under this outcome more patients will be offered Gem+Carb, which, in this case, 
is assumed to be more costly and more effective than Gem+Cisp. As obtaining an additional 
QALY in this case is expected to cost less than the ceiling ratio of £30,000, conducting 
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research is expected to result in positive INMBs of about £2.22 million (ICER of £18,450 per 
QALY). Given an ‘inconclusive’ outcome, conducting the trial would result in no additional 
QALYs (as no change in prescription is expected to take place) for an extra cost equal to the 
cost of the trial. As a result, this outcome is associated with negative INMBs of £336,700. 
Last, under the ‘unfavourable’ outcome, conducting the trial is associated with an increase 
in QALYs and cost savings. This is because, under the specific outcome, clinical practice will 
move towards restricting the use of the more costly and less effective Gem+Carb. In this 
situation, carrying out research appears particularly appealing, leading to additional NMBs 
of approximately £3.82 million.  
To reflect the fact that different outcomes are associated with different likelihoods of 
occurrence, each possible outcome was assigned a likelihood weight and formed different 
combinations. In line with methods used in previous applications of the PATHS model67;116, 
three combinations were formed: 
a. ‘Optimistic’, where the probability of observing a ‘favourable’, ‘inconclusive’ and 
‘unfavourable’ outcome is 0.5, 0.25 and 0.25, respectively; 
b. ‘Neutral’, where each outcome has an one-third probability of being observed, and 
c. ‘Pessimistic’, where the probability of observing a ‘favourable’, ‘inconclusive’ and 
‘unfavourable’ outcome is 0.25, 0.25 and 0.5, respectively. 
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The weighted net costs, net QALYs and INMBs for each of these combinations are given in 
Table 6.5, Table 6.6 and Table 6.7. In each of these tables—and in all tables of the same 
form throughout this chapter—the second column gives the attached likelihood weight, 
while the third and fourth columns give the weighted costs and QALYs, respectively. For 
each possible outcome, the weighted cost (or, equivalently, the weighted QALYs) is 
calculated by multiplying the relevant net cost (net QALYs) as found in the non-weighted 
analysis (Table 6.4) by the respective likelihood weight (e.g. weighted cost of ‘favourable’ 
outcome in ‘optimistic’ combination = 3,549,820  0.5 = 1,774,910).  
The last column in each table gives the weighted INMBs calculated as weighted QALYs 
multiplied by the ceiling ratio, minus weighted costs (e.g. weighted INMBs of ‘favourable’ 
outcome in ‘optimistic’ combination = 96   £30,000   £1,774,910 = £1,111,181. Last, the 
total weighted INMBs for a specific combination are calculated as the sum of the weighted 
INMBs of each outcome and are given in the bottom-right cell of each table. According to 
the results, carrying out the proposed BTOG-2 trial is estimated to lead to positive INMBs of 
£1.98 million, £1.88 million and £2.38 million under the ‘optimistic’, ‘neutral’ and 
‘pessimistic’ combinations, respectively. 
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Table 6.5: Weighted costs and benefits of research in base case analysis (‘optimistic’ combination) (NSCLC) 
 
Optimistic combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted 
INMB(with research vs. 
without research) 
Favourable 0.50 £1,774,910 96 £1,111,181 
Inconclusive 0.25 £84,180 0 -£84,180 
Unfavourable 0.25 -£545,245 14 £955,441 
Sum of weighted net costs 
and QALYs 
- £1,313,846 110 - 
Weighted ICER and INMBs £11,958 per additional QALY £1,982,442 
 
 
Table 6.6: Weighted costs and benefits of research in base case analysis (‘neutral’ combination) (NSCLC) 
 
Neutral combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted 
INMB(with research vs. 
without research) 
Favourable 0.33 £1,171,441 63 £733,380 
Inconclusive 0.33 £111,118 0 -£111,118 
Unfavourable 0.33 -£719,723 18 £1,261,182 
Sum of weighted net costs 
and QALYs 
- £562,836 82 - 
Weighted ICER and INMBs £6,902 per additional QALY £1,883,444 
 
 
Table 6.7: Weighted costs and benefits of research in base case analysis (‘optimistic’ combination) (NSCLC) 
 
Pessimistic combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted 
INMB(with research vs. 
without research) 
Favourable 0.25 £887,455 48 £555,591 
Inconclusive 0.25 £84,180 0 -£84,180 
Unfavourable 0.50 -£1,090,489 27 £1,910,882 
Sum of weighted net costs 
and QALYs 
- -£118,854 75 - 
Weighted ICER and INMBs  
Cost savings of £118,854 and 75 
additional QALYs 
£2,382,292 
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In summary, the results of this analysis suggest that conducting the trial and changing 
clinical practice according to its results would result in additional health benefits at a value 
lower than society (or a decision-maker) is assumed to be willing to pay for these benefits, 
resulting in positive NMBs. In this respect, according to the interpretation used in ‘payback’ 
studies67;116, the BTOG-2 trial represents a ‘cost-effective’ use of resources. 
6.2.3. Additional analyses 
Highly uncertain parameters, such as hypothesised prescription shares and likelihood 
weights attached to outcomes, are expected to have an effect on ‘payback’ results. Different 
assumptions about these parameters were tested in sensitivity analyses. Probabilistic 
analysis was also carried out, where uncertain parameters were characterised by probability 
distributions. These analyses are described below. 
6.2.3.A. Deterministic sensitivity analyses  
One of the possibilities investigated in sensitivity analyses is that clinical practice may be 
more responsive to research results than it was assumed in the base case analysis. 
According to this scenario, following a ‘favourable’ outcome for Gem+Carb, there would be 
a greater uptake of the treatment in clinical practice (80 and 85 percent of the eligible 
patients would use Gem+Carb, as opposed to 75 percent in the base case) and, equivalently, 
‘unfavourable’ results would lead to a greater decrease in the number of patients using 
Gem+Carb (20 and 15 percent, as opposed to 25 percent). This was estimated to lead to 
increased INMBs as compared to the base case results for all combinations, suggesting that, 
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if such an implementation pattern was prevalent, the option of carrying out research would 
be even more appealing (Table 6.8 and Table 6.9). 
Table 6.8: Deterministic sensitivity analysis assuming higher uptake (80 percent) following ‘favourable’ results (NSCLC) 
 
 
Favourable 
outcome 
Inconclusive 
outcome 
Unfavourable 
outcome 
Gem+Carb current prescription share 50% 
Gem+Carb future prescription share 80% 50% 20% 
INMBs optimistic combination £2,446,275 
INMBs neutral combination £2,326,803 
INMBs pessimistic combination £2,926,095 
 
 
Table 6.9: Deterministic sensitivity analysis assuming higher uptake (85 percent) following ‘favourable’ results (NSCLC) 
 
 
Favourable 
outcome 
Inconclusive 
outcome 
Unfavourable 
outcome 
Gem+Carb current prescription share 50% 
Gem+Carb future prescription share 85% 50% 15% 
INMBs optimistic combination £2,910,107 
INMBs neutral combination £2,770,163 
INMBs pessimistic combination £3,469,897 
 
On the other hand, it is possible that clinical practice may change in a less marked way than 
that assumed in the base case analysis. In such a case, it would be expected that, following 
‘favourable’ outcomes, there would be a lower rate of Gem+Carb uptake than in base case 
and, following ‘unfavourable’ outcomes, there would be a smaller decrease in the number 
of patients using Gem+Carb. The results suggested that carrying out research in this case 
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would still be beneficial, but it would result in slightly lower INMBs than those observed in 
the base case results (Table 6.10 and Table 6.11). 
Table 6.10: Deterministic sensitivity analysis assuming lower uptake (70 percent) following ‘favourable’ results (NSCLC) 
 
 
Favourable 
outcome 
Inconclusive 
outcome 
Unfavourable 
outcome 
Gem+Carb current prescription share 50% 
Gem+Carb future prescription share 70% 50% 30% 
INMBs optimistic combination £1,518,609 
INMBs neutral combination £1,440,084 
INMBs pessimistic combination £1,838,489 
 
 
Table 6.11: Deterministic sensitivity analysis assuming lower uptake (65 percent) following ‘favourable’ results (NSCLC) 
 
 
Favourable 
outcome 
Inconclusive 
outcome 
Unfavourable 
outcome 
Gem+Carb current prescription share 50% 
Gem+Carb future prescription share 65% 50% 35% 
INMBs optimistic combination £1,054,777 
INMBs neutral combination £996,725 
INMBs pessimistic combination £1,294,687 
 
A further possibility explored in deterministic sensitivity analyses relates to the current 
prescription share of Gem+Carb. Assuming that this share is actually higher than the base 
case estimate (i.e. 60 percent of the eligible patients receive Gem+Carb as opposed to 50 
percent in the base case analysis) resulted in higher INMBs than in the base case for the 
‘neutral’ and ‘pessimistic’ combinations, and in slightly lower INMBs for the ‘optimistic’ 
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combination. On the other hand, setting the current prescription percentage of Gem+Carb 
to a lower value than that in the base case (40 percent) led to lower, although still positive, 
INMBs for the ‘neutral’ and ‘pessimistic’ combinations, and higher INMBs for the ‘optimistic’ 
combination (Table 6.12 and Table 6.13). This indicates that more pronounced moves 
towards extending the use of a cost-effective treatment—or restricting the use of non-cost-
effective treatments—are anticipated to result in greater numbers of benefits. 
Table 6.12: Deterministic sensitivity analysis assuming higher current prescription (60 percent) for Gem+Carb (NSCLC) 
 
 
Favourable 
outcome 
Inconclusive 
outcome 
Unfavourable 
outcome 
Gem+Carb current prescription share 60% 
Gem+Carb future prescription share 75% 60% 25% 
INMBs optimistic combination £1,886,474 
INMBs neutral combination £2,094,564 
INMBs pessimistic combination £2,958,080 
 
 
Table 6.13: Deterministic sensitivity analysis assuming lower current prescription (40 percent) for Gem+Carb (NSCLC) 
 
 
Favourable 
outcome 
Inconclusive 
outcome 
Unfavourable 
outcome 
Gem+Carb current prescription share 40% 
Gem+Carb future prescription share 75% 40% 25% 
INMBs optimistic combination £2,078,410 
INMBs neutral combination £1,672,323 
INMBs pessimistic combination £1,806,504 
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In the base case analysis, the ‘unfavourable’ outcome was set so that Gem+Carb is more 
expensive and less effective than Gem+Cisp, that is, it is dominated by the latter. However, 
an alternative scenario for the ‘unfavourable’ outcome may be that Gem+Carb is neither 
cost-effective at £30,000 per QALY, nor is it dominated (i.e. it is more costly but also slightly 
more effective than Gem+Cisp). This outcome would transpire if the BTOG-2 trial showed a 
lower probability of progression at one-year follow-up for Gem+Carb than that in the base 
case, for instance 0.75 as opposed to 0.87 in the base case. In such a case, Gem+Carb would 
be associated with an additional cost of £870 and 0.02 additional QALYs compared to 
Gem+Cisp.  
Given the alternative ‘unfavourable’ scenario of Gem+Carb not being dominated, a situation 
with research would result in cost savings (due to restricting the use of the more costly 
Gem+Carb) and a loss in QALYs (due to limiting the prescription of the more effective 
Gem+Carb) as compared to the situation without research. Here, cost savings would offset 
the loss of QALYs to give additional non-weighted INMBs of £422,800. The non-weighted 
INMBs for the ‘unfavourable’ outcome under this scenario are lower than those for the 
same outcome under the base case scenario, indicating that there is more value in 
restricting the use of a dominated treatment, than there is in limiting the prescription of a 
treatment that is effective, but not cost-effective. This is also reflected on the weighted 
results shown in Table 6.14 which are lower than the equivalent results in the base case 
analysis. 
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Table 6.14: Deterministic sensitivity analysis for alternative ‘unfavourable’ outcome (NSCLC) 
 
 Optimistic 
combination 
Neutral 
combination 
Pessimistic 
combination 
Alternative scenario for unfavourable 
outcome (Gem+Carb not dominated) 
£1,132,705 £761,791 £682,818 
 
Last, the base case time horizon—the period over which information from a trial is expected 
to be useful—was replaced by alternative values. Time horizon has a significant bearing on 
results, as it determines the number of future patients that are expected to benefit from 
decision-making in the light of the generated information. Assuming that information 
produced by the BTOG-2 trial would be useful for ten years almost doubled the expected 
gains from the trial, making the case for funding and carrying out the BTOG-2 study even 
stronger (Table 6.15). 
Table 6.15: Deterministic sensitivity analysis assuming different time horizons (NSCLC) 
 
Time horizon Eligible 
patients 
Optimistic 
combination 
Neutral 
combination 
Pessimistic 
combination 
One year 2,856 £143,304 £125,484 £226,066 
Five years 13,797 £1,982,442 £1,883,444 £2,382,292 
Ten years 25,270 £3,910,826 £3,726,711 £4,643,152 
 
6.2.3.B. Gradual change in uptake analysis 
The analyses above are based on the assumption that, once research results are 
disseminated, changes in treatments’ prescription share take place almost instantly. 
However, in practice, a treatment’s uptake is likely to change progressively, over time. With 
this in mind, further sensitivity analyses were carried out to explore the effect of gradual 
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change in treatments’ uptake. In this illustrative analysis it was assumed that uptake 
changes in a linear fashion over the five-year time horizon. On this premise, prescription 
shares would assume the values given in Table 6.16 and would result in the non-weighed 
results given in Table 6.17 below. 
Table 6.16: Assumed prescription share for gradual change in uptake (NSCLC) 
 
Year 
Favourable outcome Inconclusive outcome Unfavourable outcome 
Gem+Carb Gem+Cisp Gem+Carb Gem+Cisp Gem+Carb Gem+Cisp 
Current 50% 50% 50% 50% 50% 50% 
Year 1 55% 45% 50% 50% 45% 55% 
Year 2 60% 40% 50% 50% 40% 60% 
Year 3 65% 35% 50% 50% 35% 65% 
Year 4 70% 30% 50% 50% 30% 70% 
Year 5 75% 25% 50% 50% 25% 75% 
 
According to this analysis, for a ‘favourable’ outcome, a hypothetical situation where the 
BTOG-2 trial has taken place would be associated with additional NMBs of £1.16 million. 
Compared to the ‘favourable’ outcome of the base case analysis, these benefits are lower by 
about £1.07 million. Under an ‘inconclusive’ outcome, there is a loss of £336,700 in NMBs, 
representing the cost of the trial. Last, an ‘unfavourable’ outcome would result in additional 
NMBs of £2.09 million, which is approximately £1.73 million lower than the NMBs of the 
equivalent outcome in the base case analysis.  
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As expected, the trend shows that delays in moving towards a treatment that appears cost-
effective has a negative impact on the benefits expected to accrue to the eligible 
population. 
Table 6.17: Non-weighted costs and benefits of research for gradual change in uptake (NSCLC) 
 
 
Favourable 
outcome 
Inconclusive 
outcome 
Unfavourable 
outcome 
With research  
Cost £88,744,040 £86,511,060 £84,008,195 
Trial cost £336,721 £336,721 £336,721 
QALYs 8537 8241 7963 
Without research 
Cost £86,868,565 £86,511,060 £85,477,767 
QALYs 8425 8241 7931 
Net implications 
Net cost £2,212,195 £336,721 -£1,132,851 
Net QALYs 112 0 32 
Cost per QALY 
£19,698 per 
additional QALY 
Costs for no 
additional QALYs 
Cost savings for 
additional QALYs 
NMBwith research £167,038,324 £160,370,345 £154,536,752 
NMBwithout research £165,881,317 £160,707,066 £152,446,181 
INMBs (£30,000 per QALY) £1,157,007 -£336,721 £2,090,571 
 
This trend can be also seen in the weighted results of this analysis (Table 6.18, Table 6.19 
and Table 6.20), which appear consistently lower than the corresponding results in the base 
case analysis. It must be noted that results in this analysis are highly dependent on 
assumptions around the pattern of change in clinical practice over the five-year time period.  
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Table 6.18: Weighted costs and benefits of research for gradual change in uptake (‘optimistic’ combination)(NSCLC) 
 
Optimistic combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted INMB(with 
research vs. without research) 
Favourable 0.50 £1,106,098 56 £578,503 
Inconclusive 0.25 £84,180 0 -£84,180 
Unfavourable 0.25 -£283,213 8 £522,643 
Sum of weighted net 
costs and QALYs 
- £907,065 64 - 
Weighted ICER and 
INMBs  
£14,143 per additional QALY £1,016,966 
 
 
Table 6.19: Weighted costs and benefits of research for gradual change in uptake (‘neutral’ combination)(NSCLC) 
 
Neutral combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted INMB(with 
research vs. without research) 
Favourable 0.33 £730,024 37 £381,812 
Inconclusive 0.33 £111,118 0 -£111,118 
Unfavourable 0.33 -£373,841 11 £689,888 
Sum of weighted net costs 
and QALYs 
- £467,301 48 - 
Weighted ICER and INMBs  £9818 per additional QALY £960,583 
 
 
Table 6.20: Weighted costs and benefits of research for gradual change in uptake (‘pessimistic’ combination)(NSCLC) 
 
Pessimistic combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted INMB(with 
research vs. without research) 
Favourable 0.25 £553,049 28 £289,252 
Inconclusive 0.25 £84,180 0 -£84,180 
Unfavourable 0.50 -£566,426 16 £1,045,285 
Sum of weighted net costs 
and QALYs 
- £70,803 44 - 
Weighted ICER and INMBs £1608 additional QALY £1,250,357 
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6.2.3.C. Probabilistic sensitivity analysis 
Further work was undertaken to illustrate the potential use of probabilistic sensitivity 
analysis in ‘payback’. Such analysis aimed to assess the effect of uncertainty around the 
hypothesised change in clinical practice and the likelihood weights associated with possible 
outcomes. For change in clinical practice, 1000 values of the possible levels of uptake were 
drawn from a uniform distribution in a way that drawn values were limited to the intervals 
between 0.5 (current prescription share) and 1 (maximum possible prescription share), and 
0.5 (current prescription share), and 0 (minimum possible prescription share) for a 
‘favourable’ and ‘unfavourable’ outcome, respectively. As prescription under an 
inconclusive outcome is assumed not to change, this was fixed at its current value (0.5). 
Results were calculated for each of the 1000 drawn prescription values. The average costs, 
QALYs and INMBs together with 95 percent confidence intervals are given in Table 6.21. 
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Table 6.21: Non-weighted costs and benefits of research in probabilistic analysis (NSCLC) 
 
 Favourable outcome 
(Lower and upper 95% 
confidence intervals) 
Inconclusive outcome 
(Lower and upper 95% 
confidence intervals) 
Unfavourable outcome 
(Lower and upper 95% 
confidence intervals) 
With research 
Cost 
£90,143,177 
(£90,029,124 to £90,257,230) 
£86,511,060 
 
£83,008,830 
(82,918,557 to 
£83,099,105) 
Trial cost £336,721 £336,721 £336,721 
QALYs 
8621 
(8614 to 8627) 
8241 
7984 
(7982 to 7986) 
Without research 
Cost £86,868,565 £86,511,060 £85,477,767 
QALYs 8425 8241 7931 
Net implications 
Net cost 
£3,611,332 
(£3,497,280 to £3,725,385) 
£336,721 
-£2,132,215 
(-£2,222,490 to                    
-£2,041,941) 
Net QALYs 
196 
(189 to 203) 
0 
54 
(52 to 56) 
Cost per QALY £18,417 per additional QALY 
Cost for no additional 
QALYs 
Cost savings for additional 
QALYs 
NMBwith research 
£168,152,672 
(£168,061,834 to 
£168,243,509) 
£160,370,345 
£156,187,402 
(£156,038,296 to 
£156,366,507) 
NMBwithout research £165,881,317 £160,707,066 £152,446,181 
INMBs (£30,000 per 
QALY) 
£2,271,355 (£2,180,517 to 
£2,362,192) 
-£336,721 
£3,741,221 (£3,592,115 to 
£3,890,327)  
 
The results of this analysis appeared considerably similar to those in the base case analysis 
above; if further research revealed a ‘favourable’ or ‘unfavourable’ outcome for Gem+Carb 
and clinical practice changed accordingly, there would be additional NMBs, while in the case 
of an inconclusive outcome there would be a cost equal to the cost of the trial. It must be 
acknowledged that, the extent to which these results would differ to those in the base case 
analysis depends largely on the distribution assigned to prescription share values. ‘Steep’ 
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distributions that concentrate around the mean (base case) prescription share will naturally 
give values closer to the base case results. 
Further probabilistic sensitivity analysis was carried out to propagate the uncertainty 
around likelihood weights used in forming combinations. Likelihood weights were 
considered to be random values, drawn from distributions with means equal to those in the 
base case and standard errors set, for illustration purposes, at one-quarter of their 
respective means. To account for the multinomial nature of the likelihood weights, where 
three independently drawn values need to sum up to one, likelihood weights were drawn 
from Dirichlet distributions using the normalized sum of independent gamma draws 
method51;261. Each of the drawn likelihood weights was combined with the probabilistic 
results obtained from varying the prescription rates to give 1000 estimates of the weighted 
net costs and QALYs for each combination.  
Mean values of these estimates are given in Table 6.22, Table 6.23 and Table 6.24. The 
results of this analysis showed all combinations to be associated with positive INMBs 
ranging from about £1.88 million for the ‘neutral’ combination to £2.31 million for the 
‘pessimistic’ combination. 
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Table 6.22: Weighted costs and benefits of research in probabilistic analysis (‘optimistic’ combination)(NSCLC) 
 
Optimistic combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted INMB(with 
research vs. without research) 
Favourable 0.50 £1,783,070 97 £1,123,673 
Inconclusive 0.25 £87,339 0 -£87,339 
Unfavourable 0.25 -£529,777 13 £930,009 
Sum of weighted net 
costs and QALYs 
- £1,340,632 110 - 
Weighted ICER and 
INMBs 
£12,162 per additional QALY £1,966,343 
 
 
Table 6.23: Weighted costs and benefits of research in probabilistic analysis (‘neutral’ combination)(NSCLC) 
 
Neutral combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted INMB(with 
research vs. without research) 
Favourable 0.33 £1,183,358 64 £743,478 
Inconclusive 0.33 £112,327 0 -£112,327 
Unfavourable 0.33 -£710,116 18 £1,246,941 
Sum of weighted net 
costs and QALYs 
- £585,568 82 - 
Weighted ICER and 
INMBs 
£7130 per additional QALY £1,878,092 
 
 
Table 6.24: Weighted costs and benefits of research in probabilistic analysis (‘pessimistic’ combination)(NSCLC) 
 
Pessimistic combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted INMB(with 
research vs. without research) 
Favourable 0.25 £906,743 49 £570,500 
Inconclusive 0.25 £86,754 0 -£86,754 
Unfavourable 0.50 -£1,041,717 26 £1,828,483 
Sum of weighted net 
costs and QALYs 
- -£48,219 75 - 
Weighted ICER and 
INMBs 
Cost savings of £48,219 and 75 additional QALYs £2,312,228 
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In summary, results from the base case and additional analyses suggest that, given the 
specific assumptions about possible results and change in clinical practice, funding and 
conducting the proposed BTOG-2 trial would results in additional benefits to the population.  
6.3. ‘Payback’ analysis for HRPC 
This section gives the methods and results of applying the PATHS methodology to the HRPC 
case study. In this case study, the TRAPEZE phase III randomised controlled trial was 
proposed to assess the effectiveness of four chemotherapy combinations (DP, DP+ZA, 
DP+Sr89, DP+ZA+Sr89). 
Applications of PATHS to case studies involving comparisons between more than two 
treatments are rare and require stronger assumptions than those for two-treatment 
comparisons. Given this, two separate analyses were carried out and are reported below. 
The first analysis is concerned with a two-treatment analysis, focusing on the treatments 
which were non-dominated in the cost-effectiveness analysis reported in Chapter 5 (DP and 
DP+Sr89). The second analysis looks into the application of PATHS to the four-arm TRAPEZE 
trial. Both the analyses are primarily intended as an illustration of the employed methods.  
6.3.1. Base case analysis of the two-treatment HRPC case study 
The section reports the methods and results of the base case analysis applied to the two-
treatment version of the HRPC case study. 
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6.3.1.A. Required information 
The annual number of new cases of prostate cancer has been estimated at approximately 
40,800234, nearly half of which cases are expected to eventually develop hormone-refractory 
disease239. About 50 percent of these cases are expected to be eligible for first-line 
chemotherapy [personal communication with Professor N. James, Oncologist, University of 
Birmingham, 16-02-2011] and, of those patients, approximately 33 percent will be 
candidates for docetaxel-based treatment188. This results in about 3330 eligible patients per 
year. Given the emergence of new chemotherapy agents, such as cabazitaxel, DP-based 
treatments may be soon superseded. Thus, based on expert opinion, the time horizon for 
which the information generated by the proposed trial is expected to be relevant was 
chosen to be two years [personal communication with Professor N. James, Oncologist, 
University of Birmingham, 16-02-2011]. Results from the TRAPEZE phase III trial were 
expected to be disseminated in 2013. Given this, the discounted number of patients 
affected by the adoption decision over the hypothesised time horizon after research results 
are disseminated was estimated at 5101 patients.  
No estimates of the possible prescription shares of DP and DP+Sr89 in 2013 were identified. 
Given the fact that DP+Sr89 is not provided routinely to patients and on the assumption that 
in the absence of further information practice will remain as in 2011, experts suggested that 
in 2013 the treatment may be given to as little as 5 percent of the eligible population 
[personal communication with Ms K. Metcalf and Mr A. Stanley, NHS Pan Birmingham 
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Cancer Network, 11-11-2011]. This value represents the ‘current’ prescription share for 
DP+Sr89.  
The fixed cost of the trial (i.e. expenditure for researchers’ salaries and facilities) amounted 
at £627,156. For the analysis involving only the DP and DP+Sr89 arms, the excess cost due to 
trial patients receiving treatments other than usual care provided by the NHS (DP) was 
estimated at £57,720, resulting in a total trial cost of £684,876. As before, the value of the 
ceiling ratio used is £30,000 per additional QALY.  
6.3.1.B. Specification of possible outcomes 
Similarly to the NSCLC case study, three broad possible outcomes were specified: 
a. ‘Favourable’ outcome: Trial shows results (disease progression rates) such that, 
when these results are entered in the HRPC decision model, DP+Sr89 is cost-
effective compared to DP (i.e. ICERDP+Sr89 well below £30,000 per additional QALY);  
b. ‘Inconclusive’ outcome: Trial shows results (disease progression rates) such that, 
when these results are entered in the HRPC decision model, DP+Sr89 appears non-
conclusively more (or less) cost-effective than DP (i.e. ICERDP+Sr89 near £30,000 per 
additional QALY), and 
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c. ‘Unfavourable’ outcome: Trial shows results (disease progression rates) such that, 
when these results are entered in the HRPC decision model, DP+Sr89 appears not 
cost-effective compared to DP (i.e. ICERDP+Sr89 well above £30,000 per additional 
QALY). 
Values representing the probability of a patient on DP+Sr89 moving from a progression-free 
to a progressive health state needed to be specified in order to match the ‘favourable’, 
‘inconclusive’ and ‘unfavourable’ outcomes. In the HRPC model, the probability of transition 
between these states under DP+Sr89 was derived from observed counts of patient 
transitions taken from the TRAPEZE phase II trial and was calculated to be 0.05. To match 
the specified outcomes, new values of this transition were specified to be 0.04, 0.12 and 
0.14 for the ‘favourable’, ‘inconclusive’ and ‘unfavourable’ outcomes, respectively. Given 
these transition probabilities, the new costs and QALYs associated with DP+Sr89 appear in 
Table 6.25 in bold.  
Table 6.25: Cost-effectiveness results based on ‘favourable’, inconclusive and ‘unfavourable’ outcomes (two-treatment 
HRPC) 
 
Outcome 
DP DP+Sr89 
ICER 
 (DP+Sr89 vs. DP) 
Total Cost Total QALYs Total Cost Total QALYs 
Favourable to DP+Sr89 £8949 0.81 £10,164 0.99 £6602 
Inconclusive £8949 0.81 £10,190 0.85 £30,395 
Unfavourable to DP+Sr89 £8949 0.81 £10,193 0.83 £58,270 
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6.3.1.C. Change in clinical practice 
As before, possible change in clinical practice, in terms of treatments’ prescription shares, 
was determined with the help of experts from the NHS Pan Birmingham Cancer Network 
(Mrs K. Metcalf, Dr D. Ford and Mr A. Stanley). Under ‘current’ (2013) practice, only a 
limited number of the eligible patients, about 5 percent, are expected to receive DP+Sr89. 
This is because of uncertainty about the treatment’s clinical and cost-effectiveness, as well 
as due to limitations in the infrastructure for administering strontium-89 radioisotope 
fractions. For the purposes of this two-treatment analysis, it was assumed that other 
chemotherapy treatments (DP+ZA, DP+ZA+Sr89) were given to a negligible proportion of the 
population. 
In the absence of a further trial, experts agreed that clinical practice would be unlikely to 
change and the great majority of patients would still receive DP. In the light of a ‘favourable’ 
outcome for DP+Sr89, there was a general agreement that DP+Sr89 uptake would increase, 
although the treatment’s prescription share would be unlikely to reach a high level within 
the specified time horizon, mostly due to practical obstacles around the wider introduction 
and use of the treatment. Under the inconclusive outcome, the expectation was that clinical 
practice will remain as it was before the results became available, with the great majority of 
patients receiving the well-established and easily accessible DP. Last, under an 
‘unfavourable’ outcome, it was expected that even fewer patients would be treated with 
DP+Sr89. The assumed changes in treatment uptake associated with the ‘with research’ and 
‘without research’ states are given in Table 6.26.  
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Table 6.26: Treatment uptake following the specified research outcomes (two-treatment HRPC) 
 
Outcome Prescription in ‘with research’ 
state 
Prescription in ‘without research’ 
state 
Favourable to DP+Sr89 
(i.e. DP+Sr89 cost-effective) 
DP: 60% 
DP+Sr89: 40% 
DP: 95% 
DP+Sr89: 5% 
Inconclusive  
(i.e. DP+Sr89 not clearly cost-
effective) 
DP: 95% 
DP+Sr89: 5% 
Unfavourable to DP+Sr89 
(i.e. DP+Sr89 not cost-effective) 
DP: 99% 
DP+Sr89: 1% 
 
6.3.2. Results of the base case analysis for the two-treatment HRPC case study 
As in the PATHS application to NSCLC, the cost and QALYs associated with the ‘with 
research’ and the ‘without research’ states in HRPC can be estimated according to the cost-
effectiveness of each treatment and the proportion of the eligible population expected to 
receive each treatment in the view of the specified possible outcomes. The calculated costs, 
QALYs and INMBs for each possible outcome are given in Table 6.27.  
The results show that, given an outcome ‘favourable’ to DP+Sr89, carrying out research 
would be associated with a gain of 329 QALYs at an extra cost of about £2.85 million, 
suggesting positive INMBs of about £7 million. On the other hand, observing an 
‘unfavourable’ outcome for DP+Sr89 (that is, DP+Sr89 being slightly more effective and 
more costly than DP, but overall not being cost-effective at £30,000 per QALY) and switching 
clinical practice away from this treatment would result in additional costs (largely due to the 
cost of the trial) and a few QALYs forgone (due to the fact that less people would be taking 
the slightly more effective DP+Sr89). The latter case is associated with negative INMBs of 
about £561,800. Under the ‘inconclusive’ scenario, as always, there are costs equal to the 
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expenditure for the trial for no additional QALYs, which translates to negative INMBs of 
£684,900. 
Table 6.27: Non-weighted costs and benefits of research in base case analysis (two-treatment HRPC) 
 
 
Favourable outcome Inconclusive outcome Unfavourable outcome 
With research 
Cost £48,129,173 £45,966,706 £45,713,552 
Trial cost £684,876 £684,876 £684,876 
QALYs 4489 4124 4114 
Without research 
Cost £45,960,005 £45,966,706 £45,967,268 
QALYs 4160 4124 4119 
Net implications 
Net costs £2,854,044 £684,876 £431,161 
Net QALYs 329 0 -4 
Cost per QALY 
£8686 per additional 
QALY 
Costs for no 
additional QALYs 
Additional costs for 
QALYs forgone 
NMBwith research £85,845,233 £77,054,816 £77,028,156 
NMBwithout research £78,842,093 £77,739,692 £77,589,940 
INMBs (£30,000 per QALY) £7,003,141 -£684,876 -£561,784 
 
As before, an ‘optimistic’, a ‘neutral’ and a ‘pessimistic’ combination were formed by 
attaching weights to possible outcomes. The weighted results of this analysis appear in 
Table 6.28, Table 6.29 and Table 6.30 below. Under the ‘optimistic’ combination, conducting 
the TRAPEZE phase III trial appears to be beneficial, resulting in INMBs of £3.19 million. The 
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trial appears less beneficial under the ‘neutral’ and ‘pessimistic’ combinations, resulting in 
INMBs of £1.90 million and £1.30 million, respectively. 
Table 6.28: Weighted costs and benefits of research in base case analysis (‘optimistic’ combination)(two-treatment 
HRPC) 
 
Optimistic combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted 
INMB(with research vs. 
without research) 
Favourable 0.50 £1,427,022 164 £3,501,570 
Inconclusive 0.25 £171,219 0 -£171,219 
Unfavourable 0.25 £107,790 -1 -£140,446 
Sum of weighted net costs 
and QALYs 
- £1,706,031 163 - 
Weighted ICER and INMBs  £10,454 per additional QALY £3,189,905 
 
 
Table 6.29: Weighted costs and benefits of research in base case analysis (‘neutral’ combination)(two-treatment HRPC) 
 
Neutral combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted 
INMB(with research 
vs. without research) 
Favourable 0.33 £941,835 108 £2,311,036.41 
Inconclusive 0.33 £226,009 0 -£226,009.08 
Unfavourable 0.33 £142,283 -1 -£185,388.71 
Sum of weighted net costs 
and QALYs 
- £1,310,127 107 - 
Weighted ICER and INMBs £12,245 per additional QALY £1,899,639 
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Table 6.30: Weighted costs and benefits of research in base case analysis (‘pessimistic’ combination)(two-treatment 
HRPC) 
 
Pessimistic combination 
Outcome 
Likelihood 
weight 
Weighted net cost 
Weighted net 
QALYs 
Weighted 
INMB(with research 
vs. without research) 
Favourable 0.25 £713,511 82 £1,750,785.16 
Inconclusive 0.25 £171,219 0 -£171,219.00 
Unfavourable 0.50 £215,580 -2 -£280,891.99 
Sum of weighted net costs 
and QALYs 
- £1,100,310 80 - 
Weighted ICER and INMBs £13,760 per additional QALY £1,298,674 
As noted earlier, the difference between the NSCLC and the HRPC case studies is that in the 
latter patient-level evidence around the effectiveness of the compared treatments was 
available from the TRAPEZE phase II trial. This information can be used as an indication of 
the likelihood of observing different outcomes in subsequent trials. In the phase II trial 
DP+Sr89 was shown to be more effective than DP. Therefore, it appears reasonable to 
assume that a further study—the TRAPEZE phase III trial—is likely to show similar results for 
DP+Sr89. On this premise, the most relevant outcome would be a ‘favourable’ one with the 
most relevant combination being the ‘optimistic’. Given this, conducting the TRAPEZE phase 
III trial would be expected to result in NMBs of about £3.19 million.  
6.3.3. Additional analyses for the two-treatment HRPC case study 
As in the NSCLC case study, additional analyses were carried out to assess the sensitivity of 
the results to different assumptions. Additional, probabilistic sensitivity analysis was also 
undertaken by attaching probability distributions to key parameters. 
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6.3.3.A. Deterministic sensitivity analyses 
Deterministic sensitivity analysis was undertaken to look into the impact of alternative 
assumptions on the results. First, it was hypothesised that research results may have a more 
pronounced impact on clinical practice than that assumed in the base case analysis. On this 
premise, a ‘favourable’ outcome would lead to a more marked uptake of DP+Sr89 (i.e. 50 
percent or 60 percent of eligible patients taking DP+Sr89 as opposed to 40 percent in base 
case analysis), while an ‘unfavourable’ outcome would result in a sharper decrease in 
prescription shares (0.5 percent or 0 percent taking DP+Sr89 as compared to 1 percent in 
the base case analysis). For these values, results revealed increased INMBs for all 
combinations, suggesting that, if this was the prevailing implementation pattern, the option 
of conducting research would be more desirable than that associated with the base case 
pattern (Table 6.31 and Table 6.32). 
Table 6.31: Deterministic sensitivity analysis assuming higher uptake (50 percent) following ‘favourable’ results (two-
treatment HRPC) 
 
 
Favourable 
outcome 
Inconclusive 
outcome 
Unfavourable 
outcome 
DP+Sr89 current prescription 5% 
DP+Sr89 prescription following a possible 
outcome 
50% 5% 0.5% 
INMBs optimistic combination £4,292,040 
INMBs neutral combination £2,629,586 
INMBs pessimistic combination £1,855,511 
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Table 6.32: Deterministic sensitivity analysis assuming higher uptake (60 percent) following ‘favourable’ results (two-
treatment HRPC) 
 
 
Favourable 
outcome 
Inconclusive 
outcome 
Unfavourable 
outcome 
DP+Sr89 current prescription 5% 
DP+Sr89 prescription following a possible 
outcome 
60% 5% 0% 
INMBs optimistic combination £5,394,175 
INMBs neutral combination £3,359,534 
INMBs pessimistic combination £2,412,349 
 
In contrast, it is possible that change in clinical practice may be less responsive to research 
results. This could be, for instance, due to obstacles in implementation. In such a case it 
would be expected that, following a ‘favourable’ outcome, there would be a weaker uptake 
of DP+Sr89 than in base case (30 percent and 20 percent as opposed to 40 percent in the 
base case analysis) and following ‘unfavourable’ outcomes there would be a smaller 
decrease in the number of patients using DP+Sr89 (2 percent and 3 percent of all patients 
would be receiving DP+Sr89, as opposed to 1 percent in the base case). The analysis showed 
this uptake pattern to result in lower INMBs for all combinations, suggesting that carrying 
out research in this case would still be the preferable option, but, as this pattern is 
associated with uptake rates further away from the ‘optimal implementation’ (i.e. all 
patients receiving the most cost-effective treatment), conducting research would be less 
beneficial than in the base case (Table 6.33 and Table 6.34, below). 
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Table 6.33: Deterministic sensitivity analysis assuming lower uptake (30 percent) following ‘favourable’ results (two-
treatment HRPC) 
 
 
Favourable 
outcome 
Inconclusive 
outcome 
Unfavourable 
outcome 
DP+Sr89 current prescription 5% 
DP+Sr89 prescription following a 
possible outcome 
30% 5% 2% 
INMBs optimistic combination £2,083,924 
INMBs neutral combination £1,164,613 
INMBs pessimistic combination £734,144 
 
 
Table 6.34: Deterministic sensitivity analysis assuming lower uptake (20 percent) following ‘favourable’ results (two-
treatment HRPC) 
 
 
Favourable 
outcome 
Inconclusive 
outcome 
Unfavourable 
outcome 
DP+Sr89 current prescription 5% 
DP+Sr89 prescription following a 
possible outcome 
20% 5% 3% 
INMBs optimistic combination £977,943 
INMBs neutral combination £429,588 
INMBs pessimistic combination £169,613 
 
Last, assuming that the current prescription share of DP+Sr89 is higher than the base case 
estimate (10 percent as opposed to 5 percent in the base case) while clinical practice change 
is as in base case resulted in lower INMBs for all combinations (Table 6.35). This is driven by 
the fact that, here, the proportion of people who would benefit from a switch in clinical 
practice under the ‘favourable’ outcome (from the assumed level of 10 percent to 40 
percent) is smaller than that in the base case (from 5 percent to 40 percent).  
By analogy, assuming that DP+Sr89 is currently not prescribed at all (0 percent as opposed 
to 5 percent in the base case) and this would remain the case after ‘inconclusive’ or 
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‘unfavourable’ outcomes, led to slightly higher INMBs than in the base case for all 
combination. This is not surprising given that, under a ‘favourable’ outcome, more patients 
(40 percent, from 0 percent to assumed uptake of 40 percent) would switch to a beneficial 
treatment than in the base case analysis (35 percent, from 5 percent to 40 percent) (Table 
6.36). 
Table 6.35: Deterministic sensitivity analysis assuming higher current prescription (10 percent) for DP+Sr89 (two-
treatment HRPC) 
 
 
Favourable 
outcome 
Inconclusive 
outcome 
Unfavourable 
outcome 
DP+Sr89 current prescription 10% 
DP+Sr89 prescription following a 
possible outcome 
40% 10% 1% 
INMBs optimistic combination £2,679,228 
INMBs neutral combination £1,587,979 
INMBs pessimistic combination £1,101,035 
 
 
Table 6.36: Deterministic sensitivity analysis assuming no current prescription for DP+Sr89 (two-treatment HRPC) 
 
 
Favourable 
outcome 
Inconclusive 
outcome 
Unfavourable 
outcome 
DP+Sr89 current prescription 0% 
DP+Sr89 prescription following a 
possible outcome 
40% 0% 0% 
INMBs optimistic combination £3,708,276 
INMBs neutral combination £2,221,453 
INMBs pessimistic combination £1,511,700 
 
In the base case analysis, the ‘unfavourable’ outcome was specified so that DP+Sr89 is not 
cost-effective compared to DP (i.e. DP+Sr89 is much more costly and slightly more effective 
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than DP), neither is it dominated by this treatment. An alternative scenario for the 
‘unfavourable’ outcome could be that DP+Sr89 is more costly and less effective than DP (i.e. 
DP+Sr89 is dominated). This scenario would be observed if the probability of a patient on 
DP+Sr89 moving from the ‘progression-free’ state to progressive disease was set at a higher 
value than in base case (i.e. at 0.185 compared to 0.140 for the ‘unfavourable’ outcome in 
the base case). This made the treatment more costly by about £1246 and less effective by 
0.004 QALYs compared to DP. For the specific ‘unfavourable’ outcome, this scenario 
resulted in additional non-weighted NMBs in the population, due to restricting the use of a 
more costly and less effective treatment. When these results were combined with likelihood 
weights in weighted analysis, there were positive INMBs for the comparison between the 
‘with research’ and ‘without research’ situations, and additional NMBs as compared to the 
base case analysis. This suggests that gains in NMBs are more pronounced when practice 
switches away from relatively ‘worse’ (i.e. dominated) treatments, than from treatments 
which may be effective but not cost-effective (Table 6.37). 
Table 6.37: Deterministic sensitivity analysis for alternative ‘unfavourable’ outcome (two-treatment HRPC) 
 
 Optimistic 
combination 
Neutral 
combination 
Pessimistic 
combination 
Alternative scenario for ‘unfavourable’ outcome 
(DP+Sr89 dominated) 
£3,228,068 £1,950,013 £1,374,999 
 
Last, the effect of different time horizons can be seen in Table 6.38. The results confirm that 
as the number of patients to be affected by a beneficial change in practice increases, so do 
the expected NMBs from conducting research and changing clinical practice. 
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Table 6.38: Deterministic sensitivity analysis assuming different time horizons (two-treatment HRPC) 
 
Time horizon  Eligible 
patients 
Optimistic 
combination 
Neutral 
combination 
Pessimistic 
combination 
One year 2668 £1,341,357 £669,907 £352,378 
Five years 12,057 £8,473,396 £5,414,437 £4,003,361 
Ten years 22,314 £16,265,010 £10,597,743 £7,991,988 
 
6.3.3.B. Gradual change in uptake analysis  
While the above analyses presume that research results have an immediate effect on 
treatments’ uptake, it is likely that change in clinical practice occurs gradually. Thus, 
additional analysis was based on the assumption that uptake may change in a linear fashion 
over the two-year period. Under this assumption, prescription would be expected to 
develop as shown in Table 6.39 below. 
Table 6.39: Assumed prescription rates in gradual uptake analysis (two-treatment HRPC) 
 
Year 
Favourable outcome Inconclusive outcome Unfavourable outcome 
DP+Sr89 DP DP+Sr89 DP DP+Sr89 DP 
Current 5.0% 95.0% 5.0% 95.0% 5.0% 95.0% 
Year 1 22.5% 77.5% 5.0% 95.0% 3.0% 97.0% 
Year 2 40.0% 60.0% 5.0% 95.0% 1.0% 99.0% 
 
Based on these uptake patterns, non-weighted results were re-calculated and are given in 
Table 6.40. 
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Table 6.40: Non-weighted costs and benefits of research in gradual uptake analysis (two-treatment HRPC) 
 
 Favourable 
outcome 
Inconclusive 
outcome 
Unfavourable 
outcome 
With research  
Cost  £48,246,889 £46,651,582 £46,464,766 
Trial cost £684,876 £684,876 £684,876 
QALYs 4403 4124 4115 
Without research 
Cost £45,960,005 £45,966,706 £45,967,268 
QALYs 4160 4124 4119 
Net implications 
Net cost £2,286,884 £684,876 £497,498 
Net QALYs 243 0 -3 
Cost per QALY 
£9424 per 
additional QALY 
Costs for no 
additional QALYs 
Additional costs for 
QALYs forgone 
NMBwith research £83,835,093 £77,054,816 £76,995,972 
NMBwithout research £78,842,093 £77,739,692 £77,589,940 
INMBs (£30,000 per QALY) £4,993,000 -£684,876 -£593,968 
 
In general, non-weighted results predicted lower INMBs than those found in the base case 
analysis. This is unsurprising given that, in this case, the move to a more cost-effective 
treatment is introduced gradually. Accordingly, weighted results, given in Table 6.41, Table 
6.42 and Table 6.43 below, are also lower than in the base case analysis, at £2.18 million, 
£1.23 million and £780,000 NMBs for an ‘optimistic’, ‘neutral’ and ‘pessimistic’ combination 
(as opposed to £3.19 million, £1.9 million and £1.3 million for the respective combinations 
in base case). As in the gradual uptake analysis for NSCLC, it must be noted that the results 
dependent largely on the hypothesised prescription rates and the assumed pattern of 
change in uptake. 
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Table 6.41: Weighted costs and benefits of research in gradual uptake analysis (‘optimistic’ combination)(two-treatment 
HRPC) 
 
Optimistic combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted INMB(with 
research vs. without research) 
Favourable 0.50 £1,143,442 121 £2,496,500 
Inconclusive 0.25 £171,219 0 -£171,219 
Unfavourable 0.25 £124,375 -1 -£148,492 
Sum of weighted net costs 
and QALYs 
- £1,439,036 121 - 
Weighted ICER and INMBs £11,939 per additional QALY £2,176,789 
 
 
Table 6.42: Weighted costs and benefits of research in gradual uptake analysis (‘neutral’ combination)(two-treatment 
HRPC) 
 
Neutral combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted INMB(with 
research vs. without research) 
Favourable 0.33 £754,672 80 £1,647,690 
Inconclusive 0.33 £226,009 0 -£226,009 
Unfavourable 0.33 £164,174 -1 -£196,009 
Sum of weighted net costs 
and QALYs  
£1,144,855 79 - 
Weighted ICER and INMBs £14,489 per additional QALY £1,225,671 
 
 
Table 6.43: Weighted costs and benefits of research in gradual uptake analysis (‘pessimistic’ combination)(two-
treatment HRPC) 
 
Pessimistic combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted INMB(with 
research vs. without research) 
Favourable 0.25 £571,721 61 £1,248,250 
Inconclusive 0.25 £171,219 0 -£171,219 
Unfavourable 0.50 £248,749 -2 -£296,984 
Sum of weighted net costs 
and QALYs 
- £991,689 59 - 
Weighted ICER and INMBs £16,792 per additional QALY £780,047 
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6.3.3.C. Probabilistic sensitivity analysis  
The impact of change in clinical practice on weighted and non-weighted ‘payback’ results 
was assessed in probabilistic sensitivity analyses. In doing so, 1000 estimates of the possible 
levels of uptake were drawn from distributions attached to the ‘favourable’ and 
‘unfavourable’ outcomes. As in the equivalent NSCLC analysis, the distributions had means 
equal to the base case uptake rates and standard errors hypothesised to be one-quarter of 
the mean values. As DP+Sr89 prescription in the light of an ‘inconclusive’ outcome is 
assumed to remain unchanged, this parameter was held at its current prescription value (5 
percent). The mean values and confidence intervals for costs, QALYs and INMBs resulting 
from the probabilistic analysis are given in Table 6.44.  
The results of this analysis are almost identical to those in the base case analysis, suggesting 
that further research would be beneficial only if it showed a ‘favourable’ outcome for 
DP+Sr89. In the case of ‘inconclusive’ or ‘unfavourable’ outcomes, conducting research 
would result in negative INMBs of £684,900 and £562,100, respectively. It must be stressed 
that, similarly to the NSCLC study, the results are highly dependent on assumptions about 
the distributions representing the uptake levels.  
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Table 6.44: Non-weighted costs and benefits of research in probabilistic analysis (two-treatment HRPC) 
 
 Favourable outcome 
(Lower and upper 95% 
confidence intervals) 
Inconclusive outcome 
(Lower and upper 95% 
confidence intervals) 
Unfavourable outcome 
(Lower and upper 95% 
confidence intervals) 
With research 
Cost 
£48,122,483 
(£48,084,132 to 
£48,160,834) 
£45,966,706 
£45,714,133 
(£45,713,155 to 
£45,715,110) 
Trial cost £684,876 £684,876 £684,876 
QALYs 
4488  
(4482 to 4493) 
4124 
4114  
(4113 to 4414) 
Without research 
Cost £45,960,005 £45,966,706 £45,967,268 
QALYs 4160 4124 4119 
Net implications 
Net cost 
£2,847,355 
(£2,809,004 to 
£2,885,705) 
£684,876 
£431,741 
(£430,764 to £432,718)  
Net QALYs 
328  
(322 to 333) 
0 
-4  
(-4 to -4) 
Cost per QALY 
£8516 per additional 
QALY  
Costs for no additional 
QALYs 
Additional costs for 
QALYs forgone 
NMBwith research 
£85,821,525 (£85,685,602 
to £85,957,448) 
£77,054,816 
£77,027,874 
(£77,027,400 to 
£77,028,348) 
NMBwithout research £78,842,093 £77,739,692 £77,589,940 
INMB (£30,000 per QALY) 
£6,979,432 (£6,843,509 to 
£7,115,355) 
-£684,876 
-£562,065 
(-£562,539 to -
£561,591) 
 
Additional analysis was carried out to assess the uncertainty around likelihood weights used 
in forming combinations. As in the NSCLC application, likelihood weights were drawn from a 
Dirichlet distribution using the normalized sum of independent gamma draws method51;261. 
The drawn likelihood weights were combined with the probabilistic results obtained from 
varying the prescription rates to give 1000 estimates of the weighted net costs and QALYs 
198 
 
for each combination. Results, in the form of average values across the 1000 cost and QALY 
estimates are given in Table 6.45, Table 6.46 and Table 6.47. These showed values from 
£1.31 million to £3.13 million for the ‘pessimistic’ and ‘neutral’ combinations, respectively, 
supporting the conclusion that the two-arm trial would be a ‘cost-effective’ investment.  
Table 6.45: Weighted costs and benefits of research from probabilistic analysis (‘optimistic’ combination)(two-treatment 
HRPC) 
 
Optimistic combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted INMB(with 
research vs. without 
research) 
Favourable 0.50 £1,406,860 162 £3,445,261 
Inconclusive 0.25 £172,382 0 -£172,382 
Unfavourable 0.25 £109,283 -1 -£142,288 
Sum of weighted net 
costs and QALYs 
- £1,688,526 161 - 
Weighted ICER and 
INMBs 
£10,511 per additional QALY £3,130,591 
 
 
Table 6.46: Weighted costs and benefits of research from probabilistic analysis (‘neutral’ combination)(two-treatment 
HRPC) 
 
Neutral combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted 
INMB(with research vs. 
without research) 
Favourable 0.33 £949,019 109 £2,324,863 
Inconclusive 0.33 £225,899 0 -£225,899 
Unfavourable 0.33 £145,184 -1 -£189,060 
Sum of weighted net 
costs and QALYs 
- £1,320,102 108 - 
Weighted ICER and 
INMBs 
£12,261 per additional QALY £1,909,903 
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Table 6.47: Weighted costs and benefits of research from probabilistic analysis (‘pessimistic’ combination)(two-
treatment HRPC) 
 
Pessimistic combination 
Outcome 
Likelihood 
weight 
Weighted net 
cost 
Weighted net 
QALYs 
Weighted 
INMB(with research vs. 
without research) 
Favourable 0.25 £718,251 83 £1,761,200 
Inconclusive 0.25 £172,569 0 -£172,569 
Unfavourable 0.50 £214,134 -2 -£278,772 
Sum of weighted net 
costs and QALYs 
 £1,104,953 80 - 
Weighted ICER and 
INMBs 
£13,727 per additional QALY £1,309,859 
 
6.3.4. Base case analysis of the four-treatment TRAPEZE trial 
While the steps in carrying out PATHS analysis for two-treatment comparisons are well 
documented67, applications involving more than two treatments are scant and their 
methodology is relatively unclear. Particular ambiguity exists around the most appropriate 
way of specifying possible outcomes. Given this, additional analyses were carried out to 
illustrate a possible way of applying PATHS to multi-treatment assessments.  
6.3.4.A. Specification of outcomes  
Only one application of PATHS on a case study involving multiple treatments was found in 
the literature116. In this study, Fleurence116 used PATHS to assess the value of funding and 
conducting a particular study, the Record Trial, which compared three active treatments 
(vitamin D and calcium (VDC), vitamin D (VD), and calcium (C)) against placebo for the 
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prevention of fractures in patients with osteoporosis. In this application, the active 
treatments were grouped together, so that the study was, in essence, reduced to a two-
treatment comparison. For instance, under the ‘positive’ outcome, the author assumed that 
the trial would show all of the active treatments (VDC, VD and C) to be effective and cost-
effective, with different degrees of effectiveness attached to them. While in a trial more 
than one treatment may be shown effective against placebo, in an economic evaluation, 
where the cost-effectiveness of a treatment is determined in relation to the rest of the 
compared treatments, only one of VDC, VD and C can be cost-effective. Therefore, 
additional sub-scenarios need to be specified in order to account for the fact that each of 
the compared treatments may be proven cost-effective.  
6.3.4.B. Specification of possible outcomes 
With this in mind, possible outcomes were specified as follows: 
a. The TRAPEZE phase III trial gives results such that, when these results are entered 
into the HRPC model, the most cost-effective treatment is shown to be DP+Sr89 
(i.e. DP+Sr89 shows the highest NMBs amongst the compared treatments); 
b. The TRAPEZE phase III trial gives results such that, when these results are entered 
into the HRPC model, all treatments are shown to be of similar cost-effectiveness 
(NMBDP = NMBDP+ZA = NMBDP+Sr89 = NMBDP+ZA+Sr89), 
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c. The TRAPEZE phase III trial gives results such that, when these results are entered 
into the HRPC model, the most cost-effective treatment is shown to be DP (i.e. DP 
shows the highest NMBs amongst the compared treatments), 
d. The TRAPEZE phase III trial gives results such that, when these results are entered 
into the HRPC model, the most cost-effective treatment is shown to be DP+ZA (i.e. 
DP+ZA shows the highest NMBs amongst the compared treatments), and 
e. The TRAPEZE phase III trial gives results such that, when these results are entered 
into the HRPC model, the most cost-effective treatment is shown to be DP+ZA+Sr89 
(i.e. DP+ZA+Sr89 shows the highest NMBs amongst the compared treatments).  
The cost of the four-treatment TRAPEZE trial, as stated in the trial proposal submitted for 
funding, was £2.54 million. 
The first task involved working out the trial results that would be expected from the 
proposed trial, if the specified outcomes (i.e. ‘favourable’, ‘inconclusive’ and ‘unfavourable’) 
were to transpire. These results—expressed in terms of probabilities of transition from a 
progression-free state to progressive disease—are given in the last column of Table 6.48, 
alongside the existing probabilities used in the HRPC model (second column in the table). 
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Table 6.48: Transition probabilities used in four-treatment HRPC case study 
 
Outcome Base case transition probability 
from ‘Progression-free, not on 
treatment’ to ‘Progression’ 
Adjusted transition probability to 
match each possible outcome 
DP+Sr89 cost-effective 0.05 0.04 
DP cost-effective 0.06 0.01 
DP+ZA cost-effective 0.09 0.01 
DP+ZA+Sr89 cost-effective 0.04 0.01 
 
On the basis of the specified transition probabilities, the cost and QALY estimates would 
assume the values in Table 6.49. In scenarios where a particular treatment was not cost-
effective, it was assumed that its cost and benefits remained at their ‘current’ values, as 
calculated in the HRPC decision model (non-bold values). 
For example, under the specified outcome of DP being the cost-effective treatment, the cost 
and QALYs associated with this treatment was £8901 and 0.92, respectively, so that DP is 
the most cost-effective of all treatments (i.e. it results in the highest NMBs), while the 
values for the rest of the treatments remained as in base case. In the case of an 
‘inconclusive’ scenario, transition probabilities were adjusted so that all treatments are of 
comparable cost-effectiveness (i.e. all treatments showed very similar NMBs). 
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Table 6.49: Cost-effectiveness results based on ‘favourable’, ‘inconclusive’ and ‘unfavourable’ outcomes (four-treatment 
HRPC) 
 
Outcome 
DP DP+ZA DP+Sr89 DP+ZA+Sr89 
Total 
cost 
Total 
QALYs 
Total 
cost 
Total 
QALYs 
Total 
cost 
Total 
QALYs 
Total 
cost 
Total 
QALYs 
Base case £8949 0.81 £9855 0.83 £10,172 0.96 £11,436 0.87 
DP+Sr89 cost-
effective 
£8949 0.81 £9855 0.83 £10,164 0.99 £11,436 0.87 
Inconclusive £8928 0.87 £9842 0.90 £10,181 0.91 £11,405 0.96 
DP cost-
effective 
£8901 0.92 £9855 0.83 £10,172 0.96 £11,436 0.87 
DP+ZA cost-
effective 
£8949 0.81 £9822 0.95 £10,172 0.96 £11,436 0.87 
DP+ZA+Sr89 
cost-effective 
£8949 0.81 £9855 0.83 £10,172 0.96 £11,381 1.00 
 
6.3.4.C. Change in clinical practice 
As before, estimates of possible prescription rates were obtained through discussion with 
experts from the NHS Pan Birmingham Cancer Network. Such estimates were based on 
deliberations about the direction and strength of change in practice in the light of different 
eventualities and are given in Table 6.50. In general, should a treatment appear cost-
effective, its uptake would be expected to increase, although the magnitude of increase 
would depend on possible obstacles to implementation. For example, the available 
infrastructure for strontium-89 administration is limited and thus, if treatments involving 
radioisotope fractions (i.e. DP+Sr89 or DP+ZA+Sr89) were found to be cost-effective, their 
uptake would be expected to be lower than that of treatments not requiring strontium-89 
administration (i.e. DP, DP+ZA). This is reflected in the assumed prescription shares, where 
finding in favour of DP+Sr89 or DP+ZA+Sr89 is presumed to lead to 40 percent of the eligible 
patients taking those treatments, as opposed to 50 percent for DP+ZA. 
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In the case that DP (the usual practice) appeared cost-effective, the uptake of this treatment 
would be expected to increase (from 85 percent to 90 percent), while the uptake of the rest 
of the treatments would decrease (from 5 percent to 3.3 percent). This reflects the 
presumption that, if the currently standard treatment (DP) is confirmed to be cost-effective, 
there will be a pressure for restrictions in the use of non-standard, experimental treatments 
(DP+ZA, DP+Sr89, DP+ZA+Sr89). On the other hand, if any of the non-standard treatments 
appears cost-effective (either of DP+ZA, DP+Sr89, DP+ZA+Sr89), the pressure for restrictions 
would be expected to ease off and the non-cost-effective experimental treatments would 
be likely to remain at current implementation levels (5 percent).  
Table 6.50: Treatment uptake following the specified research outcomes (four-treatment HRPC) 
 
Prescription 
Possible 
outcome 
Percentage 
use of DP 
Percentage 
use of DP+ZA 
Percentage of 
DP+Sr89 
Percentage of 
DP+ZA+Sr89 
Current prescription 85.0% 5.0% 5.0% 5.0% 
Prescription in the 
light of each 
possible outcome 
DP cost-
effective 
90.0% 3.3% 3.3% 3.3% 
DP+Sr89 cost-
effective 
50.0% 5.0% 40.0% 5.0% 
DP+ZA cost-
effective 
40.0% 50.0% 5.0% 5.0% 
DP+ZA+Sr89 
cost-effective 
50.0% 5.0% 5.0% 40.0% 
 
6.3.5. Results of the four-treatment HRPC case study 
The non-weighted results of the base case analysis are given in Table 6.51. Under a 
‘favourable’ scenario for DP+Sr89, there would be costs due to conducting the trial and 
moving towards a more costly interventions but also gains in QALYs, resulting in overall 
gains of £5.13 million in NMBs.  
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Table 6.51: Non-weighted costs and benefits of research in base case analysis (four-treatment HRPC) 
 
Outcome DP+Sr89 cost-
effective 
Inconclusive DP cost-effective DP+ZA cost-
effective 
DP+ZA+Sr89 cost-
effective 
With trial 
Cost £48,994,528 £46,727,957 £46,213,291 £48,822,245 £51,156,266 
Trial cost £2,537,116 £2,537,116 £2,537,116 £2,537,116 £2,537,116 
QALYs 4511 4487 4655 4525 4549 
Without trial  
Cost £46,825,405 £46,727,957 £48,838,426 £46,818,994 £46,813,533 
QALYs 4183 4487 4648 4204 4206 
Net implications 
Net costs £4,706,240 £2,537,116 -£88,019 £4,540,368 £6,879,849 
Net QALYs 328 0 7 320 342 
Cost per QALY 
£14,351 per 
additional 
QALY 
Costs for no 
additional 
QALYs 
Cost savings for 
additional QALYs 
£14,175 per 
additional 
QALY 
£20,101 per 
additional QALY 
NMBwith research £83,798,160 £85,358,679 £90,893,840 £84,383,144 £82,763,340 
NMBwithout 
research 
£78,666,300 £87,895,795 £90,586,669 £79,313,999 £79,375,245 
INMBs 
(£30,000 per 
QALY) 
£5,131,860 -£2,537,116 £307,171 £5,069,145 £3,388,095 
 
Under the ‘inconclusive’ scenario, there would be a loss of £2.54 million due to the 
expenditure for the ‘inconclusive’ trial. If DP was found cost-effective, there would be cost 
savings from restricting the use of more expensive non-standard treatments and additional 
QALYs, resulting in overall positive NMBs of £307,200. In the case of DP+ZA or DP+ZA+Sr89 
being cost-effective, there would be gains in QALYs, which would offset the increased costs 
to result in positive NMBs of £5.07 million and £3.39 million, respectively.  
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Each outcome was attached a likelihood of being observed, to form combinations. In each of 
a series of alternative combinations, a weight of 0.5 was given to observing ‘favourable’ 
results for a specific treatment, with the likelihood weight for the rest of the results being 
0.125. For example, in alternative combination B where DP is specified as the most cost-
effective treatment the weight for DP being associated with a ‘favourable’ outcome was 0.5, 
while a weight of 0.125 was given for the rest of the outcomes.  
According to the results, funding and conducting the more expensive four-arm TRAPEZE 
phase III trial would be beneficial, and it is expected to lead to NMBs between £468,500 and 
£3.34 million (Table 6.52).  
Table 6.52: Weighted costs and benefits of research (four-treatment HRPC) 
 
Combination Weighted INMB(with research vs. without 
research) 
Alternative combination A (i.e. greater weight on 
‘favourable’ results for DP+Sr89) 
£3,344,342 
Neutral combination £468,476 
Alternative combination B (i.e. greater weight on 
‘favourable’ results for DP) 
£1,535,084 
Alternative combination C (i.e. greater weight on 
‘favourable’ results for DP+ZA) 
£3,320,824 
Alternative combination D (i.e. greater weight on 
‘favourable’ results for DP+ZA+Sr89) 
£2,690,430 
 
On the premise that the phase III trial will show results similar to the phase II study, the 
most likely combination would be Combination A, which is at the top end of the estimated 
range of ‘payback’ results. 
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6.3.6. Additional analyses for the four-treatment HRPC case study 
As noted earlier, the four-treatment HRPC analysis was conducted to illustrate a possible 
way to using PATHS in multi-treatment comparisons, rather than to obtain results and draw 
conclusions on possible patterns. However, additional deterministic sensitivity analyses 
were carried out to assess the sensitivity of the obtained results to different assumptions. 
These are given in Table 6.53. 
Table 6.53: Deterministic sensitivity analysis results (four-treatment HRPC) 
 
Combination Base case 
results 
 
 
(Weighted 
INMBwith research 
vs.without research) 
Sensitivity 
analysis: greater 
change in clinical 
practice 
(Weighted 
INMBwith research 
vs.without research) 
Sensitivity 
analysis: less 
marked change in 
clinical practice 
(Weighted 
INMBwith research 
vs.without research) 
Sensitivity 
analysis: perfect 
implementation 
 
(Weighted 
INMBwith research 
vs.without research) 
Alternative combination 
A (i.e. greater weight on 
‘favourable’ results for 
DP+Sr89) 
£3,344,342 £6,310,375 £1,536,599 £12,297,626 
Neutral combination £468,476 £1,791,157 -£517,591 £4,426,801 
Alternative combination 
B (i.e. greater weight on 
‘favourable’ results for 
DP) 
£1,535,084 £3,278,912 £315,045 £5,961,351 
Alternative combination 
C (i.e. greater weight on 
‘favourable’ results for 
DP+ZA) 
£3,320,824 £5,277,360 £1,067,046 £10,176,529 
Alternative combination 
D (i.e. greater weight on 
‘favourable’ results for 
DP+ZA+Sr89) 
£2,690,430 £5,282,799 £1,069,519 £10,163,452 
 
As before, a first analysis looked into the possibility that research results would have a 
greater impact on clinical practice than that hypothesised in the base case analysis (i.e. a 
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‘favourable’ outcome for a treatment would result in greater uptake of this treatment in 
practice). As expected, a more pronounced move towards the cost-effective treatment 
would be associated with greater expected NMBs than those predicted in the base case 
analysis. Alternatively, on the assumption that change in clinical practice would be less 
marked than that assumed in the base case, the expected NMBs from research are expected 
to be lower, and, in the case of a ‘neutral’ combination, they become negative suggesting 
that, in this situation, the benefits from the trial would not exceed its cost. Last, if change in 
clinical practice was ‘perfect’, namely, all patients were given the treatment shown to be 
the most cost-effective, the gains from conducting research and informing clinical practice 
would be substantial, from £4.43 million to £12.30 million.  
6.4. Discussion 
This chapter reports the application of the PATHS model to the NSCLC and HRPC case 
studies. The application aimed to give results on the potential value of carrying out the 
BTOG-2 and TRAPEZE phase III trials, as well as to give an insight into the employed 
methods, their strengths and their limitations. Overall, the analysis suggested that funding 
and conducting the proposed trials would be beneficial. In the base case analysis, carrying 
out the BTOG-2 trial and changing clinical practice according to its findings was estimated to 
result in additional NMBs of between £1.88 million and £2.38 million. Similarly, in the case 
of HRPC, the base case analysis predicted gains from conducting the TRAPEZE phase III trial 
between £1.30 million and £3.19 million for the two-treatment comparison, and between 
£468,500 and £3.34 million for the four-treatment comparisons. On the premise that the 
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TRAPEZE phase III trial may show results similar to those observed in the phase II study (i.e. 
‘favourable’ to DP+Sr89), conducting the proposed phase III trial would be expected to 
result in NMBs of about £3.19 million and 3.34 million for the two-treatment and four-
treatment comparisons, respectively.  
The application followed the core methods of the PATHS model, as laid out by Townsend 
and colleagues67, with two notable diversions. First, the present analysis accounts for the 
fact that evidence from clinical trials typically comes in the form of measures of clinical 
effectiveness (e.g. disease progression rates associated with a treatment), and, for this 
evidence to be useful in decision-making, it need to be translated into estimates of the 
treatments’ per-patient costs and benefits. In the present study, this was done by using the 
NSCLC and HRPC decision analytic models. The second modification relates to specifying 
how different results are expected to affect clinical practice, which is a key requirement in 
‘payback’ models67;90;98. In previous applications, this was determined by asking local 
experts and decision-makers to indicate the level of effectiveness and cost-effectiveness 
above which they would expect an assessed technology to be adopted in clinical practice67. 
Although local decision-makers are likely to give ‘richer’ answers that, in addition to cost-
effectiveness, may reflect other relevant considerations (e.g. a local authority’s budget, 
need for other services, local population’s epidemiological profile), such answers appear to 
be restricted to the specific locality and may not be appropriate for assessing the costs and 
benefits of research the results of which would be disseminated nationally (or even 
internationally) and inform decision-making at central level. In the present application, 
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evidence on a treatments’ cost-effectiveness was linked to changes in clinical practice—that 
is, adoption or restriction of treatments—on the basis of the rationale that underpins 
adoption decisions made by NICE: a health care intervention is likely to be recommended if 
it offers and additional unit of benefit at a cost lower than a willingness-to-pay 
threshold114;246. Here, this threshold was set at £30,000 per QALY.  
Additional analyses were carried out to look into factors that may have a bearing on the 
results. Deterministic analyses showed that the magnitude of the obtained results depends 
largely on the treatments’ effectiveness and cost-effectiveness as specified in possible 
outcomes, as well as on how clinical practice (prescription shares) is expected to develop in 
view of these outcomes. Scenarios where changes in practice occur gradually, over time, 
were also explored; these suggested that the ‘sharper’ the move towards adopting a cost-
effective treatment (or restricting the use of a non-cost-effective one), the greater the 
expected benefits to the population.  
A further, probabilistic component was added to the analyses, where uncertain parameters, 
such as treatments’ prescription shares and likelihoods of observing particular outcomes, 
were given probability distributions, rather than single values. These analyses gave results 
together with ranges within which the results are expected to fall, although, as noted 
earlier, results in this case are highly dependent on the characteristics of the distributions 
assigned to the parameters. A way of addressing multiple-treatment comparisons which 
involved specifying several possible outcomes was also outlined and applied to the four-
treatment HRPC case study. 
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In order for the model to work, certain assumptions were required. First, in line with 
existing ‘payback’ models67;90;92;100, possible outcomes need to be specified under the 
assumption that a discrete number of well-defined results may appear, although, in 
practice, results can assume values anywhere between the specified effectiveness 
estimates. Further, the application assumed that a trial would give evidence on a single 
parameter of one treatment (here, rates of disease progression for Gem+Carb and DP+Sr89) 
though, in practice, a trial would look into more parameters (e.g. adverse events and quality 
of life) and different treatments. Accounting for different parameters and treatments would 
make the specification of possible outcomes particularly complex, as there would be an 
infinite number of combinations of different parameter values that would make a treatment 
appear cost-effective, inconclusive or non-cost-effective. 
The analysis made extensive use of assumptions. Information on future uptake of 
treatments and time horizons does not usually exist in empirical form and thus in line with 
existing studies67;92 it was obtained through expert opinion. Similarly, the employed 
likelihood weights for combinations were based on previous applications of PATHS in the 
literature67;116. In this illustrative analysis, assumptions were also needed for the gradual 
implementation analysis (i.e. rate of treatments’ uptake increase or decrease over the 
specified time horizons) and the probabilistic sensitivity analysis. In the latter, no values on 
the variance of the distributions for uptake rates and likelihood weights were available and, 
thus, in order to illustrate the methods, estimates were chosen arbitrarily. 
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Last, the views of experts on possible changes in clinical practice were obtained through 
discussion in the context of semi-structured interviews. The use of formal elicitation 
techniques might have added rigour to this exercise, however, such an undertaking was 
considered to be beyond the pragmatic constraints of this doctoral project.  
6.5. Chapter overview 
The chapter presents and discusses the application of the latest ‘payback’ model (PATHS) to 
the NSCLC and HRPC case studies. For each case study, the application involved a base case 
analysis, as well as additional deterministic and probabilistic sensitivity analyses. An 
approach to carrying out PATHS analysis for four-treatment comparisons was also illustrated 
and applied to the HRPC study.  
In summary, results suggested that, given specific assumptions about possible research 
outcomes, change in clinical practice and likelihoods of the outcomes to transpire, 
undertaking the BTOG-2 and TRAPEZE trials would result in additional benefits. In addition 
to giving results, the analysis provided useful information around the methodological and 
practical challenges associated with the framework. These are discussed in more detail in 
Chapters 8 and 9. 
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CHAPTER 7. Practical application of ‘value of information’ to 
case studies 
This chapter focuses on the application of ‘value of information’ (VoI) to the case studies of 
NSCLC and HRPC. As in the ‘payback’ analysis, the application aims to give an insight into the 
frameworks’ strengths and challenges, rather than to inform actual funding decisions. The 
first part of the chapter gives a description of the methods involved in VoI analysis, while 
the second part reports and interprets the obtained results. The chapter concludes with a 
discussion of points which arose in the course of this analysis.  
7.1. Description of methods in ‘value of information’ 
A description of the rationale underpinning the VoI framework has been given earlier in this 
thesis, in Chapter 3. In essence, the framework seeks to establish the gains from—and thus 
the value of—obtaining further information through evaluative research by looking into the 
additional benefits that would be expected to accrue from decision-making in the light of 
this information97;179;180. Given this, the framework has been often advocated as a means of 
establishing the value of conducting further evaluative research55;80;121. 
Different concepts exist in ‘value of information’ analysis, such as the expected value of 
perfect information for all or a subset of uncertain parameters, expected value of sample 
information, as well as concepts related to the value of implementation. These concepts are 
described below with a focus on the methods involved in calculating relevant results.  
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7.1.1. Expected value of perfect information  
A first, core step in ‘value of information’ analysis relates to establishing the expected value 
of perfect information (EVPI). EVPI represents the difference between the net monetary 
benefits (NMBs) to be gained if a treatment adoption decisions (e.g. the decision on which 
NSCLC treatment to adopt) was made under perfect information (effectively, with no 
uncertainty) and the NMBs expected from the same decision made in the light of current, 
imperfect information. EVPI can be estimated parametrically, using analytic formulae97;262; 
however, such calculations require assumptions about normally distributed NMB results to 
hold true, which is in practice rare, especially when cost-effectiveness results and estimates 
of uncertainty are obtained from non-linear decision analytic models51;190. In such cases, 
EVPI can be calculated non-parametrically, using estimates of uncertainty in the form of 
simulated results obtained from probabilistic sensitivity analysis. Adopting the notation in 
Briggs et al.51, for j alternative interventions and a set of all uncertain parameters θ, EVPI is 
given by the formula: 
                                     
and can be estimated following the steps given in Box 7.151;263. EVPI calculated in this way 
represents the expected additional benefits due to making a decision about treating a single 
patient under perfect information, as opposed to making the same decision under current 
information. Once information is generated, it can be used to inform all decisions for all 
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current and future eligible patients over a specific time horizon representing the period over 
which the information is expected to be useful183. 
 
Box 7.1: Steps in non-parametric calculation of EVPI 
 
1. Carry out probabilistic sensitivity analysis to obtain a large number of cost and effect (e.g. 
QALYs) pairs for each treatment   under assessment. Each of these pairs represents the results 
for a specific resolution of the uncertain parameters. Convert cost and effects into NMBs. 
 
2. For each treatment  , calculate the average across all the simulated NMBs estimates, to 
obtain the expected NMBs associated with each treatment. Compare the expected NMBs 
across treatments to establish the treatment associated with the highest expected NMBs 
(               ). This represents the optimal treatment under current information. 
 
3. If perfect information about the correct values of the uncertain parameters (i.e. the correct 
resolution of parameters) affecting the decision was available, one would always choose the 
treatment resulting in the maximum NMBs (            ). As it is not known which 
resolution of parameters represents the true NMBs, calculate the average over all the 
maximum expected NMBs to get the expectation of the maximum NMBs 
(              ). This represents the expected benefits from a decision with perfect 
information. 
 
4. Find the difference between the expectation of the maximum NMBs (              ) 
and the maximum of the expected NMBs (               ), in other words the difference 
between the expected gains from a decision with perfect and current information. This value 
represents the EVPI associated with the adoption decision (i.e. choice between treatments). 
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The EVPI for the population of eligible patients is the sum of the individual EVPI multiplied 
by the discounted number of patients affected by the decision in each period over the time 
horizon for which the generated information is expected to be useful (   ), starting from the 
point when information is disseminated. The formula for calculating the population EVPI is: 
                                ∑
  
      
              
 
Here,   is the time lag between a funding decision and dissemination of results, measured 
in relevant time periods, and   is the discount rate. As EVPI shows the maximum NMBs from 
pursuing perfect information around a treatment adoption decision through conducting 
research, EVPI results represent the maximum amount of resources that a rational decision-
maker should devote to research around this adoption decision. If EVPI exceeds the cost of 
research, conducting research is potentially—although not necessarily—worthwhile110;123.  
7.1.2. Expected value of perfect parameter information  
EVPI analysis can be extended to establish the value of undertaking research to eliminate 
uncertainty around one or a subset of all the uncertain parameters affecting an adoption 
decision. Formally, the expected value of perfect parameter information (EVPPI) for a group 
of uncertain parameters   of all uncertain parameters   associated with a decision between 
  alternative interventions is given by the formula below:  
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This represents the difference between the NMBs expected to accrue from a decision made 
with perfect information about the parameters of interest   (and imperfect information 
about the remaining parameters  ) and a decision made with current, imperfect 
information about all parameters  . Individual EVPPI can be extrapolated to the population 
of patient that stand to benefit from further information in a way identical to that of EVPI. 
Different ways of calculating EVPPI have been proposed, discussed and evaluated in the 
literature55;180;264. The method which is commonly suggested as the most appropriate makes 
use of nested two-level Monte Carlo simulation loops, in recognition of the fact that 
calculation of the expected NMBs under perfect information involve two 
expectations190;263;264. The process of calculating the EVPPI for one (or a group of) uncertain 
parameter(s)  through the nested two-level Monte Carlo approach is given in  
 
Box 7.2. 
As a result of using two loops, EVPPI calculations typically require a large number of 
simulations265, although under certain assumptions (i.e. linear relationship between input 
parameters and calculated NMBs, and no correlation between parameter of interest and 
remaining parameters) shortcuts such as single-level Monte Carlo simulations may also be 
appropriate190;264. The minimum number of inner and outer loop runs required to obtain 
accurate EVPPI has been subject to debate, although it is generally agreed that this number 
depends on factors related to the structure of the decision model, the number of uncertain 
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parameters of interest and the impact of these parameters on the final cost-effectiveness 
results263;264. Brennan and colleagues263 carried out an empirical investigation on the impact 
of the number of inner and outer loop runs on the EVPPI result and concluded that a 
combination of 100 outer and 500 inner loops would, in most situations, lead to 
convergence and sufficiently accurate EVPPI results. In general, higher numbers of inner and 
outer loop simulations result in lower levels of sampling error and improved 
accuracy263;264;266. 
EVPPI shows the difference between the NMBs expected to arise from a decision made 
under perfect information around a group of parameters, over the NMBs expected under 
current information around all parameters affecting the decision. Given this, EVPPI analysis 
has been suggested as a means of indicating those parameters for which pursuing further 
information would be beneficial184;185;263;267. Similarly to EVPI, if the expected benefits of 
eliminating uncertainty around a group or a single parameter through carrying out a 
research programme (e.g. a clinical trial) exceed the cost of the programme, research to 
obtain better information on the parameter(s) would be potentially cost-effective51;185. 
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Box 7.2: Steps in non-parametric calculation of EVPPI 
1. Draw a set of values (i.e. one value for each parameter) from the probability distributions of 
parameters   (outer loop). 
 
2. Holding the drawn set of values for parameters   fixed, carry out a large number (e.g. m= 
1000) of Monte Carlo simulations, where values are drawn randomly for the remaining 
uncertain parameters   (inner loop). For each simulation and each treatment, calculate costs 
and effects, and convert these into NMBs. Record the 1000 NMBs for each treatment.  
 
3. For each treatment, calculate the average across the obtained 1000 NMB estimates. This 
gives a set of expected NMB values (one for each treatment), given a fixed (considered certain) 
set of values of   and non-fixed (uncertain) values of the remaining parameters 
  (               ). Repeat steps 1 to 3 a large number of times (e.g.   =1000) to obtain 
1000 sets of expected NMBs (1000 NMBs for each treatment)  
 
4. Calculate the average across all the expected NMB estimates generated in step 3. Choose 
the treatment with the highest average NMBs (              ). This is the optimal 
treatment under current information (continued in the following page). 
 
5. For each set of expected NMB estimates obtained in step 3, calculate and record the 
maximum expected NMBs. Taking the average of the maximum expected NMBs will give the 
expected value of the maximum expected NMBs (                     ).This value 
represents the average gains from making a decision with perfect information about the 
parameters of interest  . 
 
6. Last, subtract the average gains with current information (              ) from the 
gains expected from a decision with perfect information about the parameters of interest   
(                     ). This gives the EVPPI for the specific group of parameters  . 
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7.1.3. Expected value of perfect information and implementation 
It has often been argued that benefits expected from treatment adoption decisions are 
rarely realised in full, as, in many cases, the uptake (or implementation) of cost-effective 
treatments does not reach an optimal level186;268. Implementation programmes can be 
undertaken to improve the uptake of beneficial treatments, but such programmes come at 
a cost188. In view of this, Fenwick and colleagues187 have introduced a conceptual framework 
which considers the value of devoting resources to implementation strategies. 
Value of implementation analysis focuses on the benefits expected to accrue in different 
‘states of the world’, where each state represents a unique combination of different levels 
of information available for making a decision and implementation of the decision in clinical 
practice. Implementation is expressed as the prescription share, or uptake, of a treatment in 
clinical practice; this can be ‘current’, where only a proportion of the eligible patients 
receive the treatment that appears cost-effective, or ‘optimal’, where all eligible patients 
receive the cost-effective treatment. Different ‘states of the world’, as summarised by 
Fenwick and colleagues187 are given in Table 7.1.  
Table 7.1: Possible eventualities regarding information and implementation 
 
Possible ‘states of the world’ 
Information 
Current Perfect 
Implementation 
Current state A state B 
Optimal state C state D 
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The NMBs associated with each of the above states can be estimated from the results of the 
probabilistic model, using the following formulae187: 
              ∑    
 
                
               ∑    
               
                            
                           
Here,     represents the eligible population of patients,   
  represents the proportion of 
patients taking treatment   given implementation   ( =current or perfect) and   represents 
the uncertain parameters affecting a decisions. Comparisons between the NMBs expected 
to accrue in different states are thought to give useful measures of the value of pursuing 
better implementation124. An important assumption underpinning such comparisons is that 
acquiring additional information will not, in itself, have an impact on implementation, which 
will always remain at current level unless active implementation strategies are put in place 
to alter it. Fenwick et al.187 acknowledged that this is a somewhat simplistic view and it is 
more likely that acquisition of information does affect subsequent implementation. 
7.1.4. Expected value of sample information and expected net benefit of sampling 
As explained above, EVPI and EVPPI results show the NMBs expected to accrue from 
eliminating uncertainty around all or a subset of parameters affecting a decision. However, 
eliminating uncertainty is in practice unfeasible, as this would require carrying out ‘perfect 
research’, in the form of a study involving an infinitely large number of participants. In 
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reality, research studies, such as clinical trials, employ finite, and often small, sample sizes 
and are expected to reduce, but not eliminate, uncertainty51;107.  
The expected reduction in uncertainty due to conducting research of a particular sample 
size and, thus, the expected value of sample research, can be quantified by the expected 
value of sample information (EVSI) measure. The measure gives the actual expected NMBs 
from a particular study of a particular sample size. EVSI is calculated as the difference 
between the NMBs expected to accrue from a decision based on sample information 
obtained from a study of sample size   and the NMBs of a decision made with current 
information51;97;115;178. 
EVSI calculations are based on the concept of Bayesian inferrence107;189. In simple terms, 
before a study (e.g. a clinical trial) is conducted, adoption decisions are made in view of 
cost-effectiveness results calculated on the basis of existing (prior) evidence about 
parameters (e.g. existing evidence on a treatment’s effectiveness). Conducting a study 
generates new evidence (e.g. evidence on disease progression), which can be combined 
with the prior evidence to provide improved, ‘posterior’ information. Decisions made on the 
basis of posterior information are expected to be less uncertain and, as a result, they will be 
associated with additional NMBs as compared to decisions made under existing evidence. 
Given the above, the main aim in EVSI is to compare the benefits from a decision made with 
current information against the benefits expected to accrue from a decision made under 
‘improved’ information obtained from conducting a proposed clinical trial. Improved 
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(posterior) information is a combination of existing information and sample (simulated) 
evidence from the trial.  
Early applications of EVSI analysis have been carried out parametrically using simple 
mathematical formulae, under the assumption that results of economic evaluations— 
expressed, for example, as net monetary benefits—are normally distributed97;115. However, 
the recognition that results from decision analytic models are characterised by complex, 
non-linear structures and are very unlikely to be normally distributed175 has turned the 
attention towards non-parametric simulation methods190;269.  
Combining prior and sample (trial) information is fairly straightforward when prior and 
sample evidence is expressed in terms of distributions which are conjugate, that is, they can 
be combined by using simple analytic solutions (e.g. beta-binomial, normal, gamma-Poisson 
distribution). Often, prior and sample data are expressed as distributions which are 
disconnected (e.g. prior information parameterised as Weibull distribution and sample 
information expressed as Normal distribution). When this is the case, as Brennan and 
Kharrubi270[p.1206] explain, combining existing evidence with simulated sample results is “a 
substantial computational expense itself and must be repeated for each simulated data-set, 
which can result in very substantial computation times”. In such cases, possible ways of 
combining prior and data involve Bayesian approximation methods and Bayesian updating 
in specialist software, typically WinBUGS271.  
EVSI can be calculated from the output of probabilistic analytic model using non-parametric 
methods, which usually involve running Monte Carlo simulations and taking advantage of 
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special relationships between distribution of parameters (i.e. conjugacy)190;263. Owing to the 
complexity of EVSI calculations, the method is typically restricted to assessing the value of a 
clinical trial in informing one or a group of similar parameters (e.g. disease progression), 
rather than all parameters investigated in the trial51.  
Assuming that a study of sample   is considered to provide evidence on a single parameter 
or a group of parameters of interest   of all uncertain parameters  , the per-patient EVSI 
can be calculated following the sequence of steps described in Box 7.3 and is given by the 
formula:  
                                           
The EVSI for the population that is expected to benefit from a decision in the light of 
improved information is calculated in the same way as the population EVPI and EVPPI.  
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Box 7.3: Steps in non-parametric calculation of EVSI 
1. Draw a set of values of the uncertain parameters   from their existing (prior) distributions. 
 
2. On the basis of the drawn values, simulate possible sample results  on  . 
 
3. Combine the prior distribution and sample results obtained from step 2 to get a posterior 
distribution. Repeat steps 1 to 3 a large number of times (e.g.   =1000) for each treatment  . 
 
4. Draw a large number of values (e.g.   =1000) from each of the posterior distributions 
obtained in step 3, and calculate the resulting NMBs for each treatment  . 
 
5. Average across the NMBs obtained in step 4, to get the expected NMBs (            ) 
for each posterior distribution and for each treatment  .  
 
6. Find the maximum expected NMBs across treatments for each posterior distribution 
(                   ). 
 
7. As it is not known which posterior distribution (i.e. trial results) will transpire, average 
across the maximum expected NMBs to obtain the expected maximum NMBs 
(                    ). This represents the expected NMBs from making a decision with 
sample information. 
 
8. Subtract the NMBs associated with a decision with sample information 
(                    ) from those based on a decision made under current information 
(                ) to get the EVSI.  
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7.2. ‘Value of information’ analysis for NSCLC 
This section reports the results of the application of EVPI, EVPPI and value of 
implementation analyses to the NSCLC case study. 
7.2.1. Expected value of perfect information analysis for NSCLC 
EVPI analysis was carried out to establish whether conducting further research to inform the 
choice between Gem+Cisp and Gem+Carb—that is, the relevant treatment adoption 
decision in NSCLC—would be potentially worthwhile or should be ruled out. EVPI results for 
the individual patient were obtained by using the output of the probabilistic NSCLC model. 
Individual (per-patient) and population EVPI results are given in Table 7.2.  
Table 7.2: Individual and population EVPI (NSCLC) 
 
Ceiling ratio Individual Population 
(five-year time horizon) 
£0 per QALY £66 £908,419 
£30,000 per QALY £948 £13,077,504 
£80,000 per QALY £2287 £39,827,506 
Population EVPI was calculated by projecting the individual EVPI to the population of 
current and future patients which is expected to be affected by the NSCLC adoption 
decision. As noted in the previous chapter, assuming a five-year time horizon and an 
estimated number of 3830 eligible patients per year, the total discounted number of eligible 
patients was estimated to be 13,797. 
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At a ceiling ratio value of £0 per QALY (that is, when a decision-maker is not willing to pay 
any amount of money for additional QALYs), there is little uncertainty around Gem+Cisp 
being the optimal treatment. Thus, the value of eliminating this uncertainty, that is, the 
EVPI, is relatively low, at about £66 for the individual patient and £908,400 for the 
population. As the ceiling ratio increases, so does the uncertainty around Gem+Cisp being 
the optimal treatment, which, in turn, leads to increases in EVPI. This trend can be seen in 
the plots of the population EVPI shown in Figure 7.1. At £30,000 per QALY, the EVPI is £950 
and £13.08 million for the individual and the population, respectively, while at a high ratio 
of £80,000 per QALY, individual and population EVPI values are £2290 and £39.83 million.  
 
Figure 7.1: Population EVPI for NSCLC 
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The obtained EVPI results suggest that, at £30,000 per QALY, conducting further research 
(such as the proposed BTOG-2 trial) to provide further evidence around the NSCLC 
treatment adoption decision would be potentially worthwhile if the research programme 
costs less than £13.08 million. On this basis, funding and carrying out the proposed BTOG-2 
trial, which costs £336,700, would be a potentially worthwhile investment. 
7.2.2. Expected value of perfect parameter information analysis for NSCLC 
Additional analysis was carried out to investigate the expected gains from acquiring perfect 
information about specific parameters. Five groups of parameters were formed:  
a. utility values for the ‘Progression-free’ and ‘Progression’ health states in the NSCLC 
model;  
b. transition probabilities (rates of progression and survival) associated with 
Gem+Cisp;  
c. transition probabilities (rates of progression and survival) associated with 
Gem+Carb; 
d. costs associated with Gem+Cisp, and  
e. costs associated with Gem+Carb. 
EVPPI calculations were carried out through nested two-level (inner and outer loop) Monte 
Carlo computations51;263. The analysis involved a relatively high number of simulations—
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1000 for the inner loop and 1000 for the outer loop—in order to improve accuracy in the 
results and was carried out in Microsoft Excel 2007® using commands (macros) written in 
the VBA® programming language.  
Individual and population EVPPI for different parameters assuming a ceiling ratio of £30,000 
per QALY are given in Figure 7.2 and Figure 7.3. Parameters with the highest individual 
EVPPI were transition probabilities for Gem+Cisp and Gem+Carb, at £400 and £657, 
respectively, while the equivalent values for all eligible patients over five years were £5.52 
million and £9.07 million. On the other hand, the value of research associated with 
Gem+Cisp and Gem+Carb costs appeared low, at £4 (£51,250) and £3 (£35,000) for the 
individual patient (entire population), respectively. The EVPPI associated with utility scores 
at £30,000 per QALY was zero for both an individual patient and the population. 
 
Figure 7.2: Individual patient EVPPI for NSCLC at £30,000 per QALY 
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Figure 7.3: Population EVPPI for NSCLC at £30,000 per QALY 
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Gem+Carb when the ceiling ratio is low (i.e. when the cost of treatments is important) but, 
as the ceiling ratio increases, the importance of costs in overall decision uncertainty 
diminishes.  
 
Figure 7.4: Population EVPPI at different ceiling ratios for NSCLC 
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utility scores should be ruled out. Similarly, EVPPI for costs was low and it is unlikely that 
research on this parameter only would be potentially cost-effective; nonetheless, there may 
be scope for including cost and utility parameters as additional endpoints in a trial with a 
primary focus on disease progression rates.  
7.2.3. Impact of parameter uncertainty on results 
As explained above, VoI measures translate the uncertainty around a decision problem into 
possible gains expected from obtaining better information. Because of this, EVPI and EVPPI 
results are highly dependent on the degree of the uncertainty around a decision, with 
higher uncertainty resulting in higher EVPI and EVPPI. Often, estimates of the uncertainty 
around parameters affecting a decision are not available and, in such situations, they are 
replaced by assumptions. With this in mind, further analysis was carried out to explore how 
different assumptions about the extent of uncertainty around key parameters in the NSCLC 
model may affect the generated VoI results. In doing so, it was assumed that uncertainty 
around key parameters, represented by standard errors, may take on values double or half 
as high as the base case values. Results of this analysis are given in Table 7.3.  
Introducing greater uncertainty around cost and preference-based quality of life parameters 
had a small effect on EVPI results, which became less than five percent higher than the base 
case value. However, increasing the standard errors around transition probabilities for 
Gem+Cisp and Gem+Carb had a sizeable impact on EVPI, which rose by about 40 percent 
and 80 percent, respectively. This is explained by the fact that transition probabilities are a 
233 
 
key determinant in the choice between Gem+Cisp and Gem+Carb (i.e. in the adoption 
decision) and thus uncertainty around such parameters has an impact on the uncertainty 
around the adoption decision and, in turn, on the EVPI. As expected, an effect of the 
opposite direction was observed when the standard errors around parameters were set at 
lower values. In this case, the greatest reduction in EVPI (about 43 percent) resulted by 
decreasing the uncertainty around transition probabilities for Gem+Carb.  
Table 7.3: Results of illustratory sensitivity analysis on impact of uncertainty on EVPI 
 
Varied parameter 
Population EVPI  
(£30,000 per QALY; five-year time horizon) 
Base case  £13,077,504 
Gem+Cisp transition probabilities  
(standard error twice the base case value) 
£17,941,963 
Gem+Carb transition probabilities  
(standard error twice the base case value) 
£29,264,503 
Gem+Cisp costs  
(standard error twice the base case value) 
£13,280,117 
Gem+Carb costs  
(standard error twice the base case value) 
£13,288,161 
Preference-based quality of life (utility) scores  
(standard error twice the base case value) 
£13,538,582 
  
Gem+Cisp transition probabilities  
(standard error half the base case value) 
£11,376,279 
Gem+Carb transition probabilities  
(standard error half the base case value) 
£7,422,768 
Gem+Cisp cost  
(standard error half the base case value) 
£12,697,379 
Gem+Carb cost  
(standard error half the base case value) 
£12,895,010 
Preference-based quality of life (utility) scores  
(standard error half the base case value) 
£12,928,053 
 
As noted in Chapter 4, estimates of preference-based quality of life (utility scores) for 
different states of advanced NSCLC were not available in the literature. Thus, mean utility 
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scores and estimates of the uncertainty around them (standard errors) were obtained from 
expert opinion. On the basis of these scores, the EVPPI analysis reported above showed a 
very low value of research on utility values. Additional EVPPI analyses were carried out to 
explore whether assigning greater uncertainty around the utility scores (i.e. higher standard 
errors than those specified by experts) would suggest this parameter as a good candidate 
for further research. However, even when the uncertainty around utility scores was 
doubled, EVPPI at £30,000 per QALY was zero, suggesting that, at conventional ceiling ratio 
values, the impact of utility scores on the adoption decision and thus the value of obtaining 
better estimates around such scores, is negligible.  
7.2.4. Value of information and implementation analysis for NSCLC 
VoI analysis was extended to take into account different situations regarding availability of 
information and treatments’ uptake (implementation) using the conceptual framework 
introduced by Fenwick and colleagues187. The main analysis was based on the assumption 
that there is no direct relationship between acquisition of information and treatment 
uptake (i.e. implementation), that is, uptake changes only in response to implementation 
strategies. Further analysis was carried out to illustrate a possible extension to the 
framework by looking into the more realistic scenario where availability of improved 
information has an impact on implementation. In these analyses, results reflect NMBs 
expected to accrue from decisions made under different ‘states of the world’ related to 
information and implementation, using a ceiling ratio of £30,000 per QALY.  
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7.2.4.A. Assuming acquisition of information has no impact on implementation  
In this analysis, information is needed on ‘current implementation’ (that is, treatments’ 
prescription shares in the absence of any implementation strategies) and ‘optimal’ 
implementation. Information on current implementation, that is treatments’ prescription 
shares in the year evidence from research is expected to become available (i.e. 2011), 
suggested that each of Gem+Cisp and Gem+Carb is provided to 50 percent of the eligible 
patients. On the other hand, optimal implementation means that the treatment that 
appears cost-effective would be implemented perfectly, (i.e. it would be provided to the 
entire population of eligible patients) and, on the other hand, the treatment which is not 
cost-effective will not be provided to any patients. 
The expected NMBs for different ‘states of the world’, assuming that improved information 
has no impact on the level of implementation, are given in Table 7.4. A treatment adoption 
decision with current information implemented at current levels (state A) is expected to 
bring about benefits of £152.70 million, the same as in the case of making a decision with 
perfect information and current implementation (state B). A decision with current 
information followed by optimal implementation (state C) is expected to result in NMBs of 
approximately £160.76 million, while a decision with perfect information that will be 
implemented optimally (i.e. the ‘ideal’ situation), is expected to result in NMBs of about 
£173.84 million (state D). 
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Table 7.4: Expected NMBs for different ‘states of the world’ regarding information and implementation (NSCLC) 
 
States of the world 
Information 
Current Perfect 
Implementation 
Current 
£152,696,292 
(state A) 
£152,696,292 
(state B) 
Optimal 
£160,760,214 
(state C) 
£173,837,480 
(state D) 
 
On the basis of these results, one can calculate different measures of the value of acquiring 
better information and improving implementation. These measures are given in Table 7.5. 
The EVPI (i.e. difference between states D and C) was estimated at £13.08 million. This 
figure represents the expected NMBs from a decision made with perfect as opposed to 
current information given that in either case the decision will be implemented optimally, 
and indicates the maximum returns to pursuing better information through research. 
Table 7.5: Expected NMBs for different measures of information and implementation (NSCLC) 
 
Measure* 
NMBs 
(at £30,000 per QALY) 
EVPI (state D – state C) £13,077,266 
rEVPI (state B – state A) £0 
EVPIMperfect information (state D – state B)  £21,141,187 
EVPIMcurrent information (state C – state A) £8,063,922 
EVP (state D – state A) £21,141,187 
EVIIT (state B – state C) -£8,063,922 
*Featured measures are explained in the following text 
 
The comparison between current and optimal implementation gives the expected value of 
implementation (EVPIM). Under current information, that is, with Gem+Cisp being superior 
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to Gem+Carb, the difference between providing the superior treatment to the whole 
population (i.e. optimal implementation) and continuing with current prescription shares 
(i.e. current implementation) is £8.06 million. This value is the EVPIMcurrent information and 
represents the maximum expected gains from investing resources in the pursuit of better 
implementation of the treatment which is believed to be cost-effective under current 
evidence.  
On the other hand, the EVPIMperfect information is the difference between the expected benefits 
obtained with current and optimal implementation, assuming that perfect information is 
available. The EVPIMperfect information was estimated at £21.14 million and represents the 
maximum gains from ensuring optimal implementation of the treatment that appears cost-
effective under perfect information. This is seen as the maximum value that decision-
makers should commit to implementation strategies under the premise that perfect 
information is available187. 
This comparison between the value of a decision made with perfect information and 
optimal implementation, and one made with current information and current 
implementation gives the expected value of perfection (EVP). In this analysis, EVP is £21.14 
million, the same as the EVPIMperfect information, owing to the assumption that acquiring perfect 
information does not improve implementation and it is only implementation strategies that 
can affect treatment uptake in clinical practice. In other words, as long as the practice 
remains at current levels, it is irrelevant whether there is perfect or current information. As 
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a result, EVP provides the maximum gains from, and thus the maximum value of, acquiring 
perfect information and pursuing perfect implementation. 
The difference between the expected NMBs in a situation with perfect information and 
current implementation (state B) and one with current information and current 
implementation (state A) gave the realisable EVPI (rEVPI). As expected, under the 
assumption that acquiring perfect information does not improve implementation, there is 
no ‘realisable’ benefits from acquiring perfect information, that is, rEVPI is zero. 
The final comparison is between perfect information and current implementation (state B), 
and current information and optimal implementation (state C). Observing a positive 
difference from this comparison would mean that acquiring further information should take 
priority over investing in better implementation, assuming that the cost of further research 
and the cost of implementation programmes are comparable. If the difference is negative, 
the gains from a decision with current information and optimal implementation are 
expected to exceed those from a decision with perfect information which will only be 
implemented at current, sub-optimal levels. Obviously, a decision between investing in 
research or implementation will also depend on the cost of information and implementation 
programmes. To the author’s best knowledge, no published work has explored this 
comparison before, which, for the purposes of this project, has been termed ‘expected 
value of information-implementation trade-off’ (EVIIT).  
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EVIIT is useful in that it shows whether priority should be given to further research, or 
resources should be committed to programmes that would improve adherence to the 
treatment that appears cost-effective under current information. The results gave a value of 
-£8.06 million, suggesting that a decision under perfect information which will be 
implemented only at current rates will be expected to result in lower NMBs than a perfectly 
implemented decision made under current information. Assuming comparable costs for 
research and implementation programmes, EVIIT suggested that pursuing better 
implementation is potentially more beneficial than carrying out a study such as the BTOG-2 
trial to obtain better information. 
7.2.4.B. Assuming acquisition of information affects implementation 
Fenwick et al.124 recognise that the assumption of no interaction between acquisition of 
information and implementation (i.e. only implementation strategies can improve 
adherence to cost-effective treatments) may be simplistic. Given this, additional analysis 
was carried out to look into a situation where acquisition of information is expected to 
affect implementation. This illustrative analysis makes use of estimates of future 
prescription shares obtained for the purposes of the ‘payback’ analysis through discussion 
with experts at the Pan-Birmingham Cancer Network (Table 7.6). 
In general, having better information is expected to lead to an increase in the uptake of the 
treatments shown to be cost-effective and a decline in the use of non-cost-effective 
treatments. However, in the absence of active implementation strategies, uptake would be 
240 
 
expected to only reach an ‘improved’ level of implementation, which would be higher than 
the equivalent level under the assumption of no interaction between information and 
implementation, but lower than the ‘optimal’ implementation level. 
Table 7.6: Prescription shares in the light of different eventualities about treatments’ cost-effectiveness (NSCLC) 
 
Implementation Eventuality Percentage use of 
Gem+Cisp 
Percentage use of 
Gem+Carb 
Current implementation 50% 50% 
Improved 
implementation 
Gem+Cisp cost-
effective 
75% 25% 
Gem+Carb cost-
effective 
25% 75% 
 
For example, if further information showed Gem+Cisp to be the most cost-effective 
treatment, this was hypothesised to bring about an increase in the treatment’s prescription 
share, from the current level of 50 percent to 75 percent and, equivalently, trigger a 
decrease in the use of the non-cost-effective treatment (Gem+Carb), from 50 percent to 25 
percent. Given this, the expected NMBs given perfect information and ‘improved’ 
implementation will be approximately £163.27 million (Table 7.7).  
Table 7.7: Revised expected NMBs for different ‘states of the world’ regarding information and implementation (NSCLC) 
 
State of the world NMBs 
(at £30,000 per QALY) 
Current information 
Current implementation (state A) £152,696,292 
Optimal implementation (state C) £160,760,214 
Perfect information 
Improved implementation (state B) £163,266,886 
Optimal implementation (state D) £173,837,480 
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The assumption that perfect information induces a beneficial change in implementation has 
an impact on three measures: the rEVPI, the EVPIMperfect information and the EVIIT. Revised 
results for these measures are shown in Table 7.8.  
Table 7.8: Revised expected NMBs for different measures of information and implementation (NSCLC) 
 
Measure 
NMBs 
(at £30,000 per QALY) 
rEVPI (state B- state A) £10,570,594 
EVPIMperfect information (state D- state B) £10,570,594 
EVIIT (state B- state C) £2,506,672 
 
The revised rEVPI was estimated to be £10.57 million. This value shows the difference in the 
expected NMBs between a decision with perfect information and improved 
implementation, and one with current information and current implementation. Similarly, 
the EVPIMperfect information is revised and it now shows the difference between perfect 
information followed by optimal implementation and perfect information followed by 
improved implementation. This value was calculated to be £10.57 million, which is half of 
the £21.14 million estimated under the assumption of no connection between information 
and implementation. This reflects the fact that the revised EVPIMperfect information is calculated 
given that there has already been a change of 25 percent in prescription shares after further 
information became available (i.e. from ‘current’ implementation to ‘improved’ 
implementation) therefore the scope for further improvements in uptake through 
implementation—and, thus, the scope for further NMBs—is more limited. 
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Finally, when the assumption of no interaction between improved information and 
implementation is relaxed, the revised EVIIT is positive. This is in contrast to the negative 
EVIIT calculated with the above assumption holding and it reflects the fact that, in the 
current case, research is expected to bring about additional benefits due to inducing greater 
adherence to the recommended treatment. Under the assumption that further research will 
provide information as well as prompt a beneficial change in practice, carrying out a trial 
such as the BTOG-2 would be potentially more beneficial than funding implementation 
strategies.  
7.2.5. Expected value of sample information and expected net benefits of sampling for 
NSCLC 
As explained at the beginning of this chapter (section 7.1.4) a central task in undertaking 
EVSI analysis involves combining existing (prior) information (in NSCLC, taken from Zatloukal 
et al.208) with new (sample) information which is hypothesised to arise from a proposed 
trial. This task typically represents the main difficulty in undertaking EVSI, as combining prior 
and sample information represented by probability distributions requires these distributions 
to be connected by a special relationship, termed ‘conjugacy’, where one quantity can be 
combined with the other using a simple analytic solution. Examples of conjugate 
distributions are the beta/Dirichlet distributions, gamma distribution and the normal 
distribution261. When parameters of interest (e.g. progression to a worse health state) are 
not expressed as conjugate distributions (as was the case in HRPC, where progression was 
derived from counts of events and was represented as beta and Dirichlet distributions), 
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there is no simple analytic solution, and other ways of combining prior and sample 
information need to be explored. 
As explained in Chapter 4, evidence on the effectiveness of Gem+Cisp and Gem+Carb was 
obtained from a randomised controlled trial following 87 and 89 patients on Gem+Cisp and 
Gem+Carb, respectively. The outcomes of the trial were given in the form of overall survival 
(OS) and time-to-progression (progression-free survival (PFS)) curves, showing the 
probability of a NSCLC patient being alive and progression-free, respectively, at different 
points in time (months) after randomisation. This information was used as the basis for 
fitting Weibull overall survival and progression-free survival curves to the available data by 
using ordinary least squares (OLS) regression (see Chapter 4, section 4.4.2): 
  [       ]                                   
where      can be either of the OS and PFS curve,   is time in months after the onset of the 
observation and   is the random error term of the regression model. The model intercept 
and the regression coefficient of       (i.e. the slope of the fitted regression model) were 
used to derive the shape parameter alpha ( ) and the scale parameter beta ( ) of the 
Weibull functions for OS and PFS. The specified Weibull functions, which can be seen in 
Appendix 3.C, gave the probability of a patient being alive and progression-free at different 
points in time, which was used to populate the three health states of the NSCLC model. 
Estimates of uncertainty around these probabilities were obtained directly from the 
regression analysis, in terms of the standard errors around the intercept and regression 
coefficient parameters.  
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7.2.5.A. Process for obtaining posterior distributions of effectiveness (progression-free 
survival and overall survival) 
A way to circumvent the problem of combining non-conjugate distributions such as the 
Weibull distributions used in NSCLC is by representing prior and sample information in 
terms of the same type of outcomes. In this application, an appropriate and convenient 
representation is in terms of numbers of patients who are alive and progression-free at 
different points in time.  
Translating prior information from Zatloukal et al.208 to numbers of patients alive and 
progression-free at different points was relatively straightforward. Under the assumption 
that patients had not been lost to follow-up, the PFS and OS curves can be obtained by 
multiplying the probability of a patient being at a particular state (alive or progression-free) 
by the number of patients in a trial arm at the beginning of the trial 
                                                
                                                                       
Here,    represents a point in time after randomisation (e.g. month 3) and   represents the 
number of participants in the trial arm at the onset of the follow-up period. For example, for 
patients on Gem+Cisp, given a probability of being progression-free at 3 months of 0.75, 65 
out of the total 87 patients on treatment would be expected to be alive.  
In terms of sample information, hypothetical results of a proposed trial—expressed in terms 
of numbers of progression-free and alive patients at different points in time—were 
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generated through individual patient sampling. The process of individual sampling aimed to 
simulate the results that a future trial of a specific sample size may produce, based on 
current indications of the effectiveness of the treatments. The process involved the 
following steps.  
First, a set of parameters (intercept and regression coefficient, and resulting   and   
parameters of the Weibull model) was drawn from the existing distribution of the intercept 
and regression coefficient obtained from the OLS regression. In essence, these parameter 
gave possible PFS and OS drawn from the distribution of the prior OS and PFS. For example, 
if the drawn intercept and regression coefficient are -2.88 and 1.34 for PFS and -3.01 and 
1.09 for OS, the resulting Weibull curves will give a probability of a patient being 
progression-free at 3 months of 0.8 and a probability of death at the same point in time of 
0.05. 
An individual patient who starts the trial is expected to progress according to the drawn 
parameters and the resulting PFS and OS curves. To replicate the stochastic process of 
patient progression, at each point in time a random number between 0 and 1 is drawn. 
Using the probabilities in the previous paragraph, if the number is lower or equal to 0.8, the 
patient remains progression-free, if the number is between 0.8 and 0.95 (i.e. 1-0.05) the 
person presents progressive disease, and if the number is between 0.95 and 1, the patient 
dies. For later time points, appropriate conditional probabilities were used. 
Repeating this process for patients   equal to the number of the proposed trial gives 
numbers of patients who are alive, progression-free and dead at specific points in time. 
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These represent the simulated sample information produced by a hypothetical trial of   
patients. The sample size of the proposed BTOG2 trial was 450 patients per arm, and thus 
the size   of the simulated trials is 450 patients. As these results represent one possible 
outcome of the trial (based on one draw from the prior distribution of the parameters of 
interest), the process is repeated a large number of times (k = 1000) to give 1000 simulated 
trial results, as seen in Table 7.9.  
Table 7.9: Illustrative table showing data (number of patients alive on different follow-up points) generated from 1000 
simulated trials for Gem+Cisp 
 
Time point (month) 0 3 6 … 27 30 
Prior information (derived from Zatloukal et 
al.
208
)  
87 72 59  9 9 
Sample informationtrial 1 450 382 312 … 37 31 
Sample informationtrial 2 450 355 258 … 14 10 
Sample informationtrial 3 450 383 307 … 74 54 
… … … … … … … 
Sample informationtrial 1000 450 397 327 … 63 55 
 
The process was repeated to replicate the sample OS and PFS curves for both Gem+Cisp and 
Gem+Carb. Having obtained 1000 simulated data, each of them was combined with prior 
information as 
                                               
For example, for OS in Gem+Cisp at three months, the results for Posterior1—expressed in 
terms of number of patients alive—are equal to the prior information (72 patients alive at 
month 3) and simulated sample informationtrial 1 (382 patients alive) resulting in a total of 
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454 patients alive at month 3 out of the 537 (i.e. 87+450) patients under observation, giving 
a probability of being alive at 3 months of approximately 0.85. 
Having obtained a representation of the posterior distribution, this information needs to be 
translated into Weibull curves, which can then be used in the NSCLC model. For each of the 
posterior values for OS and PFS, Weibull curves were fitted by the same process that was 
used to fit Weibull curves to prior information from Zatloukal et al.208. In brief, fitting 
Weibull to posterior data involved translating number of patients (fourth row in Table 7.10) 
into probabilities of a patient staying alive at different points (fifth row in Table Table 7.10), 
manipulating the Weibull survival function to obtain a linear relationship between time 
(logarithm of time) and      (logarithm of the negative logarithm of the survival function) 
and regressing      against time.  
Table 7.10: Table illustrating the steps in translating posterior information to quantities (ln(t) and ln(-ln(S(t))) to be used 
in OLS regression.  
 
Month 0 3 6 9 12 15 18 21 24 27 30 
Prior information 
(number of patients 
alive at different points) 
87 72 59 43 29 23 15 15 15 9 9 
Sample informationtrial 1 
(number of patients 
alive at different points) 
450 382 312 240 187 142 106 79 55 37 31 
Post1 (no of patients 
alive at different points) 
537 454 371 283 216 165 121 94 70 46 40 
S(t|Post1) (i.e. 
probability of patient 
being alive on basis of 
Post1)  
1 0.85 0.69 0.53 0.4 0.31 0.23 0.18 0.13 0.09 0.07 
Ln(t) (i.e. natural 
logarithm of time) 
- 1.1 1.79 2.2 2.48 2.71 2.89 3.04 3.18 3.3 3.4 
Ln(-ln(S(t|Post1))) - -1.78 -0.99 -0.44 -0.09 0.16 0.4 0.56 0.71 0.9 0.95 
 
248 
 
For each Posti (i=1,2,…1000), OLS regression gave a set of parameters (intercept, regression 
coefficient of time, standard errors of the intercept and regression coefficient) and the 
resulting   and   parameters of the Weibull models for PFS and OS (see Table 7.11 and 
Table 7.12 for an example of generated data for Gem+Cisp and Gem+Carb).  
Each of the obtained 1000 sets (i.e. Post1, Post2,…, Post1000) was treated as a representation 
of the true progression-free survival and overall survival associated with Gem+Cisp and 
Gem+Carb. These sets were subsequently entered in the NSCLC model one at a time and, 
for each set, 1000 Monte Carlo simulations were carried out to give 1000 estimates of each 
treatment’s NMBs given the specific posterior.  
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Table 7.11: Example of set of parameters representing the posterior distributions of PFS and OS for Gem+Cisp given a trial of 450 patients. 
 
Posteriors 
(translated into Weibull 
curves) 
Progression-free survival (PFS) Overall survival (OS) 
Intercept SE 
intercept 
Slope SE slope alpha beta Intercept SE 
intercept 
Slope SE slope alpha beta 
Post1  -3.298 0.038 1.530 0.016 1.53 12.50 -3.117 0.033 1.209 0.012 1.21 19.08 
Post2 -2.735 0.043 1.227 0.019 1.23 13.46 -2.772 0.034 1.181 0.013 1.18 15.13 
…             
Post1000 -3.132 0.031 1.485 0.014 1.48 11.93 -3.272 0.053 1.206 0.020 1.21 21.84 
 
 
Table 7.12: Example of set of parameters representing the posterior distributions of PFS and OS for Gem+Carb given a trial of 450 patients. 
 
Posteriors  
(translated into Weibull 
curves) 
Progression-free survival (PFS) Overall survival (OS) 
Intercept SE 
intercept 
Slope SE 
slope 
alpha beta Intercept SE 
intercept 
Slope SE slope alpha beta 
Post1  -2.336 0.030 1.248 0.013 1.248 9.417 -3.176 0.053 1.249 0.020 1.249 18.40 
Post2 -2.502 0.026 1.169 0.011 1.169 12.304 -3.645 0.046 1.271 0.017 1.271 25.49 
…             
Post1000 -2.180 0.033 1.205 0.014 1.205 8.835 -3.022 0.074 1.207 0.028 1.207 
17.70
5 
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7.2.5.B. EVSI and ENBS results 
Generated NMBs estimates were averaged across their distribution to give an estimate of 
the expected NMBs (                ) given the specific posterior value. The process was 
repeated for all the 1000 posteriors, to give 1000 estimates of                  for each 
treatment (second and third columns in Table 7.13), of which estimates the maximum 
expected NMBs (                     ) were selected (fourth column in Table 7.13).  
Table 7.13: Illustrative example of EVSI calculations for a trial in NSCLC of sample size of 450 patients per arm 
 
 
Gem+Cisp Gem+Carb                       
E  Post          £11,728 £9,790 £11,728 
E  Post2         £9,674 £14,849 £14,849 
E  Post3         £13,047 £10,032 £13,047 
… … … … 
                   £9,825 £10,983 £10,983 
                    £13,254 £9,350 £13,254 
  
                           £12,328 
 
As it is not known which of the                           will be observed (i.e. which 
posterior distribution represents the true underlying distribution), the 
                     need to be averaged over their posterior distribution, to give the 
                            (bottom right cell in Table 7.13). 
This value represents an estimate of the expected NMBs from making a decision under 
sample information and, when compared to the expected NMBs of making a decision under 
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current information (              ), it gives the EVSIn for the particular trial of size  . 
In this analysis, for the proposed BTOG2 trial of 450 patients per treatment arm and given a 
ceiling ratio of £30,000 per QALY, the expected maximum NMBs with sample information 
were estimated at £12,328. Given the estimated expected NMBs from a decision under 
current information of £11,652 at £30,000 per QALY, EVSI for an individual patient was 
found to be 
                                                                      
EVSI for the population of eligible patients over five years following dissemination was 
calculated at £9.33 million (at £30,000 per QALY).  
Similarly to other measures of value of information, EVSI results vary according to the 
assumed value of the ceiling ratio. The population EVSI (dotted line) for ceiling ratios ranging 
from £0 to £80,000 can be seen in Figure 7.5 alongside the population EVPI (solid line). As 
anticipated, at each ceiling ratio the benefits from a decision with sample information (EVSI) 
are lower than those of a decision made under perfect information (EVPI). The EVSI curve 
follows a pattern analogous to the EVPI curve; in this case of NSCLC, EVSI increases for 
higher values of the ceiling ratio.  
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Figure 7.5: Population EVSI (for sample size of 450 patients per arm) and EVPI at different ceiling ratio values 
 
The obtained EVSI estimates can be compared with the cost of the trial to give the expected 
net benefits of sampling (ENBS) for a trial such as BTOG2. In the context of the NSCLC case 
study, the cost of the BTOG2 phase III trial consisted of a fixed component, which is assumed 
not vary with the size of the trial and includes researchers’ salaries and expenditure for trial 
co-ordination (£134,220), as well as a variable part, which depends on the size of the trial. 
This includes a ‘support service’ cost (£202,500) covering expenditures for patient 
recruitment, collection of QoL information through questionnaires and additional clinic time. 
As patients in the trial were treated with chemotherapies which would have been also used 
in usual practice outside the trial, no excess treatment cost due to receiving care different 
than that routinely provided was included. On the basis of the above, the marginal cost of 
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recruiting an additional patient in the trial was estimated at a relatively low value of £225. 
The total cost of the trial of 450 patients per treatment arm, including fixed and variable 
costs, was stated as £336,720. Given this, the ENBS for a trial of 450 participants per 
treatment arm was estimated at:  
                                                 
According to the obtained ENBS figure, the proposed trial of 450 patients per arm aiming to 
obtain better information on disease progression for NSCLC patients treated with Gem+Cisp 
and Gem+Carb would result in ENBS of about £9 million.  
Additional analyses were carried out for different possible sample sizes (400 and 500 
participants per arm). As expected, increases in the number of trial participants led to 
decreases in the uncertainty around the treatments’ effectiveness and increases in the EVSI 
(second and third columns in Table 7.14). At the same time, recruiting more participants 
raises the cost of the trial due to increase in variable costs (fourth column in Table 7.14).  
For the particular sample sizes investigated here ( =400, 450 and 500 patients per arm), the 
expected benefits exceeded the increase in costs (i.e. there are positive marginal benefits), 
thus, a study involving any of these sample sizes would be beneficial. This will be the case up 
to the point where the additional benefits from recruiting an additional participant would be 
offset by the additional cost from involving this extra person. Assuming no additional 
benefits from allocating participants unequally between arms, the ‘optimal’ sample size is 
found at the level where the ENBS is maximum, that is, when the difference between trial 
cost and NMBs is the greatest possible. For a ceiling ratio of £30,000 per QALY, the resulting 
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ENBS suggest that the preferable sample size for BTOG2 among the sizes considered here 
would be 500 patients in each arm. As in this proposal the cost of recruiting further patients 
is very low due to the fact that no excess treatment costs are involved, the ‘value’ of 
recruiting more patients comfortably exceeds the marginal cost of recruitment, and, it is 
anticipated that this will also be the case for sample sizes over 500 patients per arm. 
Table 7.14: Individual EVSI for studies of different sample sizes 
 
Trial sample size Individual EVSI 
(£30,000 per 
QALY) 
Population EVSI 
(£30,000 per 
QALY) 
Total cost of trial 
(£30,000 per 
QALY) 
ENBS 
(£30,000 per 
QALY) 
400 participants per 
arm 
£654 £9,023,757 £314,221 £8,709,536 
450 participants per 
arm 
£677 £9,333,882 £336,721 £8,997,161 
500 participants per 
arm 
£758 £10,453,550 £359,221 £10,094,329 
 
In summary, the EVSI analysis suggested that a proposed trial to provide better information 
on disease progression employing 450 patients per arm and of a cost of about £340,000, 
such as the BTOG2 phase III trial, would result in benefits in excess of its cost. On this basis, 
carrying out such a trial appears to be a ‘cost-effective’ use of research funds.  
7.3. ‘Value of information’ analysis for HRPC 
This section presents the results of ‘value of information’ analyses (EVPI, EVPPI, value of 
implementation and EVSI) applied to the HRPC case study. 
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7.3.1. Expected value of perfect information for HRPC 
EVPI for an individual patient was estimated by using the output (i.e. simulated costs and 
QALYs) of the probabilistic HRPC model, which compared docetaxel plus prednisolone (DP), 
against DP plus zoledronic acid (DP+ZA), DP plus strontium-89 (DP+Sr89) and DP plus 
zolendronic acid and strontium-89 (DP+ZA+Sr89) as a first-line treatment option for HRPC. 
Individual patient EVPI was subsequently weighted by the discounted number of eligible 
patients over a two-year time horizon (5101 patients; see Chapter 6) to give the population 
EVPI. Individual and population EVPI results are given in Table 7.15. At a ceiling ratio of £0 
per QALY, the per-patient EVPI was estimated at approximately £190 (£947,100 for the 
population), while at a ceiling ratio of £30,000, the value rose to £1680 (£8.55 million for the 
population). At a very high ceiling ratio of £80,000, individual and population EVPI were 
approximately £4330 and £22.09 million, respectively. 
Table 7.15: Individual and population EVPI for HRPC 
 
Ceiling ratio Individual EVPI Population EVPI 
(two year time horizon) 
£0 per QALY £186 £947,120 
£30,000 per QALY £1676 £8,550,438 
£80,000 per QALY £4331 £22,093,720 
 
The relationship between EVPI and the ceiling ratio can be seen in the EVPI curve in Figure 
7.6. Starting from £0 per QALY, as the ceiling ratio increases, the EVPI rises. When the ceiling 
ratio becomes equal to the ICER for DP+Sr89—the point where the NMBs of DP are equal to 
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the NMBs of DP+Sr89 and uncertainty is high—EVPI reaches a local maximum of about £4.50 
million.  
 
Figure 7.6: Population EVPI for HRPC 
 
In summary, the EVPI at a ceiling ratio of £30,000 per QALY appears high, at £8.55 million. 
Further research that costs less than this amount would be potentially cost-effective and, 
given this, funding and conducting the proposed TRAPEZE phase III trial, which is expected to 
cost approximately £2.54 million, would be a potentially cost-effective investment. 
7.3.2. Expected value of perfect parameter information analysis for HRPC 
EVPPI analysis was carried out to establish the benefits of eliminating the uncertainty around 
specific parameters affecting the HRPC adoption decision. For each treatment, three subsets 
of uncertain parameters were investigated:  
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a. transition probabilities (disease progression rates);  
b. utility scores for different health states, and  
c. costs. 
This gave a total of 12 different parameter subsets to be investigated. EVPPI calculations 
were carried out following the two-level (inner and outer loop) Monte Carlo simulations 
method detailed in Briggs et al.51 and Brennan et al.263, and calculations involved 1000 runs 
in each loop.  
EVPPI for a single patient and the population of eligible patients at a ceiling ratio of £30,000 
per QALY are presented in Figure 7.7 and Figure 7.8.  
 
Figure 7.7: Individual EVPPI for HRPC at £30,000 per QALY 
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Figure 7.8: Population EVPPI for HRPC at £30,000 per QALY 
 
The analysis indicated a relatively low value of EVPPI associated with transition probabilities; 
at £30,000 per QALY, population EVPPI ranged from £536,000 for DP+ZA+Sr89 to 
approximately £645,000 for DP. The results also suggest a relatively low population EVPPI for 
utility scores associated with DP and DP+Sr89 (£605,000 and £593,000 respectively). Cost 
parameters had a negligible impact on the decision uncertainty and, at £30,000 per QALY, 
population EVPPI associated with these parameters was zero for all treatments.  
Population EVPPI curves for each of the 12 subsets of parameters are given in Figure 7.9. For 
low values of the ceiling ratio, where DP is more likely to be the optimal treatment, acquiring 
better estimates of specific subsets is unlikely to change the decision and further research 
on any of the specific parameters has low value. EVPPI for each subset of parameters 
increases as the ceiling ratio approaches the value where decision uncertainty is greatest 
£0
£100,000
£200,000
£300,000
£400,000
£500,000
£600,000
£700,000
EV
P
P
I 
(p
o
p
u
la
ti
o
n
) 
 
259 
(i.e. the ICER) and peaks near the £8000 mark, above which the decision switches from DP to 
DP+Sr89. 
In summary, the EVPPI analysis suggests that the maximum benefits from carrying out 
studies to eliminate the uncertainty around transition probabilities, costs or quality of life 
are relatively low and unlikely to exceed the cost of separate trials for each of these 
parameters. However, a trial which would investigate transition probabilities, resource use 
and utility scores simultaneously may be potentially worthwhile. In the light of the EVPI and 
EVPPI results, the TRAPEZE phase III trial which investigates transition probabilities, quality 
of life and resource use, appears potentially worthwhile. 
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Figure 7.9: Population EVPPI at different ceiling ratios for HRPC 
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7.3.3. Value of information and implementation analysis for HRPC 
Additional analysis was conducted to explore the value of implementation associated with 
HRPC under the assumptions that acquisition of information does, and does not, lead to a 
beneficial change in implementation. 
7.3.3.A. Assuming acquisition of information has no impact on implementation  
At a ceiling ratio of £30,000 per QALY and under current information, the treatment that 
appears cost-effective is DP+Sr89. Expert opinion suggested that, at the time information 
from further research is expected to become available, that is, in 2013, the majority of the 
HRPC patients treated with chemotherapy are anticipated to receive DP (85 percent) with 
the remaining treatments provided to a low proportion of patients (5 percent each for 
DP+ZA, DP+Sr89 and DP+ZA+Sr89). These values represent the prescription share under 
current implementation. Under current information and optimal implementation, DP+Sr89 
would be provided to all eligible patients (100 percent implementation). 
The results of this analysis are given in Table 7.16. As expected, the greatest gains—
approximately £103.10 million in NMBs—are anticipated from a decision made under 
perfect information which will be implemented perfectly (state D). The benefits from a 
decision with current information but optimal implementation (state C) are somewhat 
lower, at about £94.56 million. Under the assumption that acquisition of further information 
does not affect implementation, the benefits expected to arise from a decision with perfect 
information and current implementation (state B) are the same as those from a decision 
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with current information and current implementation (state A), at approximately £78.40 
million. 
Table 7.16: Expected NMBs for different ‘states of the world’ regarding information and implementation (HRPC) 
 
States of the world 
Information 
Current Perfect 
Implementation 
Current 
£78,396,604 
(state A) 
£78,396,604 
(state B) 
Optimal 
£94,555,968 
(state C) 
£103,104,695 
(state D) 
 
The estimated values of different measures of implementation are given in Table 7.17. EVPI, 
that is, the difference between a decision made under perfect information and optimal 
implementation and current information and optimal implementation, was estimated at 
£8.55 million. This estimate gives the upper bound of the value of conducting further 
research. The values of EVIMPperfect information and EVIMPcurrent information were calculated at 
£24.71 million and £16.16 million, respectively. These values provide a measure of the upper 
ceiling of resources to be devoted to implementation strategies, under perfect and current 
information, respectively. The EVP, a measure of the benefits due to moving from current 
information and current implementation to perfect information and perfect implementation 
was found to be at £24.71 million. This is an estimate of the maximum amount of resources 
to be devoted to research and implementation programmes.  
As expected, under the assumption of no interaction between information and 
implementation, the realisable EVPI (i.e. the difference between the expected NMBs in a 
situation with perfect information and current implementation (state B) and a situation with 
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current information and current implementation (state A)) is zero, as no change in 
implementation implies no additional benefits.  
Last, the ‘expected value of information-implementation trade-off’, that is, the comparison 
between perfect information and current implementation (state B), and current information 
and optimal implementation (state C), gave a negative value of -£16.16 million. This suggests 
that the NMBs from a decision with current information and optimal implementation exceed 
those from a decision with perfect information implemented at current levels. On this basis, 
if the cost of research is similar to the cost of implementation strategies, investing in 
programmes to improve adherence to cost-effective treatments appears to be more 
beneficial than funding and conducting research to obtain better information. 
Table 7.17: Expected NMBs for different measures of information and implementation (HRPC) 
 
Measure NMBs 
(at £30,000 per QALY) 
EVPI (state D – state C) £8,548,728 
rEVPI (state B – state A) £0 
EVPIMperfect information (state D - state B)  £24,708,092 
EVPIMcurrent information (state C – state A) £16,159,364 
EVP (state D – state A) £24,708,092 
EVIIT (state B – state C) -£16,159,364 
 
7.3.3.B. Assuming acquisition of information affects implementation 
The assumption that the level of available information has no bearing on implementation 
rates was relaxed using hypothesised estimates of treatments’ prescription shares. These 
were obtained from discussion with experts, based on a series of guesses about the direction 
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and strength of change in practice in the light of different eventualities regarding research 
results, and are given in Table 7.18. In general, should a treatment appear cost-effective, its 
uptake would be expected to increase, although the magnitude of this increase would vary 
across treatments and would depend on obstacles to implementation. For example, if 
treatments which require radioisotope fractions (i.e. DP+Sr89 or DP+ZA+Sr89) were found 
cost-effective, the increase in their uptake would be expected to be lower than that of 
treatments not involving radioisotopes (i.e. DP, DP+ZA).  
Table 7.18: Prescription shares in the light of different eventualities about treatments’ cost-effectiveness (HRPC) 
 
Implementation Eventuality 
Prescription 
share of DP 
Prescription 
share of DP+ZA 
Prescription 
share of 
DP+Sr89 
Prescription 
share of 
DP+ZA+Sr89 
Current implementation 85.0% 5.0% 5.0% 5.0% 
Improved 
implementation 
DP cost-
effective 
90.0% 3.3% 3.3% 3.3% 
DP+ZA cost-
effective 
40.0% 50.0% 5.0% 5.0% 
DP+Sr89 cost-
effective 
50.0% 5.0% 40.0% 5.0% 
DP+ZA+Sr89 
cost-effective 
50.0% 5.0% 5.0% 40.0% 
 
The assumption that perfect information induces a beneficial change in implementation has 
an impact on three measures: the rEVPI, EVPIMperfect information and EVIIT. The new results for 
these measures are shown in Table 7.19. The NMBs of the revised rEVPI were estimated at 
£7.43 million; this value reflects the maximum expected NMBs from undertaking both 
research and implementation strategies. The revised EVPIMperfect information was calculated at 
£17.27 million; this value shows the difference between the NMBs expected to arise from a 
state where perfect information is followed by optimal implementation and a state where 
perfect information is followed by improved implementation. Last, the revised EVIIT was 
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negative, suggesting that a decision in a state with perfect information and improved 
implementation would result in lower NMBs than the same decision taken under current 
information and perfect implementation. The revised EVIIT results are in the same direction 
as those under the assumption of no interactions between information and implementation, 
suggesting that, despite the hypothesised improvements in implementation following 
research, resources would still be more prudently invested in implementation strategies. 
Table 7.19: Revised expected NMBs for different ‘states of the world’ regarding information and implementation (HRPC) 
 
Measure 
NMBs 
(at £30,000 per QALY) 
rEVPI (state B- state A) £7,433,518 
EVPIMperfect information (state D- state B) £17,274,574 
EVIIT (state B – state C)  -£8,725,846 
 
7.3.4. Expected value of sample information and expected net benefits of sampling for 
HRPC 
Expected value of sample information (EVSI) analysis was carried out to explore the 
applicability of the method, as well as to develop a basis for a subsequent discussion of its 
practicality, usefulness and limitations. The application was carried out using the HRPC 
Markov model described in Chapter 5. Non-parametric applications of EVSI on the basis of 
the output of Markov models are rare; no other such EVSI analyses carried out in Microsoft 
Excel®—a spreadsheet application commonly used for model building—are known to the 
author and the supervisory team of this thesis. The analysis was assisted by the fact that 
parameters of interest (transition probabilities) were represented by distributions with 
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specific properties (conjugate distributions), as well as by the use of an ‘individual sampling 
model’ exercise.  
EVSI seeks to establish the additional benefits expected to arise from making an adoption 
decision under ‘improved’ (posterior) information about a parameter affecting the 
decision—for instance, effectiveness of treatments, expressed as transition probabilities to a 
worse health state—as opposed to making the same decision under existing (prior) 
information. In such analyses, ‘improved’ information is a combination of existing evidence 
(e.g. currently known transition probabilities) and possible evidence from further research, 
that is, ‘sample’ information from a proposed trial. As the trial has not taken place, sample 
information has not been observed and needs to be predicted.  
Combining prior and sample information is feasible when the distributions representing the 
prior and new information are conjugate, that is, they are of the same family and can be 
brought together using simple analytic formulae51;107. Such were the beta and Dirichlet 
distributions which were used to characterise transition probabilities in the HRPC model. 
Analyses based on non-conjugate distributions are in principle possible, but they are 
considerably more complex51;190. 
7.3.4.A. Process for obtaining posterior distributions of effectiveness  
The first step in this analysis involved drawing a set of values from the prior distribution (   ) 
of the parameters of interest, here, transition probabilities. The prior distribution of 
transition probabilities is represented by a Dirichlet distribution, with parameters of this 
distribution showing counts of 21-day cycles that participants spent in specific health states: 
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The next step involved predicting the possible ‘sample’ information, in the form of possible 
results of the proposed TRAPEZE phase III trial. This was done by carrying out an ‘individual 
patient sampling’ exercise. In contrast to cohort models which follow a group of patients 
(such as the NSCLC and HRPC models reported in Chapters 4 and 5), individual sampling 
models trace the progression of hypothetical patients through health states one at a time. 
The aim of the individual patient sampling exercise in the particular context is to predict the 
possible results (in terms of accumulated transitions and, thus, transition probabilities) of a 
hypothetical trial of a given sample size.  
The process involved in individual patient sampling is outlined below. A patient starts in a 
specific health state (e.g. state A). The probability of the patient transitioning to another 
state B is based on existing (prior) information (e.g. probability of moving from state A to 
state B is 0.05). A number between 0 and 1 is drawn at random; if this number is smaller or 
equal to 0.05, the patient moves to state B; if the number is larger than 0.05, the patient 
stays at the current state. This process is repeated for a sufficient period of time (i.e. for a 
large number of discrete model cycles) and the number of cycles the patient spent at each 
state is counted and can be used to give the probability of the patient transitioning across 
states. This process is run for each of the patients in the simulated trial. In the context of this 
study, the proposed TRAPEZE phase III trial was expected to recruit 300 participants per arm 
and thus individual patient sampling was run for 300 hypothetical patients in each arm. The 
obtained counts of cycles spent in specific health states can be expressed as a probability 
distribution, in this case a Dirichlet distribution.  
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Next, the set of transition probabilities from the prior distribution were combined with the 
possible trial results to give the transition probabilities for the posterior distribution      , 
as: 
                                                         
This process was repeated 1000 times and gave 1000 sets of values for the posterior 
transition probabilities (                      ) for each treatment  . Each of these sets 
was subsequently entered in the HRPC model one at a time, where Monte Carlo simulations 
were carried out to give 1000 estimates of each treatment’s NMBs, by drawing values from 
each set of posterior values. 
7.3.4.B. EVSI and ENBS results 
For each treatment (i.e. DP, DP+ZA, DP+Sr89 and DP+ZA+Sr89) and for the parameter of 
interest   (transition probabilities), obtained NMBs estimates were averaged across their 
distribution to give an estimate of the expected NMBs (                ) given the specific 
posterior distribution. The process was repeated 1000 times, to give 1000 estimates of 
                 for each treatment (columns 2 to 5 in Table 7.20), of which the maximum 
expected NMBs (                     ) were selected (column 6 in Table 7.20). As it is 
not known which of the sample results    will be observed (i.e. which posterior distribution 
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represents the true underlying distribution), the                      need to be 
averaged over their posterior distribution, to give the                             
(bottom right cell in Table 7.20). 
Table 7.20: Illustrative example of EVSI calculations for a sample size of 300 patients per arm 
 
 
DP DP+ZA DP+Sr89 DP+ZA+Sr89                       
                £18,513 £15,973 £16,316 £13,720 £18,513 
                £15,995 £16,408 £21,307 £16,811 £21,307 
                £15,981 £16,704 £18,120 £12,793 £18,120 
… … … … … … 
                   £14,589 £12,074 £13,911 £12,922 £14,589 
                    £15,312 £13,471 £24,018 £13,399 £24,018 
 
                           £19,145 
 
This value represents an estimate of the expected NMBs from making a decision under 
sample information and, when compared to the expected NMBs of making a decision under 
current information (              ), it gives the EVSIn for the particular trial of size  , 
investigating the parameters .  
In this analysis, for a new trial of 300 participants per treatment arm and given a ceiling ratio 
of £30,000 per QALY, the expected maximum NMBs with sample information were 
estimated at £19,145. Subtracting the estimated expected NMBs of making a decision under 
current information (i.e. £18,540 at £30,000 per QALY) from this value gave the EVSI for a 
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trial of 300 participants per arm. This was found to be £605 and £3.09 million for the 
individual and the population, respectively.  
Similarly to EVPI and EVPPI, EVSI results vary with the employed ceiling ratios. The 
population EVSI (dotted line) for a range of ceiling ratios can be seen in Figure 7.10, along 
with the population EVPI (solid line). As expected, at each ceiling ratio the benefits from a 
decision with imperfect, sample information (EVSI) are lower than those of a decision made 
under perfect information (EVPI) (solid line). The EVSI curve follows a pattern analogous to 
the EVPI curve: as the ceiling ratio increases, EVSI increases and reaches a local maximum 
when uncertainty around a decision is greatest (i.e. near the ICER of the most cost-effective 
treatment). 
 
Figure 7.10: Population EVSI (for sample size of 300 patients per arm) and EVPI at different ceiling ratio values 
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The obtained EVSI estimates can be compared with the cost of the trial to give the expected 
net benefits of sampling (ENBS) for the particular trial. In the context of the HRPC case study, 
the cost of the TRAPEZE phase III trial consisted of a fixed component, which includes 
researchers’ salaries and expenditure for trial co-ordination (£627,156), as well as a variable 
part, which depends on the size of the trial. For a trial of 300 patients per treatment arm, 
this includes an excess treatment cost (i.e. additional cost due to patients in experimental 
arms receiving care different than that routinely provided outside the study) of £1,457,560, 
as well as service support costs related to patient recruitment and additional clinic time of 
£452,400. On the basis of above, the marginal cost of recruiting an additional patient in the 
trial was estimated at £1590. The total cost of the trial of 300 patients per treatment arm, 
including fixed and variable costs, was stated as £2.54 million. Given the above, the ENBS for 
a trial of 300 participants per treatment arm was estimated at:  
                                                
According to this, the proposed trial of 300 patients aiming to obtain better information on 
disease progression would result in ENBS of about £550,000.  
Additional analyses were carried out for different possible sample sizes ( =100, 200 and 400 
participants per arm). Increases in the number of trial participants led to increases in the 
‘value’ of the trial (EVSI) (second and third columns in Table 7.21) while, at the same time, 
recruiting more participants raises the cost of the trial due to increase in variable costs 
(fourth column in Table 7.21).  
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For the particular sample sizes investigated here ( =100, 200, 300 and 400 patients per 
arm), the expected benefits exceeded the increase in costs (i.e. there are positive marginal 
benefits), thus, a study involving any of these sample sizes would be beneficial. This will be 
the case up to the point where the additional cost of recruiting an additional participant in 
the study will exceed the additional benefits from involving this extra person. Under the 
assumption that there is no additional benefits from allocating participants to one arm over 
another, the ‘optimal’ sample size can be found at the point when the difference between 
trial cost and NMBs is the greatest possible (that is, when ENBS is maximum). Assuming 
equal allocation between trial arms is optimal and a ceiling ratio of £30,000 per QALY, the 
resulting ENBS suggest that the preferable sample size for TRAPEZE among the ones 
considered here would be 200 patients in each arm.  
It must be noted that significantly greater numbers of simulations may be needed to 
minimise the influence of sampling error and derive more accurate results. The influence of 
sampling error can be seen in the fluctuations in the obtained EVSI and ENBS results. For an 
increase in sample size from the ‘optimal’ size of 200 to 300 patients per arm, the EVSI and 
ENBS increase at a diminishing rate, whereas increasing the number of participants from 300 
to 400 per arm shows the EVSI and ENBS to be rising at an increasing rate. 
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Table 7.21: Individual EVSI for studies of different sample sizes 
 
Trial sample size Individual EVSI 
(£30,000 per 
QALY) 
Population EVSI 
(£30,000 per 
QALY) 
Total cost of trial 
(£30,000 per 
QALY) 
ENBS 
(£30,000 per 
QALY) 
100 participants per 
arm 
£411 £2,095,813 £1,263,809 £832,004 
200 participants per 
arm 
£569 £2,900,836 £1,900,463 £1,000,373 
300 participants per 
arm 
£605 £3,086,341 £2,537,116 £549,225 
400 participants per 
arm 
£739 £3,769,606 £3,173,769 £595,836 
 
In summary, the EVSI analysis suggested that a trial to provide better information on disease 
progression, such as the TRAPEZE phase III trial, would result in benefits in excess of its cost. 
On this basis, funding and carrying out such a trial appears to be ‘cost-effective’.  
7.4. Discussion 
The chapter reports the application of VoI methods to inform a decision on funding primary 
research in the areas of NSCLC and HRPC. At a ceiling ratio of £30,000 per QALY and 
assuming a five-year time horizon, results for the NSCLC case study showed a high EVPI value 
in excess of £13 million and relatively high EVPPI values for clinical progression. In light of 
these results, the maximum expected gains from research exceed the cost of the proposed 
BTOG-2 trial, funding and conducting the trial is potentially worthwhile. In addition, EVSI 
analysis was carried out to compare the benefits expected from a trial of a particular sample 
size to the cost of the trial. For the BTOG2 phase III trial, which was expected to cost 
£336,700 and involve 450 participants per treatment arm, the EVSI exceeded the cost of the 
trial, resulting in positive ENBS of about £9 million. This suggested that the particular study 
274 
satisfies both the necessary (i.e. EVPI in excess of trial cost) and the sufficient (EVSI in excess 
of trial cost) conditions, and it is worth funding and conducting.  
Similar results were observed in the HRPC case study: at £30,000 per QALY and a two-year 
time horizon, EVPI was found to be about £8.5 million. The value far exceeds the cost of the 
proposed TRAPEZE phase III trial (£2.54 million), suggesting that study would be potentially 
beneficial and is worth considering further. EVPPI analysis suggested that the parameter 
where research may be most beneficial is clinical disease progression. Although investigating 
each parameter in separate trials is unlikely to be cost-effective, carrying out a trial which 
would look into disease progression, cost and quality of life for all the chemotherapy options 
of interest—such as the TRAPEZE phase III trial—would be potentially beneficial. Last, EVSI 
analysis for the TRAPEZE phase III trial (cost of £2.54 million, 300 participants per treatment 
arm) the EVSI outweighed the cost of the trial, resulting in positive ENBS of about £550,000. 
In this case, too, conducting the TRAPEZE phase III study satisfies both the necessary and the 
sufficient conditions, and it is worth prioritising.  
The analysis followed well-established methods for calculating EVPI51;180;190 and EVPPI51;263-
265results and EVSI51;190;272. Additional analyses were conducted to explore measures of the 
value of implementation using the framework proposed by Fenwick and colleagues187. This 
framework was extended to illustrate the calculations of different measures of the value of 
implementation under the assumption that acquisition of perfect information is expected to 
have an impact on implementation.  
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EVSI analysis was also carried out to estimate the benefits from decision-making in the light 
of information from the proposed BTOG2 and TRAPEZE phase III trials. These analyses were 
novel in that they simulated the evidence that the hypothesised trials may give by using 
individual patient sampling simulations methods. Observations made throughout this 
application regarding the practicality of undertaking VoI analysis and its potential to assist 
research funding decisions are discussed in Chapters 8 and 9.  
7.5. Chapter overview 
This chapter described an application of VoI methods to case studies representing decisions 
to fund primary evaluative research (BTOG-2 and TRAPEZE phase III trials) in NSCLC and 
HRPC. According to the obtained EVPI and EVPPI results, the maximum expected gains from 
evaluative research in NSCLC and HRPC are high and exceed the cost of the proposed trials in 
these areas. Given this, both the BTOG-2 and the TRAPEZE trials are potentially worth 
conducting. EVSI analysis carried out for NSCLC HRPC showed that the benefits from trials 
such as BTOG2 and TRAPEZE outweigh their respective cost and thus funding and carrying 
out these trials would be beneficial. The applications allowed observations on the practical 
and methodological challenges of ‘value of information’ methods; these are discussed and 
summarised in the following chapters. 
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PART III. Assessment, discussion and conclusions 
The last part of this thesis, Part III, aims to summarise and discuss the findings of the project. 
Chapter 8 identifies strengths, limitations, potentials and challenges associated with 
‘payback of research’ and ‘value of information’ by drawing on observations made 
throughout the practical application of the frameworks to case studies.  
The concluding chapter of this thesis, Chapter 9, summarises the project aims and methods, 
discusses and interprets the findings, forms conclusions and makes recommendations for 
further research.  
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CHAPTER 8. Assessment of ‘payback of research’ and ‘value 
of information’ 
This chapter aims to assess the ‘payback’ and ‘value of information’ (VoI) frameworks by 
drawing on observations made throughout this study. Strengths, limitations and challenges 
associated with the approaches are looked at from the viewpoint of potential users of the 
methods. Important points arising from this assessment form the basis for the discussion 
and conclusions presented in Chapter 9.  
8.1. Existing assessments of ‘payback of research’ and ‘value of information’ 
Two studies which looked at the strengths and limitations of ‘payback’ and ‘value of 
information’ in a comparative way were identified in the literature. In the first study, Chilcott 
et al.55 undertook a review to assess the role of decision modelling in designing and 
prioritising clinical trials. The authors discussed the potential of VoI and ‘payback’-based 
models published up to 1999 to help with research funding decisions, by drawing on 
evidence from the existing literature, without applying the methods to case studies. Chilcott 
et al.55 found ‘payback’ to be an intuitive and potentially feasible approach and suggested 
further research into incorporating sensitivity analysis in aspects where assumptions are 
typically needed (e.g. extent of change in clinical practice, specification of possible outcomes 
and likelihood of these outcomes to occur). With respect to VoI, the authors55 pointed out 
that the framework has a sound theoretical underpinning, while, at the same time, it may be 
useful in indicating the type of research that may be needed and determining optimal study 
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characteristics. The authors recognised the complexities of carrying out decision modelling 
and VoI analyses, particularly as compared to more simple, deliberative approaches.  
In the second study, Fleurence116 applied ‘value of information’ (expected value of perfect 
information (EVPI)) and ‘payback’ (PATHS model) to case studies of proposed clinical trials in 
the areas of osteoporosis and pressure ulcers. The author pointed out that, although the use 
of ‘payback’ and VoI for research priority-setting appears beneficial, both the frameworks 
have limitations. In the case of EVPI, it was highlighted that the method fails to translate the 
expected benefits from research to benefits in clinical practice, while, on the other hand, 
‘payback’ was criticised on the basis of the assumption that a clinical trial is valuable only if it 
can lead to changes in clinical practice, which, it is argued, should not be the primary aim of 
research116. Both Chilcott et al.55 and Fleurence116 agreed that the use of analytic approaches 
may bring about improvements in decision-making as compared to currently used 
deliberative methods.  
Although these studies offer a useful insight into the strengths and limitations of ‘payback’ 
and VoI, their scope and conclusions appear limited. The study by Chilcott et al.55 was 
intended as a review and did not involve a ‘hands-on’ application of VoI or recent ‘payback’ 
models (e.g. PATHS67) to a case study; therefore conclusions about the practicality and 
methodological challenges associated with the frameworks were not based on actual 
observations. On the other hand, the study by Fleurence116 did involve a practical application 
of PATHS and VoI to case studies, but VoI analysis was limited to EVPI analysis only.  
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Work undertaken in the present study aimed to address limitations and extent the methods 
used in the existing literature, with a view to providing a more comprehensive assessment of 
‘payback’ and VoI. To this end, VoI analysis reported in Chapter 6 involved not only EVPI, but 
also expected value of partial information (EVPPI) and expected value of sample information 
(EVSI) analyses. EVPPI and EVSI are central concepts and, without looking into these 
concepts, a discussion on the potentials and challenges associated with VoI analysis is bound 
to be incomplete. In addition, the analysis accounted for the value of implementation, a 
recently introduced conceptual framework aimed to strengthen VoI. The concept is 
important as it aspires to address the widespread criticism that VoI results do not present 
the real, tangible benefits that would accrue to the patients, as they are based on the unlike 
assumption that adoption decisions will always be implemented perfectly. Work reported in 
Chapter 6 incorporated this conceptual framework into the VoI analysis, and attempted to 
extend it by acknowledging that additional information is likely to result in improved, rather 
than perfect, implementation.  
With regards to the application of ‘payback’, additional empirical work involved sensitivity 
analysis to identify and pinpoint the main parameters affecting ‘payback’ results, illustrated 
the addition of probabilistic sensitivity analysis and looked into the methodology of 
conducting ‘payback’ analysis for research involving multiple treatment comparisons. 
This additional analysis gave the opportunity for a more comprehensive assessment of the 
frameworks. In particular, undertaking this additional analysis helped to identify 
methodological weaknesses associated with the frameworks, gave a more complete idea of 
the type and nature of assumptions required by the methods, and allowed an insight into 
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the feasibility and difficulties of conducting especially complex and time-intensive concepts 
such as EVPPI and EVSI. Overall, the additional analyses offered a more complete picture of 
‘payback’ and VoI, which allowed a closer insight into the potentials, strengths and 
weaknesses of these analytic frameworks. 
8.2. Interpretation and validity of results  
Both ‘payback’ and VoI generated estimates of the expected benefits from research in NSCLC 
and HRPC. In general, ‘payback’ and VoI results appeared to agree in direction, suggesting 
that both the BTOG-2 and TRAPEZE phase III trials are potentially cost-effective investments. 
In particular, VoI results showed that, given certain assumptions about the eligible 
population and the time horizon over which the produced information is expected to be 
relevant, the additional benefits expected from research in NSCLC and HRPC exceeded the 
cost of the proposed trials in these areas, suggesting that funding and carrying out the trials 
would be beneficial. Similarly, the PATHS analysis revealed additional NMBs from 
undertaking the trials and changing clinical practice according to their results. 
Despite this broad agreement, there are important differences in the way in which results 
are derived and interpreted. ‘Payback’ seeks to predict the NMBs that would be realised 
should research take place and generate results that would trigger a hypothetical change in 
clinical practice. Three factors have a major effect on the magnitude of ‘payback’ results: a) 
the extent to which the cost-effectiveness of the treatment of interest as revealed by 
research will differ to the currently perceived cost-effectiveness, b) the magnitude of the 
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beneficial change in clinical practice in the light of new evidence from a trial and c) the cost 
of the trial. 
In the case of VoI, the expected value of perfect information and the expected value of 
perfect parameter information (EVPPI) show the maximum NMBs that would be expected 
from making a decision under perfect as opposed to current information about all or a 
specific parameter, while the expected value of sample information (EVSI) gives the 
additional expected benefits from a decision made in the light of improved, as opposed to 
current, information. In this context, results are driven by the extent of existing uncertainty 
(i.e. the probability that the treatment which appears inferior under current information is 
actually more cost-effective than the currently preferred option) and the expected loss of 
benefits if the latter turns out to be the case. Given this, further research appears more 
desirable when a) uncertainty is high and b) the expected (possible) loss due to uncertainty 
is expected to be substantial, and c) the cost of the trial is low.  
A first question arising relates to whether the generated results are valid. For assessing the 
predictive validity of VoI and ‘payback’, generated results need to be compared against 
actual, post-research observations55;67;273. In order to establish that the frameworks produce 
valid results, the NMBs predicted in the pre-research analysis must agree with the actual 
results which will be realised after research has taken place.  
Attempts for result validation are hindered by difficulties. First, comparisons between 
predicted and actual results would only be possible for research programmes which are 
subsequently funded and carried out, as studies that are not carried out cannot produce 
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actual, post-research evidence55;67. Second, a long time horizon would be needed before the 
actual post-research benefits were observed and care would be required to isolate the 
benefits which can be attributed to the specific research programme taking place, so that 
these could be compared against the prospective estimates. 
Validation of ‘payback’ results has been attempted by Townsend and colleagues67. In their 
study, the authors compared prospective PATHS results obtained from case studies against 
post-research results, the latter being estimated by combining actual research results with 
predictions about change in clinical practice. The authors67 reported that the value of the 
predicted (ex ante) results agreed with those of the presumed actual (ex post) results in two 
of the three case studies where such a comparison was feasible. One of the difficulties with 
this approach is that pre-research ‘payback’ methods give a number of possible results 
(usually three: ‘favourable’, ‘inconclusive’ and ‘unfavourable’) while the actual, post-
research result is unique. Given this, the comparison is only meaningful when post-research 
results are put against the equivalent possible results, which, however, cannot be known at 
the time when a proposal is considered for funding. 
Validation of EVPI and EVPPI poses similar difficulties. First, comparisons between pre and 
post-research results will only be possible for studies which have taken place. Second, EVPI 
and EVPPI results will show the maximum potential reduction in opportunity loss (i.e. the 
maximum expected benefits to be gained by eliminating uncertainty), whereas further 
research will only result in partial reduction in opportunity loss and thus less-than-maximum 
benefits. A possible way of validation may involve carrying out pre-research EVPI and EVSI 
analyses (for the specified number of patients in a proposed study’s research protocol) and, 
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after research has taken place, calculating the post-research EVPI. For EVPI to be able to 
capture the reduction in uncertainty—and the subsequent expected benefits due to this 
reduction—the difference between post-research and pre-research EVPI should be 
comparable to the pre-research EVSI.  
Overall, practical and methodological problems make ‘payback’ and VoI results validation 
difficult, although, as it is argued in the next chapter, the extent to which formal validation is 
needed before the results are used in practice is questionable.  
8.3. Theoretical and methodological robustness 
An important consideration in assessing ‘payback’ and VoI relates to the frameworks’ 
theoretical and methodological soundness. Points related to these aspects are raised below. 
8.3.1. Observations related to the frameworks’ theoretical soundness 
As it was explained earlier in this work, the ‘payback of research’ framework is based on the 
notion that research is valuable because it provides information that stimulates a beneficial 
change in practice. Therefore, according to this framework, the desirability of a research 
programme can be inferred by the additional benefits that the programme is expected to 
generate through informing a change in practice.  
This is an intuitive idea, which seeks to account for the ‘real’, tangible benefits that may 
accrue to the population due to research. However, a direct implication of this notion is that 
the framework may attach greater weights to research in areas where there is a great scope 
for gains from a beneficial change in clinical practice, over areas where there is much 
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uncertainty about the appropriate use of treatments, but a lesser scope for change in 
practice80. This was confirmed in sensitivity analyses carried out in the present study, where 
assumptions about greater potential for change in clinical practice (i.e. greater change in 
prescription rates) led to greater expected NMBs from research.  
In addition, an implicit assumption in this approach appears to be that new information 
produced by research is the sole reason for a beneficial change in practice. Research may 
indeed have a major effect in triggering change in clinical practice and may be responsible 
for a large share of the benefits due to greater use of cost-effective treatments; nonetheless 
other factors may be also contributing to a change in clinical practice, such as increasing 
familiarity with a new technology or active promotion by a treatment’s manufacturers. As a 
result, attributing all the benefits from a change to research may overestimate the value of a 
proposed study. 
As far as VoI is concerned, the approach has firm foundations on well-established principles 
of statistical decision theory. The framework is based on a ‘decision-theoretic’ stance, 
according to which research, such as a clinical trial, should be seen as a source of evidence 
for decision-making115;189. In particular, this viewpoint stipulates that a clinical trial is worth 
conducting as long as it is expected to add to the existing evidence base and provide input 
for decision-making, no matter whether the generated results will reach statistical 
significance, or whether the trial was powered to do so in the first place. According to this 
viewpoint, a trial of a few participants would be worth conducting if it produces evidence 
that reduces uncertainty and can be used for decision-making115.  
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Although this viewpoint gains popularity191, it is at odds with the established view that 
clinical trials should be carried out to test hypotheses about treatments and should be 
designed and powered for this purpose. As an implication, before a funding organisation 
decides to take VoI results into account when making funding decisions (or, more 
importantly, when specifying the design requirements of clinical trials), it is important that it 
subscribes to this ‘decision-theoretic’ stance.  
Last, common to both approaches is the notion that research resources should be allocated 
with efficiency in mind, so that the greater the likely benefits associated with a research 
programme, the greater the desirability for conducting the programme. This notion is in 
agreement with currently used decision rules based on the utilitarian view that resources 
should be allocated to achieve ‘the greatest benefits for the greatest numbers’23;144;260. 
However, just as the public may have a preference for health care resources to be used in 
pursuing objectives other than economic efficiency (e.g. equity274-276), society may also 
prefer to give priority to research programmes that may not necessarily result in the 
greatest number of benefits. It must be noted that objectives beyond maximisation of 
benefits are not reflected explicitly on the results of ‘payback’ and VoI analyses, and, in 
situations where they are perceived relevant, these objectives will need to be taken into 
account as additional considerations.  
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8.3.2. Observations related to the frameworks’ methodological soundness 
The core methods of conducting ‘payback’ and VoI analysis are, in general, well-established. 
However, a number of points and challenges related to the frameworks’ methodologies 
were identified.  
 First, a central, although implicit, assumption in ‘payback’ models is that research results are 
expected to reveal the true values of parameters, on the basis of which one can calculate the 
stream of costs and benefits expected to accrue to the health care system. This assumption 
appears to overlook the fact that information from research (e.g. clinical trials) comes in the 
form of uncertain estimates from samples, which may have been observed by chance, or, if 
the study is flawed, may be incorrect or biased. As a result, the benefits that are predicted to 
accrue on the basis of specified trial results are also uncertain and may or may not reflect 
the true benefits that would be expected in the population.  
A second issue pertains to the specification of possible trial results and change in practice in 
the light of different results. Possible trial results have a substantial impact on the stream of 
costs and benefits predicted to accrue from a treatment. Although these are selected 
according to specified outcomes (e.g. in order for a ‘favourable’ outcome to transpire, the 
BTOG-2 trial should show a probability of disease progression of 0.64 at one-year follow up), 
the choice of values is to some extent arbitrary. This is because other values for transition 
probabilities in the range of the chosen value may also result in a ‘favourable’ outcome.  
Similarly, the pace and magnitude of change in clinical practice is difficult to predict, as it 
depends on a number of factors, including the magnitude and strength of the results per se, 
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the effectiveness of existing dissemination mechanisms, the availability of the infrastructure 
needed to make the change in practice possible, as well as the degree to which change 
towards cost-effective treatments (or restrictions in non-cost-effective treatments) is 
compulsory. Obviously, weighting up all these factors is complex and predictions about the 
possible change in practice are inherently prone to error. In the present study, estimates of 
the possible change in clinical practice were obtained through discussion with experts, who, 
nonetheless, highlighted that their estimates were mere guesses.  
Methodological challenges also arise when applying ‘payback’ to case studies involving 
multiple comparisons. As mentioned in Chapter 6, the correct approach for dealing with 
such applications is unclear, while, at the same time, this task requires stronger assumptions 
when specifying possible outcomes; for instance, under the ‘inconclusive’ scenario, all four 
treatments are assumed to be of similar cost-effectiveness, which is an unlikely situation. In 
comparisons between multiple treatments, different possible outcomes need to be specified 
in a way that covers all the possible eventualities (i.e. each treatment to be cost-effective, as 
well as all treatments to be of similar cost-effectiveness). As a result, the number of 
weighted and non-weighted ‘payback’ results increases (in the analysis of the four-treatment 
TRAPEZE, there were five different combinations (see Chapter 6)) which may pose difficulties 
for selecting the combination that is more likely to transpire.  
With regards to VoI, an important point relates to the conflict that appears to exist between 
research that is needed in order to improve scientific knowledge, and research that is useful 
for reducing decision uncertainty. This is clear in the case of preference-based quality of life 
(utility) scores for health states in NSCLC. Searches in the literature revealed a lack of 
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evidence on these parameters and, given this, it would be reasonable to suggest that further 
research should be carried out to look into patients’ quality of life. However, the expected 
value of perfect parameter information for such scores was low, even when the uncertainty 
around this parameter was set at a high level (see Chapter 7) and, thus, utility values were 
not suggested as an area where further research should focus on.  
To a large extent, this is due to the way EVPI and EVPPI results are calculated. In general, the 
expected value of perfect information around a parameter will be sizeable when there is a 
high probability that the parameter will resolve at extreme values, and, at the same time, 
the parameter itself has a significant impact on the difference in the cost-effectiveness 
between treatments and thus on the adoption decision. In this study, NSCLC utility scores 
affected the results for Gem+Carb and Gem+Cisp in a proportional fashion, and thus, from 
the perspective of decision-making, obtaining information around these parameters is not 
seen as a priority.  
Last, it must be noted that the degree to which VoI results are correct depends largely on 
the validity of the decision model through which results are produced. Serious flaws in the 
model—for example incorrect structure, biased input estimates and, most importantly, 
inappropriate representation of uncertainty—are all expected to give inaccurate cost-
effectiveness results, biased estimates of uncertainty and, as a consequence, incorrect VoI 
results. Importantly, placing confidence in the results of the cost-effectiveness analysis 
preceding VoI analysis is a prerequisite for taking into account the results of VoI itself.  
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8.4. Sensitivity to assumptions  
A further important consideration relates to the extent to which ‘payback’ and VoI results 
are sensitivity to assumptions. As noted earlier, ‘payback’ requires a series of assumptions 
around possible outcomes, change in clinical practice and likelihood of observing each of the 
specified outcomes. Deterministic and probabilistic sensitivity analyses reported in Chapter 6 
revealed that different patterns of possible change in practice, alternative research 
outcomes and different likelihood weights all had a sizeable effect on ‘payback’ results.  
On the other hand, ‘value of information’ results were greatly affected by the degree of 
uncertainty surrounding parameters which affect the adoption-related decisions, with 
greater uncertainty being associated with greater estimates of expected benefits from 
research. As it was shown in Chapter 7, the effect is more pronounced when greater 
uncertainty surrounds parameters that are instrumental in determining the most cost-
effective treatment—in the specific applications, rates of disease progression. Further, both 
‘payback’ and VoI are sensitive to assumptions about the employed time horizon for which 
the produced evidence is expected to be useful; as expected, long time horizons inflated the 
number of patients that are affected by the availability of improved information, increased 
the expected benefits in the population and made further research appear more desirable.  
8.5. Practicality and ease of use 
Practical aspects, such as the time and expertise needed to conduct ‘payback’ and VoI 
analysis, are likely to be an important consideration for research funding organisations.  
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Based on observations made in the course of this study, preliminary steps needed for the 
application of the analytic frameworks, that is, systematic reviews and modelling, required a 
fair amount of time. Systematic reviews of the literature to identify evidence for the NSCLC 
and HRPC case studies took six and four weeks to complete, respectively. Most of this time 
was devoted to assessing articles for inclusion and extracting relevant information. 
Considerable amounts of time were required for planning the structure of the decision 
analytic models, for converting data (e.g. patient-level observations obtained from the 
TRAPEZE Phase II and survival curves taken from the published literature) into a form 
appropriate for use in the models, and for carrying out deterministic and probabilistic 
sensitivity analyses. In total, systematic reviews and modelling for the NSCLC and HRPC case 
studies took 24 and 28 weeks, respectively (Table 8.1).  
Table 8.1: Time required for preliminary tasks of practical application (collection of evidence and decision modelling) 
 
Task NSCLC HRPC 
Identification of evidence 6 weeks 4 weeks 
Development of model structure 6 weeks 6 weeks 
Conversion of raw information into appropriate form for use in the models 3 weeks 8 weeks 
Model analysis (including deterministic and probabilistic sensitivity analyses) 9 weeks 10 weeks 
 
Carrying out ‘payback’ analysis using the PATHS model was relatively straightforward. 
Excluding the time needed for familiarising with the methods, the base case PATHS analysis 
took approximately two weeks, including the time needed to gather information through 
meetings with the involved experts. A further two weeks were required for undertaking 
additional deterministic and probabilistic sensitivity analyses. No particular expertise other 
291 
than knowledge of basic concepts in cost-effectiveness analysis was needed to carry out the 
‘payback’ analysis. 
EVPI and ‘value of implementation’ analyses were also relatively straightforward and were 
completed soon after the probabilistic results of the models became available. EVPPI 
analysis was more complex and required between six and seven weeks to undertake. A share 
of this time was taken up by recurring calculations of simulated results. Running a single 
outer loop (i.e. 1000 inner loop simulations) through Microsoft Excel® macro commands on 
a personal computer equipped with an Intel Core 2 Duo® processor took approximately 50 
seconds. A combination of 1000 outer   1000 inner loop simulations, which was needed to 
derive EVPPI results for one group of parameters in NSCLC, required approximately 14 hours 
of continuous computation. EVPPI analysis for the five groups of parameters in NSCLC 
completed in approximately 70 hours (nearly three days). EVPPI calculations for HRPC were 
more demanding due to the more complex structure of the HRPC model: a combination of 
1000 outer   1000 inner loop simulations for one group of parameters took approximately 
35.5 hours (nearly one and a half day) to complete, while running EVPPI calculations for all 
the 12 separate groups of parameters in this analysis would require 423 hours 
(approximately 18 days). However, it was possible to run parts of these simulations in 
parallel on many computers at the same time, which allowed completing the computations 
in approximately one week using 12 separate machines. No particular expertise other than 
an understanding of the concept was needed for conducting EVPI; nonetheless, undertaking 
EVPPI analysis required acquiring familiarity with command writing in the Visual Basic® 
programming language.  
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Conducting EVSI was more complex, as it involved a two-part process. The first part involved 
generating a set of 1000 posterior distributions for the group of parameters of interest 
(effectiveness of treatments of interest) and needed to be carried out for each of the 
assessed treatments in NSCLC (Gem+Cisp, Gem+Carb) and HRPC (DP, DP+ZA, DP+Sr89, 
DP+ZA+Sr89). For one treatment, generating posterior distributions required approximately 
30 minutes of continuous computational time for HRPC, and approximately 120 minutes for 
NSCLC. The difference in these times appears to be due to the more complex calculations 
needed for generating posterior distributions for NSCLC, where existing data needed to be 
translated into number of patients alive and progression-free at different points in time, and 
simulated data needed to be translated back into survival and progression-free curves. 
 For each of the 1000 posterior distributions, the second part involved running 1000 Monte 
Carlo simulations (1000 posteriors (outer loop)   1000 MC simulations (inner) loop) for each 
of the assessed treatments. Generating EVSI results for one treatment and one sample size 
(300 patients in base case analysis of TRAPEZE, 450 patients in the base case analysis of 
BTOG2) took approximately 11 hours for HRPC and 12 hours for NSCLC. The process was 
repeated for all treatments and for different sample sizes. The time needed for payback and 
VoI analyses is given in Table 8.2.  
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Table 8.2: Time required for application of ‘payback’ (PATHS) and VoI methods to case studies. 
 
Task NSCLC case study HRPC case study 
EVPI analysis < 1 week* < 1 week* 
EVPPI analysis 6 weeks 7 weeks 
EVSI and ENBS analysis 5 weeks 10 weeks 
Value of implementation analysis 1 week 1 week 
Payback analysis (using the PATHS 
model) 
4 weeks 4 weeks 
*After cost-effectiveness results from Monte Carlo simulations became available.  
 
In summary, the average time needed for information gathering and decision modelling was 
six and a half months for one case study. Excluding the time needed to familiarise with the 
respective methods, ‘payback’ and VoI analyses for a single case study required on average 
one and three month to complete, respectively. The above observations should be seen in 
the light of the following considerations. First, in the present study all tasks were carried out 
by a single researcher, whereas, if this work was to be commissioned, systematic reviews 
and modelling would be undertaken by a team of researchers with expertise in different 
areas, such as information specialist, systematic reviewers and health economists. Clearly, if 
the latter was the case, these tasks would have been completed in a shorter time. Second, it 
is likely that researchers who have undertaken ‘payback’ and ‘VoI’ analyses before would 
complete the applications and obtain results in a shorter period. Last, running EVPPI and 
EVSI calculations in software other than Microsoft Excel®, for example WinBUGS, may have 
been more time-efficient, although familiarity with such software would, in itself, require 
considerable expertise and investment in time. Notwithstanding this, it is thought that the 
time for undertaking these analyses as recorded here is a fair reflection of the time that 
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would be needed for applying the frameworks in actual practice, for decision making 
purposes.  
8.6. Ability to inform relevant priority-setting decisions 
The ultimate purpose of analytic approaches is to inform research funding allocation 
decisions and, with this in mind, this section looks into how ‘payback’ and VoI can assist with 
different tasks relevant to priority-setting. The section starts by looking into the meaning of 
final ‘payback’ and VoI results, and explores whether the methods can help with ranking 
research proposals and establishing optimal trial design characteristics. 
8.6.1. Meaning of results and decision rules 
A first step in establishing the potential of the approaches to assist with research funding 
requires clarifying what the results show and how they can be used.  
With regards to ‘payback’, results express estimates of the additional cost and benefits (or 
NMBs) expected to accrue from carrying out a given research study, under specific 
assumptions about the possible study results and specific hypotheses about change in 
clinical practice in view and in the absence of these results. The decision rules used in the 
framework are alike to those used in cost-effectiveness and cost-utility analyses: research is 
worth undertaking if a unit of incremental health benefit arising from conducting research 
(over not conducting research) can be obtained at a cost less than the maximum value that 
society (or a decision-maker) is willing to pay for this benefit (i.e. ceiling ratio):  
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or, equivalently, if the NMBs associated with research at a specific ceiling ratio exceed those 
of no research:  
                               
Given this, ‘payback’ results offer an indication of the value of carrying out a specific 
research study (e.g. a trial) and can be used by research funders as a simple rule for deciding 
if the research study should be taken forward.  
On the other hand, VoI results quantify the benefits expected to arise from eliminating or 
reducing uncertainty around a decision by obtaining better information through research. In 
particular, EVPI and EVPPI show the expected additional NMBs from making a decision with 
no uncertainty and perfect information about all or specific parameters affecting a decision 
problem, as opposed to making the same decision under current, imperfect information. 
Because of this, EVPI and EVPPI do not show the value of a specific study per se, but 
represent the maximum expected benefits that could be realised through research and, as a 
result, the maximum possible value of conducting research around a specific decision 
problem. According to the decision rule attached to EVPI, a study is potentially—although 
not necessarily—worthwhile if: 
                                             
Results from the application of EVPI to NSCLC and HRPC showed that the maximum benefits 
from conducting research in these areas exceeded the cost of the BTOG-2 and TRAPEZE 
phase III trials, thus conducting the trials would be potentially worthwhile. 
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Last, EVSI results show the additional benefits expected from reducing uncertainty through 
conducting a specific piece of research (e.g. clinical trial), of a specific sample size  51;115. 
EVSI can be compared against of cost of this study to give the expected net benefit of 
sampling (ENBS). Positive ENBS suggests that the specific study is worth conducting:  
                                   
While EVPI and EVPPI provide only a criterion—or a hurdle— for judging whether research in 
the area would be potentially beneficial and should not be ruled out, EVSI provides an 
estimate of the benefits associated with a specific study (e.g. the TRAPEZE phase III trial) 
and, thus, its results can indicate whether a specific study is worth undertaking. In the 
application of EVSI to the HRPC case study, results showed that conducting the TRAPEZE 
phase III trial is worthwhile, as it would bring about expected NMBs of approximately 
£550,000. In the NSCLC case study, EVSI analysis suggested considerable NMBs from 
conducting the proposed BTOG2 trial, of the order of £9 million.  
8.6.2. Priorities across research proposals 
Comparisons between different research proposals would be highly useful to research 
funders, as this would allow ranking these proposals in order of expected returns. Such 
comparisons require knowing the exact—rather than the maximum—amount of benefits 
that a research programme may offer.  
In theory, different proposals could be ranked in order of their ‘payback’ results. However, 
the recognition that ‘payback’ estimates are based on a number of assumptions and 
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uncertainties about possible research outcomes and change in clinical, make ranking 
challenging. An additional level of complexity arises from the fact that ‘payback’ generates a 
range of possible results (e.g. ‘optimistic’, ‘neutral’ and ‘pessimistic’) rather than a single 
estimate, which may also overlap. For example, ‘payback’ results for NSCLC range from £1.88 
to £2.38; while the results for HRPC span from £1.30 to £3.19. In this case, it is not clear 
whether the BTOG-2 trial should take priority over the TRAPEZE trial. 
In VoI, EVPI/EVPPI results express the maximum possible NMBs from conducting research 
thus these methods cannot indicate the exact (marginal) NMBs that would be expected from 
a specific study. Comparing research proposals on the basis of EVPI/EVPPI estimates would 
only be appropriate under the assumptions that: a) the marginal benefits expected from a 
specific research programme in a given area are proportional to the maximum expected 
benefits from research in this area51, b) the cost of research is the same across the compared 
proposals and c) these assumption hold true across different areas. For instance, knowing 
that the estimated population EVPI for the NSCLC decision problem is higher than that of 
HRPC (£13.08 million compared to £8.55 million) does not suggest that a trial in NSCLC 
would necessarily result in greater marginal benefits than a trial in HRPC.  
Nonetheless, comparisons across programmes are, in principle, possible by using EVSI 
analysis where a series of trials of different designs, in different areas, can be ranked in 
terms of their ENBS. Given the ENBS results for BTOG2 and TRAPEZE, it is sensible to infer 
that priority should be given to the BTOG2 trial (£9 million in NMBs) over the TRAPEZE trial 
(£550,000 in NMBs). 
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8.6.3. Additional decision points 
Having information around different aspects of research funding may be advantageous to 
funding organisation. The potential of VoI to help with trial design decisions is well 
documented. This is based on the principle that a trial is designed optimally when the 
difference between the marginal benefits expected from the specific trial (i.e. EVSI) and the 
cost of the trial is the maximum possible (i.e. ENBS is maximum)262. In theory, this principle 
can provide a guide for identifying an array of optimal design characteristics such as sample 
size, choice of treatment arms as well as allocation of participants across trial arms51. As 
reported in Chapter 7, EVSI analysis applied to the NSCLC case study indicated that sample 
sizes greater than 450 patients per arm would result in positive ENBS, with maximum ENBS 
achieved when employing the largest sample size (n=500 patients) amongst those 
investigated in this case study. Similarly, EVSI for the HRPC case study was able to suggest 
that the sample size for the TRAPEZE phase III trial that maximised the ENBS at £30,000 per 
QALY amongst the assessed sample sizes was 200 patients per arm.  
Signs of the potential of ‘payback’ to assist with design decisions have been seen in existing 
studies. One way of determining appropriate trial design characteristics is by asking decision-
makers to indicate what trial outcomes they consider relevant and what magnitude of 
difference would persuade them to adopt or refute an assessed treatment. For example, in a 
case study of a trial for postnatal midwife support, Townsend et al.67 found that decision-
makers tasked with deciding on whether or not to commission a midwife programme would 
prefer trial evidence on the programme’s impact on mothers’ breast feeding rates or 
postnatal depression and, owing to this, the authors recommended changes in the trial 
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design to incorporating these as the primary outcomes. Additional work related to trial 
design considerations has looked into the relationship, or trade-off, between the choice of 
minimum clinical difference between treatments (  ) to be detected as significant in a trial 
(smaller values of   require larger sample sizes and greater cost) and the fact that observing 
a smaller differences as significant improves the chances of accepting the trial results and 
changing practice in a beneficial way91;102. 
An additional design characteristic relates to selecting treatments that should be assessed in 
a proposed trial. Excluding irrelevant treatments from comparisons is expected to lead to 
cost savings, as well as to benefits from not subjecting patients to ineffective treatments. As 
far as ‘payback’ is concerned, the method may indicate treatments that are not expected to 
lead to changes in clinical practice and this may help decision-makers to exclude the 
irrelevant treatment arms from further comparisons. A more systematic criterion is 
suggested by VoI: at a specific ceiling ratio, a treatment is not worth considering further if, in 
a large number of simulations, it is never the treatment that offers the greatest NMBs (i.e. 
the probability of the treatment being the most cost-effective option is zero)51. In the EVSI 
applications for NSCLC and HRPC, all treatments were associated with a non-zero probability 
of being cost-effective, suggesting that no treatment should be excluded from comparison in 
the proposed BTOG2 and TRAPEZE trials.  
Often, decisions are needed as to whether a phase II trial should continue to a subsequent 
phase III stage and, in general, whether an on-going trial should continue or terminate. Such 
decisions are typically made on the basis of data collected for interim analysis or at the end 
of phase II trials. As noted earlier, this was the case with the TRAPEZE phase III trial, where 
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data from the phase II stage of the trial were available and could be taken into consideration 
when deciding whether to continue on to a phase III study.  
In essence, decisions around funding trial continuation from phase II to phase III are similar 
to those about starting a new phase III trial, with the difference that, the availability of 
interim (phase II) data offers additional advantages. Data monitoring committees deciding 
whether a study should continue into phase III are traditionally interested in exploring if a) 
there is overwhelming evidence that one or more of the assessed treatments is clearly 
superior to the rest (in which case it is unethical not to treat patients with the superior 
treatment), b) there is evidence that the trial is futile (in this case it is evident that 
treatments are of similar effectiveness and further experimentation will be futile), or c) 
there are concerns about participants’ safety. No economic criteria are taken into account 
when deciding whether an on-going study should be terminated, although there is potential 
for the analytic approaches to inform such decisions277.  
In ‘payback’, existing phase II data can be used to give an indication of the likelihood of a 
proposed phase III trial to show a particular result and they can point towards the most likely 
‘combination’ (i.e. ‘optimistic’, ‘neutral’ or ‘pessimistic’). In the present study, existing results 
from the TRAPEZE phase II trial showed DP+Sr89 to be effective. This information pointed 
towards a greater likelihood of the proposed TRAPEZE phase III trial to show positive results 
for this treatment, indicated that a greater weight may be placed on an ‘optimistic’ 
combination (i.e. higher possibility of DP+Sr89 being cost-effective) and suggested that a 
phase III trial would be likely to result in positive NMBs.  
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In other cases, where phase II data may indicate that ‘inconclusive’ results are more likely to 
transpire—which may mean no change in practice and no additional health benefits, but 
additional costs due to conducting the trial—potential users of the method may decide 
against conducting a phase III trial. In situations where early-stage patient-level data are 
available, there may be scope for combining available trial information with expert opinion 
to obtain a priori indications of the likely results of a future trial, possibly by using Bayesian 
methods.  
In VoI, available phase II data are considered as ‘existing evidence’, they are incorporated in 
the decision model and they are taken into account when assessing the extent of uncertainty 
and the value of conducting further research. The fact that such data come from an 
experimental study which is directly relevant to the population of interest gives greater 
confidence in the results. The availability of phase II data, especially when those are 
expressed in terms of ‘convenient’ (conjugate) distributions is also beneficial in EVSI analysis. 
There, phase II data can be used directly to express ‘prior’ evidence. All in all, trial 
continuation decision can be addressed by ‘payback’ and VoI in the same way as decisions 
for new phase III trials, with additional advantages due to the availability of interim data.  
8.6.4. Ability to inform priority-setting for evidence synthesis studies 
Apart from primary evaluative research, funding organisations such as the NIHR HTA are 
often called to make decisions on funding secondary studies, such as evidence syntheses and 
economic evaluations. 
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‘Payback’ models appear to be able to help with such tasks; on this, Townsend et al.67[p.x in 
Executive Summary] point out that the PATHS model “could be applied to any form of research, 
including secondary analysis and reviews’’. In cases where formal cost-effectiveness 
evidence on a decision problem is not available, ‘payback’ can be carried out to establish the 
value of undertaking a joint evidence synthesis and economic evaluation study by following 
the usual sequence of steps (i.e. specification of possible outcomes of the evidence 
synthesis, estimation of subsequent change in practice and calculation of costs and benefits). 
Here, instead of looking into the value of research aimed to generate new primary evidence, 
the question is whether it would be worth summarising the existing evidence in the first 
place.  
On the other hand, a joint evidence synthesis and economic evaluation study that assesses 
all available information is a prerequisite for conducting VoI, as it is needed to establish the 
extent of current evidence and give estimates of the existing uncertainty around an adoption 
decision. Thus, on the premise that all the available information need to have been already 
gathered and synthesised, there will be no benefit in carrying out VoI analysis to explore the 
value of conducting another study to synthesise the existing information.  
8.7. Fit into priority-setting 
The extent to which ‘payback’ and VoI can be incorporated into existing priority-setting 
arrangements is a crucial consideration for potential users of the frameworks [personal 
communication with Dr P. Davidson, Director of NIHR Evaluation Trials and Studies 
Coordinating Centre, 13-01-2012]. As noted in Chapter 2, funding for primary evaluative 
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research is typically distributed via ‘researcher-led’ (‘reactive’) and ‘commissioned’ 
(‘proactive’) streams65. These work streams are commonly employed by major funders of 
primary research in the UK, including the NIHR Health Technology Assessment (NIHR HTA) 
programme, the Efficacy and Mechanisms Evaluation (EME) and medical charities such as 
Cancer Research UK (CRUK)41;45;46;49. The following section looks into the scope for, and 
possible ways of, incorporating ‘payback’ and VoI into these funding streams.  
8.7.1. Scope for use of ‘payback’ and VoI in ‘researcher-led’ funding streams 
The aim of ‘researcher-led’ streams is to prioritise and fund research proposals submitted 
directly by researchers on topics of their choice. ‘Researcher-led’ streams are the main 
funding route used by medical charities such as the CRUK, but they are also employed by 
organisations such as the NIHR HTA and EME. A variation of such streams which is employed 
by the NIHR HTA are ‘themed calls’; these follow the same processes as in ‘researcher-led’ 
routes with the difference that, in ‘themed calls’, researchers submit proposals on broad 
predetermined disease areas. There are only subtle differences in the prioritisation 
processes followed by different ‘researcher-led’ programmes, with the core steps are similar 
to those in the NIHR HTA ‘researcher-led' stream. These are shown in Figure 8.1 and are 
described below. 
The first step in the process involves researchers responding to requests for applications by 
submitting outline proposals. Outline proposals are checked for competitiveness and 
eligibility and those which fall within the programme’s remit are forwarded to one of six 
Advisory Panels for consideration. Advisory Panels assess the outline proposals, shortlist 
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those that are deemed as good candidates and forward the list of them to the HTA 
Prioritisation Group (HTA PG) for further consideration. About half of the outline proposals 
are rejected by the HTA PG at this stage, while the remaining proposals are sent to the HTA 
Clinical Evaluation and Trials Board (HTA CET Board). The HTA CET Board makes the final 
decision about which proposals to reject and which to invite back as full proposals. Once full 
proposals are submitted, these are considered further by the HTA CET Board. Proposals are 
scored and those which rank high are recommended to the HTA PG for final approval78;81;278.  
In this process, either ‘payback’ or VoI can be carried out to indicate whether conducting 
research on the topic or research question that the proposed study deals with would be 
potentially worthwhile. Clearly, proposals on topics where further research is not expected 
to be worthwhile can be filtered out. For example, if primary evaluative research on 
chemotherapies for non-small cell lung cancer is not considered worthwhile—for example 
due to limited uncertainty and/or little scope for gains due to change in practice—there will 
be no benefit in conducting a trial on NSCLC, in which case the proposal can be ruled out. 
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Figure 8.1: Flow chart showing prioritisation process in NIHR HTA 'researcher-led' stream 
 
In addition, there may be scope for conducting EVSI and ENBS analysis to indicate the 
marginal benefits expected from a specific research proposal and to provide guidance about 
appropriate trial design (e.g. sample size, relevant comparators). In principle, such 
information can serve as a reference against which to compare the costs and the design 
characteristics of the proposed studies, although, as discussed in the next chapter, such 
comparisons will inevitably present challenges. In the context of the current arrangements, it 
is envisaged that ‘payback’ and VoI analyses could take place once full proposals are 
Outline proposals submitted 
Eligibility checks 
Outline proposals shortlisted by Advisory Panels 
HTA PG discuss shortlisted outline proposals.  
Further filtering.  
List of remaining outline proposals sent to HTA CET Board 
HTA CET Board meet and discuss outline proposals 
Successful outline proposals are invited as full proposals 
Full proposals submitted for consideration 
Full proposals considered by the HTA CET Board 
Recommendations made to the HTA PG 
HTA PG approves and ratifies proposals  
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submitted for consideration, so that their results become available when full proposals are 
assessed by the HTA CET Board, before final recommendations are made to the HTA PG. 
8.7.2. Scope for use of ‘payback’ and VoI in ‘commissioned’ funding streams 
‘Commissioned’ streams are central in the NIHR HTA and the EME programmes. In such 
streams, the aim is to identify and prioritise topics—rather than proposals—on which 
research is needed, as well as to commission teams of researchers to undertake this 
research. The process involved in the ‘commissioned’ stream of the NIHR HTA is shown in 
Figure 8.2.  
A two-stage process is usually followed in commissioned streams. In the first stage, funding 
organisations gather suggestions for topics identified through various sources, including key 
stakeholders and the public. Once potential topics are gathered, they undergo an initial 
filtering stage to ensure that they are relevant to the NHS and do not overlap with past or 
on-going research. Topics deemed relevant are forwarded to a relevant Advisory Panel 
where they are assessed with reference to their importance. Topics that appear promising 
are shortlisted and are developed into 'vignettes', that is, brief documents which specify the 
topic question and summarise the existing evidence on the topic. Panels meet again to 
discuss the topics in view of the produced vignettes and decide which of the topics should be 
forwarded to the HTA PG for further consideration. The HTA PG meets to decide on topics to 
shortlist and advertise in calls for research41;279.  
Calls are typically for primary evaluative research and, less often, for secondary, evidence 
synthesis studies280. Topics are advertised together with commissioning briefs giving 
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clarifications about the topic, in response to which researchers submit outline proposals. 
Outline proposals are discussed and shortlisted by the Commissioning Board, taking into 
account considerations regarding the scientific quality of the proposal, justification of 
estimated sample size calculations and recruitment rates, ethical and social considerations 
related to the proposed research, as well as the proposal’s cost. The most competitive 
outline proposals are shortlisted and invited back as full proposals. Once full proposals are 
received, they are discussed by the Commissioning Board in the light of external referees’ 
comments and selected proposals are forwarded to the HTA PG for ratification40;279;281. 
 
Figure 8.2: Flow chart showing prioritisation process in NIHR HTA 'commissioned' stream 
Initial checks for remit 
Advisory Panel meeting 
Request for vignettes 
Advisory Panel shortlist topics in the light of vignettes 
Recommendations forwarded to HTA PG 
 
Prioritised topics advertised in calls 
Outline proposals submitted to HTA CB 
Good candidate topics requested as full proposals 
HTA PG approves and ratifies proposals 
Full proposals submitted to HTA CB 
Recommendations on proposals to fund made to HTA PG 
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In this process, ‘payback’ and VoI can be equally useful as an initial filter to exclude topics for 
which further research is not potentially worthwhile (i.e. topics for which the expected 
NMBs from research are unlikely to exceed the cost of commissioning and conducting 
research). In addition to suggestions on whether there are sufficient gains to be made from 
research on the topic, the approaches may be able to provide an indication of the maximum 
cost that a further study should not exceed. A previous study by Claxton et al.110 suggested 
that VoI work could be carried our alongside the preparation of vignettes; however this may 
be problematic as, at this early stage, the research question (e.g. compared interventions) 
within the topic is unlikely to be well defined110. Thus, it is thought that ‘payback’ and VoI 
analysis would be better suited to a later stage in the process, just before the HTA PG makes 
recommendations for calls about topics to commission. 
The ways ‘payback’ and VoI can help in the main funding streams of clinical evaluative 
research are further summarised in Table 8.3 below. 
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Table 8.3: Potential use of 'payback of research' and 'value of information' in 'researcher-led' and 'commissioned' 
funding streams 
 
Funding stream ‘Payback’ VoI 
Researcher-led (such as the 
NIHR HTA Clinical 
Evaluation and Trials; EME; 
CRUK) 
Undertake ‘payback’ for proposal 
which have been submitted as full 
versions.  
Results of ‘payback’ analysis can be 
used to inform final deliberations on 
whether the proposal should be 
funded. 
 
Undertake VoI (EVPI) for proposals 
which have been invited as full 
submissions.  
EVPI results can be used to inform 
final deliberations as to the usefulness 
of research in the area.  
EVSI can be undertaken after the full 
proposal so that its results can help 
the HTA PG make recommendations 
for appropriate design, or it can be 
undertaken by researchers in the 
process of developing the proposal, to 
guide the design of the proposed 
study.  
 
Commissioned (such as the 
NIHR HTA commissioned 
scheme) 
Undertake ‘payback’ analysis for 
proposals which are considered by the 
HTA Prioritisation Group.  
Undertake VoI (EVPI) analysis for 
proposals which are considered by the 
HTA Prioritisation Group. 
 
It can be seen that, in principle, either of the frameworks can be suitable for either of the 
funding streams. In ‘researcher-led’ funding streams, ‘payback’ and VoI can be undertaken 
after a proposal has passed the first prioritisation state (i.e. after researchers have 
developed their preliminary proposal and submitted it as a full application) to provide 
information (i.e. expected NMBs of the study) which can be taken into account at the point 
where funding decisions are finalised. Similarly, in ‘commissioned’ programmes, VoI and 
‘payback’ can be undertaken for topics that have passed an initial filtering topics, that is, 
topics which Advisory Panels judge to be important candidates for research. In this way, the 
filtering process is thought to provide a realistic solution to the possible concern that 
conducting ‘payback’ and VoI for the hundreds of topics and proposals submitted for funding 
will be, in essence, unrealistic.  
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8.8. Chapter overview 
The chapter aimed to look into ‘payback’ and VoI by highlighting and discussing strengths 
and limitations of the methods with relation to considerations deemed relevant to potential 
users of the frameworks. Such considerations related to the validity and robustness of the 
results, practicality of undertaking the analyses, potential to inform different aspects of 
research funding decisions and scope for being incorporated in current priority-setting 
processes. Information presented in this chapter is taken forward and forms the basis for the 
discussion and conclusions presented in the last chapter of this thesis. 
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CHAPTER 9. Discussion and conclusions 
This final chapter aims to discuss the findings of this research project, draw conclusions and 
make recommendations for further research. The first part summarises the project’s aims, 
methods and main results. This is followed by a discussion around findings and relevant 
observations. The last part draws conclusions, makes policy recommendations and highlights 
areas for future research.  
9.1. Overview of project aims and methods 
Patient-level evidence generated from clinical trials is considered key input in assessing the 
effectiveness and cost-effectiveness of health care technologies4;114. Given the increasing 
demand for primary evidence and limited public resources for health care research, research 
funding organisations are routinely called to make decisions on which research proposals to 
fund. Although resource allocation decisions need to be informed by explicit and systematic 
assessments of the cost and benefit of different research programmes55;80;90;92;100, such 
assessments are, at the moment, carried out implicitly, by panels of experts who infer the 
merits of proposals through discussion and deliberations.  
A review of the literature identified nine analytic models which can assess the cost and 
potential benefits of proposed research in a systematic way. According to the principles 
underpinning them, the majority of the models were categorised into one of two 
overarching frameworks: ‘payback of research’ and ‘value of information’ (VoI). The 
‘payback’ framework is based on the notion that research is worth conducting insofar as its 
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results can trigger a beneficial change in clinical practice. On the other hand, VoI stipulates 
that the value of research lies in its ability to reduce uncertainty about treatment adoption 
decisions and thus funding and conducting a research programme such as a clinical trial is 
potentially worthwhile when the expected benefits from eliminating or reducing decision 
uncertainty exceed its cost. Although the methodologies underpinning the frameworks are 
well established, their usefulness and role in informing research priority-setting remain, to a 
great extent, unclear. Despite the fact that this is not the first attempt to appraise ‘payback’ 
and VoI, existing studies present limitations which preclude a comprehensive assessment of 
the frameworks.  
With this in mind, this project set out to explore the potential role and usefulness of the two 
most prominent analytic frameworks put forward for assisting priority-setting in primary 
evaluative research—‘payback of research’67 and ‘value of information’97;110. To this end, the 
frameworks are assessed with regards to their ability to inform funding decisions, 
practicality, robustness and reliance to assumptions, theoretical and methodological 
soundness, and potential to fit into the existing priority-setting framework.  
To obtain an insight into the frameworks’ strengths and limitations, ‘payback’ and VoI were 
applied to two case studies. These represented proposals for primary evaluative research 
(BTOG-2 and TRAPEZE phase III trials) aimed to provide evidence for treatment adoption 
decisions in non-small cell lung cancer (NSCLC) and hormone-refractory prostate cancer 
(HRPC). At the time the present analysis took place the trials were funded and on-going thus 
the practical application was carried out in a retrospective manner, by looking at the points 
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in time when the BTOG-2 and TRAPEZE trials were considered for funding (2004 and 2006, 
respectively).  
The analysis involved two steps. The first, preliminary step involved summarising the 
available pre-trial information around the treatment adoption decisions. This involved 
carrying out literature reviews to identify the information existing at the time that the 
decision to commission further research was considered, and constructing decision models 
to synthesise this information.  
As a next step, ‘payback’ and VoI analyses were carried out to assess the need for, and the 
benefits from, obtaining additional information through funding and conducting the 
proposed BTOG-2 and TRAPEZE phase III trials. ‘Payback’ analysis was based on the PATHS67 
methodology and was applied to research projects looking into two-treatment and four-
treatment comparisons (NSCLC and HRPC, respectively). VoI analysis involved all the relevant 
concepts, including expected value of perfect information (EVPI), expected value of perfect 
parameter information (EVPPI), expected value of sample information (EVSI) as well as 
analyses on the value of implementation.  
The empirical work aimed to give a comprehensive view of the methods. In addition to 
estimates of the expected benefits from conducting the proposed trials, the practical 
application revealed strengths and limitations of the frameworks and formed the basis for 
the following discussion and conclusions. 
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9.2. Summary of practical application results 
‘Payback’ and VoI results were calculated on the basis of a ceiling ratio of £30,000 per QALY. 
The assumed time horizons for the non-small cell lung cancer (NSCLC) and hormone-
refractory prostate cancer (HRPC) case studies were five and two years, respectively. 
‘Payback’ analysis for the NSCLC case study showed positive net monetary benefits (NMBs) 
for all the formed combinations, ranging from £1.88 million (‘neutral’ combination) to £2.38 
million (‘pessimistic’ combination) in net monetary benefits (NMBs). Overall, ‘payback’ 
results suggested that, on the premise that the BTOG-2 trial would show the assumed results 
and would triggered a change in clinical practice of the hypothesised magnitude, carrying 
out the trial would result in additional benefits to the population.  
For the same case study, VoI analysis showed a population EVPI in excess of £13 million and 
a relatively high EVPPI for clinical progression parameters. As the EVPI value exceeds the 
cost of the BTOG-2 trial, funding the trial would be potentially beneficial. Additional analysis 
around the value of implementation suggested that undertaking either research or 
implementation strategies is expected to be potentially worthwhile, although, in the specific 
case, pursuing better implementation would be preferable (i.e. it would results in greater 
numbers of NMBs). Last, EVSI analysis suggested that the benefits of obtaining more 
accurate information from the BTOG2 trial are expected to far exceed the cost of the trial, 
resulting in net benefits of sampling (ENBS) in excess of £9 million. Overall, both the 
frameworks suggested that funding and conducting the BTOG-2 trial is expected to result in 
additional benefits and should be funded. 
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In the prostate cancer case study, ‘payback’ results for the two-treatment comparison 
showed additional NMBs in the range of £1.30 million (‘pessimistic’ combination) to £3.19 
million (‘optimistic’ combination), with a greater likelihood placed on the ‘optimistic’ 
combination. For the four-treatment comparison, results spanned from £468,000 to £3.34 
million. In summary, ‘payback’ results suggested that, given the employed assumptions 
about possible outcomes and change in clinical practice, conducting the TRAPEZE phase III 
trial would result in additional NMBs.  
The application of VoI to the prostate cancer case study showed a population EVPI of about 
£8.55 million. This value exceeds the cost of the proposed TRAPEZE phase III trial (£2.54 
million), suggesting that the trial would be potentially beneficial and it is worth considering 
further. EVPPI was higher for clinical disease progression than for other parameters, such as 
costs and quality of life scores. The analysis suggested that carrying out a trial which would 
look into disease progression, cost and quality of life for all the chemotherapy options of 
interest—such as the TRAPEZE phase III trial—would be, on the basis of the obtained EVPPI 
values, potentially cost-effective. Further, value of implementation analysis suggested that 
funding either research or implementation strategies would be potentially worthwhile, 
although pursuing better implementation is expected to lead to greater benefits than 
conducting research. Last, expected value of sample information (EVSI) analysis showed that 
the EVSI associated with the TRAPEZE phase III study exceeded the cost of the trial, resulting 
in positive expected net benefits of sampling (ENBS) of about £550,000 and suggesting that 
the trial is a worthwhile investment.  
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It must be stressed that the sizeable difference between ‘payback’ and VoI results is, to a 
large extent, expected, given the differences in the methods employed to calculate them. On 
the one hand, EVPI results are high as they show the maximum expected benefits from 
conducting ‘perfect’ research, given that the results of research will be implemented 
optimally (e.g. all eligible patients will receive the most cost-effective treatment). On the 
other hand, ‘payback’ results represent the actual—not maximum—benefits that would be 
realised on the basis of less-than-perfect uptake of a cost-effective treatment in clinical 
practice and are net of the cost of the proposed trial.  
9.3. Discussion  
In a context of scarce public resources, normative decisions on how to allocate the available 
budget across different activities need to be guided by evidence on the opportunity costs 
and the expected benefits of competing activities132;282. Consistently with this, systematic, 
comparative assessments of treatments’ costs and consequences are now routinely 
undertaken to inform decisions about funding and providing health care interventions and 
technologies13;128;283. On the same grounds, there is a clear justification for the use of 
explicit, analytic methods to assess the costs and potential benefits from funding different 
research programmes, given that information generated from such programmes is a public 
good, funded by limited public resources.  
To date, none of the analytic models identified in the literature is used to guide funding 
decisions in the United Kingdom or, to the best of the author’s knowledge, elsewhere in the 
world. Although as discussed in Chapter 3 there is a fair amount of literature around analytic 
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models—especially value of information—publications have mostly concentrated on 
methodological aspects, with the literature on how, and to what extent, these methods may 
be useful in assisting organisations with research funding decisions being limited. On this 
basis, it is believed that an in-depth exploration of the frameworks’ potentials and 
limitations with regards to aspects deemed relevant to research funding organisations would 
help to resolve existing uncertainties.  
9.3.1. Aspects related to the frameworks’ theoretical and methodological validity  
An important consideration for potential users relates to the validity of the produced results. 
As explained in the previous chapter, formal assessment of the predictive validity of 
‘payback’ and VoI results poses significant difficulties, for both practical and methodological 
reasons. However, the degree to which validating ‘payback’ and VoI results is a strict 
requirement before they can be used in practice is debatable. On the one hand, confirming 
the validity of ‘payback’ and VoI results is likely to strengthen the case for using the 
frameworks in research priority-setting. On the other hand, unconfirmed validity does not 
necessarily imply that the produced results—and by extension the approaches—are invalid 
or flawed. It is worth noting that, despite the fact that results of widely used cost-
effectiveness and cost-benefits analyses are rarely validated, these are widely accepted and 
used, as they are generated through methods which are thought to have robust theoretical 
and methodological bases132;157. 
The theoretical underpinning and methodological basis of ‘payback’ and VoI appear sound; 
however, there exist points that potential users need to be aware of. With regards to 
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‘payback’, the approach tends to give greater weight to research topics in areas where there 
is scope for a substantial change in clinical practice (i.e. significant increase in the use of a 
cost-effective treatment, or decrease in the use of a non-cost-effective treatment). In 
addition, the framework attributes a beneficial change in clinical practice—either greater 
adoption of a cost-effective treatment or restrictions on the use of a non-cost-effective 
treatment—solely to research. This, however, tends to overlook the impact of other factors 
on changes in clinical practice, such as effective marketing strategy by manufacturer or 
increased familiarity with a treatment. Thus, the actual contribution of research into a 
beneficial change towards cost-effective treatments, and therefore, the associated payback 
of research, is likely to be overestimated. 
With reference to VoI, the framework tends to prioritise research in areas where there is 
substantial uncertainty around parameters affecting a treatment adoption decision. Central 
in this framework is the notion that research is useful insofar as it provides evidence that 
facilitates treatment adoption decisions. Although this notion, termed the ‘decision-maker’s 
viewpoint’189 has supporters115;284, it is in contrast with the currently prevalent paradigm 
which advocates that evaluative research should be conducted to test hypotheses and make 
inference about treatments’ efficacy, effectiveness or cost-effectiveness285.  
In addition, in both the frameworks the estimated benefits from research—and thus, the 
inferred value of research—is directly proportional to the population that stands to benefit 
from improved information. As a result, proposals affecting larger eligible populations are 
more likely to result in greater NMBs. In such cases, the benefits from research are more 
likely to exceed the cost of research, making proposals in such areas good candidates for 
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funding. This, however, may be undesirable when it comes to research for rare conditions, 
where the fact that less people stand to benefit—and consequently less NMBs are expected 
from research—may lead to evaluative research in such areas appear unattractive and being 
overlooked. 
Methodological challenges around the frameworks also exist. As discussed in Chapter 8, a 
prominent issue in ‘payback’ relates to the ambiguity in the way that ‘possible outcomes’ 
and ‘likelihood weights’ are specified. At the same time, the method becomes increasingly 
complicated for research proposals involving more than two treatments, and there is 
currently uncertainty around the optimal ‘payback’ methodology for multiple-treatment 
comparisons. Different methodological challenges are present in VoI. These relate to 
difficulties in conducting comprehensive EVSI analysis in situations where no simple analytic 
solution exists for combining prior evidence with predicted trial data, as well as issues 
related to the value of implementation in pragmatic situations where acquisition of further 
information is expected to have an impact on implementation.  
Last, common to both the frameworks are challenges related to estimating the number of 
people who are expected to benefit from the research and results in the future. Such 
information is essential in projecting the benefits from research to the population, but it is 
inherently uncertain as it requires informed guesses on the number of years for which a 
technology of interest is expected to retain its usefulness. 
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9.3.2. Robustness of results and sensitivity to assumptions 
A further important consideration relates to the extent to which ‘payback’ and VoI results 
are dependent on, and sensitive to, different assumptions. The empirical application of the 
framework showed that a series of assumptions are required in ‘payback’, some of which are 
necessary to ‘operationalise’ the method (e.g. assumptions about possible research results), 
while other assumptions are employed to compensate for lack of data (e.g. extent of change 
in clinical practice, likelihood of observing different results). Sensitivity analyses reported in 
Chapter 6 and discussed further in Chapter 8 showed that different assumptions had a 
notable effect on the results. On the other hand, VoI results are greatly affected by 
assumptions used in the decision analytic model, especially when these assumptions have an 
impact on the uncertainty around key parameters.  
As mentioned above, both the frameworks are highly sensitive to assumptions around the 
number of patients who are expected to benefit from the results of research. A 
straightforward way of estimating this involves weighting the number of patients eligible for 
treatment—that is, the number of new cases per year—by the number of years before the 
technology is rendered obsolete. As explained later in this chapter, the latter component—
commonly called the ‘time horizon’ of a technology—is subject to great uncertainty and it is 
particularly difficult to estimate with any degree of accuracy. Inevitably, this issue adds an 
extra layer of uncertainty to the obtained results.  
Given the above, the difference between ‘payback’ and VoI appears to be that, in the former 
framework, assumptions are typically unavoidable because they are either inherent to its 
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methodology (e.g. specification of possible outcomes) or they represent ‘guesses’ for which 
empirical evidence is typically not available (e.g. rates of future change in clinical practice). In 
contrast, assumptions employed in VoI are often potentially avoidable, in that they are 
typically used to replace empirical data which may be unavailable in the particular instance, 
but they are, in general, accessible.  
It must be noted that the use of assumptions in processes evaluating the costs and benefits 
of different activities, be it health care programmes or projects of public infrastructure, is, to 
a large extent, inevitable132;286. This would be expected to hold true for assessments of the 
value of future research, especially because such research is yet to take place and estimating 
its benefits requires ‘guesses’ and predictions. It is thought that, rather than discarding 
findings which, to some extent, are based on assumptions, the effort should be towards 
making sure the employed assumptions are made explicit, are plausible, and they are based 
on the best of the available knowledge. 
9.3.3. Ease of use and practicality 
It is anticipated that the extent to which ‘payback’ and VoI analyses are practical to 
undertake will be a crucial consideration for potential users. The empirical work showed that 
preliminary steps in the analysis—literature reviews and decision modelling—took 
approximately six and a half months to complete. Once decision models were constructed 
and their results were available, ‘payback’ was carried out in a relatively short period of 
time, within a month, while VoI took about three months, mostly due to time required for 
setting up the programming codes for EVPPI and EVSI, and running computations.  
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It must be noted that, while a probabilistic decision model is necessary for VoI analysis as it 
quantifies the uncertainty around an adoption decision on the basis of which VoI measures 
are calculated, ‘payback’ can be carried out without a model67;92. This is possible in situations 
where a trial is expected to give final—rather than intermediate—outcomes, such as QALYs, 
which can be easily combined with the cost of the assessed intervention to given summary 
cost-effectiveness results. In such cases, ‘payback’ can be calculated within a few weeks. 
Given the short time frames within which research funding organisations operate, this 
suggests a notable advantage for ‘payback’.  
None of the methods requires particular expertise other than an understanding of main 
concepts in economic evaluation, fair familiarity with decision analytic modelling and basic 
programming skills. ‘Payback’ analysis is straightforward to comprehend and undertake, 
involving only simple calculations which can be performed in commonly used spreadsheet 
applications. While VoI concepts are more complex and require some form of programming, 
there exists a wealth of resources, including textbooks and published articles, which offer 
guidance on how to carry out value of information analysis.  
Previous work has looked into the time frames within which VoI (EVPI and EVPPI) and 
‘payback’ (PATHS) analysis can be carried out. In their study, Claxton and colleagues110 found 
that modelling and VoI (EVPI and EVPPI only) would take a team of researchers with 
different levels of experience approximately 10 to 12 weeks to carry out. Townsend et al.67 
found that the PATHS analysis can be undertaken within 1 to 4 weeks, depending on the 
complexity of the project. These estimates are in broad agreement with observations from 
the present study, considering that the latter was undertaken by a single researcher and 
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required building new models from the beginning. Evidently, if a systematic review and/or a 
decision model are already available for use, the time required for conducting the analyses 
would be considerably shorter.  
9.3.4. Usefulness of ‘payback’ and ‘value of information’ results 
As explained in the previous chapter, ‘payback’ and VoI are able to inform decisions on 
which topics or proposals to fund, and, when data is available they can assist in addressing 
questions related to determination of optimal research design and continuation of a phase II 
trial to phase III. A central question relates to how the generated results should be 
interpreted and, by extension, how they can be used to inform funding decisions. 
‘Payback’ results show the expected benefits from conducting a research study given specific 
assumptions about the study’s results and their impact on clinical practice. Positive NMBs 
indicate that a study is worth conducting, while negative NMBs indicate that the possible 
benefits from conducting research are exceeded by the cost of the study. Despite this 
relatively simple rule, making decisions in the light of ‘payback’ results poses challenges. 
First, because of the way ‘payback’ results are calculated and presented, decision-makers 
will need to make a judgement around which ‘combination’ (e.g. ‘optimistic’, ‘neutral’ or 
‘pessimistic’) is more likely to transpire. Such judgements may be difficult, especially in cases 
where, as part of the same analysis, a particular scenario may show net losses (i.e. negative 
INMBresearch vs. no research) associated with research while another scenario may show net gains 
(i.e. positive INMBresearch vs. no research). Second, although in theory positive INMBs indicate that 
a proposal is a worthwhile investment, it is unclear whether there is a level of expected 
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returns—for example, NMBs less than £50,000—below which proposals would be unlikely to 
be funded. In the absence of clear rules, ‘payback’ results would still leave room for different 
interpretations and value judgements. 
VoI measures that quantify the potential gains from ‘perfect’ information (such as EVPI and 
EVPPI) show the maximum expected benefits from research. Such information can be used 
as a ‘hurdle’, to rule out proposed research studies which are not potentially worthwhile (i.e. 
where the cost of research is greater than the expected maximum NMBs from further 
research). However, EVPI results can only provide a ‘necessary’ condition, that is, even if a 
research study passes the first hurdle and is deemed potentially worthwhile, this does not 
automatically imply that the study will be actually worth conducting51;123. This is because the 
actual (marginal) benefits from conducting the study may turn out to be outstripped by its 
cost. To decide on whether a particular study should be funded, one must know whether the 
marginal benefits of a research study exceed its cost.  
Such indications can be given by EVSI and ENBS. These measures have been advocated as 
the most appropriate means of assisting priority-setting55;123 and have been suggested as a 
toolbox for determining the design of clinical trials115;262;287. However, EVSI and ENBS have 
notable limitations.  
First, EVSI is challenging to undertake on the basis of model results, as such analysis is 
particularly intricate in all but the most straightforward situations, where the considered 
‘prior’ evidence and the simulated trial results are expressed as conjugate distributions51. 
Second, although in principle the method can indicate a study’s optimal design, in practice 
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this is complex and particularly demanding. This is because establishing the optimal design 
for one aspect of the trial (e.g. optimal sample size) requires making sure that other design 
aspects (e.g. allocation of patients to trial arms) are also optimised. To date, the majority of 
the applications of non-parametric, model-based EVSI analyses—including the present EVSI 
analysis for HRPC and NSCLC—are based on the assumption that equal allocation of patients 
between trial arm is optimal (i.e. the marginal benefits of allocating a patient in one arm are 
the same as the marginal benefits of allocating the same patient in another arm). However, 
as Briggs et al.51 point out, this is not usually the case, and different (unequal) allocation of 
patients is likely to result in greater benefits. In essence, recognising this would require 
assessing all possible sample sizes (i.e. by starting from no participants in the trial and adding 
one participant at a time) across all possible ways of allocating participants to trial arms, 
which makes the method highly complex and computationally demanding51;262 
Third, even if the optimal design characteristics of a trial as a whole were specified, it is 
uncertain whether funding organisations would be inclined to use this information to 
determining the requirements (e.g. sample size) of studies for commissioning, or as a ‘gauge’ 
against which to assess the design of submitted research proposals. This is especially true in 
cases where these indications may contradict widely used and accepted ways of determining 
trial design characteristics (e.g. traditional power and sample size calculations). For example, 
according to widely-used power calculations based on minimising the chance of type II error, 
the minimum sample size for the TRAPEZE phase III study was determined at 300 patients 
per arm. However, the results of EVSI analysis in Chapter 7 suggested that recruiting 200 
patients per arm is preferable. It is unclear whether and to what degree funding 
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organisations would be prepared to follow EVSI indications and fund a trial which, according 
to established methods, would appear underpowered.  
A common criticism of VoI is that calculations in all concepts assume that the estimated 
NMBs from a decision represent the true NMBs that would be realised in the population. 
This overlooks the fact that, in practice, the predicted NMBs are rarely realised due to sub-
optimal implementation. To address this criticism, Fenwick et al.187 proposed a conceptual 
framework comprising a series of measure of the expected value of implementation. This 
work can, in principle, indicate the situations where undertaking research may be less 
beneficial than improving adherence to recommended treatments. However, the framework 
does not appear to answer the question ‘what is the expected value of conducting research 
to generate information around a treatment adoption decision, given that the treatment 
adoption decision may not be perfectly implemented?’ As it stands at the moment, the 
framework is limited by the restrictive assumption that acquiring better information will 
have no effect on implementation, while it is unclear whether the results of value of 
implementation analysis can be of help to funding organisations with no remit—or budget—
to fund implementation strategies.  
Notwithstanding these issues, it is thought that there is value in using ‘payback’ and VoI as a 
means of assisting research funding decisions. However, given the above limitations, it is 
advocated that the most appropriate use of such results would be as indications for ruling 
out research which is not expected to bring about additional benefits, rather than as strict 
directions on which research programme should be funded. 
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9.3.5. Suitability of ‘payback’ and VoI in different contexts 
The extent to which ‘payback’ and VoI can be compared against each other in order to 
establish which framework is ‘overall superior’ is unclear. The frameworks are based on 
sound underpinning principles and share the same overarching objective—to provide 
evidence that will inform research funding decisions. However, due to differences in the 
methodologies they use, the frameworks present distinctive characteristics, strengths and 
limitation. Although, as explained in Chapter 8, both frameworks are able to provide 
information that can be of use in the main streams of publicly funded research, there exist 
situations where each of ‘payback’ and VoI may be preferable. 
VoI analysis aims to quantify the loss of benefits due to uncertainty around treatment 
adoption decisions, and identify the situations where further information to support such 
decisions would be beneficial. Given this, VoI is closely connected with treatment adoption 
decisions. Undertaken in conjunction with decision modelling, VoI has been advocated as a 
unified framework—often called decision-analytic value of information DA-VOI111;120—which 
aims to address treatment-related and research-related prioritisation simultaneously. 
With this in mind, the framework is well placed to assist in situations where 
recommendations on conducting further research may be made conditional to, or even in 
parallel with, treatment adoption decisions288. This is typically the case for new treatments 
or devices which are considered for adoption by the National Institute for Health and Clinical 
Excellence (NICE). Indeed, recent work122;289 has advocated that treatment approval 
decisions made by NICE need to consider whether further research is required in order to 
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substantiate a choice between policy options such as a) approval of a new treatment for the 
whole of the eligible population, without requesting further research; b) approval of the 
treatment only for those who already receive it in the context of research (i.e. patients in 
clinical trials), or c) approval under the condition that more research will be conducted. The 
latter option is particularly relevant in cases where conducting research after approval is 
granted may be infeasible or unethical289;290. In this context, VoI can be carried out as an 
adjunct to the NICE Technology Appraisal process looking at new medicines, devices or 
procedures, so that the whole exercise provides the necessary information to guide joint 
treatment approval and research recommendations. In practical terms, the fact that decision 
models developed for the purposes of technology appraisals can be readily accessible 
suggests that an important prerequisite for carrying out VoI analysis is already present. 
On the other hand, ‘payback’ can provide timely indications on whether research and 
change in clinical practice would be beneficial, by identifying the situations where the 
benefits that would accrue from research and practice change would be enough to 
compensate for the cost of research. As the framework links research with the benefits of a 
change in clinical practice, it is well placed to assess research questions related to whether 
or not current practice is satisfactory, or a change would be beneficial. Given this, the 
framework appears to be in a stronger position to evaluate the benefits from research on 
topics related to treatments, services and arrangements which are currently in use at 
different rates, but for which good quality evidence is lacking. Such questions are particularly 
pertinent to the health care system and are routinely suggested as topics for research by the 
NHS and its stakeholders40;41. In addition, the fact that decision models are typically not 
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available for topics suggested to NIHR through sources other than the NICE Technology 
Appraisal programme is a practical hindrance for using VoI, but it does not impede ‘payback’, 
which, as Townsend et al.67 have demonstrated, can be also used when a decision model is 
not available. Owing to the above, ‘payback’ appears to be particularly useful in assessing a 
wide range of topics. This, together with the fact that ‘payback’ can be carried out in 
situations where a decision model is not available make the method particularly practical 
and versatile.  
9.3.6. Implementation of the approaches in research priority-setting 
If analytic approaches are to be used routinely in research priority-setting, a number of 
practical questions around their use are expected to arise. A first, important question relates 
to the role of analytic approaches, in relation to the way in which results from ‘payback’ and 
VoI analyses should be considered and used in research priority-setting. Different options 
exist. Under one option, results of analytic frameworks could be used in a ‘prescriptive’ 
manner, to replace the existing deliberative processes. In such a case, these results would be 
the only determinant of funding decisions. As expected, under this option there would be no 
need for panel discussions, and deliberative approaches would be rendered obsolete. 
However, such a radical approach would be undesirable, as there exist ethical and 
distributional considerations which, while they are not reflected in the results of analytic 
approaches, they may be considered pertinent. For instance, analytic approaches may find 
the NMBs from research on particular topics to be low, but society may consider the topic as 
a priority. This may be the case where research on a topic may facilitate a more equitable 
distribution of health care among the population, or target ‘rare’ diseases for which the 
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aggregate gains in the population may be low, but for which research is needed to establish 
the most appropriate care.  
A more pragmatic approach would involve using the results of analytic approaches as 
additional input in the process of decision making, alongside other relevant considerations 
and criteria. Such an approach would be more aligned to the way evidence from analytic 
methodologies such as cost-effectiveness, cost-utility and cost-benefit analyses are used in 
the process of making decisions for treatment recommendations291;292. Under this, more 
realistic, scenario there would still be a clear role for deliberative approaches, which would 
be useful at different stages of the prioritisation process. At early stages, panel discussion 
would continue to take place in order to filter out proposals and topics which are out-of-
remit, irrelevant, or for which there is wide agreement that there is little need for further 
research. Most importantly, deliberative methods would still be needed at the last stages of 
the prioritisation process, to combine the output of analytic approaches with other criteria 
and judgments, and to ensure that all relevant ethical and distributional considerations are 
discussed and taken into account in final funding recommendations.  
A further question relates to who should be tasked with undertaking the additional analyses. 
In the context of ‘proactive’ funding streams, where institutions such as the NIHR 
commission research on proposed topics, ‘payback’ or VoI analysis could be undertaken 
either internally, within the organisation, or externally, by academic teams commissioned to 
carry out this work on behalf of the organisation. The latter is more consistent with current 
arrangements where primary and secondary research commissioned on behalf of different 
NHS stakeholders is undertaken by contracted teams of researchers293. The option of 
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institutions undertaking ‘payback’ and VoI analyses for their own use may also be feasible, 
although, given the fact that this would require significant increases in organisations’ 
capacity to deal with this additional work, it is thought that this option would represent a 
long-term, rather than a short-term goal.  
In ‘researcher-led’ streams, where teams of researchers put forward proposals for research 
on topics of their choice, these additional analyses can be undertaken by either the team of 
researchers who submit the proposal, or by commissioned academic institutions. In the 
former case, researchers can present ‘payback’ or VoI results as part of their research 
proposal. In the short term, commissioning independent academic institutions to carry out 
this work, instead of asking researchers who are involved in the specific proposal to 
undertake the analysis, is thought to offer notable advantages: it would remove the burden 
from researchers who may be lacking the expertise to carry out these additional tasks, while 
it would provide reassurance that the analyses would not come from teams of researchers 
who have a vested interest in showing that research is worthwhile and should be conducted. 
On the other hand, such an option would inevitably imply that the costs of undertaking the 
analysis would be fully borne by the organisation. In the long term, it would be beneficial for 
‘payback’ and VoI analyses to be undertaken by researchers. This would mitigate the cost of 
commissioning the analyses, while, in parallel, it would boost the interest in the frameworks 
which would be likely to lead to further development and improvements in their methods.  
It is thought that an important step to this end would involve research funding organisations 
adopting a proactive stance, where explicit analyses of the value of proposed studies are 
formally requested in commissioning briefs and calls for research, and are considered as an 
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essential part in an application for funding. As explained above, it is thought that ‘payback’ 
analysis would be the method of choice for proposals relating to existing treatments and 
procedures which are commonly used in practice, in order to establish the benefits from 
research and change in current clinical practice, while VoI would be preferable for assessing 
research proposals looking at new treatments or existing treatments proposed for different 
indications, to suggest whether further research is needed to substantiate adoption 
decisions.  
It is also believed that a more widespread use of analytic methods will be difficult without 
making the methods acceptable to committees and decision makers. It is thought that such a 
task would require explaining the principles, methods, strengths and weaknesses of the 
approaches to committee members, as well as by communicating to them the benefits of 
using explicit, systematically-produced evidence of the value of research, possibly through 
open discussion and workshops.  
Advocates of ‘payback’ and VoI have highlighted that, at present, limitations in capacity 
make it difficult to carry out these analysis for every proposal and topic considered by a 
funding organisation67;110. Thus, some judgement would be needed to determine which 
proposals should be subjected to analytic assessment. The obvious solution would be to 
carry out ‘payback’ or VoI analysis only on proposals which have reached the last stages in 
the prioritisation process. In this way, it will be assured that time and effort is not spent on 
proposals which are out-of-remit, or for which experts and reviewers agree that they do not 
represent good candidates for research.  
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Alternatively, the analyses can be restricted to proposals which are deemed particularly 
costly. As Townsend et al.67[p.54] explain, a monetary cut-off point could be used, above 
which all proposed trials should be evaluated using analytic approaches: “The authors 
recommend that formal analysis of potential payback, along these lines [i.e. the developed 
PATHS model], should be undertaken as part of an on-going evaluation for projects costing 
over a certain threshold of, say, £250,000. For very expensive projects, some formal value of 
information analysis might also be routinely appropriate.” Using a monetary threshold to 
identify costly trials is a unambiguous and straightforward criterion, although complications 
would be expected to arise if a universal threshold was to be determined, given that the cost 
of research is expected to vary across disease areas. Indeed, studies in disease areas with 
requirements for long follow up durations and large numbers of participants would 
inevitably be more expensive than smaller and shorter studies which may be adequate in 
other disease areas. Owing to this, it may be preferable for any monetary cut-off points to 
be determined by taking into account particular aspects and characteristics of research in 
different disease areas.  
It is expected that modifications in the existing prioritisation processes may be needed to 
account for the additional time required for undertaking the analyses. On the basis of the 
observations made in the present study, the time for conducting these analyses is not 
expected to be substantial and is unlikely to result in significant delays in decision-making. It 
is also anticipated that additional resources will be required to fund the analyses per se. 
These resources will have to come out of a health care budget which is already stretched 
and, although as of 2013 it will not be subject to cuts, it is planned to remain at current 
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levels294. Nonetheless, the fact that further analyses aim to provide assurance that scarce 
resources are spent more prudently is consistent with the policy aims of containing 
unnecessary spending and improving efficiency295. At the same time, it is thought that the 
cost of undertaking these additional analyses are likely to be counterbalanced by the 
potential cost-savings from not conducting a large and lengthy trial which would provide 
limited returns.  
A further question relates to which organisations would be better placed to use these 
analytic approaches. Both ‘payback’ and VoI are underpinned by the notion that the value of 
evaluative research lies in its potential to inform treatment adoption decisions which will 
provide benefits to the population. According to this stance, benefits from research other 
than those accruing from improved decision-making (e.g. advances in knowledge) are 
secondary and, therefore, are not accounted for in the results67. Owing to this, it is thought 
that organisations with greater potential to benefit from the use of analytic approaches are 
those which fund research with a view to answering specific questions on treatment 
provision within the health care system, such as the NIHR HTA. As an implication, funders 
whose primary aim is to produce scientific knowledge per se, such as medical charities, may 
be reluctant to take ‘payback’ and VoI results into account [personal communication with 
Ms J. Hearn, Head of Clinical Trials, Cancer Research UK, 29-06-2011]. Nonetheless, on the 
premise that such organisations seek to allocate their research budget in a way that provides 
the greatest benefit to the population, it is argued that indications of the ‘cost-effectiveness’ 
of research are relevant and should be accounted for in decision-making, even if they are 
deemed as secondary considerations. 
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9.4. Conclusions and policy recommendations 
It is widely agreed that decisions on how to allocate limited public resources need to be 
made in the light of explicit evidence on competing activities’ potential benefits and 
costs128;132. In recognition of this, analytic methods—such as cost-effectiveness and cost-
benefit analyses—are used widely and play an important role in informing treatment 
adoption decisions8;156;283. In the area of health care research, the crucial role of providing 
explicit information on research programmes’ cost and potential benefits can be fulfilled by 
analytic frameworks, the use of which is equally justified.  
At the moment, explicit and systematically-produced evidence on the potential cost and 
benefits of research proposals is neither generated routinely, nor is it taken into account in 
research funding decisions. Such decisions are made exclusively by using ‘deliberative’ 
processes, where panels of experts assess and infer the merits of proposals through 
discussion and deliberations. Two main analytic frameworks have been proposed to 
generate explicit evidence on the value of research proposals and enhance the transparency 
of research prioritisation decisions—‘payback of research’ and ‘value of information’. 
Although they make use of different methodologies, the frameworks have similarities and 
share a common aim: to provide prospective information that will guide and inform research 
funding decisions. In doing so, the ‘payback’ framework recognises that research is worth 
conducting insofar as its results can trigger a beneficial change in clinical practice, and infers 
the value of research from the estimated benefits due to change in practice. On the other 
hand, VoI stipulates that the value of research lies in its ability to reduce uncertainty about 
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treatment adoption decisions, and thus, it estimates the value of research according to 
decreases in uncertainty and reductions in the expected opportunity loss.  
Although there exists a fair amount of literature explaining the mechanics of the frameworks 
(particularly VoI), there is little discussion around their potential role and value in priority-
setting. Such evidence is crucial in establishing whether analytic approaches should be 
introduced and used to guide research funding decisions. With this in mind, the present 
work aimed to give a comprehensive assessment of the frameworks’ strengths, limitations 
and usefulness, and provides recommendations around their potential role and use.  
Both the frameworks are based on well-grounded principles and use sound logic. In general, 
their methodologies are clear and coherent, although, there exist aspects where further 
methodological research would be needed. Key aspects relate to the specification of 
possible outcomes in ‘payback’ methods, further development of concepts related to 
implementation, and research around the practicalities of conducting EVSI analysis.  
As expected, both the methods make use of assumptions, some of which are inherent to 
their methodologies while others are due to lack of data. Key assumptions needed to 
operationalize the methods relate to possible results of further research, the existing 
uncertainty around parameters and the future number of patients who would stand to 
benefit from research. The use of assumptions instead of empirical data adds an extra layer 
of uncertainty in the results. However, given the fact that the purpose of these analytic 
frameworks is to predict the value of research prospectively, before research takes place, 
the use of assumption is, to a large extent, unavoidable. The analyses are relatively 
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straightforward to undertake, although some concepts such as the expected value of perfect 
information for parameters (EVPPI) and the expected value of sample information (EVSI) are 
more complex and may require longer time frames to complete. Observations made in the 
context of the present empirical analyses suggest that the expertise and time required for 
undertaking ‘payback’ and VoI is unlikely to constitute a significant burden to funding 
organisations and researchers, and are comparable to those needed for conducting model-
based economic evaluations, which are nowadays well established and routinely 
undertaken. 
The frameworks are valuable in that they provide straightforward indications on whether 
the return to investments in evaluative research would justify their cost. Given this, they can 
suggest topics on which research would be beneficial, and indicate whether specific 
proposals are worth undertaking. In this way, the approaches can be helpful in 
commissioned streams, which aim to prioritise topics for research proposed by different 
stakeholders within the health care system, and ‘researcher-led’ streams, which focus on 
prioritising proposals for clinical trials submitted directly by researchers.  
In light of the above, it is thought that analytic approaches such as ‘payback of research’ and 
VoI are valuable and have a clear role in assisting priority-setting for evaluative research. The 
frameworks offer explicit estimates of the expected value of research and, in this way, they 
can provide additional assurance that scarce resources are committed to research which is 
likely to confer benefits to the population.  
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While both ‘payback’ and VoI can be used in a variety of occasions, each of them appears to 
be better placed to answer specific types of questions, and thus they may be preferable in 
different situations. VoI has been seen as a framework that is intertwined with treatment 
approval decisions and, as such, the method appears to have an advantage in dealing with 
situations where recommendations for further research need to be made for new 
treatments, often in conjunction with treatment approval decisions. This is typically the case 
when new treatments and technologies are assessed through technology appraisal 
pathways, to determine whether they should be covered and made available to the public. 
On the other hand, the principles underlying ‘payback’, and in particular the framework’s 
ability to take into account the benefits expected to be brought about by informed changes 
in the use of treatments suggest that the framework is placed favourably to help in 
situations where research is proposed to provide evidence around existing treatments and 
technologies which are currently in use, but for which evidence on their appropriateness is 
weak or inconclusive. Such questions are commonplace and constitute a large part of the 
topics and questions that the NHS is interested in addressing. This, together with the fact 
that the methods is less reliant on the existence of a decision analytic model make ‘payback’ 
applicable to a wider range of situations.  
It is important to recognise that analytic methods present specific limitations and, with this 
is mind, it is thought that the results of analytic approaches should be seen as input in the 
process of prioritisation, rather than as the sole criterion for a funding decision. Results can 
be combined with other considerations which are deemed relevant and are raised through 
discussion and deliberations. It is thought that deliberative approaches will remain a useful 
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component in the prioritisation process, but they should be used in conjunction with analytic 
methods—the latter to provide explicit evidence of the value of research, and the former to 
combine this evidence with further consideration and criteria.  
It is thought that a proactive stance will be needed in order for analytic approaches to 
become an internal part of the prioritisation process. One the one hand, this would involve 
funding organisations requesting formal analyses of the value of research as part of the 
submitted proposals. On the other hand, a more prominent role of analytic approaches 
would require making such approaches more acceptable to experts and committees, by 
conveying the benefits of using explicit, systematically produced evidence in the process of 
decision making.  
Inevitably, the likely introduction and use of the approaches would be expected to raise a 
number of practical questions. Key questions would relate to who should be tasked with 
undertaking these extra analyses and in what cases analytic approaches should be 
undertaken and how their results should be used. It is recommended that, in the short term, 
it would be beneficial for this work to be commissioned to contracted academic institutions, 
although, in the long term, there would be advantages in requesting researchers to 
undertake this analysis and present the results as part of their proposal, to substantiate their 
case for funding. Given current capacity constraints, it would appear infeasible to carry out 
‘payback’ or VoI analysis for every proposal submitted for funding. Current processes where 
research proposals are selected through different prioritisation stages can be used to filter 
specific proposals which are considered as good candidates for research, but for which 
further evidence would be needed to support a funding decision.  
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In summary, it is thought that there is a clear role for analytic approaches in the process of 
priority-setting. Although the approaches are not a panacea, it is believed that their 
introduction and use would enhance the explicitness of the process, and would provide 
additional assurance that valuable research resources are allocated in an efficient way.  
9.5. Key strengths and limitations  
Work undertaken for the aims of this thesis presents certain strengths. First, literature 
reviews carried out throughout this work followed a systematic approach and were 
undertaken through methods recommended in published guidelines56. Reviews involved 
searches in various sources (e.g. electronic bibliographic databases, portals of funding 
organisations, key articles’ reference list and the internet in general) in order to minimise 
the chance that relevant information is missed, while the selection of relevant literature 
followed an iterative approach and was carried out by using predetermined inclusion and 
exclusion criteria.  
A further strength relates to the use of decision analytic models, which were built to 
synthesise the available information and served as vehicles for applying the ‘payback’ and 
VoI to the specific case studies. Although the models did not aim to inform ‘real world’ 
treatment adoption decisions, they were developed with the intention to be as 
comprehensive as possible. Input for the analyses was identified through systematic reviews 
of the literature, while the methods used in structuring and populating the models were in 
agreement with guidelines on ‘good practice’ in modelling296;297. As suggested in the 
literature, both deterministic and probabilistic sensitivity analyses were undertaken114;170;181. 
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In addition, the case studies used throughout this work represented actual research 
proposals submitted for funding. Rather than comparing the expected benefits from 
research with vague estimates of the cost of further evaluative research as it often the case 
in VoI analysis123, comparisons in this study were made against specific proposals of specific 
design and cost. 
‘Payback’ analysis was carried out by using the latest and most comprehensive model 
available in the literature—the Preliminary Assessment of Technology for Health Services 
(PATHS)67. The application of ‘payback’ was underpinned by the acknowledgement that, 
often clinical research will give raw, patient-level evidence (e.g. probability of survival at 
different points in time), and in order for this information to have an impact on clinical 
practice, this evidence needs to be translated into final endpoints. Base case analyses using 
the PATHS model were supplemented by a series of sensitivity analyses, which were 
undertaken to explore different scenarios and investigate the effect of different assumptions 
on the results.  
VoI analysis undertaken as part of this work involved all the concepts which consist the 
framework, including measures of the value of perfect information (EVPI and EVPPI), sample 
information (EVSI and ENBS) and implementation. Undertaking these analyses is seen as a 
particular strength, as they offered an insight into the advantages and challenges associated 
with each VoI concept separately, and enabled a comprehensive assessment of the 
framework as a whole.  
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Last but not least, this assessment looks at the frameworks of interest from different 
viewpoints, and discusses their strengths, weaknesses and potential value with regards to a 
number of relevant aspects, related to their theoretical validity, methodological strengths 
and weaknesses, ease of use, sensitivity to assumptions and usefulness within priority-
setting. In addition, this thesis provides specific recommendations on the use and role of 
analytic approaches in research priority-setting, and gives suggestions around different 
aspects of introducing and employing these approaches in practice. 
Despite the above, the study has certain limitations. First, it is possible that the literature 
review conducted to identify approaches to priority-setting may have missed existing 
analytic models. This is likely to be the case if there exist analytic models which were either 
developed for specific research funding organisations and were never reported or discussed 
in journal articles, or if developed models were published in languages other than English. 
Comparing the models identified in the present project with those in existing reviews55;67;80 
showed that all the models in these reviews have been also included in this thesis.  
Second, for pragmatic reasons, the analyses were carried out after the decision about 
funding the BTOG-2 and TRAPEZE phase III trials were made. To account for this, care was 
taken so that the analyses related to the specific points in time when the funding decisions 
were considered, by using information that was available prior to the funding decisions. 
Although evidence for parameters such as costs and effectiveness existed in the pre-trial 
literature, other inputs for the analysis (for example, uptake of Gem+Cisp and Gem+Carb in 
clinical practice prior to 2004) were scarce. As a result, such information was based on 
343 
expert opinion, rather than empirical data, which has inevitably introduced additional 
uncertainty in the analysis.  
Third, both the case studies used in this analysis were concerned with ‘clinical interventions’, 
in the form of cancer medications. Thus, it is possible that using ‘payback’ and VoI on 
research proposals for other forms of treatment (e.g. public health interventions, screening 
programmes etc.) might have revealed additional strengths and limitations of the 
frameworks. This may be particularly the case for public health interventions, which present 
a series of distinctive characteristics as compared to drugs, devices or medical procedures298.  
Public health interventions are, for instance, different to clinical interventions in that the 
benefits from such programmes are often measured in outcomes other than QALYs298. While 
there exist indications of the decision maker’s willingness to pay for a QALY146, it is more 
difficult to speculate on the possible willingness to pay for an outcome expressed in natural 
units (e.g. a unit reduction in body mass index). As calculations of NMBs require an 
indication of the willingness to pay for a unit of benefit, estimating the expected benefits 
from research on public health interventions and translating these into NMBs would be 
inevitably challenging. Further, benefits from public health interventions typically accrue not 
only to the health care sector, but also to other areas of activity and economic sectors. 
Nonetheless, neither prospective ‘payback’ nor VoI is designed to capture and measure 
potential gains such as, for example, improved educational attainment arising from 
improved health as a result of a public health intervention. Notwithstanding these 
particularities, ‘payback’ and VoI have been in the past applied to case studies representing 
different types of health care programmes (for example community-based midwifery 
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postnatal support67 and screening for macular degeneration110), and it is thought that the 
main conclusions with regards to the frameworks’ value and potentials hold irrespective of 
the case studies and treatments under assessment.  
An additional limitation relates to the specification of time horizon over which the 
information provided by the proposed trials is expected to be useful. In the present study, 
time horizons were based on expert opinion (Professors L. Billingham and N. James), who 
were asked to speculate on the number of years before the treatments for NSCLC and HRPC 
may become obsolete. Although such an approach is in agreement with the way time 
horizons have been typically set in the literature299, it is, in essence, opaque and arbitrary. A 
possible way of obtaining an estimate of an intervention’s expected time horizon could 
combine expert opinion with historic data on the average ‘lifetime’ of pharmaceuticals and 
indications of the rate at which technological innovations are expected to emerge300. 
Although there is no guarantee that such an approach would necessarily provide more 
accurate estimates of the required time horizon, it would nevertheless look into this issue in 
a more systematic and objective way.  
Last, as explained in previous chapter, conducting VoI and ‘payback’ analyses requires, as a 
starting point, existing evidence about the decision problem of interest to have been 
identified and summarised. Where appropriate, this may involve techniques such as meta-
analysis, as well as indirect and mixed treatment comparisons114;301. The latter methods use 
evidence from trials that form networks where treatments of interest may be compared 
indirectly through comparisons against other treatments. Indirect and mixed treatment 
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comparisons are particularly useful in situations where no head-to-head comparisons of 
treatments are available302.  
In the context of the NSCLC case study, only one trial208 reporting a head-to-head 
comparison for NSCLC (i.e. Gem+Cisp vs. Gem+Carb) was identified; nonetheless there exist 
studies which compared Gem+Cisp or Gem+Carb against other treatments (including 
etoposide, mitomycin, vinblastine, vinorelbine and paclitaxel). In principle, indirect 
treatment comparisons could have been undertaken to account for any additional 
information that could have been drawn out from the existing literature. However, this type 
of analyses are appropriate in situations where there is certainty that specific conditions, 
such as homogeneity in the populations, similarity in disease severity and treatment 
schedules, hold across studies302;303. In addition, due to the fact that the role of the 
modelling exercise in this study is to provide a vehicle for the application of the analytic 
approaches rather than for actual decision making, these extensive analyses were felt to be 
beyond the purposes of this study. 
9.6. Contribution of this work 
As explained in Chapter 2, the existing literature on analytic frameworks for priority-setting 
is restricted; the only study116 which undertook an empirical application of VoI and ‘payback’ 
with a view to discussing their potentials and limitations has looked at the methods only 
partially, and therefore its discussion and conclusions are inevitably limited. Thus, a need has 
been identified for an exploration that builds on and extends the available literature, by 
providing an in-depth discussion around the value and potential role of analytic approaches 
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in research priority setting. To this end, the present thesis contributes to the literature in the 
following ways.  
First, the study explored all the concepts consisting the analytic frameworks of interest, by 
undertaking a ‘hands-on’ application of basic concepts relating to the expected value of 
perfect information (EVPI and EVPPI)97, extensions of these concepts concerned with the 
value of sample information (EVPI and ENBS)115;304 as well as recently suggested concepts 
related to implementation187. Observations made throughout these empirical applications 
gave an insight into the feasibility, strengths and weaknesses of these concepts, and enabled 
a more complete assessment of the frameworks. This complements and extends the work 
carried out by Fleurence116, where VoI was represented only by EVPI. 
On the basis of these observations, this work assessed aspects deemed relevant to potential 
users, including their feasibility and ease of use, robustness and reliance on assumptions, 
theoretical and methodological soundness, ability to inform funding decisions, and potential 
to fit into the existing priority-setting framework. With this in mind, the study offered 
specific recommendations around the role of the frameworks and their results in assisting 
research funding decisions, and made suggestions on practical aspects of incorporating and 
using the frameworks within the existing research-funding framework. 
In addition, it is thought that the current work has made the following methodological 
contributions. First, it highlighted a way of incorporating and using probabilistic analysis for 
hypothesised uptake rates and likelihood weights in ‘payback’ calculations. Although this 
addition does not by any means represent a significant ‘breakthrough’ in the methodology, it 
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is thought to be a useful improvement which offers a more explicit representation of the 
uncertainty in key parameters entering the analysis. Secondly, the present work highlighted 
a way of extending ‘payback’ to assess proposals for multiple-treatment comparisons, and 
demonstrated its use by applying it on the four-treatment comparison TRAPEZE case study.  
With regards to VoI, this study has illustrated the application of value of implementation 
concepts under the more realistic assumption that acquisition of information about 
treatments’ cost-effectiveness has a direct effect on their uptake in clinical practice. As 
Fenwick et al.187 explain, such an extension is essential in enabling the concept of value of 
implementation to represent ‘real world’ situations in a more accurate and realistic way. 
Moreover, the analysis indicated a relevant measure of the value of implementation, in the 
form of the ‘expected value of information-implementation trade-off’. The measure 
compares the expected value of acquiring further information against the value of investing 
in implementation, and, in principle, it can indicate the situations where pursuing treatment 
implementation may be preferable.  
Last, the work demonstrated a simple and effective way of conducting expected value of 
sample information analysis. A common difficulty in conducting EVSI analysis relates to 
combining prior and sample (simulated) information when such information is expressed in 
terms of dissimilar distributions which are non-conjugate and cannot be combined using 
simple analytic solutions. In this work, this problem was evaded by expressing the simulated 
sample information in the same units as the prior information (i.e. counts of patient 
transitions to difference health states in HRPC and proportions of patients in specific health 
states at different points in time in NSCLC). This was achieved by following up individuals in a 
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hypothetical trial, which mimicked the proposed trial, one at a time and simulating their 
patient histories. As this work was carried out in a widely-available spreadsheet application, 
it is believed that it contributes to making the mechanics of conducting EVSI analysis more 
transparent and accessible to a wider base of researchers.  
All in all, it is thought that this work helps to resolve uncertainties around the strengths and 
weakness of analytic approaches, sheds light on different aspects related to their potential 
role and value in research priority-setting, makes policy recommendations around their use 
and offers suggestions on practical aspects of introducing and using analytic methods to 
inform research funding decisions.  
9.7. Recommendations for further research 
This study identified a number of areas where further research would be valuable. With 
regards to ‘payback’, further methodological research would be needed to establish more 
explicit and systematic ways of determining possible research outcomes (also called ‘Delta 
results’90 or exemplar outcomes92), given the fact that such outcomes have an important 
impact on the final results. Additional research would also be needed to look into 
appropriate ways of obtaining robust estimates for other key uncertain parameters entering 
the analysis, most importantly a treatment’s future uptake in clinical practice and the 
likelihood of a proposed trial showing the specified results. For the former, this may involve 
formal methods of eliciting expert opinion from adequately large groups of researchers and 
decision-makers. For the latter, there may be scope for obtaining likelihood weights by 
combining expert opinion with existing evidence (e.g. existing results of other studies, phase 
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II data), possibly by using Bayesian processes305;306. Obtaining better estimates of such 
parameters would allow more confidence in ‘payback’ results and would strengthen the case 
for the use of the framework. Moreover, it is expected that further research to ascertain the 
most appropriate methodology for applying ‘payback’ for multiple treatment comparisons 
would be highly useful.  
With relation to VoI, it is thought that further research would be needed around EVSI, with a 
view to making this analysis more practical and applicable to a wider range of situations. In 
addition, there is a need for further development in the concepts of value of 
implementation. If the aim of this framework is to address the fact that, without taking into 
account imperfect implementation, the predicted benefits from research and decision 
making will be overestimated, the framework should be expanded. A first useful 
contribution would be to further develop the methodology so that it accounts for the 
realistic situation that acquisition of information about a treatment would be expected to 
have a direct impact on the treatment’s implementation. Indications of how this may be 
done have been given in this work. 
The importance of obtaining valid estimates of the expected lifetime of the produced 
information has been highlighted in a number of instances throughout this thesis. Although 
they are crucial factors in determining the value of research, time horizons are currently 
determined in a way that is, in essence, ambiguous. Thus, there would be important benefits 
from developing a systematic algorithm or process for estimating the time horizon of 
information. As pointed out earlier, such an algorithm may need to take into account 
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information from expert opinion, observations on the lifetime of treatments and projections 
of the trajectory of technological innovations. 
Finally, it is thought that a stream of research, workshops and consultations would be 
needed to determine the most appropriate ways of introducing analytic methods into 
existing research funding processes. It is envisaged that potential users of the frameworks 
will need to establish ways for incorporating analytic methods which are both efficient and 
acceptable to decision makers. As a first step, this may involve looking into process-related 
issues that are specific to funding organisations, such as how the steps they currently follow 
may be modified to incorporate analytic approaches, and whether and to what extent 
current timelines should be extended to account for the additional analyses.  
Equally importantly, funding organisations will have to address more fundamental issues 
around how ‘payback’ and ‘value of information’ results would be combined with other 
criteria considered important to the organisation, and what ‘weight’ should be attached to 
suggestions and indications obtained through analytic methods.  
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Appendices 
Appendix 1. Literature review on priority-setting for research 
Appendix 1.A. Search strategies for identifications of literature on priority-
setting for research 
1.A.A Search strategies used in MEDLINE and EMBASE 
Strategies 1.1 to 1.5 below were used for searches in MEDLINE and EMBASE (Ovid 
interface; 1946 to January Week 1 2010).  
Search strategy 1.1 
1. "priority-setting".mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
2. (assess$ adj3 priorit$).mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier]  
3. (research adj3 priorit$ adj3 set$).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]  
4. (prioritisation or prioritization).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]  
5. Research/cl, ec, mt, sn [Classification, Economics, Methods, Statistics & Numerical 
Data]  
6. priorities, research.mp.  
7. (priorit$ adj4 research).mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier]  
8. (research adj3 resourc$ adj3 allocat$).mp. [mp=title, original title, abstract, name 
of substance word, subject heading word, unique identifier] 
9. (research adj3 fund$ adj3 allocat$).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]  
10. *Research Support as Topic/  
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11. research fund$.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier]  
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11  
13. (health adj3 technology adj3 assessment).mp. [mp=title, original title, abstract, 
name of substance word, subject heading word, unique identifier]  
14. (evaluative adj3 research).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier] 
15. (assessment adj3 health adj5 technolog$).mp. [mp=title, original title, abstract, 
name of substance word, subject heading word, unique identifier]  
16. *Technology Assessment, Biomedical/cl, ec, mt, og, st, sn, td [Classification, 
Economics, Methods, Organization & Administration, Standards, Statistics & 
Numerical Data, Trends]  
17. Evaluation Studies/  
18. Research Support as Topic/  
19. clinical trial/ or clinical trial, phase i/ or clinical trial, phase ii/ or clinical trial, phase 
iii/ or clinical trial, phase iv/ or controlled clinical trial/ or multicenter study/ or 
randomized controlled trial/  
20. 13 or 14 or 15 or 16 or 17 or 18 or 19 
21. Research Support as Topic/cl, ec, mt, og, sn [Classification, Economics, Methods, 
Organization & Administration, Statistics & Numerical Data]  
22. ((fund$ or financ$ or support$ or cost$ or subsid$ or budget$) and (organi$ation 
or societ$ or body or bodies or instit$)).mp. [mp=title, original title, abstract, 
name of substance word, subject heading word, unique identifier]  
23. NIHR.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier]  
24. (research adj3 fund$ adj3 (organi$ation or institut$ or body or bodies or society or 
charit$)).mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier]  
25. 21 or 22 or 23 or 24  
26. 12 and 20 and 25  
27. ((health technol$ assess$ or research or clinical trial$) and priorit$).mp. [mp=title, 
original title, abstract, name of substance word, subject heading word, unique 
identifier]  
28. 26 and 27  
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Search strategy 1.2 
1. "priority-setting".mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
2. (assess$ adj3 priorit$).mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier] 
3. (research adj3 priorit$ adj3 set$).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier] 
4. (prioritisation or prioritization).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier] 
5. Research/cl, ec, mt, sn [Classification, Economics, Methods, Statistics & Numerical 
Data] 
6. priorities, research.mp. 
7. (priorit$ adj4 research).mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier] 
8. (research adj3 resourc$ adj3 allocat$).mp. [mp=title, original title, abstract, name 
of substance word, subject heading word, unique identifier] 
9. (research adj3 fund$ adj3 allocat$).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier] 
10. *Research Support as Topic/  
11. research fund$.mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier] 
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11  
13. (health adj3 technology adj3 assessment).mp. [mp=title, original title, abstract, 
name of substance word, subject heading word, unique identifier]  
14. (evaluative adj3 research).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]  
15. (assessment adj3 health adj5 technolog$).mp. [mp=title, original title, abstract, 
name of substance word, subject heading word, unique identifier]  
16. *Technology Assessment, Biomedical/cl, ec, mt, og, st, sn, td [Classification, 
Economics, Methods, Organization & Administration, Standards, Statistics & 
Numerical Data, Trends]  
17. Evaluation Studies/ 
18. Research Support as Topic/  
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19. clinical trial/ or clinical trial, phase i/ or clinical trial, phase ii/ or clinical trial, phase 
iii/ or clinical trial, phase iv/ or controlled clinical trial/ or multicenter study/ or 
randomized controlled trial/  
20. 13 or 14 or 15 or 16 or 17 or 18 or 19  
21. Research Support as Topic/cl, ec, mt, og, sn [Classification, Economics, Methods, 
Organization & Administration, Statistics & Numerical Data]  
22. ((fund$ or financ$ or support$ or cost$ or subsid$ or budget$) and (organi$ation 
or societ$ or body or bodies or instit$)).mp. [mp=title, original title, abstract, 
name of substance word, subject heading word, unique identifier]  
23. NIHR.mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier]  
24. (research adj3 fund$ adj3 (organi$ation or institut$ or body or bodies or society or 
charit$)).mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier]  
25. 21 or 22 or 23 or 24  
26. 12 and 20 and 25  
27. Health Priorities/  
28. 26 and 27  
 
Search strategy 1.3 
1. "priority-setting".mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier]  
2. "research priorities".mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier]  
3.  (assess$ adj3 priorit$).mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier]  
4.  (research adj3 priorit$ adj3 set$).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]  
5. "priority-setting".mp. [mp=title, original title, abstract, name of substance word, 
subject heading word, unique identifier]  
6.  (prioritisation or prioritization).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier]  
7. research/cl, ec, mt, sn [Classification, Economics, Methods, Statistics & Numerical 
Data]  
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8. priorities, research.mp.  
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8  
10. comparative Effectiveness Research/  
11. evidence-Based Medicine/ or exp Technology Assessment, Biomedical/  
12. behavioral research/ or biomedical research/ or empirical research/ or peer 
review, research/ or research design/  
13. (health adj3 technolog$ adj3 assess$).mp. [mp=title, original title, abstract, name 
of substance word, subject heading word, unique identifier]  
14. ((economic or effectiveness) adj3 (evaluat$ or assess$)).mp. [mp=title, original 
title, abstract, name of substance word, subject heading word, unique identifier] 
15. drug Approval/ or Device Approval/  
16. "costs and Cost Analysis"/ or Cost-Benefit Analysis/  
17. 10 or 11 or 12 or 13 or 14 or 15 or 16  
18. 9 and 17  
19. (priorit$ adj4 research).mp. [mp=title, original title, abstract, name of substance 
word, subject heading word, unique identifier]  
20. 18 and 19  
 
Search strategy 1.4 
1. exp Health Priorities/cl, ec, og, st, td [Classification, Economics, Organization & 
Administration, Standards, Trends]  
2. exp Technology Assessment, Biomedical/cl, ec, og, st, td, ut [Classification, 
Economics, Organization & Administration, Standards, Trends, Utilization]  
3. (health adj3 technolog$ adj3 assess$).mp. [mp=title, original title, abstract, name 
of substance word, subject heading word, unique identifier]  
4. 2 and 3  
5. 1 and 4 
 
Search strategy 1.5 
6. exp Technology Assessment, Biomedical/cl, ec, og, st, td, ut [Classification, 
Economics, Organization & Administration, Standards, Trends, Utilization] 
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7. (health adj3 technolog$ adj3 assess$).mp. [mp=title, original title, abstract, name 
of substance word, subject heading word, unique identifier] 
8. exp Research Support as Topic/cl, ec, mt, og, st, td [Classification, Economics, 
Methods, Organization & Administration, Standards, Trends]  
9. (research adj3 resourc$ adj3 (fund$ or allocat$)).mp. [mp=title, original title, 
abstract, name of substance word, subject heading word, unique identifier]  
10. (research adj3 (priorit$ or priority-sett$ or priority sett$)).mp. [mp=title, original 
title, abstract, name of substance word, subject heading word, unique identifier]  
11. 1 or 2  
12. 3 or 4 or 5  
13. 6 and 7  
 
1.A.B Search strategies used in Centre for Reviews and Dissemination (CRD) databases 
Strategies 2.1 and 2.2 were used for searches in the Database of Abstracts of Reviews of 
Effects (DARE), NHS Economic Evaluation Database (NHS EED) and Health Technology 
Assessment (HTA) databases (Ovid interface, inception to January Week 1 2010). 
Search strategy 2.1 
1. "priorit setting*"  
2. research AND priorit*  
3. MeSH Research Support as Topic QUALIFIERS CL EC ST TD EXPLODE 1  
4. MeSH Health Priorities QUALIFIERS CL EC OG ST TD UT EXPLODE 1 2  
5. health NEAR technology NEAR assessmen*  
6. MeSH Clinical Trials as Topic QUALIFIERS CL EC TD UT EXPLODE 1 2 3 4  
7. MeSH Technology Assessment, Biomedical QUALIFIERS CL EC OG EXPLODE 1 2  
8. "research fund*" 
9. (fund* OR financ* OR support* OR cost* OR subsid* OR budget* ) AND ( 
organi*ation OR societ* OR body OR bodies OR instit* )   
10. 1 OR 2 OR 3 OR 4  
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11. 5 OR 6 OR 7  
12. 8 OR 9  
13. 10 AND 11 AND 12  
 
Search strategy 2.2 
1. priorit* AND health  
2. priorit* AND health AND research  
3. research NEAR fund* NEAR allocat*  
4. MeSH Research QUALIFIERS CL EC OG EXPLODE 1  
5. 1 OR 2 OR 3  
6. 4 AND 5  
 
1.A.C Search strategy used for searches in EconLit and CINAHL 
Strategies 3.1 and 3.2 were used for searches in EconLit and CINAHL databases (inception 
to January Week 2 2010) respectively, through the EBSCO portal. 
Search strategy 3.1 
1. research AND priorit*  
2. fund* OR finance* OR allocate* OR cost OR assess* 
3. research fund*  
4. health N3 technology N3 assessment 
5. biomedical research 
6. clinical trial* 
7. research support  
8. evaluat* N3 research  
9. research N3 fund* N5 decision*  
10. National institute for Health Research OR NIHR 
 358 
11. Health N Technology N Assessment OR HTA 
12. Medical Research Council OR MRC 
13. research AND (council OR organi?ation OR body OR committee OR institute) 
14. health 
15. S1 or S2 or S3 
16. S4 or S5 or S6 or S7 or S8 
17. S9 or S10 or S11 or S12 or S13 
18. S14 and S15 and S16 and S17 
19. research AND priorit* 
20. fund* OR finance* OR allocate* OR cost OR assess* 
21. research fund*  
22. health N3 technology N3 assessment 
23. biomedical research 
24. clinical trial* 
25. research support 
26. evaluat* N3 research 
27. research N3 fund* N5 decision*  
28. national institute for Health Research OR NIHR 
29. Health N Technology N Assessment OR HTA 
30. medical Research Council OR MRC 
31. research AND (council OR organi?ation OR body OR committee OR institute)  
32. health 
33. S19 or S20 or S21 
34. S22 or S23 or S24 or S25 or S26  
35. S27 or S28 or S29 or S30 or S31   
36. S32 and S33 and S34 and S35 
 
Search strategy 3.2 
1. research AND priorit* 
2. fund* OR finance* OR allocate* OR cost OR assess* 
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3. research fund* 
4. health N3 technology N3 assessment 
5. biomedical research 
6. clinical trial* 
7. research support 
8. evaluat* N3 research 
9. research N3 fund* N5 decision* National institute for Health Research OR NIHR 
10. Health N Technology N Assessment OR HTA 
11. Medical Research Council OR MRC 
12. Research AND (council OR organi?ation OR body OR committee OR institute) 
(27889) 
13. health 
14. S1 or S2 or S3 
15. S4 or S5 or S6 or S7 or S8 
16. S9 or S10 or S11 or S12 or S13 
17. S14 and S15 and S16 and S17 
18. research funding OR research priority-setting OR reserach priorities OR  research 
funding decisions  
19. S18 and S19  
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Table 1.a: Articles identified through searches in bibliographic databases 
 
Searches in databases MEDLINE EMBASE NHS CRD  EconLit CINAHL 
Total 
number 
Search 1.1 291 315 -* - - 606 
Search 1.2 94 25 - - - 119 
Search 1.3 301 438 - - - 739 
Search 1.4 4 0 - - - 4 
Search 1.5 46 20 - - 
 
66 
Search 2.1 - - 33 - - 33 
Search 2.2 - - 2 - - 2 
Search 3.1 - - - 51 - 51 
Search 3.2 - - - - 17 17 
Total hits 736 798 35 51 17 1637 
Duplicates within 
database 
153 39 0 0 0 192 
Unique articles within 
database 
583 759 35 51 17 1445 
Duplicates between 
databases 
160 
Total number of 
unique articles  
1285 
*Hyphens indicate that the search strategy was not applied to the specific database.  
 
 
Table 1.b: Additional articles identified through searches other than in bibliographic databases 
 
Additional articles identified through additional searches* 
References citing key articles 1 
References cited in key articles 7 
References identified through ‘related articles' search in MEDLINE 5 
References identified through searches in key journals 1 
References identified through searches on the internet (using Google 
Scholar® and Dogpile®). 
1 
References identified subsequently, while conducting other searches 1 
Total number of relevant articles 16 
* Articles identified through searches other than in bibliographic databases were assessed for inclusion upon 
identification. This table givens the number of included articles only.  
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Figure 1.a: Flow chart showing the process of identifying and selecting literature on priority-setting for research 
Total number of articles 
retrieved 
(1637) 
Duplicate articles 
within databases 
(192) 
Total number of unique 
articles 
(1285) 
Total number of 
potentially relevant 
articles 
(187) 
Duplicate articles 
between databases 
(160) 
Articles excluded on 
basis of abstract 
(1098) 
Articles excluded on 
basis of full text  
(80) 
Total number of relevant 
articles 
(123) 
Articles identified 
through alternative 
searches 
(16) 
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Appendix 2. Searches for literature related to ‘payback of research’ 
and ‘value of information’ 
Appendix 2.A. Searches strategies for identification of literature relevant to 
‘payback of research’ 
2.A.A Search strategies used in electronic bibliographic databases 
Strategies 1 to 3 below were used for searches in MEDLINE, EMBASE, HMIC and Books@Ovid 
(Ovid interface; 1946 to May Week 1 2010). 
Search strategy 1 
1. (Buxton M or Townsend J or Hanney S or Harper G$).m_auts. 
2. (health and research).mp. [mp=tx, bt, ti, ab, sh, hw, tn, ot, dm, mf, nm, ui]  
3. 1 and 2  
 
Search strategy 2 
1. payback.mp. [mp=tx, bt, ti, ab, sh, hw, tn, ot, dm, mf, nm, an, hn, ui] 
2. limit 1 to abstracts [Limit not valid in Books@Ovid; records were retained]  
3. (research and health).mp. [mp=tx, bt, ti, ab, sh, hw, tn, ot, dm, mf, nm, an, hn, ui] 
4. 2 and 3  
 
Search strategy 3 
1. PATHS model.mp. [mp=tx, bt, ti, ot, ab, hw, sh, tn, dm, mf, nm, ui] 
2. payback of research.mp. [mp=tx, bt, ti, ot, ab, hw, sh, tn, dm, mf, nm, ui] 
3.  (preliminary and assessment and research).mp. [mp=tx, bt, ti, ot, ab, hw, sh, tn, dm, 
mf, nm, ui] 
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4.  ('cost-benefit of research' or 'cost benefit of research').mp. [mp=tx, bt, ti, ot, ab, hw, 
sh, tn, dm, mf, nm, ui] 
5. ('cost-effectiveness of research' or 'cost effectiveness of research').mp. [mp=tx, bt, ti, 
ot, ab, hw, sh, tn, dm, mf, nm, ui] 
6. (prospective and payback) .mp. [mp=tx, bt, ti, ot, ab, hw, sh, tn, dm, mf, nm, ui] 
7. 'research priorit*'.mp. [mp=tx, bt, ti, ab, sh, hw, tn, ot, dm, mf, dv, kw, nm, ps, rs, an, 
ui] 
8. 1 or 2 or 3 or 4 or 5 or 6 
9. 7 and 8 
 
2.A.B Additional searches 
Additional searches involved searches for articles citing key publications, scanning the 
reference lists of key publications, ‘related articles’ searches in MEDLINE, searches in the 
reference lists of key journals, searches through Google Scholar® and searches on Brunel 
University’s website (url: http://www.brunel.ac.uk/about/acad/herg/publications/payback) 
Table 2.a: Number of articles related to ‘payback’ identified in bibliographic databases 
 
Search strategies used in searches in databases Number of hits in MEDLINE, EMBASE, HMIC and 
Books@OVID 
Search strategy 1 169 
Search strategy 2 74 
Search strategy 3 9 
Total hits 252 
Duplicates  85 
Total number of unique articles  167 
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Table 2.b: Articles on ‘payback’ identified through searches other than in bibliographic databases 
 
Articles identified through additional searches 
References citing key articles 10 
References cited in key articles 2 
References identified through ‘related articles' search in MEDLINE 8 
References identified through searches in Google Scholar®  3 
References identified subsequently, while conducting other searches 2 
References identified on Brunel University website 12 
Total number of relevant articles 37 
* Articles identified through searches other than in bibliographic databases were assessed for inclusion upon identification. 
This table givens the number of included articles only.  
 
 
 
 
Figure 2.a: Flow chart showing the process of identifying and selecting literature related to ‘payback of research' 
Total number of articles 
retrieved 
(252) 
Duplicate articles  
(85) 
Total number of unique 
articles 
(167) 
Total number of relevant 
articles 
(71) 
Number of articles 
excluded as irrelevant 
(133) 
Articles identified 
through additional 
searches 
(37) 
 365 
Appendix 2.B. Summary characteristics of practical applications of PATHS 
 
Table 2.c: Characteristics of PATHS applications in Townsend et al.
67
 
 
Characteristic Study: Postnatal midwifery 
support study 
Study: Infusion protocol in adult 
pre-hospital care 
Study: Small aneurysm trial Study:  -interferon for multiple 
sclerosis 
Clinical area Postnatal support service for new 
mothers 
Pre-hospital protocol for severely 
injured adults 
Optimal management of patients 
with small abdominal aortic 
aneurysm 
Use of  -interferon for the 
treatment of patients with 
relapsing remitting RR-MS) and 
secondary progressive multiple 
sclerosis (SP-MS). 
Comparators 
 
Postnatal support service (10 
additional days) from community 
midwifery support workers 
(CMSW) 
Support service (10 visits within 1 
month post delivery) (current 
practice) 
Field stabilisation following 
severe injury 
Immediate transportation to 
hospital 
Watchful waiting 
Elective early surgery 
 -interferon 
Standard treatments 
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Characteristic Study: Postnatal midwifery 
support study 
Study: Infusion protocol in adult 
pre-hospital care 
Study: Small aneurysm trial Study:  -interferon for multiple 
sclerosis 
Exemplar 
outcomes 
Outcome A: CMSW service is 
effective and cost-effective (25-
point improvement in the GHP 
profile of the SF-36 
Outcome B: CMSW is associated 
with non-significant improvement 
in GHP between intervention and 
control 
Outcome C: CMWS service is less 
effective that current practice 
Outcome A: Immediate 
transportation to hospital more 
effective than comparator 
Outcome B: No concluding 
evidence on effectiveness of 
interventions 
Outcome C: Field stabilisation 
more effective than comparator 
Outcome A: Early surgery is 
effective and cost-effective 
Outcome B: Surveillance 
associated with higher quality of 
life 
Outcome C: No significant 
difference between elective 
surgery and watchful waiting 
exists 
Outcome A:  -interferon does 
not offer net clinical benefits and 
it is not cost-effective 
Outcome B:  -interferon offers 
net clinical benefits but it is not 
cost-effective 
Outcome C:  -interferon offers 
net clinical benefits and it is cost-
effective 
Assumed change 
in clinical practice 
Following outcome A, provision of 
CMSW increases to 25% 
Following Outcome B, service will 
be provided to 5% of the eligible 
population 
Following Outcome C, service is 
provided to only 2.5% of eligible 
population 
Following outcome A, 90% of the 
eligible population is 
immediately transported to 
hospital 
Following outcome B, up to 70% 
are immediately transported to 
hospital 
Following outcome C, 90% of the 
patients receive field stabilisation 
Following outcome A, early 
surgery rates increases to 95% of 
the eligible population 
Following outcome B, early 
surgery rates drop to 85% 
Following outcome C, early 
surgery rates drop to 50% of the 
eligible population 
Following Outcome A,  -
interferon is prescribed to a very 
limited number of patients 
Following Outcome B,  -
interferon is prescribed to a 
limited number of patients on 
the (decision made on basis of 
cost-effectiveness), or no 
restrictions apply on prescription 
of  -interferon (decision made 
on basis of clinical benefits) 
Following Outcome C,  -
interferon is prescribed to a 
greater number of patients. 
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Characteristic Study: Postnatal midwifery 
support study 
Study: Infusion protocol in adult 
pre-hospital care 
Study: Small aneurysm trial Study:  -interferon for multiple 
sclerosis 
Results Expected costs and benefits of 
research: between £2 
(‘pessimistic’ combination) and 
£3.50 (‘optimistic’ combination) 
per point improvement in General 
Function Scale of SF-36. 
EICER deemed bellow the expert 
decision-makers’ threshold for 
adoption (£150/25-point change) 
and thus the study appears ‘good 
value for money’ 
The ‘negative’ and ‘positive’ 
scenarios give EICERs between 
£2,500 and £4,000 per life saved 
(for a 40 years old patient). 
According to the authors, this is 
low compared with nearly all the 
current treatment costs and so 
would be cost-effective. 
The authors consider the study 
marginally cost-effective, at 
£175, 000 (£20,000 per life-year 
saved). 
Most likely scenario gave cost 
per QALY of £1 million. Authors 
concluded the study is highly 
unlikely to prove cost-effective. 
What is the 
decision rule? 
Comparison between EICER and 
local decision-makers’ threshold 
of accepting the technology 
The particular trial appears to be 
cost-effective 
Comparison between EICER and 
local decision-makers’ threshold 
of accepting the technology 
The particular trial appears to be 
cost-effective 
Comparison between EICER and 
local decision-makers’ threshold 
of accepting the technology 
The particular trial appears to be 
marginally cost-effective 
Comparison between EICER and 
local decision-makers’ threshold 
of accepting the technology 
The trial is highly unlikely to be 
cost-effective 
 
 
Table 2.d: Characteristics of PATHS applications in Fleurence
116
 
 
Characteristic Study: RECORD Trial  Study: Vitamin D and Calcium 
Trial  
Study: Hip Protector Trial Study: Pressure Trial 
Clinical area Preventive treatment against 
osteoporotic fractures in 
elderly people 
Preventive treatment against 
osteoporotic fractures in elderly 
people 
Prevention of hip fractures in 
elderly people 
Prevention and treatment of 
pressure ulcers 
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Characteristic Study: RECORD Trial  Study: Vitamin D and Calcium 
Trial  
Study: Hip Protector Trial Study: Pressure Trial 
Comparators Vitamin D and Calcium (VDC) 
Vitamin D (VD) 
Calcium (C)  
Placebo 
 Vitamin D and Calcium tablet 
daily (VDC) 
Information leaflet 
Hip protectors (HP) 
No treatment 
Alternating pressure overlay (AO) 
Alternating pressure 
replacement mattress (AR)  
Standard care (high-specification 
foam mattresses) 
Exemplar outcomes Outcome A (‘positive’): The 
trial shows that VDC, VD and C 
are effective and cost-effective 
in preventing fractures  
Outcome B (‘inconclusive’): 
The trial shows no difference 
between VDC, C and VD and 
placebo in preventing 
fractures 
Outcome C (‘negative’): The 
trial shows that VDC, C and VD 
are less effective than placebo 
in preventing fractures 
Outcome A (‘positive’): The trails 
shows that VDC is effective and 
cost-effective for the prevention 
of fractures 
Outcome B (‘inconclusive’): The 
trial shows no difference between 
VDC and no treatment for the 
prevention of fractures 
Outcome C (‘negative’): The trial 
shows that VDC is less effective 
than no treatment for the 
prevention of fractures.  
Outcome A (‘positive’): The trial 
shows that HP is effective and 
cost-effective for the prevention 
of fractures. 
Outcome B (‘inconclusive’): The 
trial shows no difference 
between HP and no treatment 
for the prevention of fractures 
Outcome C (‘negative’): The trial 
shows that HP is less effective 
than no treatment for the 
prevention of fractures. 
Outcome A (‘positive’): The trial 
shows that AO and AR are 
effective and cost-effective for 
the prevention and treatment of 
pressure ulcers  
Outcome B (‘inconclusive’): The 
trial shows no difference 
between AO and AR for 
prevention and treatment of 
pressure ulcers.  
Outcome C (‘negative’): The trial 
shows that AO and AR are less 
effective than standard care for 
the prevention and treatment of 
pressure ulcers 
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Characteristic Study: RECORD Trial  Study: Vitamin D and Calcium 
Trial  
Study: Hip Protector Trial Study: Pressure Trial 
Assumed change in 
clinical practice 
Following outcome A, 
implementation of VDC, C and 
VD extends to 20%, 50% and 
5% of patients at risk, 
accordingly. 
Following outcome B, current 
practice continues as it is. VDC, 
VD and C are given to 30%, 
15% and 5% of the population 
at risk, respectively. 
Following outcome C, VDC, VD 
and C are given to 5%, 5% and 
5% of the population at risk, 
respectively. 
Following outcome A, 
implementation of VDC extends 
to 75% of patients at risk 
Following outcome B, current 
practice continues, with VDC 
provided to 30% of the population 
at risk 
Following outcome C, VCD is given 
to 5% of the population at risk. 
Following outcome A, 
implementation of HP extends 
to 50% of the population at risk 
Following outcome B, current 
practice continues as it is. HP is 
provided to 1% of the 
population at risk 
Following outcome C, HP is not 
provided to the population at 
risk.  
Following outcome A, 
implementation extends to 5%, 
10% and 85% of the population 
for AO, AR and standard care, 
respectively, in the first year and 
15%, 20% and 65% in the 
subsequent years 
Following outcome B, the rate of 
use is 5%, 10% and 85% for AO, 
AR and standard care, 
respectively. 
Following outcome C, the first 
year rate of the treatments’ use 
is 5%, 10% and 85% for AO, AR 
and standard care, respectively. 
In years 2 and 3 use changes to 
1%, 1% and 98% for AO, AR and 
standard care respectively. After 
this, AO and AR are no longer 
used and the use of standard 
care reaches 100%.  
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Characteristic Study: RECORD Trial  Study: Vitamin D and Calcium 
Trial  
Study: Hip Protector Trial Study: Pressure Trial 
Results 
Results were presented in the form of Net Monetary Benefits using a decision-maker’s ceiling ratio of £30,000 per QALY. 
Expected NMBs of research 
were £186.19 million for an 
‘optimistic’ combination, 
£145.8 million for a ‘neutral’ 
combination and £145.52 
million for a ‘pessimistic’ 
combination. 
Expected NMBs of research were 
£133.39 million for an ‘optimistic’ 
combination, £108.04 million for an 
‘inconclusive’ combination and 
£112.19 million for a ‘pessimistic’ 
combination. 
Expected NMBs of research 
were £7.74 million for an 
‘optimistic’ combination, 
£48.42 million for a ‘neutral’ 
combination and £24.6 million 
for a ‘pessimistic’ combination.  
Expected NMBs were £13.81 
million for an ‘optimistic’ 
combination, -£62.76 million 
for a ‘neutral’ combination and 
-£24.6 million for a ‘pessimistic’ 
combination. 
What is the employed 
decision rule?  
Is the research 
proposal 
recommended for 
funding? 
Positive expected Net 
Monetary Benefits. 
The particular trial appears to 
be cost-effective. 
Positive expected Net Monetary 
Benefits. 
The particular trial appears to be 
cost-effective 
Positive expected Net 
Monetary Benefits. 
Positive NMB suggest the trial 
appears to be cost-effective. 
Positive expected Net 
Monetary Benefits. 
The trial is cost-effective only 
under the ‘optimistic’ 
combination. 
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Appendix 2.C. Search strategies for identification of literature relevant to 
‘value of information’ 
2.C.A Searchers used in electronic bibliographic databases 
Strategies 1 to 3 below were used for searches in MEDLINE, EMBASE, HMIC and Books@Ovid 
(Ovid interface; 1946 to May Week 2 2010). 
Search strategy 1 
1.  (claxton or claxton k or claxton kp).au.  
 
Search strategy 2 
1.  ("value of information" or "expected value of information" or "expected value of 
perfect information" or "expected net benefit of sampling" or "expected value of 
perfect information for parameters" or "expected value of implementation").mp. 
[mp=tx, bt, ti, ab, sh, hw, tn, ot, dm, mf, nm, an, hn, ui] 
2. (health and research).mp. [mp=tx, bt, ti, ab, sh, hw, tn, ot, dm, mf, nm, an, hn, ui]  
3. 1 and 2  
 
Search strategy 3  
1.  (("EVPI" or "VoI" or "EVSI" or "EVPPI") and information and value and cost-
effectiveness).mp. [mp=tx, bt, ti, ab, sh, hw, tn, ot, dm, mf, nm, an, hn, ui] (46) 
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2.C.B Additional searches 
Additional searches were carried out for articles citing key publications, articles in the 
reference lists of key publications, ‘related articles’ identified through MEDLINE, reference 
lists of key journals, as well as free searches through Google Scholar®. 
Table 2.e: Number of articles related to VoI identified in bibliographic databases 
 
Search strategies used in searches in databases Number of hits in MEDLINE, EMBASE, HMIC and 
Books@OVID 
Search strategy 1 130 
Search strategy 2 249 
Search strategy 3 46 
Total hits 425 
Duplicates 201 
Total number of unique articles  224 
 
 
Table 2.f: Articles related to VoI identified through searches other than in bibliographic databases 
 
Articles identified through additional searches 
References citing key articles 5 
References cited in key articles 2 
References identified through ‘related articles' search in 
MEDLINE 
3 
References identified through searches in Google 
Scholar®  
0 
References identified subsequently, while conducting 
other searches 
0 
References identified on University of York website  3 
Total number of relevant articles 13 
* Articles identified through searches other than in bibliographic databases were assessed for inclusion upon identification. 
This table givens the number of included articles only.  
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Figure 2.b: Flow chart showing the process of identifying and selecting literature related to ‘value of information’.  
 
Total number of articles 
retrieved 
(425) 
Duplicate articles 
(201) 
Total number of unique 
articles 
(224) 
Total number of relevant 
articles 
(128) 
Number of articles 
excluded as irrelevant 
(109) 
Articles identified 
through additional 
searches 
(13) 
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Appendix 3. Literature review and parameters for NSCLC 
Appendices 3.A. and 3.B. provide information on the literature review for evidence on the 
effectiveness, costs and cost-effectiveness of chemotherapy treatments for NSCLC. 
Appendices 3.C. and 3.D. provide information related to the NSCLC decision model. 
Appendix 3.A. Search strategies for evidence on NSCLC 
Search strategies 1 to 3 below were used for searches in MEDLINE (PubMed interface; 1946 
to September Week 2 2011).  
Search strategy 1 
1. ((("Carcinoma, Non-Small-Cell Lung/drug therapy"[Mesh] OR "Carcinoma, Non-
Small-Cell Lung/economics"[Mesh] OR "Carcinoma, Non-Small-Cell 
Lung/epidemiology"[Mesh]))) AND "Cisplatin"[Mesh] AND "Carboplatin"[Mesh] AND 
"gemcitabine "[Substance Name] 
 
Search strategy 2 
1. "Carcinoma, Non-Small-Cell Lung"[Mesh] AND "Cost-Benefit Analysis"[Mesh] 
 
Search strategy 3 
1. non-small AND cell AND lung AND cancer 
2. metastatic AND lung AND cancer 
3. cisplatin OR carboplatin OR gemcitabine 
4. "cost-effectiveness" OR "cost effectiveness" OR "model" 
5. #1 OR #2 
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6. #3 AND #4 AND #5 
 
Search strategy 4 
Search strategy 4 involved searches in published NICE clinical guidelines on non-small cell 
lung cancer, searches for reviews in the Cochrane Library, ‘related articles’ searches in 
PubMed and ISI Web of Science, searches in the reference lists of identified articles, and 
general searches through Google Scholar®. 
Table 3.a: Identified articles on NSCLC by search strategy 
 
Searches in databases MEDLINE  
 
General searches  
(NICE; Cochrane Library; CRD; ISI 
Web of Science; Google Scholar®; 
‘related article’ searches; reference 
lists of identified articles) 
Search strategy 1 84 - 
Search strategy 2 157 - 
Search strategy 3 65 - 
Search strategy 4 - 26 
Total hits 306 26 
Duplicate articles across searches 34 0 
Unique articles within databases 272 26 
Duplicate articles between databases 12 
Total number of unique articles 286 
Note: dashes indicate that the particular search strategy was not applied to the specific database.  
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Figure 3.a: Flow chart showing the process of identifying and selecting studies on chemotherapy for NSCLC 
 
 
Total number of articles 
retrieved 
(332) 
Duplicate articles across 
searches 
(34) 
Total number of unique 
articles 
 (286) 
Total number of relevant 
articles 
(21) 
Duplicate articles 
between databases  
(12) 
Articles excluded as 
irrelevant 
(265) 
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Appendix 3.B. Summary of identified studies in NSCLC 
 
Table 3.b: Summary of identified clinical effectiveness studies (NSCLC) 
 
Reference Study type Intervention Comparison Outcome measures Authors’ conclusion 
Cardenal eta 
l(1999)
226
 
RCT Gemcitabine + 
cisplatin 
Etoposide + cisplatin Response 
Survival 
Toxicity 
Time-to-progression 
QoL (EORTC QLQ-C30-
LC13) 
Gemcitabine + cisplatin showed superior 
response and superior (longer) time-to-
progression 
No significant difference in survival 
No significant difference in QoL between 
treatments 
The treatments showed similar toxicity 
Crino et al. 
(1999)
227
 
RCT Gemcitabine + 
cisplatin 
Mitomycin + 
ifosfamide + cisplatin 
Response 
Survival 
Toxicity 
Time-to-progression 
QoL (EORTC QLQ-C30-
LC13) 
No significant difference in survival and time-
to-progression between treatments 
Gemcitabine + cisplatin showed superior ( 
higher) response rate 
Similar toxicity between treatments 
No significant difference in QoL between 
treatments 
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Reference Study type Intervention Comparison Outcome measures Authors’ conclusion 
Comella et al. 
(2000) 
RCT Gemcitabine + 
cisplatin + vinorelbine 
Gemcitabine + 
cisplatin 
Vinorelbine + cisplatin 
Response 
Survival 
Toxicity 
Time-to-progression 
QoL (EORTC QLQ-C30-
LC13) 
Gemcitabine + cisplatin + vinorelbine showed 
superior response and survival 
Similar toxicity between treatments 
Sandler et al. 
(2000)
307
 
RCT Gemcitabine + 
cisplatin 
Cisplatin Response 
Survival 
Toxicity 
Time-to-progression 
QoL (FACT-L) 
Gemcitabine + cisplatin showed superior 
response and survival and time-to-progression 
Similar toxicity between treatments 
Similar QoL between treatments 
Clegg et al. 
(2001)
201
 
Systematic 
review of 
RCTs 
Gemcitabine+ cisplatin Various doses and 
treatment schedules 
of: 
Vinorelbine + cisplatin 
Paclitaxel + cisplatin 
Docetaxel 
Best supportive care 
Response 
Survival 
Toxicity 
QoL  
Active treatments (i.e. treatments other than 
best supportive care) showed modestly 
superior response and survival 
QoL was similar between treatments 
Active treatments showed similar toxicity 
compared to best supportive care 
Giaccone et al. 
(2002)
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RCT Paclitaxel + cisplatin Gemcitabine + 
cisplatin 
Paclitaxel + 
gemcitabine 
Response 
Survival 
Paclitaxel + cisplatin showed superior response 
and survival 
Similar toxicity between treatments 
 379 
Reference Study type Intervention Comparison Outcome measures Authors’ conclusion 
Grigorescu 
(2002)
309
 
RCT Vinblastine + cisplatin Gemcitabine + 
carboplatin 
Response 
Survival 
Toxicity 
Gemcitabine + cisplatin showed superior 
response and survival 
Similar toxicity between treatments 
Scagliotti et al. 
(2002)
231
 
RCT Gemcitabine + 
cisplatin 
Paclitaxel + 
carboplatin 
Vinorelbine + cisplatin 
Response  
Survival curves  
Toxicity 
Time-to-progression 
QoL (EORTC QLQ-C30-
LC13) 
No significant difference in response, survival 
and time-to-progression 
Differences in toxicity between treatments 
(vinorelbine + cisplatin) showed higher rates of 
neutropenia; gemcitabine + cisplatin showed 
higher rates of alopecia and neurotoxicity) 
No difference in QoL between gemcitabine + 
cisplatin and vinorelbine + cisplatin. Compared 
to vinorelbine + cisplatin, paclitaxel + 
carboplatin showed superior QoL in 
functioning, fatigue and nausea dimensions, 
and inferior QoL related to peripheral 
neuropathy and alopecia.  
Schiller et al. 
(2002)
217
 
RCT Gemcitabine + 
cisplatin 
Docetaxel + cisplatin 
Paclitaxel + 
carboplatin 
Paclitaxel + cisplatin Response 
Survival 
Time-to-progression 
Toxicity 
No significant difference in response and 
survival between treatments 
Gemcitabine + cisplatin showed superior 
(longer) time to progression 
Gemcitabine + cisplatin showed inferior toxicity  
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Reference Study type Intervention Comparison Outcome measures Authors’ conclusion 
Alberola et al. 
(2003)
209
 
RCT Gemcitabine + 
cisplatin + vinorelbine 
Gemcitabine + 
vinorelbine + 
isofamide 
 
Gemcitabine + 
cisplatin 
Response 
Survival 
Time-to-progression 
Toxicity 
Gemcitabine + cisplatin + vinorelbine showed 
inferior response 
No significant difference in survival and disease 
progression between treatments 
Gemcitabine + cisplatin + vinorelbine showed 
inferior (higher) toxicity 
Danson et al. 
(2003)
228
 
RCT Gemcitabine and 
carboplatin 
Mitomycin + 
ifosfamide + cisplatin 
Mitomycin + 
vinblastine + cisplatin 
Response 
Survival 
Time-to-progression 
QoL (EORTC C30 and 
HADS) 
No significant difference in survival, response 
and time-to-progression between treatments 
Similar toxicity between treatments 
No significant difference in QoL between 
treatments 
Gridelli et al. 
(2003)
229
 
RCT Gemcitabine + 
vinorelbine 
Gemcitabine + 
cisplatin 
Vinorelbine + cisplatin 
Response 
Survival 
Toxicity 
Time-to-progression 
QoL (EORTC QLQ-C30-
LC13) 
No significant difference in response and 
survival between treatments 
Similar toxicity between treatments 
Gemcitabine + vinorelbine showed superior 
QoL 
Smit et al. 
(2003)
206
 
RCT Gemcitabine + 
cisplatin 
Paclitaxel + cisplatin 
Paclitaxel + 
carboplatin 
Response 
Survival 
Toxicity 
Time-to-progression 
QoL (EORTC QLQ-C30-
LC13) 
No significant difference in survival, response 
and time-to-progression between treatments 
Similar toxicity between treatments 
No significant difference in QoL between 
treatments 
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Reference Study type Intervention Comparison Outcome measures Authors’ conclusion 
Zatloukal et al. 
(2003)
208
 
RCT Gemcitabine + 
cisplatin 
Gemcitabine + 
carboplatin 
Response 
Survival 
Toxicity 
Time-to-progression 
No significant difference in response, time-to-
progression and survival between treatments 
Similar toxicity between treatments 
RCT: randomised controlled trial 
 
 
 382 
Table 3.c: Summary of identified economic studies (NSCLC) 
 
Study Type of economic 
evaluation 
Intervention Comparison Authors’ conclusion 
Clegg et al. 
(2001)
201
 
CEA based on evidence 
from multiple studies and 
decision analytic modelling 
Gemcitabine + cisplatin Various doses and treatment 
schedules of: 
Vinorelbine +cisplatin 
Paclitaxel+cisplatin 
Docetaxel 
Best supportive care 
Active treatments result in improved survival at a 
low cost per life-year gained (£2190 to £10,040 
per life-year gained). 
 
Palmer and 
Brandt 
(1996)
214
 
CEA based on evidence 
from multiple study 
Gemcitabine + cisplatin Mitomicyn + ifosfamide + cisplatin 
Etoposide + cisplatin 
Vinorelbine + cisplatin 
No significant difference between the cost-
effectiveness of treatments 
The use of the comparator treatments in place of 
gemcitabine + cisplatin will result in additional 
costs. 
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Study Type of economic 
evaluation 
Intervention Comparison Authors’ conclusion 
Lees et al. 
(2002)
213
 
CEA based on evidence 
from multiple studies 
Gemcitabine + best 
supportive care 
Gemcitabine + cisplatin 
Best supportive care 
Standard chemotherapies 
(etoposide + cisplatin; mitomycin + 
ifosfamide + cisplatin; mitomycin + 
vinolastine+platinum) 
Novel chemotherapies (paclitaxel + 
cisplatin; paclitaxel + carboplatin; 
docetaxel + cisplatin; vinorelbine + 
cisplatin) 
 
Gemcitabine + best supportive care resulted in 
£5230 per additional progression-free life-year 
compared to best supportive care alone. 
Gemcitabine + cisplatin resulted in cost per 
additional progression-free life year of £1750 and 
£5680 against etpoposide + cisplatin and 
mitomycin + vinoblastine + platinum, 
respectively. 
Gemcitabine + cisplatin resulted in cost savings in 
comparison to all novel chemotherapies. 
Khan et al. 
(1999)
210
 
CMA Carboplatin in 
combination with other 
agents for non-small cell 
lung cancer, small cell 
lung cancer and ovarian 
cancer  
Cisplatin in combination with other 
agents for non-small cell lung 
cancer, small cell lung cancer and 
ovarian cancer 
In NSCLC, carboplatin-based combinations result 
in higher total cost. 
Sacristan et al. 
(2000)
211
 
CEA based on a single 
study 
Gemcitabine + cisplatin  Etoposide + cisplatin Gemcitabine + cisplatin appear to be cost-
effective, resulting in ‘favourable’ cost-
effectiveness ratios  
Schiller et al. 
(2004)
212
 
CMA Gemcitabine + cisplatin Vinorelbine + cisplatin 
Paclitaxel + cisplatin 
Paclitaxel + carboplatin 
Docetaxel + cisplatin 
Gemcitabine + cisplatin resulted in lower total 
cost than vinorelbine + cisplatin, paclitaxel + 
cisplatin and paclitaxel + carboplatin.  
Against docetaxel + cisplatin, gemcitabine + 
cisplatin resulted in similar or lower cost. 
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Study Type of economic 
evaluation 
Intervention Comparison Authors’ conclusion 
Minshall and 
Liepa (1998)
215
 
Inference on the cost-
effectiveness of 
gemcitabine by drawing on 
published economic 
studies. 
Gemcitabine versus cisplatin + etoposide 
Gemcitabine versus ifosfamide + etoposide 
Gemcitabine versus cisplatine + etoposide versus ifosfamide + 
etoposide 
Gemcitabine versus cisplatin + etoposide versus carboplatin + 
etoposide 
Gemcitabine versus best supportive care 
Gemcitabine + cisplatin versus cisplatin + etoposide versus 
cisplatin + vinorelbine versus mitocycin + ifosfamide + cisplatin 
The review suggests that gemcitabine alone or in 
combination with other agents may result in cost 
savings or my even be cost-effective. 
Szczepura 
(2002)
216
 
Inference on the cost-
effectiveness of 
gemcitabine by drawing on 
published economic 
studies. 
Gemcitabine + best supportive care versus best supportive care 
alone 
Gemcitabine + cisplatin versus ‘traditional combinations’ 
(etoposide + cisplatin; mitomycin + isosfamide + cisplatin; 
mitomicyn+vinblastine+cisplatin) 
Gemcitabine + cisplation versus ‘newer combination’ (paclitaxel 
+ cisplatin; paclitaxel + carboplatin; docetaxel + cisplatin) 
Gemcitabine + cisplatin versus vinorelbine + cisplatin  
Gemcitabine-based therapies appeared to be 
cost-effective against standard chemotherapies 
CEA: cost-effectiveness analysis; CMA: cost-minimisation analysis 
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Appendix 3.C. Parameters for estimation of transition probabilities for NSCLC 
model 
 
Table 3.d: Results of regression model for disease progression for Gem+Cisp (NSCLC) 
 
Regression 
parameters 
Coefficients Standard 
error 
t stat P-value Lower 95% 
CI 
Upper 95% 
CI 
Intercept -2.99 0.11 -27.63 0.00 -3.22 -2.76 
ln(t) 1.4 0.05 29.9 0.00 1.31 1.50 
 
 
Table 3.e: Parameters for Weibull time-to-progression model for Gem+Cisp (NSCLC) 
 
Parameters of Weibull model 
Alpha ( ) 1.40 
Beta ( ) (21-day cycle) 12.17 
 
 
 
Figure 3.b: Fitted Weibull curve representing time-to-progression for Gem+Cisp (NSCLC) 
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Table 3.f: Results of regression model for disease progression for Gem+Carb (NSCLC) 
 
Regression 
parameters 
Coefficients Standard 
error 
t stat P-value Lower 95% Upper 95% 
Intercept -2.47 0.11 -22.56 0.00 -2.70 -2.25 
ln(t) 1.29 0.05 27.02 0.00 1.19 1.39 
 
 
Table 3.g: Parameters for Weibull time-to-progression model for Gem+Carb (NSCLC) 
 
Parameters of Weibull model 
Alpha ( ) 1.29 
Beta ( ) (21-day cycle) 9.91 
 
 
 
 
Figure 3.c: Fitted Weibull curve for time-to-progression for Gem+Carb (NSCLC) 
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Table 3.h: Results of regression model for survival for Gem+Cisp (NSCLC) 
 
Regression 
parameters 
Coefficients Standard 
error 
t stat P-value Lower 95% Upper 95% 
Intercept -2.81 0.15 -18.93 0.00 -3.15 -2.47 
ln(t) 1.10 0.05 20.1 0.00 0.98 1.23 
 
 
Table 3.i: Parameters for Weibull survival model for Gem+Cisp (NSCLC) 
 
Parameters of Weibull model 
Alpha ( ) 1.10 
Beta ( ) (21-day cycle) 18.4 
 
 
 
Figure 3.d: Fitted Weibull curve for survival for Gem+Cisp (NSCLC) 
 
 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 5 10 15 20 25 30
Time (months) 
Survival (Gem+Cisp) 
Survival curve (Zatloukal et al., 2003) Fitted Weibull (1.1, 18.4)
 388 
Table 3.j: Results of regression model for disease progression for Gem+Carb (NSCLC) 
 
Regression 
parameters 
Coefficients 
Standard 
error 
t stat P-value Lower 95% Upper 95% 
Intercept -3.35 0.21 -16.04 0.00 -3.83 -2.87 
ln(t) 1.3 0.08 16.82 0.00 1.12 1.48 
 
 
Table 3.k: Parameters for Weibull survival model for Gem+Carb (NSCLC) 
 
Parameters of Weibull model 
Alpha ( ) 1.30 
Beta ( ) (21-day cycle) 18.99 
 
 
 
Figure 3.e: Fitted Weibull curve for survival for Gem+Carb (NSCLC) 
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Appendix 3.D. Parameters for probabilistic sensitivity analysis 
 
Table 3.l: Parameters and assigned distributions for model transitions per treatment (NSCLC) 
 
Treatment Target parameter Varied parameter Distribution/ parameter values Source/comment 
Probability of a patient staying in the ‘Progression-free’ state at each cycle 
Gem+Cisp Probability of a patient 
staying at ‘Progression-free’ 
state 
Alpha and beta parameters of the fitted 
Weibull time-to-progression model, by 
varying the model’s intercept and 
regression coefficient 
Interceptnormal(-2.99, 0.11) 
 
Regression 
coefficientnormal(1.40, 0.05) 
From time-to-progression curve 
reported in Zatloukal et al.
208
 
Gem+Carb Probability of a patient 
staying at ‘Progression-free’ 
state 
Alpha and beta parameters of the fitted 
Weibull time-to-progression model, by 
varying the model’s intercept and 
regression coefficient 
Interceptnormal(-2.48, 0.11) 
 
Regression coefficient 
normal(1.29, 0.05) 
From time-to-progression curve 
reported in Zatloukal et al.
208
 
Probability of a patient dying at each cycle 
Gem+Cisp Transition probability from 
‘Progression’ to ‘Death’. 
Alpha and beta parameters of the fitted 
Weibull survival model, by varying the 
model’s intercept and regression 
coefficient 
Interceptnormal(-2.81, 0.15) 
 
Regression coefficientnormal 
(1.10, 0.06) 
From survival curve reported in 
Zatloukal et al.
208
 
Gem+Carb Transition probability from 
‘Progression’ to ‘Death’. 
Alpha and beta parameters of the fitted 
Weibull survival model, by varying the 
model’s intercept and regression 
coefficient 
Interceptnormal (-3.35, 0.21) 
 
Regression coefficient 
normal(1.30, 0.08) 
From survival curve reported in 
Zatloukal et al.
208
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Table 3.m: Parameters and assigned distributions for resource use and cost by treatment (NSCLC) 
 
Treatment Target parameter Varied parameter Distribution/ parameter values Comment/Source 
Drug acquisition and administration costs 
Gem+Cisp Cost of drug acquisition and administration Gamma(100, 9.46) Gamma distribution fitted by the 
method of moments on the basis of: 
Mean value: £946 (from cost 
analysis) 
Standard error: £95 (assumption, 10 
percent of mean value) 
Gem+Carb Cost of drug acquisition and administration Gamma(100, 11.33) Gamma distribution fitted by the 
method of moments on the basis of: 
Mean value:£1133 (from cost 
analysis) 
Standard error:£113 (assumption, 
10 percent of mean value) 
Adverse events-related cost 
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Treatment Target parameter Varied parameter Distribution/ parameter values Comment/Source 
Gem+Cisp Cost of adverse events Probability of patients 
experiencing different adverse 
events 
Anaemiabeta(10.58, 73.42) 
Thrombocytopeniabeta(13.78, 
70.22) 
Neutropeniabeta(7.98, 76.02) 
Granulocytopenia beta(19.74, 
64.26) 
Based on proportions of patients 
experiencing adverse events as 
reported in Zatloukal et al.
208
 
Gem+Carb Cost of adverse events Probability of patients 
experiencing different adverse 
events 
Anaemiabeta(15.84, 72.16) 
Thrombocytopeniabeta(28.69, 
59.31) 
Neutropeniabeta(12.85, 75.15) 
Granulocytopenia beta(26.66, 
61.34) 
Based on proportions of patients 
experiencing adverse events as 
reported in Zatloukal et al.
208
 
Cost of other medical resources (same across treatments) 
Gem+Cisp 
Gem+Carb 
Cost of other medical 
resources 
Cost of other medical resources Gamma(16, 45.5) Gamma distribution fitted on the 
basis of 
Mean value:£728 (from Schiller et 
al.
212
) 
Standard error: £182 (assumption, 
25 percent of the mean value) 
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Treatment Target parameter Varied parameter Distribution/ parameter values Comment/Source 
Cost of terminal care (same across treatments) 
Gem+Cisp 
Gem+Carb 
Terminal care cost Terminal care cost Gamma(16, 91.25) Gamma distribution fitted on the 
basis of 
Mean value:£1460 (from Clegg et 
al.
201
) 
Standard error: £365 (assumption, 
25 percent of the mean value) 
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Table 3.n: Parameters and assigned distributions for preference-based quality of life scores (NSCLC) 
 
Treatment Target parameter Varied parameter Distribution/ 
parameter values 
Comment/Source 
Utility values for ‘Progression-free’ and ‘Progression’ states 
Gem+Cisp 
Gem+Carb 
Utility value of 
‘Progression- free’ 
state  
Utility value of 
‘Progression-free’ 
state 
Normal(0.65,0.08) Values based on 
expert opinion 
(Professor L. 
Billingham, 
University of 
Birmingham) 
Utility value of 
‘Progression’ state  
Difference between 
utilities of 
‘Progression-free’ 
and ‘Progression’ 
states 
Normal(0.2, 0.04) 
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Appendix 4. Literature review and parameters for HRPC 
Appendix 4.A. reports the literature review carried out to retrieve information on the 
effectiveness, costs and cost-effectiveness of chemotherapy treatments for HRPC. 
Appendices 4.B. to 4.F. provide information related to parameters used in populating the 
HRPC decision model. 
Appendix 4.A. Search strategies for evidence on HRPC  
Search strategies 1 to 5 below were used for searches in MEDLINE (PubMed interface; 1946 
to October Week 2 2011).  
Search strategy 1 
1.  (hormone refractory prostate cancer) AND (strontium 89 OR zoledronic acid) 
 
Search strategy 2 
1. (((("Prostatic Neoplasms/drug therapy"[Mesh] OR "Prostatic 
Neoplasms/economics"[Mesh])) AND "docetaxel "[Substance Name]) AND 
("strontium chloride "[Substance Name]) OR "zoledronic acid "[Substance Name]) 
AND (prostate cancer) AND (cost effectiveness OR cost-effectiveness OR cost-benefit 
OR cost benefit) 
 
Search strategy 3  
1. tax 327 OR tax-327 
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Search strategy 4  
1.  ("cost-benefit analysis"[MeSH Terms] OR ("cost-benefit"[All Fields] AND 
"analysis"[All Fields]) OR "cost-benefit analysis"[All Fields] OR ("cost"[All Fields] AND 
"effectiveness"[All Fields]) OR "cost effectiveness"[All Fields]) AND ("prostatic 
neoplasms"[MeSH Terms] OR ("prostatic"[All Fields] AND "neoplasms"[All Fields]) OR 
"prostatic neoplasms"[All Fields] OR ("prostate"[All Fields] AND "cancer"[All Fields]) 
OR "prostate cancer"[All Fields]) AND ("clinical trial"[Publication Type] OR "clinical 
trials as topic"[MeSH Terms] OR "clinical trial"[All Fields] 
 
Search strategy 5  
Search strategy 5 was used for searches in the NHS CRD databases (Database of Abstracts of 
Reviews of Effects (DARE), NHS Economic Evaluation Database (NHS EED) and Health 
Technology Assessment (HTA) databases) in October 2011.  
1. “prostate” AND “cancer” AND “bone” 
 
Search strategy 6  
Search strategy 6 involved searches for guidelines around chemotherapy for HRPC on the 
NICE website, ‘related articles’ searches in PubMed and ISI Web of Science, searches in the 
reference lists of identified articles and reports, and general searches through Google 
Scholar®. 
Search strategy 7  
Search strategy 7 involved searches in the Cochrane Library for systematic reviews in the 
area of prostatic diseases and urological cancer.  
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Table 4.a: Identified articles on HRPC by search strategy (HRPC) 
 
Searches in databases MEDLINE NHS CRD General searches  
(NICE; ISI Web of 
Science; Google 
Scholar® reference 
lists of identified 
articles) 
Cochrane 
Collaboration 
Reviews 
Search strategy 1 85 - - - 
Search strategy 2 5 - - - 
Search strategy 3 39 - - - 
Search strategy 4 105 - - - 
Search strategy 5 - 36 - - 
Search strategy 6 - - 6 - 
Search strategy 7 - - - 4 
Total hits 234 36 6 4 
Duplicate articles across 
searches 
23 0 0 0 
Unique articles within 
databases 
211 36 6 4 
Duplicate articles 
between databases 
26 
Total number of unique 
articles 
231 
Note: dashes indicate that the particular search strategy was not applied to the specific database. 
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Figure 4.a: Flow chart of identified literature (HRPC) 
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Appendix 4.B. Data used in estimating transitions probabilities for HRPC 
model 
 
Table 4.b: Counts of transitions from ‘Progression-free, on treatment’ to other model states during cycles 1-6 by 
treatment (HRPC) 
 
From/To Progression-
free, on 
treatment 
Progression-
free, not on 
treatment 
Progression Death Total 
‘Progression-free, on treatment’ 
DP 204 5 5 5 219 
PD+ZA 203 4 4 6 217 
DP+Sr89 204 5 3 2 214 
DP+ZA+Sr89 218 5 2 3 228 
 
 
Table 4.c: Counts of transitions between model states from cycle 6 onwards by treatment (HRPC) 
 
From/To 
Progression-free, not 
on treatment 
Progression Death Total 
DP 
Progression-free, not 
on treatment 
371 24 13 408 
Progression - 567 29 596 
DP+ZA 
Progression-free, not 
on treatment 
248 26 11 285 
Progression - 590 31 621 
DP+Sr89 
Progression-free, not 
on treatment 
461 25 15 501 
Progression - 454 26 480 
DP+ZA+Sr89 
Progression-free, not 
on treatment 
479 21 18 518 
Progression - 294 21 315 
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Appendix 4.C. Comparison of Kaplan-Meier survival curves from data and 
model  
Kaplan-Meier survival curves were plotted to test the fit between survival as given by a) the 
observed patient-level data (solid line), and b) the HRPC model, using the estimated non-
time-dependent transition probabilities (dotted line). Close fit between the curves suggests 
that the estimated non-time-dependent transition probabilities are appropriate for 
representing the observed survival data. 
 
Figure 4.b: Data and model-generated Kaplan-Meier survival curves for DP (HRPC) 
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Figure 4.c: Data and model-generated Kaplan-Meier survival curves for DP+ZA (HRPC) 
 
 
 
Figure 4.d: Data and model-generated Kaplan-Meier survival curves for DP+Sr89 (HRPC) 
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Figure 4.e: Data and model generated Kaplan-Meier survival curves for DP+ZA+Sr89 (HRPC) 
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Appendix 4.D. Input parameters for estimation of costs and health-related 
quality of life for HRPC model 
 
 
Table 4.d: Occurrence of Grade III/VI adverse events by treatment (HRPC) 
 
Adverse event DP DP+ZA DP+Sr89 DP+ZA+Sr89 Total across 
treatment arms 
Diarrhoea 1 1 1 2 5 
Febrile neutropenia 3 3 6 2 14 
Haemoglobin 1 1 0 2 4 
Infection 5 4 2 2 13 
Neutrophils/granulocytes 4 0 2 0 6 
Pain 5 3 7 3 18 
Urinary retention 0 4 0 1 5 
Other 20 13 9 24 66 
Total number of adverse 
events 
39 29 27 36 131 
Total number of patients in 
arm 
50 49 51 50 200 
 
 
Table 4.e: Unit costs of adverse events (HRPC) 
 
Adverse event Unit cost Source 
Diarrhoea £288 NHS Reference Cost Schedules 2009-10
221
 
Febrile neutropenia £433 NHS Reference Cost Schedules 2009-10
221
 
Haemoglobin £517 NHS Reference Cost Schedules 2009-10
221
 
Infection £369 NHS Reference Cost Schedules 2009-10
221
 
Neutrophils/granulocytes £433 NHS Reference Cost Schedules 2009-10
221
 
Pain £902 NHS Reference Cost Schedules 2009-10
221
 
Urinary retention £414 NHS Reference Cost Schedules 2009-10
221
 
Other adverse events £2025 Curtis et al.(2010)
220
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Table 4.f: Counts of patients in receipt of second-line treatment (HRPC) 
 
Second-line treatment DP DP+ZA DP+Sr89 DP+ZA+Sr89 Total across 
treatment arms  
Radiotherapy 20 19 20 17 76 
Further chemotherapy 2 6 5 3 16 
Radioisotopes 6 3 2 0 11 
Total no of patients in arm 50 49 51 50 200 
 
 
Table 4.g: Unit costs of second-line treatment (HRPC) 
 
Second-line treatment Administration 
cycles 
Unit cost Cost per 
course 
Source 
Radiotherapy 1 £578 £578 
NHS Reference Cost 
Schedules 2009-10
221
 
Further chemotherapy 4 £1160 £4640 Calculated cost of DP 
Radioisotope (strontium-89) 1 £1576 £1576 
Personal communication, 
Dr C. Boivin, University 
Hospital Birmingham 
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Appendix 4.E. Parameters for probabilistic sensitivity analysis 
 
Table 4.h: Transition parameters and assigned distributions per treatment (HRPC) 
 
Treatment Parameter Distribution Source/comment 
Transition probabilities from state ‘Progression-free, on treatment’ (PGF-OT) to states ‘Progression-free, not on treatment’ (PGF), ‘Progression’ (PG) and ‘Death’ 
(D) 
DP 
Transition probabilities from state PGF-OT to 
states PGF, PG and D 
Dirichlet(204, 5 ,5, 5) 
Calculated according to data from the TRAPEZE 
phase II trial 
DP+ZA 
Transition probabilities from state PGF-OT to 
states PGF, PG and D 
Dirichlet(203, 4, 4, 6) 
DP+Sr89 
Transition probabilities from state PGF-OT to 
states PGF, PG and D 
Dirichlet(204, 5 ,3, 2) 
DP+ZA+Sr89 
Transition probabilities from state PGF-OT to 
states PGF, PG and D 
Dirichlet(218, 5 ,2, 3) 
Transition probabilities from state ‘Progression-free, not on treatment’ (PGF) to ‘Progression’ (PG) and ‘Death’ (D) 
DP 
Transition probabilities from state PGF to states 
PG and D 
Dirichlet(371, 24, 13) 
Calculated according to data from the TRAPEZE 
phase II trial 
DP+ZA 
Transition probabilities from state PGF to states 
PG and D 
Dirichlet(248, 26, 11) 
DP+Sr89 
Transition probabilities from state PGF to states 
PG and D 
Dirichlet(461, 25, 15) 
DP+ZA+Sr89 
Transition probabilities from state PGF to states 
PG and D 
Dirichlet(479, 21, 18) 
Transition probabilities from state ‘Progression’ (PG) to ‘Death’ (D) 
DP Transition probabilities from state PG to state D Beta(29, 567) Calculated according to data from the TRAPEZE 
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Treatment Parameter Distribution Source/comment 
DP+ZA Transition probabilities from state PG to state D Beta(31, 590) phase II trial 
DP+Sr89 Transition probabilities from state PG to state D Beta(26, 454) 
DP+ZA+Sr89 Transition probabilities from state PG to state D Beta(21, 294) 
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Table 4.i: Parameters and assigned distributions for resource use and cost (HRPC) 
 
Treatment Target parameter Varied parameter Distribution/ parameter values Comment/Source 
Cost of drug acquisition and administration 
DP Cost of drug acquisition and administration Gamma(100,11.60) Gamma distribution fitted by the method of 
moments on the basis of: 
 
Mean value: £1160(from cost analysis) 
Standard error: £116 (assumption, 10 
percent of mean value) 
DP+ZA Cost of drug acquisition and administration Gamma(100, 13.29) Gamma distribution fitted by the method of 
moments on the basis of: 
 
Mean value: £1329(from cost analysis) 
Standard error: £133 (assumption, 10 
percent of mean value) 
DP+Sr89 Cost of drug acquisition and administration Gamma(100, 11.60) Gamma distribution fitted by the method of 
moments on the basis of: 
 
Mean value: £1160(from cost analysis) 
Standard error: £116 (assumption, 10 
percent of mean value) 
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Treatment Target parameter Varied parameter Distribution/ parameter values Comment/Source 
DP+ZA+Sr89 Cost of drug acquisition and administration Gamma(100, 13.29) Gamma distribution fitted by the method of 
moments on the basis of: 
 
Mean value: £1329(from cost analysis) 
Standard error: £133 (assumption, 10 
percent of mean value) 
Cost of 
strontium-89 
acquisition and 
administration  
Cost of strontium-89 acquisition and administration  Gamma(100, 15.76) Gamma distribution fitted by the method of 
moments on the basis of: 
 
Mean value: £1576 (expert opinion) 
Standard error: £133 (assumption, 10 
percent of mean value) 
Cost of adverse events 
DP Cost of adverse events Probability of patients 
experiencing different adverse 
events 
Diarrhoeabeta(1, 49) 
Febrile neutropenia beta(3, 47) 
 
Haemoglobinbeta(1, 49) 
 
Infectionbeta(5, 45) 
 
Neutrophils/granulocytesbeta(4, 
46) 
 
Painbeta(5, 45) 
 
Urinary retentionbeta(0, 50) 
 
Otherbeta(20, 30) 
Based on proportions of patients 
experiencing adverse events obtained from 
TRAPEZE phase II trial 
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Treatment Target parameter Varied parameter Distribution/ parameter values Comment/Source 
DP+ZA Cost of adverse events Probability of patients 
experiencing different adverse 
events 
Diarrhoeabeta(1, 48) 
 
Febrile neutropeniabeta(3, 46) 
 
Haemoglobin: Beta(1, 48) 
 
Infectionbeta(4, 45) 
 
Neutrophils/granulocytes 
beta(0, 49) 
 
Painbeta(3, 46) 
 
Urinary retentionbeta(4, 45) 
 
Otherbeta(13, 36) 
Based on proportions of patients 
experiencing adverse events obtained from 
TRAPEZE phase II trial 
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Treatment Target parameter Varied parameter Distribution/ parameter values Comment/Source 
DP+Sr89 Cost of adverse events Probability of patients 
experiencing different adverse 
events 
Diarrhoeabeta(1, 50) 
 
Febrile neutropeniabeta(6, 45) 
 
Haemoglobinbeta(0, 51) 
 
Infectionbeta(2, 49) 
 
Neutrophils/granulocytesbeta (2, 
49) 
 
Painbeta(7, 44) 
 
Urinary retentionbeta(0, 51) 
 
Otherbeta(9, 42) 
Based on proportions of patients 
experiencing adverse events obtained from 
TRAPEZE phase II trial  
 410 
Treatment Target parameter Varied parameter Distribution/ parameter values Comment/Source 
DP+ZA+Sr89 Cost of adverse events Probability of patients 
experiencing different adverse 
events 
Diarrhoeabeta(2, 48) 
 
Febrile neutropenia 
beta(2, 48) 
 
Haemoglobinbeta (2, 48) 
 
Infectionbeta(2, 48) 
 
Neutrophils/granulocytes 
beta(0, 50) 
 
Painbeta(3, 47) 
 
Urinary retentionbeta(1, 49) 
 
Otherbeta(24, 26) 
Based on proportions of patients 
experiencing adverse events obtained from 
TRAPEZE phase II trial  
Cost of second-line treatment 
DP Expected cost of 
second-line treatment 
Probability of patients 
receiving second-line 
chemotherapy, radiotherapy 
or radioisotope treatment 
Chemotherapybeta(20, 30) 
Radiotherapy beta(2, 48) 
Radioisotopesbeta(6, 50) 
Based on proportions of patients who 
received second-line treatment in TRAPEZE 
phase II trial 
DP+ZA Expected cost of 
second-line treatment 
Probability of patients 
receiving second-line 
chemotherapy, radiotherapy 
or radioisotope treatment 
Chemotherapybeta(19, 30) 
Radiotherapy beta(6, 43) 
Radioisotopesbeta(3, 46) 
Based on proportions of patients who 
received second-line treatment in TRAPEZE 
phase II trial 
DP+Sr89 Expected cost of 
second-line treatment 
Probability of patients 
receiving second-line 
chemotherapy, radiotherapy 
or radioisotope treatment 
Chemotherapy beta(20, 31) 
Radiotherapy beta(5, 46) 
Radioisotopesbeta(2, 49) 
Based on proportions of patients who 
received second-line treatment in TRAPEZE 
phase II trial 
 411 
Treatment Target parameter Varied parameter Distribution/ parameter values Comment/Source 
DP+ZA+Sr89 Expected cost of 
second-line treatment 
Probability of patients 
receiving second-line 
chemotherapy, radiotherapy 
or radioisotope treatment 
Chemotherapybeta(17, 33) 
Radiotherapy beta(3, 47) 
Radioisotopesbeta(0, 50) 
Based on proportions of patients who 
received second-line treatment in TRAPEZE 
phase II trial 
Cost of terminal care 
DP 
DP+ZA 
DP+Sr89 
DP+ZA+Sr89 
Terminal care cost Terminal care cost Gamma(16, 101.39) Gamma distribution fitted on the basis of 
Mean value:£1532 (from Clegg et al.
201
) 
Standard error: £406 (assumption, 25 
percent of the mean value) 
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Table 4.j: Parameters and assigned distributions for preference-based quality of life scores by treatment (HRPC) 
 
Treatment Distribution 
Utility score for state ‘Progression-free, on treatment’ (PGF-OT) 
DP Beta(93.14, 55.99) 
DP+ZA Beta(156.75, 53.4) 
DP+Sr89 Beta(109.46, 43.78) 
DP+ZA+Sr89 Beta (151.39, 50.52) 
Utility score for state ‘Progression-free, not on treatment’(PGF)* 
DP Normal(0.019, 0.062) 
DP+ZA Normal(0.006, 0.044) 
DP+Sr89 Normal(0.212, 0.05) 
DP+ZA+Sr89 Normal(0.099, 0.059) 
Utility score for state ‘Progression’(PG)** 
DP Normal(0.125, 0.087) 
DP+ZA Normal(0.143, 0.072) 
DP+Sr89 Normal(0.211, 0.096) 
DP+ZA+Sr89 Normal(0.166, 0.085) 
*Calculated as score for PGF-OT + (utility increment PGF-OT – PGF) 
**Calculated as utility for PGF-OT + (utility increment PGF-OT – PG) 
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